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Abstract 
Growth hormone (GH) is a major regulator of postnatal growth, cellular proliferation and 
differentiation, as well as of metabolism. All actions of GH are mediated via its cognate Growth 
Hormone Receptor (GHR). It is now clear that the role of GH extends well beyond the conventional 
notions of longitudinal growth and childhood development. A substantial body of evidence supports 
a role for the GH/IGF-1 axis in cancer incidence and progression in animals and humans and 
because of widespread clinical application of GH, there has been considerable interest in the 
mechanism of activation of its receptor. It was originally thought that GH initiated its actions by 
sequentially binding two GHR monomers, resulting in receptor dimerisation and initiation of 
intracellular signalling cascades, including Jak/STAT and MAPK pathways. However, recent 
evidence by our group and others has indicated that the GHR is constitutively dimerised, and that 
dimerisation alone is not sufficient for GHR activation. 
 
To this end the main objective of this thesis was to evaluate the role of GH-mediated signalling via 
its GHR in mediating oncogenesis. We have taken a multi-disciplinary approach by first 
determining how the GHR is activated via its transmembrane domain (TMD) and the nature of its 
interaction with Src family of tyrosine kinase (Lyn). We have determined the basis of the 
contrasting actions of autocrine GH from independent publications and sought to evaluate the effect 
of various constitutively active GHR constructs in cancer promotion in vitro and in vivo by 
establishing a tissue-specific delivery system (TVA system) for introducing multiple genes in a 
spatial and temporally controlled manner. We have provided the molecular basis of increased 
cancer susceptibility of the first reported GHR variant from two independent epidemiological 
studies. Finally, we have evaluated cancer resistance and anti-aging pathways in various GHR 
knockin and knockout mice models.  
 
In order to determine the role of GHR transmembrane domain (TMD) and upper juxtamembrane 
domain (JMD) in signalling, cysteine-scanning mutagenesis was employed with truncated and full 
length receptors in a thiol-free background. Using these GHR constructs and sequentially 
substituting residues along the GHR JMD and TMD with cysteine we observed a ligand-
independent spontaneous dimerisation pattern of upper JMD and TMD residues with evidence for a 
‘tilt and twist’ movement for this region of GHR during activation. By using Cu-o-phenanthroline 
we were able to show that GHR activation could occur following disulfide bond formation at the 
upper TMD boundary resulting in constitutive activation. Finally we were able to conclude that 
GHR activation requires the JMD residues to come in close proximity which results in separation of 
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the lower TMD residues and activation. Another outcome of this study was the generation of the 
first full-length constitutively active receptor.   
 
GHR has been shown to activate numerous pathways and one such pathway involves Src Family 
Kinase (SFK), which have been shown to be activated independently of Jak2. As a part of 
determining the structure-function aspect of GHR, we have defined the region in the intracellular 
domain (ICD) of GHR that interacts with Lyn (a SFK member) to lie between Box1 and Box2 
motif. SFK pathways have been implicated in GH-dependent migration, invasion and even radio-
resistance in MCF-7 mammary cancer cells. Actions of GH occur through two systems: the 
classical endocrine system and through extra-pituitary mechanisms (autocrine and paracrine), the 
latter being associated with worst survival outcomes in cancers. Using promoter-driven systems for 
autocrine GH secretion (high levels via CMV and low levels via MT promoter) we have 
demonstrated contrasting effects of differential level of GH autocrine expression on proliferation. In 
doing so, we were able to bridge the gap between conflicting findings from three independent 
groups. We report here that the level of GH for the same level of GHR determines ‘cancer-like’ 
features.  
 
In addition, we have also determined the molecular basis for oncogenesis by the P495TGHR variant 
that has been reported in two separate GWAS population studies linking it with increased lung 
cancer susceptibility (OR= 12.98 and 2.04). We found that P495TGHR increased STAT5 
and AKT signalling in a cell-dependent manner. Although not constitutively active by itself this 
variant has prolonged downstream signalling and proliferation after GH stimulation due to a delay 
in GHR degradation at the cell surface. This appears to be the direct result of steric hindrance to 
SOCS2 ubiquitin ligase binding at Y487 that lies in close proximity to P495T in GHR. 
Additionally, the P495T variant was less prone to the ligand-independent constitutive endocytosis 
that was unaffected by proteasomal and/or γ-secretase inhibitors. This is the first time that a 
polymorphism in GHR has been associated with cancer and highlights the importance of GHR 
turnover in tumour promotion. 
 
We have successfully established RCAS/TVA system for tissue-specific gene delivery in mice and 
zebrafish models to directly determine the oncogenic potential of GHR in vivo. Using this system 
we intend to analyse constitutively active or gain-of-function GHR constructs generated in this 
project. 
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Finally, the GHR models lacking the full repertoire of GHR signalling (GHR 391 truncated, GHR-
Box1 mutated and ghr null) were used to analyse cancer-related cause of death and its effect on 
lifespan. We have also determined the potential cancer resistance mechanisms (and signalling 
pathways) already at play in these mouse models. Based on our results, protection against cancer is 
due to multiple interacting pathways that include but are not limited to reduction in activation of 
growth-promoting pathways, increased stress resistance, reduced inflammation markers and 
increased insulin sensitivity. Although, most of these effects have been attributed to calorie 
restriction-mediated lifespan extension but we did not find any correlation with longevity in the 
GHR mutants. Based on the survival curves were able to conclude that cancer and longevity in 
these models are sexually dimorphic with a possible correlation of IGF-1 with lymphoma incidence 
in males and lymphoma aggressiveness in females GHR mutant mice. 
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काममय एवायं पुरुष इित। 
स यथाकामो भवित तत्क्रतुभर् वित। 
यत्क्रतुभर् वित तत्कमर्  कुरुते। 
यत्कमर्  कुरुते तदिभसंपद्यते॥ 
 
kāmamaya evāyaṃ puruṣa iti | 
sa yathākāmo bhavati tatkratur bhavati | 
yatkratur bhavati tat karma kurute | 
yat karma kurute tad abhisaṃpadyate || 
 
 
You are what your deep, driving desire is 
As your desire is, so is your will 
As your will is, so is your deed 
As your deed is, so is your destiny 
     Brihadaranyakopanishat 4.4.5 
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Preface 
The Growth Hormone Receptor (GHR) was first proposed by Tsushima and Friesen following 
detection in tissues of specific high affinity 125I-hGH binding (Tsushima & Friesen, 1973). All 
initial studies were primarily focused on GH-GHR interactions, regulation of GHR expression and 
species specificity with regards to binding and GH-related disorders (Zhu et al, 2001). Cloning of 
this receptor by the Genentech team has led to the discovery of a new Class of transmembrane 
receptors, the Class I cytokine receptors (Bazan, 1990; Leung et al, 1987). The proof that the cloned 
gene was the bona fide GH receptor was provided by the demonstration of loss of function 
mutations in Laron dwarfism (Godowski et al, 1989). Since then considerable information has been 
generated in regards to the structure-function relationships, mechanisms of action, signal 
transduction pathways, single nucleotide polymorphisms and receptor antagonists of clinical 
significance. In the last decade a considerable paradigm shift has occurred in understanding its 
activation mechanism from GH-induced dimerisation to conformational change within a 
constitutive homodimer. This has been accompanied by recognition of Jak-independent signalling, 
receptor crosstalk signalling, and autocrine mode of GH activation, and finally function of nuclear-
localised receptor function. 
 
This chapter contains information on the pleiotropic actions of GHR and its ligand, GH that make 
them indispensable molecules in the field of endocrinology as of 2014.  
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Introduction 
The Growth Hormone Receptor is expressed in almost all cell types (Waters & Shang, 2002) and its 
transcript and protein have been reported as early as a 2-cell embryo (Pantaleon et al, 1997) 
together with functional responses to exogenous GH in the blastocyst which also expresses GH. 
GHR-mediated effects occur upon binding to its only ligand Growth Hormone, also known as 
somatotropin.  
 
Growth Hormone 
GH is a member of a hormone family that evolved over the last 350 million years from a common 
ancestral gene (Miller & Eberhardt, 1983). Other members of this family include prolactin, 
placental lactogen, somatolactin, and proliferin. The human GH (hGH) gene is a part of gene cluster 
consisting of five closely related genes including GH-N (normal), GH-V (variant), CSH-1 
(chorionic somatomammotropin-1), CSH-2 (chorionic somatomammotropin-2) and CSH-L (CS-
like) (Okada & Kopchick, 2001) illustrated in figure 1.1. GH-N is expressed in the pituitary gland 
and at low level in some extra-pituitary tissues such as lymphocytes. GH-N translation results in 
22kDa (191 amino acids) and 20kDa (176 amino acid splice minor variant) proteins (Longhi et al, 
2003) (Harvey, 2010). GH-V encodes for 22kDa and 20kDa placental GH, which differ from 
classical GH-N by 13 amino acids (Alsat et al, 1998; Vickers et al, 2009).  Functionally, the 22kDa 
GH-V has high somatogenic and low lactogenic activities whereas the 20kDa GH-V retains some of 
the growth promoting and all anti-lipogenic activities of 22kDa GH-N but has diminished 
diabetogenic and lactogenic properties compared with the native 22kDa GH-N (Vickers et al, 
2009).  
 
GH-N is secreted in circulation by the anterior pituitary and is primarily responsible for post-natal 
growth. It is also important for nutrient partitioning hence body composition and metabolism 
(Casanueva, 1992). It has significant roles in every physiological system, notably reproductive, 
immune, skeletal, cardiovascular, gastrointestinal tract, adipose and hepato-biliary systems (fig.1.2) 
(Lichanska & Waters, 2008). It mainly acts in an endocrine manner and its pulsatile sexually 
dimorphic secretion is regulated by a complex balance of factors (stress, exercise and sleep etc.) and 
neuro-endocrine processes (Hattori, 2009). The ability of GH to induce Insulin like Growth Factor-
1 (IGF-1) expression, in an endocrine manner via its action on liver as well as locally in a paracrine 
and autocrine manner, results in a potent growth and anabolic stimulus (Okada & Kopchick, 2001). 
At the cellular level, GH has been implicated in proliferation, differentiation and survival (Zhu et al, 
2001). Indeed, GH has been reported to have over 450 different actions in over 80 cell types 
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(Waters & Shang, 2002). All of these biological actions believed to be a result of interacting with its 
specific membrane bound receptor, GHR. Additionally, the prolactin receptor can, in many species 
including mouse and human, also be stimulated by human growth hormone (Goffin et al, 1996). 
Failure to adequately regulate GH signalling leads to metabolic disorders evident in acromegaly and 
cachexia while excessive GH signalling is linked to cancer and increasing cardiovascular risk 
(Pilecka et al, 2007).  
 
 
Figure 1.1: The human GH locus.  
Locus structure, tissue site of expression, levels of mRNAs, and protein isoforms resulting from the gene members of 
the GH multigene family are shown (Perez-Ibave et al, 2014). 
 
Extra-pituitary production of GH-N has been reported from sites such as neuronal cells (Scheepens 
et al, 2005), retinal cells (Harvey et al, 2004), lung cells (Beyea et al, 2006), bone (Kirpensteijn et 
al, 2002) and numerous immune cell types (Lantinga van Leeuwen et al, 2000). Certain embryonic 
cell types (notably in the brain) produce GH before ontogenic differentiation of pituitary 
somatotrophs (Lobie et al, 1993; Sanders & Harvey, 2004).  In addition, many tumour cells have 
been reported to express GH and GHR (Perry et al, 2006; Chhabra et al, 2011). The GH-V is 
produced in a continuous manner by the placenta, gradually replacing the pituitary GH-N in 
pregnancy, so that GH-N becomes undetectable in the maternal circulation (Lacroix et al, 2002). 
This continuous secretion appears to have important implications for physiological adjustment to 
gestation especially in the control of maternal IGF-1 levels (Alsat et al, 1998). GH-N, GH-V and 
hPL are known to act through the GH receptor, although prolactin does not. 
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Figure 1.2: Regulation of Growth Hormone secretion and its actions on the physiological systems. 
Hypothalamic growth hormone-releasing hormone (GHRH) and somatostatin positively and negatively regulate GH 
and secretion in the pituitary gland. Ghrelin, produced by the stomach, also stimulates GH secretion by stimulating 
hypothalamic release of GHRH and antagonising somatostatin. GH acts via the growth hormone receptor (GHR) 
stimulating production of insulin like growth factor (IGF)-1. IGF-1 is released into the circulation by the liver in 
response to GH and provides negative feedback on hypothalamic GHRH and pituitary GH release. IGF-1 has growth-
promoting effects and acts independently or in conjunction with GH on numerous physiological systems and mediates 
cellular functions such as growth and metabolism in maintaining normal homeostasis.  
 
Growth Hormone Receptor 
Structure  
GHR is a transmembrane glycoprotein with key structural features that characterise it as a member 
of Class I cytokine receptor family of 30 receptors, which includes erythropoietin, prolactin, leptin 
and thrombopoietin receptors (Kotenko & Langer, 2004).  The mature GHR is composed of 620 
amino acids comprising of 246-residue glycosylated GH-binding extracellular domain, a single 
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transmembrane domain predicted to be 24 amino acids in length, and an approximately 350-residue 
intracellular domain, which bears the C-terminus (Leung et al, 1987). The extracellular domain 
consists of two fibronectin type III (FNIII) subdomains, 3 conserved cysteine pairs and a conserved 
YGEFS motif (corresponding to WSxWS in other such receptors) (fig.1.3). The first FNIII domain 
spans residues 1-123 and the second residues 128-238, joined by a 4 residue long linker. Each of the 
domains contains 7 anti-parallel β-strands forming a β-sandwich similar in topology to 
immunoglobulins (Bazan, 1990). GH binds the receptor in both subdomains 1 through 2 
assymetrically placed binding sites. Even though site 1 and 2 in GH molecule are different, they 
bind to essentially same residues on the GHR. In subdomain 1, the loops connecting the β–strands 
form a ‘patch’, with residues important for GH binding (Clackson et al, 1998; Wells, 1996; Gobius 
et al, 1992). Peptide mapping studies have revealed the extracellular domain of the GHR contains 
seven cysteines, six of them are located in subdomain 1 and form three disulfide bonds (C38-48, 
C83-94 and C108-122) (Fuh et al, 1990).  
 
The lower subdomain 2 provides an interface where two GHR molecules interact connecting similar 
residues (Asn143, Ser145, Leu146, Thr147, His150, Asp152, Tyr200 and Ser201) in the opposite 
GHR via salt bridges and hydrogen bonds and called ‘dimerisation domains’ (Chen et al, 1997; 
Bernat et al, 2003).  These residues are not necessary for constitutive dimerisation but are necessary 
for signal transduction (Gent et al, 2003). The subdomain 2 also possesses the cytokine receptor 
WSxWS equivalent motif 222YGEFS226 (tyrosine-glycine-glutamate-phenylalanine-serine). 
Mutations in this motif have been shown to decrease signalling owing to lower ligand binding 
affinity and impaired receptor processing (Bazan, 1990) (Baumgartner et al, 1994). The 
extracellular domain also contains 5 well-conserved Asp-glycosylation sites at positions 28, 97, 
138, 143 and 182 (Leung et al, 1987). Mutagenesis studies have revealed that these residues are not 
important for GH binding but are necessary for maintaining a high-affinity binding state and 
internalisation of GHR (Harding et al, 1994). An unpaired cysteine residue, C241 close to 
transmembrane domain has been shown to form an intermolecular disulfide bond on ligand binding 
(Zhang et al, 1999) but mutation of this cysteine to a serine did not affect dimerisation or 
phosphorylation status of the receptor (Gent et al, 2003).  
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Figure 1.3: The structure of human Growth Hormone and its receptor.  
(A) Illustration of a monomeric hGHR with the extracellular domain (ECD) shown as the crystal structure. Subdomain1 
(D1) is shown in pink, the interdomain linker region is shown in yellow and subdomain 2 (D2) is shown in blue.  
Residues, including Trp104 (D1) and Trp169 (D2), involved in forming the hydrophobic patch that binds the hormone at 
site 1 are shown in semi-transparent space filling models (pink from subdomain 1, blue from subdomain 2). Arg39 and 
Asp132 form a salt bridge that stabilises the interdomain angle are shown as green and red semi-transparent space 
filling models respectively. The extracellular juxtamembrane linker region, transmembrane domain (TMD) and 
Intracellular domains (ICD) with no crystal structure are drawn in below the ECD. The approximate location of the Box1 
and Box2 in the ICD are indicated by green lines. (B) The crystal structure of hGH with helices 1 through 4 are shown 
as ribbon and are coloured as follows: pink, green, grey and blue, with unstructured regions coloured yellow.  Helix 4 
residues that are important for binding to site1 are shown as blue space filling models, while those from the 
unstructured region are coloured yellow. (C) The GH:GHR2 complex structure with hGH (yellow ribbon), hGHR 1 (blue 
ribbon) and hGHR 2 (pink ribbon). Receptor interactive GH site1 residues are shown in red space filling model, receptor 
interactive GH site 2 residues are shown in white space filling model and residues in the dimerisation domain are 
shown in pink and blue space filling models (Behncken & Waters, 1999). 
 
For the GHR a single transmembrane domain (TMD) comprised of hydrophobic residues spans the 
membrane as a potential helix as for other homomeric Class I cytokine receptors (Grotzinger, 
2002). The crystal structure was able to reveal the organisation of the ECD only, so the structure of 
the transmembrane and intracellular domain are unknown. However, NMR studies have shown that 
the intracellular juxtamembrane region (residues 272-280) is α–helical up to the proline-rich motif 
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referred to as Box1 (281PPVPVP286) (Waters et al, 2006), common to the cytokine receptor family, 
and required for Jak2 binding (Dinerstein et al, 1995; Postel-Vinay & Finidori, 1995). Another 
well-conserved but less defined motif called Box2, spanning 15 amino acids is located ~23 amino 
acids downstream to Box1. This domain begins with a cluster of hydrophobic residues and ends 
with 2 positively charged amino acids (Postel-Vinay & Finidori, 1995; Argetsinger & Carter-Su, 
1996). It has been shown that Box1 domain is sufficient for Jak2 binding with no requirement for 
the Box2 domain (Colosi et al, 1993; Brooks et al, 2014). The distal intracellular domain possesses 
of 9 tyrosine residues in the human sequence, and these are phosphorylated by Jak2 upon activation 
by GH, and serve as docking sites for signalling molecules such as STAT5. 
 
In addition to domains important for signalling the ICD consists of motifs important for receptor 
internalisation and degradation. One such unstructured motif is the Ubiquitin-dependent 
Endocytosis (UbE) comprised of residues 322DSWVEFIELD331 in the Box2 region (Govers et al, 
1999; da Silva Almeida et al, 2013). Finally, the ICD contains di-leucine motifs and a DSGxxS 
degradon discussed in detail later. 
 
Isoforms and species variation 
The human GHR gene is located on the short arm of chromosome 5, spanning at least 87kb and 
comprising of 9 exons in addition to several non-coding exons in the 5’ untranslated region (UTR) 
represented in figure 1.4 (Godowski et al, 1989). Exon 2 encodes the peptide signal sequence, exons 
3-7 encode the extracellular domain and exon 8 encodes for three residues of ECD, the entire TMD 
and first four residues of ICD. The remaining exons encode the cytoplasmic domain and also the 
2kb of 3` UTR (Edens & Talamantes, 1998). There are at least 13 alternatively spliced human GHR 
mRNAs generated in the 5` untranslated exons all of which splice into a common acceptor site 
upstream of the translation initiation site of exon 2. This results in generation of full-length receptor 
polypeptide but with expression levels varying in a spatial-temporal manner (Wei et al, 2006). 
Amino acid sequences of rabbit and human GHRs show 84% identity. For other species, homology 
in the sequence of the receptors is as high as 70% (Postel-Vinay & Finidori, 1995). Binding and 
activation of GHR of primate origin cannot be achieved with a non-primate GH whereas primate 
GH can bind and activate non-primate GHR (Knobil E, 1959). This species specificity is attributed 
to the Leu43Arg change in hGHR and His171Asp change in hGH (Behncken et al, 1997; Liu et al, 
2001). Similarly, mutagenic analysis has also identified a second determinant Lys165, which in 
addition to His169 restricts the ability of non-primate hormones to activate primate GHR (Wan et 
al, 2004). 
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Figure 1.4: Human GHR gene structure. 
The black horizontal line represents the intron sequence while the diagonal breaks in the lines indicate portions of 
introns. Boxes represent exons with numerical designation of the exon listed below each box. Exons with horizontal 
stripes encode untranslated regions (UTRs) of the transcripts (5'-UTRs and 3'-UTRs). Vertical striped exons encode 
signal sequence. White exons encode the hormone-binding domain. Diagonal striped exons encode the 
transmembrane domain.  Black exons encode the intracellular domain. Human liver GHR transcripts have eight known 
alternative 5'-UTR sequences (V1-V8). The exons encoding four of the 5'-UTRs (V1, V4, V7, and V8) have been 
cloned and are shown on the gene map. The human UTR V5 sequence corresponds to the intron sequence 
immediately upstream of exon 2. (Edens & Talamantes, 1998). 
 
A number of naturally occurring isoforms, alternatively spliced transcripts of GHR have been 
reported. Splice variants lacking 97% of the ICD occur in humans (corresponding to GHR 1-259 
and GHR 1-261) although, present at a small proportion of the full-length receptor (Ross et al, 
1997). These membrane-bound cytoplasmically truncated splice variants of GHR have also been 
reported in numerous tissues and cell lines with protein expression levels differing across tissues 
(Amit et al, 1997; Ayling et al, 1999; Ballesteros et al, 2000). One such receptor variant is 
generated due to 26bp deletion in the exon 9 that introduces a stop codon at amino acid position 280 
of the receptor (Dastot et al, 1996). The variants (truncations) generated can form heterodimers with 
full-length GHR and are therefore inhibitory to the downstream signalling due to lack of Jak2 and 
STAT5 binding sites acting as dominant negative receptors. These truncated isoforms also generate 
large amounts of GH binding proteins (Dastot et al, 1996) and have been reported as a contributor 
to short stature (Ross et al, 1997; Minamitani, 2002).   
 
One common isoform of GHR that is well characterised and widely expressed is exon-3 deleted 
GHR (d3-GHR) in humans. This isoform is the outcome of a genetic polymorphism resulting in 
deletion of the entire exon from mRNA without compromising the structure or function of the 
resultant protein (Stallings-Mann et al, 1996). It was initially thought that this isoform was tissue-
dependent (Urbanek et al, 1992). However, it became apparent that the exon-3 deletion was not 
tissue-dependent but individual-dependent (Wickelgren et al, 1995). The d3-GHR lacks amino acids 
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7-28 in the extracellular domain, but this does not affect GHR binding or internalisation (Mercado 
et al, 1994; Urbanek et al, 1992). There are discrepant results on the role of the d3-GHR in the 
GH/IGF-1 axis and in some studies it has been reported to increase sensitivity to exogenous GH in 
children (Wassenaar et al, 2009) and GH pharmacogenetics (Dos Santos et al, 2004; Filopanti et al, 
2011). 
 
Growth Hormone Binding Protein  
In humans, the GHBP is generated at the cell surface due to proteolytic cleavage of GHR ECD by 
ADAM-17 metalloprotease, also known as Tumour Necrosis Factor-α Converting Enzyme (TACE) 
(Zhang et al, 2000). The exact cleavage site is unknown but a site eight residues N-terminal to the 
TMD (around Glu242, Glu243, Asp244) was reported to be an important determinant for cleavage 
(Baumann & Frank, 2002; Wang et al, 2002). It was reported that spacing of the residues is more 
important than their identity. This proteolytic cleavage process (or shedding) results in a soluble, 
freely circulating GHBP in the blood that is measurable by a LIFA assay (Sotiropoulos et al, 1993) 
and provides an indication of GHR expression.  It has been reported that GH protects the GHR from 
shedding, probably by creating a conformational change blocking access for TACE (Zhang et al, 
2000; van Kerkhof et al, 2002). GHBP has the ability to bind to circulating GH and thereby increase 
the half-life (prolong bioavailability) of GH by decreasing its clearance from circulation, since the 
complex formed is too large for glomerular filtration. Therefore GHBP functions as a GH reservoir 
by damping free GH pulses (Baumann, 2001). In contrast, excessive GHBP produced by cells 
expressing truncated GHR can compete with GH for ligand binding and form an inactive 
GHR/GHBP complex (Lim et al, 1990). In addition to extracellular generation of GHBP it has been 
shown that it can be found intracellularly in the nucleus (Lobie et al, 1994a) where it interacts with 
coactivator activator (CoAA) to promote cell proliferation and this activity is dependent on S226 of 
the consensus WSXWS box equivalent YGEFS motif (Conway-Campbell et al, 2008). In addition 
to shedding, GHBP can also be synthesised by alternative splicing of mRNA especially in the case 
of rodents as evident from the presence of hydrophilic C-terminal extension in the GHBP (Edens et 
al, 1994).  
 
GHR Turnover 
GHR is present on almost every cell throughout the body at varying levels and the surface 
expression levels can vary temporally (Waters, 1999). Cell surface GHR availability is a key 
determinant of GH responsiveness. It is regulated by mechanisms that govern changes in GHR 
abundance (downregulation) in response to ligand stimulation. In addition, GH-independent 
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regulation occurs by factors that regulate receptor gene expression (Edens & Talamantes, 1998; 
Schwartzbauer & Menon, 1998) as well as factors that govern receptor protein stability, such as the 
ability of Jak2 to chaperone nascent receptor to the cell surface and to stabilise to the mature 
receptor against constitutive endocytosis and degradation (Deng et al, 2007; Schwartzbauer & 
Menon, 1998), as well as metalloproteolytic processing (Wang et al, 2002; Zhang et al, 2000) 
illustrated in figure 1.5. Metalloproteolytic GHR degradation involves cleavage of the extracellular 
domain by ADAM-17 followed by C-terminal transmembrane cleavage by presenilin-dependent γ–
secretase (Wang et al, 2002; Cowan et al, 2005). Jak2 has been reported to be a key player in 
determining susceptibility of GHR to proteolysis, suggesting yet another role for this kinase in 
determining GH sensitivity (Loesch et al, 2006).  
 
 
Figure 1.5: Growth Hormone Receptor turnover. 
GHR is synthesised in the endoplasmic reticulum (ER) (1), sorted in the Golgi complex and transported to the cell 
surface (2). Degradation of the GHR occurs in several ways: the extracellular domain (ECD) is shed into the circulation 
(3), endocytosed into the cell (4) and transported to the lysosome for degradation (5). Availability of GHR at the cell 
surface is determined by the rate of endocytosis, the rate of shedding and other unknown mechanisms. Jak2 mediates 
increased maturation and reduced ER-associated degradation (ERAD) of GHR (right panel). The GHR at cell surface 
undergoes metalloproteolytic GHR degradation (left panel) involving cleavage of the extracellular domain by ADAM-17 
generating Growth Hormone Binding Portein (GHBP) followed by C-terminal transmembrane cleavage by presenilin-
dependent γ–secretase (Strous & van Kerkhof, 2002). 
 
GHR synthesis 
GHR synthesis and expression can be regulated at transcriptional, translational and post-
translational levels and therefore regulate GH sensitivity. Factors such as nutritional status, 
endocrine context, developmental stage and various tissue-specific control mechanisms 
(Schwartzbauer and Menon 1998) are summarised in Table 1.1. GHR is synthesised and folded as a 
precursor protein in the endoplasmic reticulum, and complex-glycosylated at five potential sites 
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(Asn-X-Ser/Thr) (Harding et al, 1994) in the Golgi, resulting in a mature receptor that is transported 
to plasma membrane (Leung et al, 1987). In the ER, the three disulfide bonds (in subdomain 1) are 
formed and GHR dimerises. The immature GHR in the ER is detected on the western blot running 
at 110kDa while any misfolded GHR is subjected to ER-associated degradation mechanism with the 
aid of associated ubiquitin ligases (Loesch et al, 2007; Brodsky, 2012; Nelson et al, 2006). The 
mature ‘glycosylated’ GHR in the Golgi or at the plasma membrane is detected at 130kDa (due to 
the addition of high mannose oligosaccharides). At the cell surface the GHR is subjected to 
proteolytic cleavage, or remains unmodified until it ends up in clathrin-coated pits as a remnant 
(after proteolysis) or intact (with or without bound GH) for internalisation and degradation in the 
endosomal or lysosomal systems (van Kerkhof & Strous, 2001; Sachse et al, 2002a). Internalisation 
requires a ubiquitin/proteasome system (Strous et al, 1996). In addition, internalisation of GHR via 
caveolae has also been reported as a trafficking pathway to mitochondria (Yang et al, 2004; Perret-
Vivancos et al, 2006) but this is not widely accepted (Sachse et al, 2002b).  
 
Table 1.1: Regulation of GHR expression  
Developed from (Flores-Morales et al, 2006). 
 
  
Ubiquitin system 
 
 42 
Ubiquitin-dependent GHR internalisation 
 The GHR was initially found to be ubiquitinated upon amino acid sequencing of the receptor from 
rabbit liver (Leung et al, 1987). It was first suggested by Allevato et al. that amino acids 318-380 in 
the cytosolic tail of GHR were important for degradation (Allevato et al, 1995) nad this was later 
extended by Strous et al. who highlighted the role of a functional ubiquitin conjugating system in 
endocytosis within this region (Strous et al, 1996). In a Chinese hamster lung cell line, GHR 
availability was shown to be determined by UbE (ubiquitin-dependent endocytosis) motif (75%), 
ECD shedding (10%) and undetermined factors (15%) (van Kerkhof et al, 2003). The endocytosis 
of GHR has been reported to be relatively rapid, constitutive and GH-independent (van Kerkhof et 
al, 2002). However, binding of GH does enhance receptor ubiquitination, internalisation and 
degradation (van Kerkhof et al, 2002). Multiple ubiquitin moieties are covalently conjugated to the 
GHR protein on one or more of its 19 lysine residues in ICD as branched polymeric chains, 
resulting in the targeting of these substrates to 26S proteasomes (Strous et al, 1996).  
 
Strous’s Group have identified the target of the ubiquitin system in the GHR cytosolic tail as a 10 
residue long sequence, 322DSWVEFIELD331 (Strous et al, 1996; Govers et al, 1999). A key role for 
the ubiquitin system in GH-dependent GHR internalisation emerges from both genetic and 
molecular studies showing that GHR molecules accumulate at the plasma membrane if the ubiquitin 
system is inhibited (Strous & Govers, 1999). Moreover, GHR ubiquitination coincides with its 
recruitment into clathrin-coated pits (van Kerkhof et al, 2000). Strikingly, ubiquitination of the 
GHR itself is not required for internalisation because replacement of all lysine residues with 
arginine in the ICD did not alter the rate of internalisation (Govers et al, 1999). This indicates that 
for internalisation the ubiquitin conjugation system needs to be recruited to the UbE motif rather 
than the conjugation of ubiquitin to lysine residues of the GHR for this process, presumably 
dependent on an accessory protein. After internalisation, the GH-GHR complex is directed to early 
endosomes and then either to the proteasome or lysosome compartments (van Kerkhof & Strous, 
2001; Sachse et al, 2002a).  
 
By examining truncated receptors, the endocytosis-deficient receptor mutant F327A, and conditions 
under which clathrin-mediated endocytosis is inhibited it was found that GHR ubiquitination and 
internalisation are coupled events (Govers et al, 1997). GHR dimerisation has been shown to be 
necessary for UbE-mediated internalisation since a chimeric GHR that cannot form dimers was 
shown to undergo ubiquitin-independent internalisation (Gent et al, 2002). Importantly, GHR 
ubiquitination and internalisation besides being ligand-independent are also independent of 
downstream signalling by the GHR (Strous et al, 1996; van Kerkhof et al, 2000). However, GHR 
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internalisation is inhibited in the presence of proteasomal inhibitors and its C-terminal cytosolic tail 
is required for proteasome interaction (van Kerkhof et al, 2000). Thus, proteasomal inhibition was 
shown to prolong GHR/Jak2 phosphorylation (Alves dos Santos et al, 2001) although this may be 
because the GHR can signal even after internalisation (Frank, 2001). Recently Putters et al. have 
proposed a model with Jak2 as a negative regulator of ubiquitin-dependent endocytosis so that its 
detachment from GHR following activation is necessary for efficient endocytosis by ubiquitin 
ligases (Putters et al, 2011). This has been supported by marked reduction in surface receptor as 
determined by the fate of immunologically detectable receptor owing to GH-induced Jak2 
activation (Deng et al, 2012). In contrast, a catalytically inactive Jak2 mutant incapable of 
associating with GHR, or a receptor mutant deficient in Jak2 binding rendered GH far less able to 
promote receptor downregulation compared with expression of wildtype receptor (Deng et al, 
2012).  
 
An important accessory protein in GHR internalisation is β-TrCP (β-transducing repeat-containing 
protein) (van Kerkhof et al, 2007) which forms the F-box substrate recognition subunit of a multi-
subunit cullin-based E3 ligase, SCF (Skp, Cullin, F-box containing complex) (Winston et al, 1999). 
For most of its substrates, β-TrCP recognises the degron DSGxxS (where X is a hydrophobic 
residue) only when both the serine residues are phosphorylated (Latres et al, 1999; van Kerkhof et 
al, 2007). It has been implicated in the ubiquitination of β–catenin, IĸBα and numerous homologous 
cytokine receptors (PRLR, EPOR, etc.) via its WD-40 domain which has been shown to bind to the 
DSGxxS motif of target proteins (Winston et al, 1999; Li et al, 2004; Meyer et al, 2007). In the case 
of GHR however β-TrCP has been shown to bind to the highly conserved but unstructured 
DSWVEFIELD (UbE) motif and the 30 residue downstream DSGRTS motif (da Silva Almeida et 
al, 2012). The β-TrCP binding to the UbE motif although specific is unconventional and with a 
lower affinity than the phosphorylated DSGxxS motif (da Silva Almeida et al, 2013). Using the 
F327A (UbE mutant), a DAGxxA mutant and double mutants it was shown that β-TrCP acts mainly 
via UbE motif in GH-induced conditions, whereas both the motifs supported ubiquitination in the 
basal conditions contributing to GHR homeostasis in the cells (da Silva Almeida et al, 2012). 
 
Despite a specific interaction between β-TrCP and GHR, the receptor was reported not to be a 
necessary target for β-TrCP-directed Lys48 polyubiquitination. This meant that the GHR needs to 
interact with β-TrCP for internalisation but this does not require Lys48 ubiquitination. Slotman et al. 
have recently shown that Lys63-linked ubiquitin chain conjugation is however required for GHR 
endocytosis as it is for the prolactin receptor. These workers identified both the ubiquitin-
conjugating enzyme Ubc13 and the ubiquitin ligase COOH terminus of Hsp70 interacting protein 
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(CHIP) as required for Lys63 ubiquitination (Slotman et al, 2012). Ubc13 activity and its interaction 
with CHIP appear to precede endocytosis into clathrin-coated pits, but occur after β-TrCP directed 
Lys48 ubiquitination. These processes regulate cell surface availability of GHR. 
 
Ubiquitin-independent GHR internalisation 
GHR degradation has also been reported independently of ubiquitin through a di-leucine motif 
(Govers et al, 1997; Sachse et al, 2002b). This is however not the case of full-length GHR but for a 
truncated GHR (1-349), and possibly some GHR isoforms (Govers et al, 1998). 
 
Mechanism of Action 
GH Binding 
The team at Genentech (James Wells’ team) have conducted exhaustive mutagenic and phage 
display analyses and mapped the residues contributing energy to the binding interactions at site 1, 
site 2, and the receptor-receptor interaction domain of site 3 (Clackson et al, 1998; Walsh et al, 
2003; Bernat et al, 2003). The major energy contribution for site 1 involves two tryptophans, one 
contributed by the upper cytokine receptor β-sandwich (W104) and one by the lower sandwich 
(W169). W104 is also key for the weaker site 2 interaction, and this interaction is blocked by 
substituting a bulky arginine or lysine at the glycine 120 position in helix 3 of the hormone, which 
binds tightly to W104 of the second receptor, as shown in the case of GH receptor antagonist 
pegvisomant. The electrostatic interactions allow GH to tightly interact with the tryptophan 
residues, while hydrogen bonds also contribute to the binding energy for both the hormone-receptor 
interaction and the receptor-receptor interaction (Walsh et al, 2003; Bernat et al, 2003). 
 
Activation of constitutively dimerised receptor  
The crystal structure of the GH bound to GHR extracellular domain showed that two GHR 
molecules were bound to a single GH molecule in 2:1 stoichiometry and physicochemical studies 
showed that this required a sequential 2-step binding process (Cunningham & Wells, 1991; de Vos 
et al, 1992). The GH molecule binds asymmetrically via its opposite face to a single binding site on 
each of the two GHR molecules with different affinities (de Vos et al, 1992; Wells, 1996). These 
observations led to the hormone-induced dimerisation model for GH action (Fuh et al, 1992). It was 
reported that binding of the three bivalent monoclonal antibodies to the ECD of the receptor was 
capable of activating a hybrid receptor expressed in a FDC-P1 cell line, while monovalent 
fragments of these could not dimerise and activate this receptor. The hybrid receptor consisted of 
the ECD of the human GHR fused to the N-terminal fibronectin domain of the granulocyte colony-
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stimulating factor (G-CSF) receptor. Hence, this led to the measurement of G-CSF signalling rather 
than GHR. A second line of evidence for induced dimerisation was the bell shaped dose response 
curve for GH with this hybrid receptor, which led to a proposal that a second GH would occupy the 
second receptor at high concentration, preventing effective signalling (Ilondo et al, 1994).  
 
However when the full-length GHR was subjected to similar study undertaken by Fuh et al. (Fuh et 
al, 1992), only 2 of the 15 antibodies were able to weakly activate GHR stably expressed in BaF/3 
cells while no activation was observed in FDCP-1 (Rowlinson et al, 1998). As a positive control of 
dimerisation ability 8 of the 15 antibodies were able to activate the G-CSF/GH receptor chimera 
used by Genentech (Rowlinson et al, 1998). Based on this, it was proposed that receptor 
dimerisation alone could not activate the receptor, which required a specific 
conformation/orientation of receptor subunits. This was later supported by binding studies with the 
G120R antagonist that was shown to bind to a dimeric GHR at the cell surface (Ross et al, 2001) 
indicative that its mechanism must be induction of an antagonist conformation of the receptor 
dimer. Subsequently, co-immunoprecipitation data demonstrated that a proportion of the receptor 
exists as a constitutive dimer (Gent et al, 2002) and that the ligand-receptor complex had a 
differential susceptibility to proteasomal digestion than the G120R-receptor complex (van Kerkhof 
et al, 2002). The co-IP studies using truncated receptors also highlighted that the ECD was not 
needed for its formation since its removal with proteinase K treatment did not influence the extent 
of dimer formation in intact cells (Gent et al, 2002). In addition, it was also reported that receptor 
dimer formation occurred in the ER, which remained unaffected even after the addition of hormone 
to receptor-expressing cells. This also meant that there were separate confirmations of receptor 
dimer, one that could promote signalling (upon GH binding) and other that would inhibit it as in the 
case of G120R (Rowlinson et al, 1998). 
 
These findings were supported by co-IP studies indicating constitutive dimer formation when the 
ICD was truncated just below the Box2 sequence at residue 360 and that these dimers were held 
together by either TMD or juxtamembrane domain (Brown et al, 2005). The same study also 
reported an increase in the proportion of GHR dimer that got immunoprecipitated after GH 
addition. This was confirmed by using both fluorescent resonance energy transfer (FRET) and 
bioluminescence resonance energy target (BRET) techniques to monitor receptor association in 
intact cell membranes by appropriate placing of specific fluorescent or bioluminescent 
tags/reporters. 
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From the FRET/BRET analysis it was evident that addition of 6 residues to the C-terminus was 
sufficient to drive dimer formation. Importantly, when the reporters were successively placed closer 
to the cytoplasmic membrane surface, both FRET and BRET ratios increased markedly, indicating 
proximity of the Jak2 binding Box1 sequences. Notably, deletion of the Box1 motif by alanine 
substitution did not change the FRET or BRET ratio, indicating that receptor dimer was not a 
consequence of Jak2 association. Placement of the FRET reporters at the receptor C-terminus 
resulted in a low FRET value, indicating a wider separation. Contrary to the ligand-induced 
dimerisation model, addition of GH to cell membrane preparations overexpressing GHR did not 
change the FRET or BRET ratios when the reporters were attached at the N- or C-terminus of the 
receptor (Brown et al, 2005). These have since been confirmed using cysteine crosslinking, Tox-R 
bacterial assay and homo-FRET anisotropy (Brooks et al, 2014). It was evident from these studies 
that GHR got dimerised within the cell and that addition of GH had no effect on the dimerisation 
state. The association between the GHR monomers to form a dimer was proposed to occur via its 
TMD (Brown et al, 2005). 
 
The finding that the transmembrane helix was primarily responsible for formation of the 
constitutive GHR dimer was concordant with previous studies on EPOR and TPOR. By utilising the 
bacterial Tox-R/Tox-CAT assay of TM helix association and immunofluorescence co-patching to 
show that the homologous EPOR is constitutively dimerised through its TM helix domains by a 
leucine zipper-like motif (Kubatzky et al, 2001; Constantinescu et al, 2001). Similarly, Tox-R assay 
and cysteine substitution and crosslinking have shown that TPOR at the cell surface exists as a 
ligand-independent dimer (Matthews et al, 2011). Likewise, the homologous PRL receptor was 
shown to exist as a homodimer in ligand-independent manner and this association appears to be 
mediated by the TM helices (Qazi et al, 2006; Gadd & Clevenger, 2006). Based on these evidences 
it was clear that homo-dimerised type I cytokine receptors signalling involves a conformational 
change or a subunit arrangement. 
 
In order to determine the mechanism of GH-induced receptor conformation, crystal structure of 
unbound receptor was analysed (Brown et al, 2005). Interestingly, there was little difference in 
comparison to the receptor bound complex, indicating a rotation of the lower domain by 7° to 9° as 
a result of hormone binding. No alterations in the position of residues involved in the extracellular 
receptor-receptor “dimerisation domain” were evident, despite being reported in the 1:1 complex 
formed with the G120R antagonist (Clackson et al, 1998). There were minor changes observed in 
residue position relating to the ligand binding sites (around Trp104 and Trp169), and an alteration 
of the F’G’ loop position in the lower receptor domain. The latter has been shown to regulate 
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receptor signalling by a novel Src/ERK pathway (Rowlinson et al, 2008), but did not influence the 
Jak2 activation. On closer inspection, it was revealed that receptor 1 gets rotated approximately 25° 
respective to receptor 2, and elevated by 8 angstroms to allow the two receptor domains to lock 
together (Brown et al, 2005), which had previously been shown to be essential for signalling (Chen 
et al, 1997; Gent et al, 2003). In addition, a subunit rotation could account for the lack of change 
observed in the FRET/BRET ratio after hormone binding since the relative distances would change 
only marginally. Support for a rigid body subunit rearrangement was also achieved by molecular 
dynamics that showed when the hormone was removed from the 2:1 complex in silico, the second 
receptor subunit rotated approximately 45° counterclockwise with respect to the first (Poger & 
Mark, 2010). This model was also consistent with the epitope location for the agonist monoclonal 
antibody, which could rotate receptor subunits in molecular simulations of docking (Wan et al, 
2003).  
 
The locking of dimerisation domains could be emulated by replacing just the GHR ECD with jun-
jun zipper. This construct upon stable transduction in Ba/F3 cells was found to be constitutively 
active and could eliminate ECD movements by holding the receptor tightly at TMD and ICD in one 
configuration (Behncken et al, 2000). Initial placement of the zipper close to the cell membrane in 
4-residue increments revealed that GHR activation increased as the distance between the zipper and 
cell surface decreased (Brooks et al, 2014). In order to determine the precise movement involved, 
alanine insertions were carried out in the zipper construct near the TMD, which revealed that a 
rotation of the receptor could induce constitutive activation of Jak2/STAT5 only when the receptor 
was in a particular configuration. In particular, it was shown alanine insertion above the TMD 
resulted in an optimal rotational position for activation (approximately a 40° turn). These 
experiments showed that there was a preferred orientation for activation, suggesting a rotation of 
the transmembrane helix was involved in activation.  
 
A key element in understanding the receptor activation mechanism came from more FRET studies 
that involved the reporters to be placed just below Box1 motif (Brooks et al, 2014). These GHR 
constructs although 37 residues downstream to Box1 were able to bind and activate Jak2 normally 
upon GH binding. Contrary to the view that ligand binding induced proximity of the Box1 
sequences, a decrease in FRET signal was reported indicating increased separation. Additionally, an 
inverse relationship between cell proliferation and FRET signal that was established by using the 
alanine insertions above the TMD in a jun zipper constructs was used to determine the gating 
mechanism at TMD. In particular, the acidic residues (242EED245) in the region juxtamembrane to 
the TM helix were replaced with non-repulsive alanine residues in the jun zipper chimera enhanced 
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cell proliferation, and resulted in an even lower FRET efficiency (Brooks et al, 2014). In addition, 
co-transfection of full-length GHR (containing EED) with a mutant receptor containing a charge 
reversal of EED to KKR was associated with decreased FRET efficiency and constitutive 
activation. It was evident that these conserved acidic residues act as a gating mechanism for 
receptor activation, where the electrostatic repulsion was overcome by GH binding. Similarly, 
alanine substitution of the first lysine in submembrane SKQQRIK sequence in a jun zipper 
construct resulted in increased receptor activation as in the case of TPOR (Staerk et al, 2006).  
 
Finally by performing FRET analysis on cell membrane extract transfected with low levels of 
receptors, GH binding was shown to result in a substantial decrease in FRET efficiency. This was 
confirmed by blocking the separation movement by pre-incubation of cells with the G120R hGH 
antagonist. Importantly, in the case of D152H mutation (Duquesnoy et al, 1994) implicated in 
Laron dwarfism, no change in the FRET efficiency was observed after the addition of GH.  
 
GHR-mediated Jak2 activation 
Structurally Jak family members comprise of a modified FERM domain at its N-terminus (JH7-
JH5) which is used for binding to the receptor via the receptor Box1 motif. This domain is followed 
by an apparently non-functional SH2 domain (JH4-JH3) that links to the pseudokinase domain 
(JH2) that is followed by the kinase domain (JH1) at the C-terminus. The crystal structures of the 
kinase and pseudokinase domains have been resolved (Lucet et al, 2006; Bandaranayake et al, 
2012). It has recently been established that the pseudokinase domain functions as a serine/threonine 
kinase and in doing so the pseudokinase domain can regulate JH1 kinase activity (Ungureanu et al, 
2011). There are many other regulatory tyrosine phosphorylation sites in Jak2 identified by mass 
spectrometry analysis but not much is known in regards to their interaction and function 
(Argetsinger et al, 2010). 
 
In order to determine how the separation of the TMD helices at the C-termini Box1 sequences could 
result in Jak2 activation, few approaches were utilised by Waters’ Group (Brooks et al, 2014). 
Firstly, by strategic placements of the FRET reporters the movement of kinase and pseudokinase 
domains were measured in conjunction with the receptors made constitutively active by co-
transfecting receptor constructs with wildtype juxtamembrane EED sequence and with KKR 
replacing it, so that charge attraction at this point led to receptor activation. This showed that 
receptor activation resulted in an increased FRET for the C-terminal kinase domain placement of 
reporters, but a decrease in FRET for the pseudokinase reporter placement. This data was supported 
by Jak2 and STAT5 activation when the kinase and pseudokinase domains were swapped and co-
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transfected at very low levels. These were suggestive that upon receptor activation the kinase 
domains would come together in close proximity in the receptor/Jak2 assembly, resulting in 
activation, in a receptor-dependent manner.  The importance of receptor requirement for these 
domains to mediate activation has been confirmed by that have reported EPOR requirement for 
oncogenic V617FJak2 to manifest its constitutive activity (Lu et al, 2008). Based on the current 
model it can be reasoned that the pseudokinase domain of one Jak2 molecule could be inhibiting the 
kinase domain of the other Jak2 and vice versa. Pulling them apart would allow the kinase domains 
to come into proximity, facilitating trans activation and Jak2 action (Brooks et al, 2014).  
 
Another approach employed was the quantification of interactions between two pseudokinase-
kinase domains, or these domains separately, using Alpha screen and single molecule FRET. These 
experiments demonstrated that the pseudokinase-kinase domain pair was able to associate in trans 
with another such pair, as proposed (Brooks et al, 2014). Finally, crystal structures of the kinase and 
pseudokinase domains were docked in silico in the predicted orientation using HADDOCK (high 
ambiguity driven biomolecular docking) to attain two optimum minimum energy states. The docked 
structures predicted a close complementary interaction between the opposing kinase and 
pseudokinase domains. Moreover, the structure showed proximity between the activation loop and 
V617 residue in the pseudokinase domain which, when mutated resulted in oncogenesis because of 
impaired kinase inhibition. In support of the experimental data of Jak2/STAT5 activation covalently 
linked pseudokinase and kinase (PK-K) domains of one Jak2 were then placed with another PK-K 
pair in alternative orientations, highlighting two arrangements that were also consistent with the 
recent study which has reported that the PK-K domains are linear in solution, and bound in trans 
(Varghese et al, 2014). 
 
Signal Transduction 
Like all Class I Cytokine Receptor Family, the GHR lacks the intrinsic kinase activity and is 
therefore dependent on other kinases to initiate intracellular signalling. Recent evidence has 
indicated that GHR exists as a homodimer in its non-liganded state and each GHR monomer is 
associated with one or more inactive kinases (Gent et al, 2002; Rowlinson et al, 2008). The most 
widely reported kinase that has been reported to associate with GHR and get activated by GH is 
Jak2 (Janus Kinase 2) (Carter-Su et al, 1994).  Jak2 is also known for stabilising the GHR dimer 
(He et al, 2005), which initially forms in the endoplasmic reticulum and translocates to plasma 
membrane via Golgi (Frank & Fuchs, 2008). In addition to Jak2, members of the Src family kinases 
(SFK) have also been implicated in GHR interaction (Rowlinson et al, 2008). The signalling 
pathways are illustrated in figure 1.6. 
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Jak2-dependent Signalling 
Jak2 is a major component of GHR signalling and is one of the four Janus tyrosine kinases (Jak1, 
Jak2, Jak3 and Tyk2) (Argetsinger & Carter-Su, 1996) used by Class I cytokine receptors (Tanner 
et al, 1995; Frank et al, 1995). Structurally, Jak2 contains seven highly conserved domains, 
including N-terminal FERM which binds constitutively with GHR box1 motif, an inactive-kinase 
like (pseudokinase) domain and a functional C-terminal kinase domain (Harpur et al, 1992). 
 
As mentioned, the asymmetric ligand binding to the pre-dimerised receptors in the plasma 
membrane results in relative reorientation of the GHR molecules, each bound to a single Jak2. This 
conformational change was initially postulated to bring the two Jak2 molecules into sufficient 
proximity to allow each Jak2 molecule to transactivate (i.e. cross-phosphorylate) tyrosine residues 
in the kinase domain of the other Jak2 (Argetsinger et al, 2004; Argetsinger et al, 1993). However, 
Brooks et al. have recently provided a model for GHR bound Jak2 activation that shows that upon 
GH stimulation there is an increased separation of Box1 sequence between the two GHR molecules. 
This movement results in the removal of the inhibitory pseudokinase domain from the kinase 
domain of Jak2, which then aligns the kinase domains for transactivation and signal initiation 
(Brooks et al, 2014). 
 
Using Jak2 overexpression systems, some of the auto-phosphorylation sites in Jak2 appear to be 
regulatory in function as is evident from mutation of residues that decrease (Y221) or increase 
(Y119, Y570, Y1007) in Jak2 activity (Argetsinger et al, 2004; Feng et al, 1997).  It is proposed 
that phosphorylation of Tyr119 promotes its dissociation from its associated cytokine receptor 
(Funakoshi-Tago et al, 2008). After transactivation Jak2 phosphorylates multiple GHR cytosolic 
domain tyrosine residues (Argetsinger et al, 2010; Carter-Su et al, 1994). Hansen et al. have 
identified three redundant tyrosine residues at positions 534, 566, and 627 (in mature GHR) by 
mutagenesis, responsible for activation of GH-stimulated transcription of the serine protease 
inhibitor (Spi) 2.1 promoter (Hansen et al, 1996). In addition, Rowland et al. have identified Y487 
on GHR to get tyrosine phosphorylated using GHR knockin mouse models following GH 
stimulation (Rowland et al, 2005b). The generation of the activated GH/GHR-Jak2 complex allows 
for the recruitment of multiple signalling molecules, triggering numerous pathways which are 
dependent on the cell type, compartmentalisation and differentiation status (Waters & Brooks, 
2011; Yang et al, 2004). In addition to Jak2, GH is known to activate Jak1 and 3, although this 
represents only a minor event (Hansen et al, 1996).   
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Jak2 contains 48 tyrosine residues and hGHR has 7 in its ICD that can serve as docking sites for 
other signal transduction molecules containing Src homology 2 (SH2) or phosphotyrosine binding 
(PTP) motifs that can positively or negatively regulate GH signalling. Serine phosphorylation had 
initially been suggested not to occur (Carter-Su et al, 1989; Foster et al, 1988) however, Ishida-
Takahashi et al. have shown the Ser523 of Jak2 is phosphorylated and inhibits Jak2 activity (Ishida-
Takahashi et al, 2006). FRET studies suggest that activation of Jak2 after GH binding is a rapid and 
transient event with the signal lasting only for 2-3 minutes. This transient nature was not caused by 
receptor internalisation but suggested to be due to additional conformational changes in the 
cytosolic domains following phosphorylation and recruitment of other signalling molecules 
(Biener-Ramanujan et al, 2006). 
 
 
 
Signal Transducer and Activator of Transcription molecules  
An important and direct pathway from activated GHR to gene transcription involves a family of 
transcription factors called STATs (Signal Transducer and Activator of Trancription). At least 
seven mammalian STATs have been identified of which STAT1, 3, 5a and 5b have been shown to 
be activated by GHR upon GH action, with STAT5A and B being the key mediators (Herrington et 
al, 2000b). The regions on GHR required for activation of different STATs have been mapped. 
STAT1, 3 and 5 all require the membrane proximal part of the receptor, including Box1, and 
therefore Jak2, to become activated. Further, STAT5 binds to phosphorylated tyrosines within the 
C-terminal tail at position Y487 (Rowland et al, 2005b), Y534, Y566 and Y627 (Hansen et al, 
1996).  
 
STATs themselves harbor a highly conserved tyrosine residue near their C-terminus that following 
phosphorylation by Jak2 allows the two STATs to dimerise via their SH2 domains and the dimeric 
phosphorylated-STAT5 are then translocated to the nucleus (Herrington et al, 2000b; Waxman & 
O'Connor, 2006). Iyer et al. have reported that STAT5A is continually shuttling to and from 
nucleus and its phosphorylation allows it to bind to DNA resulting in its retention in the nucleus 
(Iyer & Reich, 2008). In the nucleus STAT1 and 3 bind the c-sis inducible element (SIE) and co-
activate the c-fos gene whereas the STAT5 isoforms activate transcription of GH-regulated genes 
such as igf-1 and serum protease inhibitor 2.1 (spi2.1) by binding to GH responsive element 
(GHRE) or interferon-gamma activated sequence (GAS)-like response element (GLE) with the 
sequence TTCNNNGAA (Wood et al, 1997). In addition to their ubiquitous tyrosine-
phosphorylation sites STATs also contain serine phosphorylation site, which is utlised by a few 
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MAPK members for activation or inhibition of their transcriptional abilities (Frank, 2001; Wen et 
al, 1995; Chatterjee-Kishore et al, 2000).  
 
Mitogen-Activated Protein Kinase  
In addition to STAT activation, phosphorylated Jak2 has been reported to bind other adaptor 
proteins. Binding of Src-homology domain containing (Shc) (Thirone et al, 1999) leads to 
sequential activation of growth factor receptor-bound protein 2 (Grb2), binding and activation of 
sons of sevenless (SOS) and finally RAS, RAF and MEK-mediated ERK1/2 serine/threonine kinase 
activation (Vanderkuur et al, 1997). The RAS-MAPK pathway has been implicated in the 
regulation of fos protooncogene expression by ternary complex factors (TCFs), p62TCF/ELK-1, 
which act in concert with serum response factor (SRF) and bind the serum response element (SRE) 
on the c-fos gene leading to its expression, then to transcription of specific gene sets (Vanderkuur et 
al, 1997; Piwien-Pilipuk et al, 2002).  
 
The MAPK pathway regulates RAF-1, phospholipase A2, cytoskeletal proteins and the transcription 
factors c-jun and c-myc (Pilecka et al, 2007). MAP kinases are important regulators of cellular 
growth and differentiation (Cobb & Goldsmith, 1995).  GH-induced MAPK activity may also be 
important in modulating signalling by other growth factors, like Erb2, a member of EGF receptor 
family (Kim et al, 1999). In addition to p44/42 MAP kinase, GH also stimulates other members of 
the MAPK superfamily, namely p38 MAPK and c-Jun N-terminal kinase (JNK) (Zhu & Lobie, 
2000; Zhu et al, 1998a) that can be Jak2-dependent and/or independent. 
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Figure 1.6: Growth Hormone Receptor-mediated signal transduction. 
The extent of the individual pathways varies between cell types, depending on the relative expression of the component 
parts. Canonical protein-tyrosine kinase Jak2 signalling via STAT5 involves phosphorylation of key tyrosine residues in 
the cytoplasmic domain (below residue 350), which bind the Src homology 2 (SH2) domain of STAT5A and STAT5B, 
recruiting these STATs to the activated JAK2 and thus facilitating their tyrosine phosphorylation and subsequent 
dimerisation through their SH2 motifs. Dimerised STAT5 translocates to the nucleus to regulate gene transcription in 
complex ways. Conversely, STAT1 and STAT3 undergo direct tyrosine phosphorylation by Jak2 without the 
requirement for receptor binding. ERK can be activated either by SRC and/or phospholipase Cγ and Ras, or by Jak2 
via the adaptors SHC, GRB and SOS. JNK is activated by SRC via RAP. The PI3-K and the serine–threonine-protein 
kinase mTOR pathway is activated by JAK2 via IRS phosphorylation. Signals are initially damped or terminated by the 
action of specific tyrosine phosphatases and receptor internalisation, then by the actions of induced SOCS proteins 
(Brooks & Waters, 2010). 
 
Insulin Receptor Substrate and Phosphoinositide 3-Kinase 
GHR activation of Jak2 can also result in phosphorylation of Insulin Receptor Substrate (IRS) 
family members, which results in PI3-Kinase/Akt pathway activation (Yamauchi et al, 1998a).  
IRS’s are large cytosolic proteins that serve as mobile adapter proteins and upon tyrosine 
phosphorylation provide binding sites for other signalling molecules such as PI3-K, SHP-2 and 
SFK. The PI3-K pathway was initially reported in insulin activation. The phosphorylated IRS-1 
provides binding sites for p85, the regulatory subunit of PI3-K resulting in the release of the 
catalytic subunit, p110 (Dey et al, 1998a; Hanada et al, 2004). Activated PI3-K phosphorylates the 
conversion of PIP-2 (Phosphatidylinositol 4,5-bisphosphate) to PIP-3 (Phosphatidylinositol 3,4,5-
triphosphate). Subsequently PIP-3 recruits PDK1 (3-Phosphoinositide-dependent kinase 1 and Akt 
to the plasma membrane through the interaction with the pleckstrin homology (PH) domains. This 
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recruitment facilitates the phosphorylation of Thr308 in Akt, triggering downstream pathways 
(Currie et al, 1999; Stokoe et al, 1997). The PI3-K pathway is implicated in several physiological 
processes such as DNA synthesis, glucose uptake, cell cycle regulation, activation and inhibition of 
apoptosis (Cheatham et al, 1994; Songyang et al, 1997). Additionally, it is implicated in cell 
proliferation by inducing expression of c-myc and cyclins A and E (Jeay et al, 2001; Jeay et al, 
2002). 
 
Focal Adhesion Kinase-multiprotein signalling complex 
GH-induced reorganisation of actin cytoskeleton and motility has been reported as a consequence of 
FAK (Focal Adhesion Kinase) activation that requires direct interaction between Jak2 and SH2-Bβ 
(Herrington et al, 2000a; Zhu et al, 1998b; Takahashi et al, 1999). These cytoskeletal changes are 
important in regulation of cell morphology and movement (Herrington & Carter-Su, 2001). GH is 
reported to stimulate the assembly of a multiprotein complex including Jak2, FAK and its substrates 
paxillin and tensin and several other proteins during cell adhesion and/or movement (Zhu et al, 
1998b). c-Src and c-Fyn kinases, c-Cbl, Bck and JNK/p38 proteins have also been reported to be 
part of the large multimeric protein complex (Zhu et al, 1998a). PI3-K and SFK pathways have 
been reported to activate FAK and may provide an alternate pathway for GH-mediated cell 
modulation (Xing et al, 1994; Chen et al, 1996; Schlaepfer et al, 1998).  
 
Activation of SIRPα and SHP-2 complex 
The tyrosine phosphatase Src-homology domain 2 containing tyrosine phosphatase (SHP-2) can 
both positively and negatively regulate GH signalling. SHP-2 is recruited to the GH-induced 
complex of GHR, Jak2, Grb2 and SIRPα (signal-regulatory protein) (Kim et al, 1998). The SH2 
domain of SHP-2 specifically associates with phosphorylated Y595 on GHR. Mutation of Y595 has 
been shown to prolong GH signalling (Stofega et al, 2000). On the contrary, expression of 
catalytically inactive SHP-2 reduces the transcriptional activity downstream of GHR (Kim et al, 
1998).  
 
Protein Kinase C Activation 
An increase in intracellular Ca2+ concentration induced by GH is dependent on calcium channel 
activation by mechanism including protein kinase C (PKC) activation. The PKC pathway is induced 
by an increase in diacylglycerol (DAG) caused by phospholipase C (PLC) activation (Sjoholm et al, 
2000). The activated PLC then hydrolyses inositol phospholipids to generate inositol phosphates 
and DAG, activator of PKC (Wakai et al, 1998). The PKC pathway is implicated in cellular growth 
and differentiation as well as lipogenesis and metabolism (Bergan et al, 2013). It has been 
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suggested that calcium transport pathway activation does not require Box1 or Jak2 activation but 
only the C-terminal part of the GHR (Billestrup et al, 1995) and therefore can be SFK-mediated. 
 
Nuclear factor-ĸB Activation 
A relatively recent report has shown that GH signalling pathway can mediate the activation of 
Nuclear Factor (NF)- ĸB via the PI3-K/Akt pathway (Jeay et al, 2001). NF- ĸB activation is 
responsible for cell survival by regulating anti-apoptotic proteins Bcl-2 and Bcl-XL and induction of 
cyclins D1 and D3 (Jeay et al, 2002). It is unclear if the NF- ĸB induction by GH occurs only under 
stress conditions or during normal endocrine/autocrine GH signalling (Jeay et al, 2000).  
 
Jak2-independent Signalling 
Src Family Kinase Activation 
Emerging evidence suggests that GHR can signal through additional pathways as has been reported 
in patients with GH resistance, that exhibit normal Jak2-mediated STAT5 activation but impaired 
ERK activation (Clayton et al, 1999). This has been supported by in vitro demonstration of Jak2-
independent Src activation (Manabe et al, 2006; Zhu et al, 2002). Zhu et al. provide evidence using 
both pharmacological inhibitors and kinase inactive proteins in NIH-3T3 cells that tyrosine kinase 
Src is activated by GH-independent of Jak2 (Zhu et al, 2002). Further, constitutive binding of Lyn 
kinase (member of SFK) with GHR has been shown in FDCP-1 myeloid cell line (Rowlinson et al, 
2008). Additionally, GH has been shown to activate Src and the ERK pathway in Jak2-deficient 
fibrosarcoma γ2A cells (Rowlinson et al, 2008). It was proposed by Rowlinson et al. that a 
movement in the F`G` loop of the lower cytokine module of GHR extracellular domain alters the 
signalling choice between Jak2 and Lyn kinase by regulating transmembrane domain realignment 
(Rowlinson et al, 2008).  The existence of SFK-mediated signalling by GHR in vivo has been 
demonstrated in targeted Box-1 mutated mouse model (complete abrogation of GHR-mediated 
Jak2/STAT signalling) and transcripts resulting from Jak-independent Src activation were reported 
(Barclay et al, 2010). 
 
Manabe et al. have shown that Src can bind and phosphorylate GHR in F-36P human leukemia cells 
(Manabe et al, 2006). They reported treatment of cells with Src inhibitors and anti-sense 
oligonucleotides decreased STAT5 activity, which was independent of Jak2. In contrast, Guren et 
al. reported no such STAT5 inhibition in primary rat hepatocytes after treatment with Src inhibitor 
(Guren et al, 2003). This discrepancy can be attributed to different cell types used in the two 
studies. Finally, GH-induced increase in the free cytosolic Ca2+ is not blocked by Jak2 inhibitor and 
therefore can be SFK-mediated, although it has been shown to be mediated by PRLR rather than 
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GHR (Zhang et al, 2006). Indeed, both PRLR and EPOR, close homologs of the GHR, have been 
shown to signal via SFK as well as Jak2 (Fresno Vara et al, 2000; Chin et al, 1998).  
 
Transcription Factors regulated by GHR 
GH regulated gene expression contributes to many of its action on cellular growth, differentiation 
and metabolism. GH first stimulates the expression of early response proto-oncogenes including c-
fos (de Vos et al, 1992), c-jun (Foster et al, 1988), c-myc (Winston & Bertics, 1992), early growth 
response (egr-1 and 2) (Campbell et al, 1993; Clarkson et al, 1999). 
 
MAPK pathway associated regulation 
Transcriptional regulation of c-fos and egr-1 through SRE in response to GH requires transcription 
factors Elk-1 and serum response factor (SRF) (Clarkson et al, 1999; Davey et al, 2001). GH-
induced serine phosphorylation of Elk1 and Elk1-dependent transcriptional activation is mediated 
by MAPK signalling components RAS, MEK, ERK1/2 (Sotiropoulos et al, 1995; Wen et al, 1995). 
GH also increases formation of complexes bound to c-fos at a consensus AP-1 site (Pircher et al, 
1999; Teglund et al, 1998). 
 
STAT association with SIE 
Upon activation, the activated STAT molecules shuttle to nucleus and bind to specific DNA 
sequences referred to as interferon gamma activated sequences (GAS) or sis-inducible element 
(SIE) of the c-fos promoter to activate transcription (Rui & Carter-Su, 1999). STAT proteins also 
contain a conserved consensus sequence for phosphorylation by MAPKs (Bergad et al, 1995; Ram 
et al, 1996). Additionally, a serine kinase downstream of PI3-K and Akt, PKC-γ or methylation 
(Meton et al, 1999) can also modulate transcriptional activity of STAT1 and 3 indicative of 
supporting interactions between GH-regulated STATs, MAPK and PI3-K signalling members. 
 
PI3-K and MAPK regulation of C/EBP 
Another GH-responsive site in c-fos is a CCAAT/enhancer-binding protein (C/EBP) site that 
overlaps the SRE (Chen et al, 1997) as evident from the binding of C/EBPβ and C/EBPδ containing 
complexes (Piwien Pilipuk et al, 2003). GH has been shown to regulate the activity of C/EBPβ via 
two signalling cascades namely PI3-K, Akt/PKB and by phosphorylation of C/EBPβ at MAPK 
consensus sequence by activation of ERK1/2. This clearly indicates that numerous signalling 
pathways can be integrated via multiple phosphorylation sites, in order to regulate a single 
transcription factor.  
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Physiological role of GHR 
In humans, the GHR is highly expressed in the liver, adipose tissue, heart, kidneys, intestine, lung, 
brain, pancreas, kidney, cartilage and skeletal muscle (Ballesteros et al, 2000; Castro et al, 2000; 
Chin et al, 1992). GHR protein has been demonstrated in all of these tissues by IHC together with 
many others (Waters, 1999). The signalling cascades downstream of GHR lead to a variety of 
cellular responses, including altered gene transcription, proliferation, differentiation, and motility. 
The resulting signalling pathways are cell-type specific and show differences with age, gender and 
signal dynamics (pulsatile vs continuous) (Pilecka et al, 2007). 
 
Longitudinal Growth  
The primary role of GH prior to adulthood has long been considered to be increased height through 
long bone growth. This is a complex process requiring the precise regulation of many endocrine and 
nutritional factors, including GH.  This process involves the proliferation and mineralisation of the 
cartilaginous growth plate at the ends of long bones.  Longitudinal bone growth is a limited process 
that in humans is completed by sexual maturity (van der Eerden et al, 2003).  Long bone growth 
eventually ceases due to cessation of chondrocyte proliferation and epiphyseal fusion.  The growth 
plate present at the ends of long bones is made up of resting zone chondrocytes (stem-like cells) 
which are acted on by GH to cause their rapid proliferation, resulting in columns of chondrocytes 
extending into the proliferative zone cartilage and elongation of the growth plate (Nilsson et al, 
2005).  Chondrocytes differentiate and cease dividing in the adjacent hypertrophic zone, then 
undergo cellular hypertrophy and become calcified.  GH is responsible for “recruiting” resting 
chondrocytes, inducing proliferative zone chondrocytes to proliferate in an IGF-1-dependent 
process involving local generation of IGF-1 (Nilsson et al, 2005). 
 
The “dual effector hypothesis” states that GH acts locally at the growth plate to recruit resting 
chondrocytes into a proliferative state (Ohlsson et al, 2009), and to stimulate local IGF-1 
production, which then stimulates proliferation of proliferative zone chondrocytes (Nilsson et al, 
2005). However, there are IGF-1-independent actions of GH in growth and these were elegantly 
demonstrated by Lupu et al. who reported that dual GHR and IGF-1 knockout mice showed a more 
dramatic loss in size than either mutation alone (Lupu et al, 2001).  
 
Rowland et al. have used transgenic mouse models to determine the signalling pathways of GHR 
that are responsible for GH-induced growth. Knockin mouse models with truncations and mutations 
of the GHR intracellular domain (ICD) at residue 569 or a more severe 391 truncation were 
compared to GHR knockout mice. The gross phenotype and in vivo GH-induced signalling pathway 
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activation, demonstrated that STAT5 signalling below residue 391 was responsible for growth 
effects of GH (Rowland et al, 2005b). The GHR 391 truncation retained full Jak2 and MAPK 
pathway activity but had no ability for STAT5 activation. This transgenic GHR 391 mouse showed 
a dramatic decrease in postnatal growth of almost 50%, comparable to that of the GHR knockout 
(KO) mouse. 
 
Metabolism 
GH has an important role in carbohydrate, fat and protein metabolism by acting on liver, skeletal 
muscle, kidney, heart and adipose tissue in particular. These tissues maintain normal energy balance 
and homeostasis (Barclay et al, 2011) and when disturbed can result in metabolic disorders such as 
diabetes, obesity, muscle wasting and cancer. GH actions in vivo are complex.  
 
The ability of GH to regulate glucose levels in plasma has been known for many years (McCann et 
al, 1987) and is the direct outcome both of increased gluconeogenesis in the liver and insulin 
antagonism in muscle. GH-mediated insulin-resistance is a consequence of downstream signalling 
mechanisms that inhibit the insulin pathway rather than the downregulation of insulin receptors 
(Davidson, 1987). The GH-mediated decrease in insulin sensitivity in mice (Dominici et al, 2005) is 
associated with decreased adiposity and hepatic lipid accumulation. Conversely, lack of GH 
signalling with its consequent obesity (and Non-Alcohol Fatty Liver Disease) is associated with 
insulin sensitivity (Dominici et al, 2002; Liu et al, 2004) as evident in GHR knockout and knockin 
mice models (Rowland et al, 2005b; Berryman et al, 2004). The state of GH excess results in insulin 
resistance as seen in bovine GH overexpressing mice and acromegalic patients (Coculescu et al, 
2007; Olsson et al, 2005) with a correlation between increased severity of insulin resistance and 
higher circulating GH levels (Coculescu et al, 2007). These observations represent the anti-insulin 
actions of GH.  
 
In addition, GH is also responsible for regulation of synthesis of enzymes involved in steroid and 
drug metabolism. These effects are mediated in part by cytochrome P450 (Legraverend et al, 1992) 
enzymes and sulfotransferases (Klaassen et al, 1998) induced as a result of the direct actions of GH 
on liver (Waxman & Holloway, 2009). 
 
Proliferation and Differentiation  
In the liver, IGF-1 production owing to GH action is well documented. However GH and not IGF-1 
promotes hepatocyte proliferation since there are no IGF-1 receptors expressed in the liver (Caro et 
al, 1988). Therefore IGF-1 secretion is an endocrine function allowing it to act systemically on 
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other target tissues and for regulating GH secretion via a negative feedback loop at the 
hypothalamus and pituitary gland (Ceda et al, 1987). Liver has been shown to have a high 
proliferative index following chemical and physical injury and this regeneration rate can be 
enhanced by exogenous GH administration (Asakawa et al, 1989) and is absent or naturally low in 
GHR knockout or GH antagonist animal models, particularly in C57Bl/6 mice (Pennisi et al, 2004) 
(Zerrad-Saadi et al, 2011). GH results in increase of hepatocyte growth factor and EGFR in the 
liver, both of which are potent mitogens (Ekberg et al, 1992; Jansson et al, 1988), but the lethal 
aspect relates to the production of a powerful immunotolerance protein (H2-Bl) by GH (Barclay et 
al, 2010).  
 
GH has been shown in vitro to directly stimulate proliferation of less differentiated cells in the 
osteoblast lineage derived from both trabecular and stromal sources (Kassem, 1997). This 
mechanism may in part mediate the in vivo effects of GH on bone formation. In the immune system, 
GH induces cell proliferation in the thymus (Savino et al, 2003) and spleen (Takada et al, 1991). In 
vitro, GH has been shown to stimulate cell numbers in lymphocytes particularly CD4 T-cells 
(Lempereur et al, 2003), plasma cells (Kimata & Yoshida, 1994), erythroid precursors (Claustres et 
al, 1987), myeloid precursors (Kotzmann et al, 1996), and adult neural stem cells (Blackmore et al, 
2012). Likewise in β-cell of pancreas, besides proliferation GH has a well established ability to 
directly increase insulin synthesis and secretion (Billestrup & Nielsen, 1991; Cousin et al, 1999). 
 
In response to GH stimulation, fibroblasts exhibit increased proliferation, collagen synthesis and 
angiogenesis and chemotaxis, which accelerates the wound healing process (Sobiczewska & 
Szmigielski, 1997). GHR expression is widespread in epidermis and dermal fibroblasts throughout 
the body (Lobie et al, 1990a) and GH is known to increase the thickness and strength of the skin, 
partly by inducing collagen synthesis (Wilson et al, 1995). This is supported by the observation that 
acromegalics have epidermal hyperplasia while GH deficient individuals have thin, elastic skin 
(Lange et al, 2001).  
 
As mentioned above, besides proliferation GH can increase chondrocyte differentiation, resulting in 
extracellular mineralisation and proteoglycan synthesis (Olney, 2003). This differentiation process 
is marked by an increase in type II collagen, cathepsin D and acid phosphatase. GH also promotes 
upregulation of enzymes, matrix proteins, and differentiation markers involved in mineralisation of 
tooth and bone matrices directly and augments the role of IGF-1 in promoting bone and tooth 
formation (Li et al, 2001). Further, GH is proposed to have necessary role in differentiation of pre-
adipocytes to functional mature adipocytes (Shang & Waters, 2003). More recently, Lu et al. have 
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provided a novel mechanism by which GH can control adipogenesis. This involves GH-mediated 
decrease in secretion of interleukin-1β by the macrophage and increase adipocyte differentiation 
(Lu et al, 2010).  
 
In light of its importance in neural development, GH can function as an autocrine mitogen, 
augmenting the proliferation of adult neurosphere cultures (McLenachan et al, 2009). Recently, a 
new population of neural stem cells has been reported which is activated by GH infusion, and can 
differentiate into neurons in mice (Blackmore et al, 2012). These stem cells are activated by 
voluntary exercise in a GH-dependent manner (Blackmore et al, 2009). GH has been shown to 
influence male sexual differentiation and alter the androgen-binding activity of the foetal 
reproductive tract (Nguyen et al, 1996). 
 
Development 
GH primarily regulates post-natal growth whereas embryonic and foetal growth is considered to be 
independent of GH. However, newborn Laron dwarf babies are 2 standard deviations shorter than 
normal (Laron, 1972) and congenitally GH deficient newborn babies are shorter as well (Waters & 
Kaye, 2002). In animal models, the growth of rat foetus transplanted under the renal capsule of 
hypophysectomised host was impaired as compared to normal foetus and this could be corrected 
with GH administration (Liu et al, 1987). In GHR KO mice GH was found to have an important 
role in early development evident from reduced litter size, smaller foetus and prolonged pregnancy 
(Danilovich et al, 1999). 
 
A number of foetal tissues and embryonic stem cells have been shown to express GHR and to 
respond to GH in vitro (Ohlsson et al, 1993) with both GHR protein and mRNA detectable from 
two-cell embryo stage to blastocyst stage in both mouse and bovine (Pantaleon et al, 1997; Kolle et 
al, 2001). Locally produced GH also plays a role in the development of the central and peripheral 
nervous system pre-natally, prior to its expression by the pituitary gland (Harvey & Hull, 2003). 
Turnley et al. have reported that neural GH promotes glial cell formation in preference to neurons 
by downregulation of neurogenin-1 (Turnley et al, 2002). However, GH also promotes proliferation 
of neural precursors and neurogenesis during brain development (Ajo et al, 2003), and brain 
structure and cell population are altered in ghr null mice (Ransome et al, 2004). 
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Subcellular localisation of GHR 
The general paradigm for cytokine signalling involves binding of the ligand to the cell surface 
localised GHR and control of receptor expression occurs at various points in the receptor life cycle 
(Strous & van Kerkhof, 2002) which determine its localisation in a spatial and temporal manner. 
The plasma membrane is made of numerous lipids and proteins forming different structural entities 
such as coated pits, glycolipid rafts and caveolae (Nabi & Le, 2003). In the plasma membrane of 
epithelial cells GHR has been found to reside within microdomains, specifically glycolipid rafts and 
caveolae (Lobie et al, 1999; Yang et al, 2004).  
 
However, it was early established that the majority of binding sites for GH in hepatocytes are not on 
the cell surface (Bergeron et al, 1978). The GHR (or GH specific binding sites) was initially 
reported in rough endoplasmic reticulum (ER), cytoplasmic matrix, golgi appartus and microsomal 
fraction (Postel-Vinay et al, 1982; Gorin et al, 1984; Mertani et al, 1999). Since then it has been 
reported in mitochondria (Mertani et al, 1996) where it is transported via the caveolar pathway and 
hypothesised to be required for GH stimulation of cellular oxygen consumption, dependent on the 
receptor Box1 motif for trafficking (Perret-Vivancos et al, 2006).  
 
Nuclear localisation  
Although a large population of GHR resides in ER and at the cell surface, an unexpected location 
for GHR and GHBP is in the nucleus. There is clear evidence of pronounced nuclear localisation in 
various cell types including cells of the blastocyst, hepatocytes and cancer cells (Lincoln et al, 
1998; Lobie et al, 1994b). The nuclear localised GHR/GHBP has been reported to have normal 
affinity for GH and a panel of anti-GHR antibodies, indicating it is antigenically identical to the 
surface GHR (Lobie et al, 1991). Inside the nucleus the GHR was localised in nuclear membrane, 
heterochromatin and nucleolus by immunogold electron microscopy (Lobie et al, 1992).  
 
The exact functional role of nuclear GHR is yet unknown but it is a common feature of tissues 
demonstrating high proliferative status; placenta (Garcia-Aragon et al, 1992), gastrointestinal tract 
(Lobie et al, 1990b), pre-implantation embryo (Pantaleon et al, 1997), epithelia of prostate gland, 
and ovaries. Analysis of a number of clinical cancer samples has shown GHR localised to the 
nucleus, including B-cell lymphomas, mammary carcinoma, melanoma and prostate tumours 
(Lincoln et al, 1998; Mertani et al, 1996). The GHBP, and by implication the nuclear GHR, has 
been shown to act as a transcription factor capable of direct transactivation in a mammalian β-
galactosidase reporter assay (Graichen et al, 2003; Conway-Campbell et al, 2008).   
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GHR translocates rapidly into the nucleus after GH stimulation of serum-starved cells and this 
receptor is full-length and glycosylated like the cell surface receptor. The kinetics of nuclear 
translocation is rapid and transient, occurring within 10 minutes of GH stimulation and ceasing 
within 60 minutes (Lobie et al, 1994a). In vitro and in vivo studies have also shown that exogenous 
GH is also translocated into the nucleus (Lobie et al, 1994a). This in vitro uptake of GH was not 
blocked by microtubule or microfilament blockers but could be increased by blocking lysosomal 
degradation (Lobie et al, 1994a) indicating that cells utilise a different nuclear localisation 
mechanism that is independent of cytoskeletal network. Importantly, the internalisation and nuclear 
uptake of GH was not observed in the absence of an intact GHR. Graichen et al. have reported that 
GH and GHR co-translocate to the nucleus and receptor phosphorylation may be the stimulus for 
nuclear translocation (Graichen et al, 2003). 
 
The phenomenon of nuclear translocation is not unique to GHR and is an attribute of several growth 
factors, cytokines and their receptors (Jans & Hassan, 1998), including the homologous PRLR 
(Rycyzyn et al, 2000). It has been shown that tyrosine kinase receptors EGFR, FGFR1, IGF-1R and 
endothelial growth factor receptors as well some G-PCRs, translocate as full-length receptors to the 
nucleus (Lin et al, 2001; Stachowiak et al, 1997; Sarfstein et al, 2012; Gobeil et al, 2006). The 
members of the EGFR (Epidermal Growth Factor Receptor) family (ErbB-1, ErbB2) have been 
reported to translocate in the nucleus by binding of their nuclear localisation signal (NLS) to the 
importin α/β complex (Lo et al, 2006). FGFR1 (Fibroblast Growth Factor Receptor) lacks a NLS 
sequence and so cannot directly bind to importin α, and as a result is translocated into the nucleus 
by binding to its ligand that contains the NLS sequence, a phenomenon referred to as ‘piggy-
backing’ (Reilly & Maher, 2001). This is thought to occur with the GHR which associates with 
importin β in vitro (Conway-Campbell et al, 2008). GHR has been reported to interact directly with 
CoAA by GST-pull down and co-immunoprecipitation assays. This association was shown to occur 
only in the presence of GH and overexpression of CoAA in GH responsive cells led to a specific 
increased proliferative response to GH (Conway-Campbell et al, 2008). CoAA is a known 
coactivator of a number of nuclear steroid receptors and has a role in mRNA splicing regulation 
(Auboeuf et al, 2004) and contains several nuclear localisation signals that could bind directly to 
importin β and be used to transport the full-length GHR protein in the nucleus (Conway-Campbell 
et al, 2007).  Nuclear expression of GHR in cancer cells shows an association with the frequent 
overexpression of CoAA (Sui et al, 2007). 
 
Although considerable evidence indicates the recruitment of importin α/β complex for nuclear 
translocation of cytokine receptor, the phenomenon of cytosol access by the receptor and its ligand 
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remained unclear until the recent study by Wang et al. (Wang et al, 2010b). They showed by co-IP 
studies that activated EGFR utilises the Sec61 translocon complex for its transport from the cell 
surface through endosomes via the Golgi/ER to the nuclear pore complex associated with importin 
β. This entire process of nuclear translocation takes 30-60 min and is referred to as the INTERNET 
(Integral trafficking from the ER to NE transport) pathway. The Sec61 translocon normally detects 
misfolded proteins in the ER and sends it back into the cytoplasm for degradation by ‘retrograde 
transport’ via the ERAD (ER-associated degradation) pathway.  
 
Waters’ lab have shown that nuclear localised GHR correlates with high proliferation status, and 
that constitutively targeting the GHR to the nucleus results in cell cycle progression, dysregulation 
of proliferative arrest, and oncogenesis (Conway-Campbell et al, 2007). This has prompted in-depth 
analysis of the effect of nuclear localisation in cellular transformation.  
 
Autocrine mode of GH signalling 
As mentioned earlier, several tissues express GH locally and it has been suggested that autocrine 
GH can serve as a cytokine, promoting cell cycle progression and preventing apoptosis (Chhabra et 
al, 2011). Autocrine GH has been implicated in oncogenic transformation and metastasis in several 
different types of malignancies (Perry et al, 2006; Waters & Barclay, 2007). Autocrine GH is 
thought to enhance the in vitro oncogenic potential of endometrial carcinoma and colorectal cells 
while its forced expression in immortalised endometrial carcinoma and breast cancer cell lines 
increased their cell number through enhanced cell cycle progression and decreased apoptotic cell 
death while promoting anchorage-independent growth and increased cell migration and invasion 
(Jenkins & Bustin, 2004; Pandey et al, 2008; Zhu et al, 2005). Both GH and GHR are expressed in 
immune cells and are implicated in the development of leukemia and lymphoma (Hooghe et al, 
1998) along with IGF-1 and its receptor (Weigent & Arnold, 2005). The overexpression of GH and 
GHR in lymphoma cells have been shown to have anti-apoptotic effects (besides increasing IGF-1) 
by decreasing the production of superoxide and associated expression of bax, Bad and caspases 3,8 
and 9 (Arnold & Weigent, 2003). 
 
Autocrine production of GH in immortalised human epithelial cells enhances proliferation and 
protects against apoptosis and promotes abnormal mammary morphogenesis with oncogenic 
transformation and tumour formation in vivo (Liu et al, 1997). Exogenous GH cannot, however, 
mimic these actions (Kaulsay et al, 2000). This is supported by microarray analysis of 19,000 
human genes that identified a subset of 305 genes that were differentially responsive to exogenous 
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or endogenous GH, as well as 167 genes that were regulated in common in mammary carcinoma 
(Xu et al, 2005).   
 
A more recent study by Nakonechnaya et al. in the LNCaP prostate cancer line revealed differential 
effects of exogenous and autocrine growth hormone cell proliferation and survival. In contrast to 
the proliferative effects observed in mammary and colorectal carcinoma lines, autocrine GH 
overexpression reduced LNCaP cell proliferation and increased apoptosis (Nakonechnaya et al, 
2013). The differential actions of endogenous and exogenous GH could be attributable to 
differences in GH concentration and secretion, since endocrine GH is secreted episodically whereas 
endogenous GH is released continuously at low concentrations (Vouyovitch et al, 2008). Moreover, 
endogenous GH is released in closer proximity to GHR and potentially at higher microenvironment 
concentrations than exogenous GH, allowing it to bind with available intracellular receptors in 
compartments not readily accessible to exogenous GH e.g. following synthesis in the ER (van den 
Eijnden & Strous, 2007). Additionally, Nakonechnaya et al. have also shown that the distinct 
actions of exogenous and autocrine GH were accompanied by differences in the involvement of 
GHR signal transduction pathways, and were paralleled by an alteration in the subcellular 
localisation of GHR, in which autocrine GH appeared to sequester GHR in the Golgi and ER 
(Nakonechnaya et al, 2013). This GH-GHR complex is then transported to the plasma membrane 
where exogenous GH is unable to bind these receptors, but signal transduction by endogenous GH 
only occurs after exiting the endoplasmic reticulum (Perry et al, 2006). This mechanism explains 
why GHR antagonists have been reported as ineffective in blocking the actions of autocrine GH 
(Tallet et al, 2008). This alteration of GHR trafficking may underlie a distinct mode of GH-
mediated signalling associated with the effect of autocrine GH. The autocrine GH can also act 
through nuclear localised GHR, which is upregulated in cancerous tissues. (Brooks et al, 2008; 
Conway-Campbell et al, 2007; Perry et al, 2008).  
 
In addition to above findings, the study of Mol et al. (Mol et al, 1995a) reported the presence of GH 
transcripts in human mammary tissue but with no evident relation to presence of carcinogenesis, 
and apparently decreased transcript in most carcinomas. A search of the Oncomine database reveals 
underexpression of GH1 and no listing for GH2 transcripts in invasive ductal breast carcinoma 
against normal tissue, in contrast to the prolactin transcript, which is highly expressed. Many human 
prostate cancers overexpress GH1 or GH2 and GHR transcripts as evidenced in the Oncomine 
database (Chhabra et al, 2011). Furthermore, an immunohistochemical study of 20 prostate cancers 
and 17 controls reported a four-fold increase in human GH expression in prostatic carcinoma where 
it is believed to act locally as almost all of them express GHR (Chopin et al, 2002; van Garderen & 
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Schalken, 2002). More recently, expression of both hGH and hPRL has been reported in mammary 
and endometrial carcinoma which associated with poor survival outcome for patients with these 
tumours (Wu et al, 2011). A similar result was also evident in dogs with high intratumoural levels 
of GH and IGF-1 reported in dogs with malignant mammary cancer (Queiroga et al, 2010). 
 
Mechanisms that control GHR signalling 
Depending on the cell type, as well as the time and extent of exposure to GH, the intracellular 
response to GH will vary. The steady state receptor turnover of receptor is rapid (half-life ~ 30-60 
minutes), and two mechanisms contribute to receptor clearance from the plasma membrane: 
proteolytic cleavage by metalloproteases, resulting in the release of soluble GH-binding protein, and 
continuous ubiquitin-dependent internalisation. The deactivation of GHR signalling occurs at 
various levels in the signalling cascade and is tightly controlled. 
 
Termination of GHR Signalling 
In vivo, GH signalling is tightly regulated by numerous mechanisms that attenuate or terminate GH-
induced signalling and operate following a GH secretory pulse. One such mechanism is endocytosis 
but since GHR/Jak2 complex is active in the endosomes additional mechanisms are required that 
can terminate the signalling cascades (Flores-Morales et al, 2006). The most important mechanisms 
involve phosphatases, members of Suppressors of Cytokine Signalling (SOCS) family and PIAS. 
 
Phosphatases 
Phosphatase activity is an important terminator of GH signalling, both at the receptor level and its 
downstream cascade. GHR is dephosphorylated by several protein tyrosine phosphatase (PTP) 
family members (Pasquali et al, 2003). Among the 44 PTPs tested, TC-PTP, PTP1B, SAP-1, PTP-
H1, PTP-β, Meg1/2 and SHP-1/2 showed binary interaction with phosphorylated GHR (Pasquali et 
al, 2003). However, further in vivo functional studies narrowed this list to PTP-H1 (Pilecka et al, 
2007) and PTP1B (Klaman et al, 2000). 
 
Earlier studies had focused on tyrosine phosphatases (SHP-1 and 2). The binding of these molecules 
is increased upon Jak2 activation by tyrosine phosphorylation, which recruits and phosphorylates 
SHP phosphatases. The enzymatic activity of SHP-1 limits the extent and duration of Jak2 
activation upon GH stimulation in in vitro expression systems (Hackett et al, 1997). By contrast, 
SHP-2 has been shown to be a both positive and negative regulator of GH signalling, depending on 
its cellular concentration and cell context. SHP-2 is recruited to the GH-induced complex, which 
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includes GHR, Jak2 and a transmembrane glycoprotein signal-regulatory protein (SIRPα) that upon 
GH stimulation induces SHP-2 binding to Grb2 (Kim et al, 1998). The SH2 domain of SHP-2 
specifically associates with phosphorylated tyr595 of human GHR and mutation of this tyrosine 
prolongs signalling in vitro (Stofega et al, 2000). The tyrosine phosphatases also bind and 
dephosphorylate other downstream signalling molecules, such as IRS-1 and FAK (Myers et al, 
1998; Yu et al, 1998).  
 
Phosphorylated Jak2 is also a physiological substrate of PTP1B, which in addition 
dephosphorylates STAT5B and B (Gu et al, 2003; Aoki & Matsuda, 2000).  This has been 
supported by the studies showing that deletion of ptp1b gene results in GH-induced hyper-
phosphorylation of Jak2 and therefore of STATs whereas its overexpression reduces GH-mediated 
gene expression (Gu et al, 2003). In addition to tyrosine phosphorylation, Jak2 can be serine 
phosphorylated at position 523, potentially by ERK1/2 and this has been shown to inhibit its kinase 
activity (Mazurkiewicz-Munoz et al, 2006). Eventually Pilecka et al. have tested all the potential 
GH-induced tyrosine phosphorylated players as substrates for a large panel of PTPs in biochemical 
and cellular studies and from this identified PTP-H1 and PTP1B as major players. In support of this 
they reported enhanced growth in mice (significant for males) lacking the PTP-H1 catalytic domain 
over their wild type littermates (Pilecka et al, 2007). These mice have increased body size with a 
high level of IGF-1 owing to enhanced GHR sensitivity. In contrast PTP1B deleted male mice were 
smaller than wild type littermates and possessed of lower fat content due to increased energy 
expenditure in those mice (Klaman et al, 2000), suggesting that PTP-H1, but not PTP1B opposes 
the actions of GH in vivo. 
 
Suppressors of Cytokine Signalling 
SOCS proteins are negative regulators of Jak/STAT signalling (Wormald & Hilton, 2004) that have 
been shown to modify cytokine action through a classic negative feedback loop. Normally, SOCS 
protein levels are constitutively low, but their expression increases rapidly following cytokine 
stimulation (Aoki & Matsuda, 2000). There are 8 members of the SOCS family, of which SOCS1, 
2, 3 and CIS (Cytokine Inducible SH2 protein) are the key SOCSs involved with GH action (Flores-
Morales et al, 2006).  GH has been reported to induce the expression of these SOCS proteins to 
varying degrees and with different kinetics in vitro (Gu et al, 2003; Hackett et al, 1997) and in vivo 
(Pasquali et al, 2003). Generally, SOCS1, SOCS3 and CIS expression is rapidly induced following 
GH stimulation but is transient, whereas SOCS2 expression increases steadily with time (Flores-
Morales et al, 2006). Each SOCS member has a different mechanism of action on GH signalling 
(Flores-Morales et al, 2006; Ram & Waxman, 1999). Structurally, all SOCS family members 
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comprise of a variable N-terminus, a central SH2 domain and a conserved C-terminal motif called 
the SOCS box (Flores-Morales et al, 2006). In addition SOCS1 and 3 contain at their N-terminus a 
kinase inhibitory region (KIR) for terminating the Jak kinase activity (Ungureanu et al, 2002). The 
common and key function of SOCS proteins is their ability to form an E3 ligase complex with their 
SOCS box and Elongin BC, cullin 2 or 5 and ring finger proteins Rbx1 or 2 (Kamura et al, 2004) 
leading to proteasome degradation of the GHR.  
 
SOCS1 and 3 can directly bind within the Jak2 activation loop on Tyr1007, blocking its kinase 
activity through their KIR (kinase inhibitory region) motif and promoting its proteasomal 
degradation (Stofega et al, 2000; Kershaw et al, 2013; Kim et al, 1998; Ungureanu et al, 2002). 
SOCS2, SOCS3 and CIS have been shown to interact with tyrosine phosphorylated GHR. Good 
evidence indicates that binding to Y487 and Y595 is required for SOCS2 and Y333 (Ram & 
Waxman, 1999) and Y338 for SOCS3-mediated inhibitory actions (Udy et al, 1997). Since Y487 
and Y595 are known STAT5 binding sites (Fuh et al, 1992), SOCS2 can competitively inhibit 
STAT5 binding to the receptor. Vesterlund et al. have recently reported the mechanistic importance 
of phosphorylated Y487 rather than Y595 on GHR for its regulation by SOCS2 (Vesterlund et al, 
2011). Little is known about CIS interaction with the GHR but phosphorylated Y487 and Y595 
have been predicted as binding sites using the mammalian two-hybrid method (Uyttendaele et al, 
2007).  The effects of SOCS proteins are also reflected in knockout mouse models. SOCS1 
knockout mice are contradictorily growth retarded and die before weaning due to fatty degeneration 
of the liver and infiltration by monocytes (Starr et al, 1998) in contrast with the inhibitory effects 
due to overexpression in vitro. The thymus size is also markedly reduced in these animals and is 
associated with progressive loss of maturing B-cells in the bone marrow, spleen, and peripheral 
blood reported as well. These defects have been traced to increased interferon sensitivity since 
SOCS1 is a critical inhibitor of IFN-gamma signalling and prevents the potentially fatal neonatal 
actions of this cytokine (Alexander et al, 1999).  
 
SOCS3 knockout mice do not exhibit any growth phenotype (Croker et al, 2003) raising the issue of 
functional redundancy across the family. Functionally only SOCS2 knockout mice are 40% larger 
compared to wild type mice (Metcalf et al, 2000). This SOCS2 deficiency mediated gigantism is 
STAT5-dependent and can be reversed by GH deficiency indicating a direct relationship of GH and 
SOCS2 (Greenhalgh et al, 2002; Greenhalgh et al, 2005). In addition, SOCS2 knockout mice only 
partially mimic state of GH excess, but also result in changes that cannot be related to known GH 
effects (Rico-Bautista et al, 2005). SOCS2 has also been shown to interact with IGF-1R and 
therefore may have the major role in growth regulation (Dey et al, 1998b). 
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The importance of tyrosine residues in GHR is evident from studies carried out on the receptor 
mutant with all intracellular tyrosine residues changed to phenylalanine, which allowed acute GH-
induced Jak2 activation but, this tyrosine phosphorylation-defective receptor underwent markedly 
reduced GH-induced ubiquitination and was only modestly downregulated (Deng et al, 2012). 
 
PIAS-mediated signalling termination 
Protein inhibitors of activated STATs (PIAS) share a common structure; the N-terminal nuclear 
receptor interaction motif and central RING-like zinc-binding domain (Schmidt & Muller, 2003). 
All members of PIAS family display E3 small ubiquitin-related modifier (SUMO) ligase activity 
(Pilecka et al, 2007). The mechanism by sumolyation leads to STAT inactivation is not clear. 
PIAS1 and 3 bind STAT1 and 3 respectively following cytokine stimulation and thus inhibit the 
association of STAT with DNA. By contrast, PIASx and PIASy inhibit their respective targets 
STAT4 and STAT1 through other mechanisms, without interfering with DNA binding of these 
STATs (Pilecka et al, 2007).   Studies on PIAS1 deficient mice show a selective effect of PIAS1 on 
blocking the transcriptional activity of STAT1 (Liu et al, 2004). It should be noted that STAT5B 
can also be negatively regulated by phosphorylation on Tyr740 and Tyr743 (Kloth et al, 2002; 
Weaver & Silva, 2007).  
 
GHR signalling crosstalk 
Recent evidence highlights the significant crosstalk between GHR and other Class I cytokine 
receptors and receptor tyrosine kinase (RTK) members. GH-mediated phosphorylation of the ErbB 
receptor family such as EGFR has been reported to regulate EGF responsiveness (Frank, 2008). 
Indeed, GH action via Jak2 directly phosphorylates EGFR in vivo and in vitro resulting in enhanced 
binding and activation of Grb2-mediated ERK1/2 pathway (Yamauchi et al, 1998b). In addition GH 
and EGF were shown to specifically synergise for activation of ERK in murine pre-adipocytes 
leading to serine-threonine phosphorylation of EGFR (Li et al, 2011). This crosstalk results in EGF-
induced ERK1/2 activation and reduced EGF-mediated EGFR downregulation. 
 
GH and Insulin are known mediators of growth and metabolic regulation, utilizing common 
signalling pathways and can directly interact and influence each other. Essentially insulin has been 
shown to regulate the GH signalling in a time-dependent manner; with short exposures leading to 
induction of MAPK pathway downstream of GHR and longer exposures (of insulin) having reverse 
effects due to negative-feedback regulation (Xu & Messina, 2009). In contrast long-term GH 
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administration has inhibitory effects on insulin signalling, producing the well-known insulin 
resistance (Dominici et al, 2005).  
 
Both GH and IGF-1 are responsible for promotion of cellular proliferation and growth. Recently it 
has been shown that both mitogens have a much closer interaction than previously thought. Huang 
et al. have reported that GH can induce a functional complex between GHR, Jak2 and IGF-1R 
(Huang et al, 2004) which is at least partially independent of the kinase activity of IGF-1R (and 
therefore IGF-1) (Gan et al, 2010). In addition by using a Cre-loxP system these authors have 
shown that deletion of IGF-1R markedly inhibits acute GH-induced STAT5 activity, while sparing 
GH-induced ERK activity in primary osteoblasts (Gan et al, 2010). Similar results on functional 
collaboration of GHR and IGF-1R but not insulin receptors were obtained in another study on 
mouse calvarial cells (Gan et al, 2013).  Ma et al. have reported that signalling crosstalk between 
GH and IGF-1 in pancreatic islet β-cells promotes synergistic activation of STAT5 and Akt 
pathways (Ma et al, 2011). 
  
An important facet of human GH and human PRL biology is that although hPRL interacts only with 
hPRLR, hGH binds and activates both hGHR and hPRLR (Goffin et al, 1996). Although homo- or 
heterodimerisation are common mechanisms for activation of cytokine receptors, crosstalk between 
two distinct receptors in this superfamily has not been shown until recently. A heterodimerisation 
interaction between PRLR and GHR has been postulated to be a novel mechanism contributing to 
the diversity of cytokine signalling (Herman et al, 2000; Xu et al, 2011). This GHR and PRLR 
interaction as well as GHR binding preferences have been shown to depend on the relative amounts 
of GHR and PRLR (Xu et al, 2011). Using both surface plasmon resonance and gel filtration 
techniques it was established early that ovine placental lactogen hetero-dimerises the extracellular 
domains of both the receptors (Herman et al, 2000) but no such effect was observed with ovine GH 
or ovine PRL (Biener et al, 2003). Functionally, homodimerisation or heterodimerisation of PRLR 
and GHR had no differential effect on activation of STAT5 and MAPK. On the contrary their 
heterodimerisation resulted in a prolonged phosphorylation of STAT1 and STAT3, suggesting that 
the heterodimerisation of α-oGHR and β-oPRLR is able to transduce a signal, which is distinct from 
that occurring on homodimeric associations (Biener et al, 2003). Furthermore, Xu et al. have shown 
by immunoprecipitation that GHR and PRLR associate in a fashion augmented acutely by GH, even 
though GH primarily activates PRLR, rather than GHR, in T47D breast cancer cells (Xu et al, 
2013). It is likely that transmembrane helix interactions are responsible for full-length GHR/PRLR 
association (Pelekanos RA PhD thesis, 2006). 
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Pathophysiological role of GH/GHR 
Clinical manifestations of GH secretory disorders 
GH/GHR-mediated signalling is involved in numerous basic physiological processes, therefore 
incorrect GH function results in several pathologies. 
 
GH deficiency   
When GH levels are low, or the GHR is rendered non-functional, post-natal growth retardation 
occurs. Hence defects in GHR signalling or in GH/IGF-1 axis account for a proportion of human 
short stature (Okada & Kopchick, 2001; Pilecka et al, 2007). Adults with congenital GH deficiency 
(GHD) or following surgical hypophysectomy (treatment for pituitary tumour) show decreased 
muscle strength and bone density, increased body fat and cardiovascular dysfunction (Rosen et al, 
1995). All these complications can be reversed by exogenous GH administration. Other evidence 
implicates GH in reproduction, regulation of immune function, mental health and aging (Savine & 
Sonksen, 2000; Brooks & Waters, 2010). The anabolic actions of GH can be beneficial in patients 
with chronic illness such as those suffering from post-surgical stress, AIDS and Prader-Willi 
syndrome (Napolitano et al, 2008; Stafler & Wallis, 2008). GH has been reported to accelerate 
wound healing in surgical and burn patients (Saito, 1998) and also prevent autoimmune diabetes in 
non-obese diabetic mice models (Villares et al, 2013). However, in adults GH treatment has 
resulted in significant side effects such as peripheral edema, carpal tunnel syndrome and insulin 
resistance (Cummings & Merriam, 1999). The use of GH agonists in GHD in regards to cancer is 
considered safe (Pekic & Popovic, 2013). However, in children with thyroid neoplasia, the risk of 
second neoplasms were increased, suggesting that GH could aggravate neoplastic tendencies 
resulting from underlying genetic abnormalities or radiotherapy (Bell et al, 2010). More recently, 
sustained-release recombinant human GH formulation (LB03002) has been shown to be effective 
and well tolerated in individuals with GH deficiency (Biller et al, 2011). 
 
GH excess 
Gigantism and acromegaly are clinical conditions that result from chronic secretion at 
supraphysiological levels of GH in childhood and adults respectively. These are primarily a result 
of pituitary adenomas and activating mutations in the subunit of Gsα protein, which activates 
Growth Hormone Releasing Hormone (GHRH) receptor (Faglia et al, 1996). GH excess is 
associated with increased morbidity and mortality; around 2-3 fold higher than age and sex matched 
normal population (Wass et al, 1999) resulting in death before the age of 50.  Since GH signalling 
antagonises the insulin pathway, acromegalics have been reported to be insulin resistant causing 
diabetes-associated pathologies (Andersen, 2014). GH transgenic mice develop progressive 
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glomerulosclerosis, not reported for IGF-1 transgenic mice (Doi et al, 1988). Patients with GH 
excess are predisposed to cardiovascular and respiratory diseases and cancers (Palmeiro et al, 2012; 
Hernandez-Gordillo et al, 2012).  
 
Growth disorders owing to GHR 
 
Mutations in GHR 
In a small cohort of the human population, growth defects arise as a result of mutations of GHR 
resulting in partial or complete loss of its function (Brooks & Waters, 2010). These mutations have 
been reported to alter features of the GHR that are required for activation of the receptor or other 
components of its signalling cascades such as STAT5B. Laron syndrome or GH insensitivity is one 
such disorder that is an autosomal, fully penetrant recessive disease. It is characterised by severe 
growth retardation, small gonads and genitalia, truncal adiposity, thin skin and hair and high levels 
of GH with low levels of IGF-1, IGFBP3 (IGF-1 binding protein), and ALS (acid labile subunit) in 
circulation (Laron et al, 1966; Brooks & Waters, 2010). The molecular defects affecting GHR, 
include exon deletion or nonsense, missense and frameshift mutations (Laron, 2002). Most of the 
mutations affect the ECD and these are diagnosed by the absence of circulating GHBP. In contrast, 
normal or high GHBP indicates that the mutation resides in the ICD of the GHR or in downstream 
components (Feigerlova et al, 2013). No mutations have been reported in the 24 amino acid residue 
TMD, although 4 splicing mutations that have resulted in excision of exon 8 and subsequent 
supraphysiological concentrations of GHBP (Aalbers et al, 2009). More recently, a second intronic 
GHR mutation has ben identified that activates a cryptic 5' donor splice site resulting in an 
abnormal splicing event leading to early protein termination and undetectable serum GHBP 
(Feigerlova et al, 2013). 
 
Expression and Activation failure 
A novel type of mutation leading to GH insensitivity has been described which results from a point 
mutation that activates an intronic pseudoexon leading to insertion of 36 residues in the 
extracellular dimerisation domain (after residue 207) (Maamra et al, 2006). This elongated receptor 
(~ 656 residues) retains the ability to bind to GH but is poorly expressed on the cell surface (trapped 
in the ER) and as a result has reduced downstream signalling, highlighting a trafficking defect. 
 
GHR mutations leading to a decrease in surface-localised GHR can manifest as a clinical phenotype 
as reported in patients expressing GHR with I153T, Q154P or V155G. These mutations result in a 
decreased level of GHR at the surface due to impaired cellular trafficking from ER as shown by co-
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localisation studies (Wojcik et al, 1998). Additionally, the substitution of aspartate at histidine152 
(D152H mutation) has been described in detail in the context of familial GH resistance (Esposito et 
al, 1998). The histidine residue is part of the dimerisation domain and was initially believed to be 
important for receptor homodimerisation (Bernat et al, 2003). This is necessarily not the case since 
the GHR was reported to be a constitutive dimer (Gent et al, 2003; Brown et al, 2005). It has now 
been proposed that D152H allows GH binding but allow locking of the dimerisation domains, hence 
abrogates signalling (Brooks et al, 2014). 
 
Signalling failure 
GH insensitivity arising from the failure to signal is largely attributed to GHR truncated mutants 
arising from mutation of splice acceptor site of exon 9. This truncated receptor lacks the entire 
cytosolic domain and besides being signalling-incompetent, exhibits impaired degradation (lack of 
UbE-motif) and therefore acts as dominant-negative towards the full-length GHR in heterozygotes 
(Ross et al, 1997). In addition, truncations have been reported in individuals arising due to 
frameshift mutations and as a result of a premature stop codon. These include mutants truncated 
after residues 449 and 581 respectively (Milward et al, 2004; Tiulpakov et al, 2005). In these 
truncations, the receptor expression, cellular distribution, GH binding and Jak2, STAT3, MAPK 
activation ability was similar to full-length receptor. In contrast, the ability to phosphorylate STAT5 
and STAT5-mediated gene transactivation was impaired, in agreement with observations reported 
in analogous mouse models (Rowland et al, 2005a; Rowland et al, 2005b). 
 
‘Downstream to GHR’ defects 
Realisation of the key role of STAT5 in GHR signalling has led to the discovery of STAT5B 
mutations linked to GH insensitivity (Kofoed et al, 2003).  The first mutation involved substitution 
of proline at alanine 630 leading to incorrectly folded protein and formation of proteasome-stable 
aggregates in the cells (Chia et al, 2006b). Since this mutation lies in the SH2 domain it prevented 
interaction with cytokine receptor interaction (including GHR) and also was unable to bind to DNA, 
hence initiate transcription (Fang et al, 2006). This mutation manifested not only as severe growth 
retardation but also immunodeficiency indicative of genetic defects shared with cytokines. 
Additional mutations in STAT5B resulting in an inactive truncated protein or others with total 
absence of mature protein have also been reported (Vidarsdottir et al, 2006; Rosenfeld et al, 2005; 
Hwa et al, 2005). 
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Modulation of GHR Activity 
GHR agonists 
GH deficiency (GHD) in paediatric and adult patients currently necessitates many years or lifelong 
treatment and persistence with a daily injection regimen. This regimen of GH replacement with 
daily injections of the hormone is inconvenient and can be distressing in young patients (de 
Schepper et al, 2011). Consequently, several approaches have been developed to produce long-
acting GH. Covalent attachment of polyethylene glycol to GH molecules has been shown to 
increase its half-life by reducing the rate of GH clearance in the kidney, and also imparts less 
susceptibility to intravascular proteolysis (Clark et al, 1996). Pegylated GH is well tolerated within 
the body and is now used as a weekly therapy in GHD patients (Sondergaard et al, 2011).  
 
As an alternative strategy sustained release of GH formulation in form of encapsulated recombinant 
GH in biodegradable polymers or microspheres are being increasingly employed (Nutropin Depot® 
and Biosphere®) (Silverman et al, 2002; Kemp et al, 2004; Jostel et al, 2005) in GHD patients. 
Another approach for long-acting GHR agonists has been developed by Wilkinson et al. based on 
ligand-receptor fusion proteins. This approach requires linking the recombinant GH C-terminus to a 
GHBP molecule via a flexible linker allowing reduced clearance rate due to size constraints. In vivo 
studies have shown that this fusion molecule has a half-life 100-fold longer than GH and clearance 
rate 300-fold slower than GH (Wilkinson et al, 2007). 
 
GHR antagonists 
Increased understanding of GH-GHR interactions and downstream GH signalling pathways have 
fostered the development of analogs. The rationale of design to generate the most potent antagonist 
was based on ability of molecules to bind preformed GHR dimers but prevent subsequent 
conformational changes within the receptor-GH complex necessary for intracellular signalling to 
occur (Zhang et al, 1999). These are all based on introduction of mutations into native GH 
polypeptide that increases its binding affinity to receptor 1 but simultaneously reduces the receptor 
2 binding, resulting in a molecule that can bind to GHR but cannot elicit the conformational change 
for activity. Such an approach was used by Chen et al. who discovered that substitution of residues 
E117 to L, G119 to R and A122 to D, in site 2 of bovine GH resulted in dwarfism in transgenic 
mice (Chen et al, 1991).  This was followed by other studies highlighting the importance of glycine 
at position 120 in helix 3 of the GH site 2 for its biological activity. As shown by Fuh et al. 
Gly120Arg resulted in a GH analogue that was unable to bind the second receptor and therefore 
block signalling (Fuh et al, 1992). Incorporation of 8 site 1 amino acid residues determined from 
phage display to increase GHR affinity and decrease PRLR affinity, making it GHR-specific 
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(Goffin et al, 1999) has led to the development of a potent antagonist, known as B2036-PEG. This 
is commercially known as Pegvisomant (brand names Somavert® or Trovert®) and pegylation 
increased its half-life from 30 minutes to 70 hours (Ross et al, 2001; van Neck et al, 2000), reduced 
its immunogenicity. Pegvisomant is used as an effective alternative to somatostatin analogues to 
treat acromegaly (Feelders et al, 2009; Neggers & van der Lely, 2011). 
 
Considerable success in reducing hepatic GHR expression and body weight gain has been shown in 
normal mice by sub-cutaneous injection of GHR antisense oligonucleotide (ATL227446). This was 
shown to be effective in reducing normal postnatal growth and plasma IGF-1 in mice (Tachas et al, 
2006). More recently, a second-generation antisense DNA drug (ATL1103, Antisense Therapeutics, 
Victoria, Australia) is currently in Phase II clinical trails for acromegaly and diabetic retinopathy. In 
recent Phase I studies, ATL1103 was shown to reduce IGF-1 levels and was well tolerated. This 
molecule has also demonstrated efficacy in an animal model of retinopathy, significantly reducing 
retinal neovascularisation (Wilkinson-Berka et al, 2007). Guesdon et al. have reported development 
of a glycophosphatidylinositol (GPI)-anchored (membrane tethered) GH or GHR ECD molecules 
that has antagonist properties (Guesdon et al, 2012). Surprisingly GH-GPI when expressed on the 
cell surface formed inactive receptor complexes that failed to internalise and blocked receptor 
activation. In addition, inhibitory mAbs that target the GHR at the dimerisation interface have also 
been reported to inhibit GH action (Jiang et al, 2011). Other strategies that reduce circulating GH 
levels include somatostatin analogues that inhibit GH release from the anterior pituitary gland, used 
widely for treatment of acromegaly (Hasskarl et al, 2011). Further benefit may be obtained in 
combination with pegvisomant. However, whether somatostatin analogues can inhibit extrapituitary 
GH action to inhibit autocrine/local GH production has not been tested. 
 
Sexual dimorphism 
The Jak2-STAT5 pathway has been shown to be central to GH-induced metabolic function, body 
growth and IGF-1 transcription (Waxman & O'Connor, 2006; Chia et al, 2006a). As reviewed 
earlier, GH acts to regulate a diverse set of target genes in hepatic tissue, including genes coding for 
receptors, secretory products, enzymes and transcription factors. Many of these genes respond to 
GH in a sex-dependent manner, giving rise to a sexually dimorphic pattern of liver metabolic 
function that is most dramatic in rodents but significant male-female differences in GH secretory 
pattern also occur in humans (Veldhuis et al, 2001). 
 
 75 
GH production in the somatotrophs of anterior pituitary is tightly controlled by the hypothalamus, 
which releases factors that stimulate (GHRH) or inhibit pituitary GH secretion (somatostatin). The 
GH is released in to the circulation in an intermittent or pulsatile manner which is ultimately 
regulated by the action of gonadal hormones on the hypothalamus giving rise to sex differences in 
the temporal pattern of GH secretion (Jansson et al, 1985). Sex-dependent differential plasma GH 
profile emerges at puberty and is regulated not only by the post-pubertal sex steroids but also by 
gonadal steroid imprinting during the neonatal period (Jansson & Frohman, 1987; Fernandez-Perez 
et al, 2013). Gender-specific GH secretion is an important determinant of the metabolic and somatic 
actions of GH in rodents. In the plasma of adult male rats, GH is secreted in a highly regular, 
pulsatile manner with hormone peaking (200-300ng/ml) every ~3.5hrs, separated by periods during 
which GH is virtually undetectable in circulation. In contrast, adult female rat have continuous 
presence of GH in plasma concentrations typically ranging from 15-40ng/ml (Jansson et al, 1985). 
Interestingly, depletion of liver-derived IGF-1 in male mice (LID mice) causes a feminisation of 
some of the GH-regulated sexually dimorphic markers of liver functions (Ohlsson et al, 2009). This 
is a consequence of losing the feedback effect exerted by IGF-1 on the hypothalamic-pituitary 
system, which results in increased GH secretion, including elevated baseline GH levels between 
pulses, resembling a female pattern of pituitary GH release.  
 
In humans, the metabolic effects of pulsatile versus continuous exposure to GH are different, as 
exemplified by sex-dependent effects in body growth and metabolism, differences in IGF-1 
production, transcriptional regulation of sex-dependent CYP genes and other hepatic phase I and II 
genes relating to drug metabolism (Shapiro et al, 1995; Jaffe et al, 2002). This suggests that GH 
pulse pattern is an independent parameter of GH action in humans. 
 
Knockout of STAT5B (Udy et al, 1997) and of STAT5A and B (Teglund et al, 1998) but not 
STAT5A alone abrogated sexual dimorphism in mice because body size and IGF-1 levels of 
STAT5B knockout males were equivalent to female mice in which these parameters were not 
affected. Male-characteristic body growth rates and male-specific liver gene expression were 
decreased to wild-type female levels in STAT5B knockout males, while female-predominant liver 
gene products were increased to a level intermediate between wildtype male and female levels. 
Although these responses are similar to those observed in GH-deficient Little mice (non-functional 
GHRH receptor), STAT5B knockout mice are not GH-deficient, suggesting that they may be GH 
pulse-resistant (Udy et al, 1997). 
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GHR and Cancer 
Traditionally, GHR is expressed on cell surface (and ER) while GH is secreted by the pituitary 
gland (Okada & Kopchick, 2001). Evidence from Waters’ Group has shown that GHR (and GHBP) 
is expressed in the nucleus (Lincoln et al, 1998; Lobie et al, 1994b) and is antigenically identical to 
the surface GHR (Lobie et al, 1991). Additionally, the nuclear-localised GHR was associated with 
increased proliferation and shown to act as a transcriptional activator (Conway-Campbell et al, 
2007; Zatelli et al, 2009). Similarly, the concept that GH-N synthesis occurs only in the pituitary 
gland has been changing since the last quarter century as evident from the presence of GH gene in 
numerous extra-pituitary tissues (Perez-Ibave et al, 2014). These discoveries clearly indicate 
towards a more complex role of somatotropic axis than previously thought (Waters & Barclay, 
2007). 
 
One of the main regulators of height is the GH/IGF-1 axis and a positive correlation exists between 
height and risk of various cancers (Gunnell et al, 2003; Tripaldi et al, 2013). Acromegaly, a 
condition attributable to GH excess is associated with considerable morbidity and reduced life 
expectancy mostly due to cardiovascular diseases and can be reduced when serum GH and IGF-1 
are effectively lowered by treatment (Andersen, 2014). In addition to numerous animal studies 
(reviewed in (Chhabra et al, 2011), human studies have associated the GH/IGF-1 axis with the 
development of some of the most common cancers in the western world (Khandwala et al, 2000). 
Several population studies indicate that individuals with higher GH/IGF-1 levels have an increased 
risk for colorectal cancer, breast cancer, thyroid cancer (Wolinski et al, 2014) and prostate cancer 
even though causality has not yet been established. Conversely, studies evaluating cancer incidence 
in patients with GH/IGF-1 deficiency and GH-resistance or Laron syndrome showed no reports of 
any malignancy whereas first- and second-degree relatives had normal cancer incidence rate 
(Shevah & Laron, 2007; Guevara-Aguirre et al, 2011). 
 
GHR-mediated signalling and mammary neoplasia 
There is increasing evidence that the GH/IGF-1 axis might provide a major link between genetic 
and environmental factors and development of cancer through its influence on the regulation of 
normal breast cell proliferation, differentiation, and apoptosis (Kleinberg et al, 2009). Pathological 
conditions that affect GH signalling in humans, both defective and excessive, may influence breast 
cancer risk (Perry et al, 2008). Epidemiological studies showed that breast cancer patients have 
significantly higher serum GH levels compared with healthy individuals (Emerman et al, 1985) and 
high IGF-1 predicts a higher breast cancer risk in premenopausal women (Renehan et al, 2004). 
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Moreover, an earlier study reported a four fold higher risk for breast cancer in female patients with 
acromegaly (Nabarro, 1987), but this finding has not been confirmed by subsequent study (Orme et 
al, 1998) or indicates only a marginal correlation that requires more number of patients (Jenkins, 
2004). The increased mortality in acromegalic patients may be attributed to GH-induced 
radioresistance (Bougen et al, 2011) and chemoresistance as reported in MCF-7 cell line with the 
latter shown to be independent of autocrine GH (Zatelli et al, 2009). Felice et al. have reported that 
GH promotes β-estradiol-dependent proliferation of T47D breast cancer cells independent of IGF-1 
and the combination of GH and β-estradiol could overcome IGF-1R activity inhibition (Felice et al, 
2013). A more recent study has shown that GHR blockade in vitro can inhibit GH-induced 
chemoresistance by restoring doxorubicin-induced apoptosis in breast cancer cells (independently 
of estrogen receptor expression) by increasing JNK phosphorylation (Minoia et al, 2012). More 
importantly, it has been reported that after exposure to cytotoxic drugs in mammary neoplasia there 
is a progression from a hormone-dependent, non-metastatic, anti-estrogen-sensitive phenotype to a 
hormone-independent, invasive, metastatic, anti-estrogen-resistant phenotype (Campbell et al, 
2001). Animal studies have demonstrated that deregulation of somatotropic axis has resulted in 
reduced tumour severity. A high frequency of mammary adenocarcinoma was reported in 
metallothionein promoter-driven hGH female mice (Tornell et al, 1992). The Lit/Lit mice due to 
inactive GHRH receptor resulting in secondary suppression of GH and IGF-1 secretion has been 
shown to significantly reduce tumour growth of mammary xenografts as compared to control mice 
(Yang et al, 1996). Moreover, five different human sarcoma cell lines have demonstrated similar 
reduced effects in xenograft assays in Lit/Lit mice (Deitel et al, 2002). Another animal model, liver 
IGF-1 delete (LID) mice with low IGF-1 levels (25% of controls) were reported to have reduced 
growth of colon cancer (Wu et al, 2002) and chemically-induced mammary cancer (Wu et al, 2003). 
In the same study, LID mice crossed with C3(1)/SV40 large T-antigen transgenic mice, the mean 
age of onset of mammary tumours was delayed as compared with controls (Wu et al, 2003). 
 
In addition to GHR, PRLR expression is present in ~70% of breast biopsies and is reportedly 
increased in breast cancer (Mertani et al, 1998; Touraine et al, 1998), whereas expression of the 
shorter, dominant-negative, form of this receptor is decreased (Meng et al, 2004). Other studies 
have shown increased stability of PRLR in breast tumours (Li et al, 2006). PRL in humans was 
shown to be produced by 70% of breast cancer lines (Clevenger et al, 1995) and by a similar 
proportion of biopsies, and antibody neutralisation of secreted autocrine PRL decreased the 
proliferation of breast cancer lines (Vonderhaar, 1998). However, a more recent study has reported 
low or undetectable PRL mRNA expression in 144 breast cancer patients and in 13 of 14 breast 
cancer cell lines when analysed by qPCR (Nitze et al, 2013). In animal model of local PRL 
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overexpression in differentiating mouse mammary gland functional defects and benign lesions were 
evident, but no carcinoma was reported (Manhes et al, 2006) while autocrine PRL (under the 
control hormonally nonresponsive promoter) overexpressing mice develop mammary 
adenocarcinoma at 15months of age (Rose-Hellekant et al, 2003). These data were strongly 
indicative that PRL signalling in the context of local vs systemic levels might be involved in 
promoting tumour growth in breast cancer patients. These two paralogous cytokine hormones seem 
to have parallel and interconnected roles in breast cancer as they do in breast development.  
 
GHR-mediated signalling and prostate cancer 
Several lines of evidence suggest the potential for endocrine GH to affect prostate tumourigenesis in 
addition to normal prostate development and function. GH has a growth stimulatory role in the 
prostate, and plasma GH-mediated IGF-1 levels may be an indicator of prostate cancer risk (Ozkan, 
2011). The first evidence came from increased expression of GHR protein in the epithelial cells of 
the tumour acini while no GHR was detectable in normal prostatic epithelium (Kolle et al, 1999). 
An increase in the incidence of benign prostate hyperplasia (BPH) is associated with increased GH 
concentrations in individuals with acromegaly (Jenkins & Besser, 2001; Clemmons, 2002), and 
increased endogenous GH expression was observed in prostate tissue biopsies taken from 
individuals with BPH that ultimately progressed to prostate cancer (Slater & Murphy, 2006). An 
inverse correlation between serum GH concentration and prostate cancer incidence has also been 
reported (Fuhrman et al, 2005). GHR transcripts have been reported in benign prostate hyperplasia 
(BPH) and prostate adenocarcinoma patient tissues, as well as in LNCaP, PC3 and DU145 human 
prostate cancer cell lines (Weiss-Messer et al, 2004). In addition, GHR mRNA levels were reported 
to be 80% higher in the carcinoma tissues than in BPH in the same study. 
 
In direct tests of the role of GH in prostate cancer, the absence of GH signalling due to GHR 
deficiency abrogated prostate tumourigenesis in rat and mouse models of prostate cancer 
susceptibility, consistent with a contribution of the GH/IGF-1 axis to prostate tumourigenesis 
(Kurmasheva & Houghton, 2006; Guan et al, 2002). Takahara et al. have shown that circulating GH 
and IGF-1 can promote androgen-responsive growth, castration-resistant progression, and 
androgen-independent expansion of PTEN-deficient human prostate cancer (PCa) cell xenografts in 
SCID Lit/Lit mice and that IGF-1 can promote cancer growth even in a suppressed GH environment 
(Takahara et al, 2011). IGF-1 has been shown to induce clusterin, a cytoprotective molecular 
chaperone through STAT3-Twist1 pathway, that can promote PCa growth (Takeuchi et al, 2014). In 
addition, GH levels have been shown to increase in prostate cancer patients undergoing androgen-
deprivation (Galvao et al, 2008). Taken together, these findings indicate that endocrine GH may 
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have the potential to influence prostate cancer, but the direct effects of GH on prostate cancer cell 
function are not well understood. 
 
GHR-mediated signalling and colon and endometrial cancer 
GH was reported to be produced by the glandular cells of the human endometrium during mid to 
late luteal phase of the female menstrual cycle (Sbracia et al, 2004). A Polish study has reported 
higher incidences of endometrium and colon cancers (Baldys-Waligorska et al, 2010). The levels of 
hGH were significantly increased in both endometriosis and endometrial adenocarcinoma (Slater et 
al, 2006) and both PRL and GH serum levels are part of five-biomarker panel that allows accurate 
discrimination between cancer and control groups and early detection of endometrial cancer in 
high-risk populations (Yurkovetsky et al, 2007). An epidemiological study in Italian population has 
reported increased colon cancer incidences in acromegalic patients (Terzolo et al, 2005). While 
colonoscopy-based studies of adenoma prevalence rates in acromegalic patients are misleading, the 
population-based studies on colorectal cancer risk are more consistent as estimated by meta-analysis 
study indicating a pooled risk ratio of 2.04 (95 % CI: 1.32, 3.14) (Renehan et al, 2003). At the 
functional level the increased colonic neoplasia in acromegalics has been attributed due to increased 
proliferation rather than reduced apoptosis (Ishizaka-Ikeda et al, 1993). This has been confirmed at 
cellular level where siRNA-mediated knockdown of GHR in SW480 colon cancer cell line was 
reported to be anti-tumourigenic (Zhou et al, 2013). 
 
GHR-mediated signalling in other cancers 
The role of the GH/IGF-1 axis has been studied on glioma cell lines. In one study both the GHR 
and IGF-1R were found to be expressed in few immortalised glioma cell lines. Treatment of two of 
these lines (U251 and U373) with IGF-1 resulted in increased mitogenesis as assessed by thymidine 
uptake (Friend et al, 2001). However these results could not be shown in xenograft models in SCID 
mice. GHR has been identified as one of the marker genes for lung adenocarcinoma (Wu et al, 
2012) with the first reported variant P495TGHR associated with increased lung cancer 
susceptibility in two separate GWAS studies (Cao et al, 2008; Rudd et al, 2006). Additionally, 
elevated levels of GHR have been reported in NCI60 panel of non-small cell lung carcinoma, CNS 
cancer and melanoma cell lines (Sustarsic et al, 2013).  
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Aims and objectives of the thesis 
GH acting through its receptor is a direct regulator of many physiological and pathological 
processes, and it is therefore important to understand the mechanism by which the GHR is activated 
following GH binding. Recent emerging findings on GHR polymorphism in relation to GH 
responsiveness and disease susceptibilities have given significant attention to the receptor signalling 
outcomes. Although over 60 loss of function mutations in GHR have been associated with deficient 
post-natal growth, to date no constitutively active GHR mutations has been reported. This study is 
aimed at identifying gain of function mutations in the receptor and analysing their consequence in 
vivo using the RCAS/TVA system. This study will focus on oncogenesis, since GHR loss of 
function results in abrogation of cancer susceptibility in men and autocrine expression of GH 
correlates with stage of cancer progression. I will also examine forced nuclear localisation of GHR 
since this has been shown to promote proliferation in vivo. This thesis will undertake a multi-
faceted approach to determine the role of GHR in mediating oncogenesis.  
 
1. Determine the structure-function basis of GHR-mediated oncogenesis 
Using cysteine scanning mutagenesis, the transmembrane domain helix interface of GHR will be 
revealed to determine the mechanism of Jak2 activation upon ligand binding. This will form the 
basis of creating mutants with constitutive Jak2/STAT5 activity. Because our group has shown that 
Src Family Kinases (SFKs) are activated by GHR independent of Jak2, mapping studies of the SFK 
binding to GHR will be undertaken to determine the basis of Jak2-independent mechanism of SFK 
activation because this may be important for oncogenesis. Finally, we intend to determine the 
molecular basis for the first cancer-associated variant of GHR identified from GWAS studies. This 
will be supported by genomic DNA analysis of polymorphisms associated with GHR and other 
signalling molecules in clinical prostate cancer at different Gleason stages. 
 
2. In vitro role of GHR-mediated oncogenesis 
Based on Waters’ Group earlier result that constitutive nuclear localised GHR is oncogenic we 
intend to determine its role in cancer cell lines in vitro. This will be carried out simultaneously with 
other constitutively active GHR constructs or those arising from the cysteine mutagenesis studies in 
Aim 1. Finally, we seek to evaluate the role of GH/GHR signalling in the autocrine MCF-7 model 
amidst reports citing contradictory effects of autocrine GH on cell transformation and proliferation.  
 
3. In vivo role of GHR-mediated oncogenesis 
Based on preliminary results from Aim 2, the potentially oncogenic GHR constructs will be tested 
for oncogenic effects in vivo to determine if GHR is a tumour initiator or a tumour promoter. The in 
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vivo delivery will be carried out using the RCAS/TVA delivery system to achieve tissue-specific 
expression. These studies will be complemented with naturally occurring end of life tumour 
incidences in GHR knockin and knockout models available in our group and their potential effect 
on longevity. These mice models will be used to analyse the potential cancer resistance pathways 
based on earlier report of reduced cancer incidences in long lived ghr null mice and lack of cancer-
related deaths in Laron dwarves. 
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Chapter 2 
Materials and General Methods 
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Chemicals 
Analytical grade chemicals were purchased from Sigma-Aldrich (MO, USA), Ajax Finechem 
(Australia). Other reagents were purchased from Invitrogen Australia Pty Ltd (Mt Waverly, VIC, 
Australia), Amersham Pharmacia (Uppsala, Sweden), Roche Boehringer (Castle Hill, NSW, 
Australia) and BioRad laboratories (Hercules, CA, USA). 
 
Tissue culture consumables 
All plastic consumables were supplied by Nunc industries (Thermo Scientific, IL, USA). Growth 
media (DMEM, RPMI 1640, LHC-9) were supplied by InvitrogenTM Life Technologies (NY, 
USA). Foetal Bovine Serum (FBS) and Serum Supreme (SS, a foetal bovine serum substitute) were 
purchased from Lonza Group Ltd (Basel, Switzerland). Geneticin418 (G418) was supplied by 
InvitrogenTM Life Technologies (NY, USA). Puromycin and Hygromycin B were purchased from 
Sigma-Aldrich (MO, USA). 
 
Antibodies and Enzymes 
Primary antibodies were supplied by Cell Signaling Technology® (MA, USA), Santa Cruz 
Biotechnology® Inc (Santa Cruz CA, USA) and Abcam® Inc (MA, USA) and Covance (NJ, USA) 
(details are listed in the Appendix VI). Secondary antibodies HRP conjugated were purchased from 
Santa Cruz Biotechnology®, Inc (Santa Cruz, CA, USA) and GE Healthcare Life Sciences 
(Dusseldorf, Germany). Enzymes used for molecular cloning were supplied by New England 
Biolabs (Genesearch Ltd, Australia).  
 
Hormones 
Recombinant human GH was expressed and purified in the laboratory of Professor Mike Waters 
(Behncken et al, 1997; Rowlinson et al, 1994). Recombinant Interleukin-3 (IL-3) was expressed and 
purified using Baculovirus expression by SRC Protein Expression Facility of Institute for Molecular 
Bioscience at University of Queensland. 
 
Buffers and Solutions 
Luria Bertani (LB) medium and LB agar plates 
Growth medium for bacteria containing 10g of tryptone, 5g of yeast extract and 5g of NaCl, was 
made up to 1L with water, the pH adjusted to 7.5 with NaOH, then autoclaved at 121°C and 20 PSI 
for 20min. For making LB agar plates, 15g of agar was dissolved in LB broth to a final volume of 
1L, then autoclaved at 121°C and 20 PSI for 20min and cooled to 50°C before the addition of the 
appropriate antibiotics. 20ml of the liquid agar was poured into 100mm petri dishes and left at room 
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temperature to solidify and plates were stored in darkness at 4°C. 
 
Phosphate Buffered Saline (PBS) 
A 10x concentrated stock was made by mixing 438.5g of NaCl (1.5M), 61.66g of Na2HPO4 
(87mM) and 11.5g of NaH2PO4 (15mM) in 5L of distilled water. After 10-fold dilution, the pH was 
adjusted to 7.4 prior to use.  
 
20% Sodium Dodecyl Sulfate (SDS) solution 
A 20% (w/v) SDS stock solution was prepared by dissolving 200g SDS in 1L of water. 
 
Tris EDTA (TE) Buffer 
TE buffer consisted of 10mM Tris base and 1mM EDTA (final concentration) in 1L of distilled 
water, adjusted to pH 8.0 with NaOH. 
 
Tris-acetate EDTA (TAE) buffer 
A 10x concentrated stock was made by mixing 48.4g Tris base (400mM), 3.72g EDTA (10mM) 
and 11.42ml of acetic acid in a final volume of 1L of water.  The stock was adjusted to pH 8.3 with 
acetic acid after dilution. This was diluted to 1x TAE buffer with distilled water prior to use. 
 
Laemmli resolving gel buffer 
Resolving gel buffer consisted of 2.5ml 20% SDS, 22.7g Tris Base and 30ml 1M HCl made up to a 
final of 100ml with distilled water (final 0.5% SDS, 625mM Tris-HCl, pH 8.8). 
 
Laemmli stacking gel buffer 
Laemmli stacking gel buffer was made with 62.5ml 1M Tris-HCl, 2.5ml 20% SDS and distilled 
water added to 100ml (final 0.5% SDS, 625mM Tris HCl, pH 6.8).  
 
Laemmli running buffer 
A 10x Laemmli running buffer concentrate consisted of 30.25g Tris Base, and 144.2g Glycine 
added to 950mL distilled water. When these had dissolved, 50ml of 20% SDS solution was added, 
then the solution was diluted 10-fold with distilled water to make 1x Laemmli Running buffer prior 
to use.  
 
6x DNA Loading Buffer 
The DNA loading buffer consisted of 30ml glycerol (final 30%) and 500ml loading dye concentrate 
 85 
(5% glycerol, 0.5% Bromophenol blue, 0.5% Xylene cyanol in distilled water), made up to 100ml 
with distilled water (stored at room temperature). 
 
Tris Buffered Saline 
A 10x Tris buffered saline (TBS) was made by combining 24.4g Tris base, 80g NaCl, and 38ml of 
1M HCl, made up to 1L with distilled water, pH 8.6. This was diluted 10-fold prior to use as a 
washing or blocking buffer, to give a final concentration of 30mM Tris, 140mM NaCl. 
 
Plasmid manipulation 
Preparation of chemically competent E. coli cells 
A starter culture of E. coli (DH5a  or stbl3 or ccdB resistant) was prepared by inoculating 15ml LB 
broth without antibiotics with a scraping of glycerol stock and incubated for 16hrs at 37°C with 
continuous shaking. The starter culture was then diluted in 500ml of LB broth without antibiotics 
and grown to an OD540 of 0.4-0.6 over a period of 3-4hrs. The cells were transferred to centrifuge 
tubes and cooled on ice.  Cells were centrifuged at 6000rpm for 5min at 4°C and the pellet was 
resuspended in 250ml of ice cold 50mM CaCl2, then incubated for 60min on ice.  The cells were 
centrifuged again as before and resuspended in 50ml of a solution containing 50mM CaCl2 and 15% 
(v/v) sterile glycerol. 0.5ml of the cell suspension was dispensed into microfuge tubes, rapidly 
frozen on dry ice and stored at -80°C. These cells were verified for competence with low 
concentrations of DNA. 
 
Plasmid or ligation mixture transformation 
Calcium chloride competent E.coli cells (200µl) were added to an ice-cold microfuge tube 
containing 10µl of the transforming plasmid DNA at an approximate concentration of 10µg/ml.  
The mixture was incubated on ice for 30min after which it was subjected to heat-shock at 42°C for 
1min. 1ml of LB broth was added and the tube was incubated for 1hr at 37°C with shaking. 
Subsequently the bacterial cells were centrifuged for 1min at 8000rpm at room temperature and 
900µl of the supernatant was removed.  The pellet was resuspended with the remaining supernatant 
and spread over an agar plate containing the specific antibiotic. The plates were inverted and placed 
in a 37°C incubator overnight. 
 
Plasmid DNA Isolation 
For routine screening of bacterial colonies, individual colonies were picked with a 200µl tip and 
cultured in 2-3ml of LB broth with antibiotics overnight in a shaking incubator at 37°C. The 
bacterial cell suspension was used for plasmid DNA extraction using InvitrogenTM Mini-Prep kit 
(CA, USA). For larger DNA preparations, Nucleobond™ Midi Plasmid Extraction kit (Macherey-
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Nagel GmbH & Co. Duren, Germany) was used as per manufacturer’s guidelines. Plasmid 
concentration was determined on NanoDropTM spectrometer (Thermo Scientific). Integrity of the 
plasmid was determined by agarose gel electrophoresis. 
 
DNA Sequencing 
The DNA to be sequenced (800-1000ng) and each primer (0.64µM) in a total volume of 12µl were 
sent to Australian Genome Research Facility (AGRF, University of Queensland, QLD, Australia) 
for the ‘purified DNA’ sequencing service. The primer sequences used for sequencing analysis are 
listed in Appendix II. 
 
Animals 
Animals were housed in the Institute for Molecular Biosciences animal facility under a 12hr 
light/dark cycle at 20±2°C. Water and food (Meat-free rat and mouse diet, Specialty Feeds, 
Australia) was available ad libitum. All experiments were approved by and performed in 
accordance with the guidelines set by the University of Queensland Animal Ethics Committee. 
 
GHR Mutant Mice 
GHR knockin mutant mice (GHR K1 (ghr 569tr), GHR K2 (ghr 391tr) and GHR K4 (Box1 prolines 
mutated to alanines) were generated previously (Barclay et al, 2010; Rowland et al, 2005b). GHR 
knockout mice (GHR KO or ghr null) were generated previously (Zhou et al, 1997a) and kindly 
provided by Prof. John Kopchick (Department of Biomedical Sciences, Ohio University, Athens, 
OH, USA). 
 
Genotyping 
Genotyping was performed by PCR on mouse genomic DNA extracted from 8 –12 day old mouse 
toe tissue (toe selection was also used as a means of identification). DNA was extracted using hot 
NaOH as described earlier (Truett et al, 2000). PCR reactions for genotyping were carried out in 
20µL reactions consisting of: 10-200ng genomic DNA, 1x Phire® Reaction Buffer (Thermo 
Scientific, Finland), 200µM dNTPs, 0.5µM primers (Table 2.1), 0.4µL Phire® Hot Start DNA 
Polymerase (Thermo Scientific, Finland). PCR reactions were performed in a Biorad i-Cycler® or 
my-Cycler® thermal cycler (BioRad) with the reaction conditions specified below. 
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Table 2.1: List of pimers and their sequences used for genotyping 
Primer Sequence 
9F 5’CCTACTTCCTGCTTAGAACTCTC 
10R 5’ GCTCAATGAACTCGACCCAGG 
In3+1  5’ CCTCCCAGAGAGACTGGCTT 
In4-1 5’ CCCTGAGACCTCCTCAGTTC 
Neo3 5’ GCTCGACATTGGGTGGAAACAT 
Cre Fwd 5’ CGAGTGATGAGGTTCGCAAG 
Cre Rev2 5’ CACCAGCTTGCATGATCTCC 
Cre Ctrl Fwd 5’ CTAGGCCACAGAATTGAAAGATCT 
Cre Ctrl Rev  5’ GTAGGTGGAAATTCTAGCATCATCC 
 
GHR Knockin genotyping 
In order to genotype the GHR knockin mutants, the 9F and 10R primers (Table 2.1) were used to 
amplify the intronic region between ghr exon 9 and 10. This produced a 593bp product in the WT 
allelles and a 746bp product in mutant alleles that included the remaining loxP site from the Cre 
deletion of the neomycin-resistant (neo) selection cassette used in the original transgene construct to 
generate the mice (Barclay et al, 2010; Rowland et al, 2005b) (fig.2.1). The PCR cycle conditions 
used were: 
Initial denaturation: 98°C for 2 min 
35 cycles of: 
Denaturation: 98°C for 5 sec 
Annealing: 58°C for 5 sec 
Extension: 72°C for 20 sec 
Final extension: 72°C for 1 min 
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Figure 2.1: Schematic Diagram of Genotyping PCR for GHR knockin mutants. 
Primers 9F and 10R amplify a 593 bp product within ghr intron 9/10 in the WT allele. Ghr mutants (GHR K1, GHR K2 and 
GHR k4) were created as described (Rowland et al, 2005b; Barclay et al, 2010). The original construct used to create the 
mice contained a loxP neomycin resistance selection cassette within ghr intron 9/10 which was excised by Cre 
recombinase. The remaining loxP site results in a 746bp product amplified by the genotyping PCR from the ghr mutant 
allele. 
 
GHR KO Genotyping 
The In3+1, In4-1 and Neo3 primers (Table 2.1) were used to genotype the GHR KO mutants. 
Primers In3+1 and In4-1 amplify the region containing exon 4 (plus some flanking intronic regions) 
in the WT allele, yielding a 390bp product. The GHR KO mutant allele contains the neo-selection 
cassette that has replaced the majority of exon 4 and ~500bp of the intron 4/5 (Zhou et al, 1997a). 
Neo3 primer binds to a repeat sequences in the neo cassette. The primers In3+1 and Neo3 amplify 
290bp and 220bp products in the GHR KO allele (fig.2.2). 
The PCR cycling conditions used were: 
Initial denaturation: 98°C for 2 min 
35 cycles of: 
Denaturation: 98°C for 5 sec 
Annealing: 62°C for 5 sec 
Extension: 72°C for 10 sec 
Final extension: 72°C for 1 min 
  
5’ 3’
9F 10R
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Exon 9 Exon 10
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9F 10R
746 bp
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Ghr knockin allele
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Figure 2.2: Schematic Diagram of Genotyping PCR for GHR KO Mutants. 
Primers In3+1 and In4-1 amplify a 390bp product spanning ghr exon 4 in the WT allele. GHR KO mutants were created 
as described (Zhou et al, 1997a). A neomycin resistance gene replaces most of ghr exon 4 and ~500 bp of intron 4/5. 
The Neo3 primer binds to a repeat sequence in the neomycin resistance gene. The In3+1 and Neo3 primers amplify 2 
products (220bp and 290bp). 
 
DNA Agarose Gel Electrophoresis 
PCR products were identified by size by electrophoresis on agarose gels. Agarose gels were made at 
2% (w/v) with analytical grade agarose (Amresco, Ohio, USA) in Trisacetate- 
ethylenediaminetetraacetate (TAE) buffer (40mM Tris, 20mM acetic acid, 1mM EDTA). Gels were 
pre-stained with Sybr Safe (Invitrogen, Australia). PCR reactions were mixed with 10x loading 
buffer (50% red food colouring, 50% glycerol) and electrophoresed at 80–100V in TAE buffer. A 
100bp DNA ladder (New England Biolabs, MA, USA) was used as a size reference. Gels were 
visualized using the Universal Hood UV Transilluminator (BioRad, Sydney, Australia) and 
Quantity One (v 4.4.0) software. 
 
Tissue Collection 
Unless, specified, all mice were 12–14 weeks (young) and 78-80 weeks (old) of age at collection. 
Mice used in this thesis were in the fed state prior to tissue collection. Mice were anaesthetised by 
placing them into a chamber flushed with CO2 until unconscious.  
 
Serum samples were obtained by blood collection via cardiac puncture using 27 gauge needles. 
5’ 3’
In3+1 In4-1
390 bp
Exon 4
5’ 3’
Neo
In3+1 Neo3
220 bp
Wt ghr allele
Ghr-/-  allele
Neo3
290 bp
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Blood was kept at room temperature for 1hr until centrifugation at 3000rpm, at 4°C for 20min for 
serum separation. After cardiac puncture, mice were euthanized by cervical dislocation. Tissue 
samples were dissected and snap frozen in liquid-nitrogen or fixed for histology. Snap frozen tissue 
and serum (aliquoted into tubes) was stored at -80°C until used for analysis. 
 
Tissue Processing for Histology 
Small pieces of liver or muscle were fixed in 4% paraformaldehyde (PFA) in phosphate buffered 
saline (PBS) at 4°C with gentle rocking overnight. Fixed tissue was then washed in PBS and either 
stored in 70% ethanol at 4°C for paraffin embedding or cryopreserved in Tissue-Tek®O.C.T™ 
compound (Sakura Fine technical, Tokyo, Japan). Tissue was paraffin embedded using a TP1020 
Tissue Processor (Leicia Microsystems, Australia). Cryopreserved samples were incubated in 30% 
sucrose in PBS at 4°C overnight, followed by embedding in Tissue-Tek® O.C.T™ compound. The 
cryopreserved samples in O.C.T compound were stored in -80°C. 
 
Quantitative Reverse Transcription Polymerase Chain Reaction (qPCR) 
RNA extraction and reverse transcription 
Cell pellets, mouse tissues and whole zebrafish were homogenised in Trizol Reagent (Invitrogen, 
USA) and RNA was extracted according to the manufacturer’s instructions. RNA was then further 
purified and DNase treated using RNeasy® Mini Kit clean up protocol (Qiagen, Maryland, USA). 
RNA was reverse transcribed using Superscript III (Invitrogen, USA) using the random hexamers 
protocol and used for qPCR with Sybr® Green Technology (ABI, CA, USA) in the 7500HT Real 
Time Cycler (ABI, CA, USA), 7900 Real Time Cycler (ABI, CA, USA) or ViiA7 Real Time Cycler 
(ABI, CA, USA). For all qPCR experiments, triplicate reactions were performed for each gene 
including controls using a two-step amplification program (Initial denaturation at 95°C for 10 
minutes, followed by 40cycles of 95°C for 20seconds and 60°C for 30seconds). A melting curve 
analysis step was added at the end of amplification, consisting of denaturation at 95°C and re-
annealing at 55°C for 1minute each. A comparative Ct method was used to determine relative 
expression in samples. 
 
Primer design for SYBR® Green Technology 
Primers for qPCR were designed using Primer Express 2.0 software (ABI, CA, USA). Standard 
curves were generated from each experimental plate using 5-fold serial dilutions of cDNA. The 
geometric mean of Ct-value for each reaction was calculated along with amplication efficiency for 
each primer pair using the equation E=10(-1/slope). Primer pairs that showed efficiency between 90%-
105% were chosen. No non-specific amplication or primer dimer was observed as confirmed by 
melting curve analysis. Final analysis was performed by calculating the change in Ct between the 
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gene of interest normalised against the housekeeping gene (such as glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) or glucoronidase beta (GusB) or beta-2 microglobulin (B2M) where 
specified) and expressed as a mRNA levels relative to control or fold change above control as 
indicated.  
 
Western Blot Analysis 
Protein Extraction 
Pieces of liver, heart, skeletal muscle and kidney tissues were homogenised or cells were scraped in 
radioimmunoprecipitation (RIPA) buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, 50mM Tris (pH8.0), 1mM Na3VO4, 30mM NaF, 10mM Na4P2O7, 10mM EDTA plus 
Complete EDTA-free protease inhibitor cocktail (Roche, Mannhein, Germany). Tissue 
homogenates were cleared by centrifugation at full speed for 10min at 4°C. Protein concentration 
was determined by BCA assay (Pierce, IL, USA). 
 
SDS Polyacrylamide Gel Electrophoresis (SDS‐PAGE) 
Equal amounts of protein were incubated at 100°C for 5min in sample buffer (15mM Tris-HCl (pH 
6.8), 2% SDS, 10% glycerol, 10mM DTT), loaded into SDS-PAGE gels and separated by 
electrophoresis. Precision Plus Protein™ Dual Color Standards (BioRad, CA, USA) was used as a 
size reference. Gels were prepared according to the Laemmli system (Laemmli, 1970). Gradient 
gels (4–20%) were purchased from BioRad (CA, USA). For single percentage gels, the appropriate 
amount of 40% acrylamide/bis (29:1 acrylamide:bis) solution (BioRad), 1mL of resolving gel 
buffer (0.5% SDS, 62.5mM Tris-HCl, pH8.8), 5µL N,N,N’-tetra-methylethylenediamine (TEMED 
[ICN Biomedicals Inc, Costa Mesa, USA]) and 30µL 10% ammonium persulphate (APS) made up 
to 5mL with distilled water (dH2O) was set in a Mini-PROTEAN® casting apparatus (BioRad). 
Water-saturated isobutanol was overlaid onto the gel to ensure a straight interface. After 
polymerisation, the isobutanol was removed and a stacking gel (250µL 40% acrylamide/bis 
solution, 500µL stacking gel buffer (62.5mM Tris-HCl, 0.5% SDS, pH 6.8), 5µL TEMED and 30µL 
10% APS made up to 2 mL with dH2O) was set on top of the resolving gel with a spacer comb 
inserted. Electrophoresis was performed in Mini-PROTEAN® Tetra cell tanks (BioRad) in Laemlli 
running buffer (0.1% SDS, 200 mM Tris-HCl, pH 8.0). 
 
Electroblotting and Probing of Membranes 
After electrophoresis, gels were transferred onto 0.2µm PVDF membranes either using the semi-dry 
Hoefer® TE-70 semi-dry electroblotter or the Trans-Blot® Turbo™ Transfer System (BioRad). 
Membranes were blocked with 5% Bovine Serum Albumin (BSA) or 5% skim milk in Tris-
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Buffered Saline containing 0.1% Tween-20 (TBST) for 1hr at room temperature. Blots were probed 
by incubating with specific primary antibody (listed in Appendix VI) diluted in blocking buffer 
overnight at 4°C or 1hr at room temperature. Blots were washed and incubated with 1:10000 
dilution of secondary anti-IgG conjugated to horseradish peroxidase (HRP) (GE Healthcare, 
Dusseldorf, Germany) in blocking buffer for 1hr at room temperature. Membranes were washed and 
proteins visualised with a chemi-luminescent reagent (GE Healthcare, Dusseldorf, Germany) via 
exposure to X-ray film (Fuji Film, Japan). The X-ray film was imaged using Epson Perfection™ 
scanner. All densitometry quantitation was performed on immunoblots using ImageJ® software. All 
test values were normalised to respective loading control and represented relative to experimental 
control and graphed with Prism 5. 
 
Stripping of PVDF Membranes 
PVDF blots were routinely stripped and re-probed for loading controls after detection of the protein 
of interest. Blots were stripped using Re-Blot Plus Mild Stripping Solution (Millipore, CA, USA) 
according to the manufacturer’s instructions. Blots were washed with TBST for 10min before re-
blocking and re-probing. 
 
Immunohistochemical analysis 
Formalin-fixed/paraffin-embedded sections were deparaffinised and rehydrated by passage through 
a graded xylene/ethanol series before antigen retrieval by boiling in 10mM Sodium Citrate Buffer 
for 5min. The sections were then washed and subjected to various blocking steps at room 
temperature with intermittent washes: (i) 3% H2O2/PBS for 30 min (blocking endogenous 
peroxidise activity), (ii) 10% animal serum in 2% BSA (IgG free Fraction V) in 0.025% Triton 
containing PBS for 1hr (blocking non-specific sites), (iii) Avidin and Biotin block for 15min each 
(blocking endogenous biotin). Rabbit anti-GFP polyclonal primary antibody (Invitrogen; 1:200 
dilution in serum containing blocking buffer) incubation was carried out in a humidified chamber at 
4°C overnight, slides were washed and subjected to goat anti-rabbit biotinylated secondary antibody 
(Sigma; 1:250 dilution in serum containing blocking buffer). The signal was amplified using 
VectaStain® ABC kit as per manufacturer’s conditions (Vector labs) and subjected to 
diaminobenzidine (DAB) staining. The reaction was stopped by incubating the slides in tap water 
and counter stained with hematoxylin for nuclear staining. The slides were dehydrated by ethanol 
gradation series, xylene treated and mounted in Entellan (Merck). The slides were then analysed on 
an Olympus IX70 Microscope. 
 
Immunofluorescence analysis 
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Frozen sections were allowed to equilibrate to room temperature and rehydrated in PBS. Antigen 
retrieval was performed by boiling the slides for 5min in 10mM Sodium Citrate buffer and the 
sections were blocked in 10% animal serum, 2% BSA in 0.025% triton containing PBS for 1hr at 
room temperature. Primary antibodies used were rabbit anti-GFP (Invitrogen; 1:5000) and 
incubated overnight at 4°C and mouse anti-HA (Covance; 1:200) incubated for 1h at room 
temperature in a humidified chamber. Following incubation, the slides were washed 5 times in 0.1% 
Tris Buffered Saline with Tween-20 (TBST) and incubated in the dark with goat anti-rabbit Alexa 
Fluor 488/594/647 conjugated secondary antibody (Invitrogen; 1:200) for visualising GFP and goat 
anti-mouse TritC conjugated secondary antibody (Sigma; 1:100) for HA tag, for 1h at room 
temperature. The slides were then washed five times in 0.1% TBST and mounted with 
VectaShield® containing DAPI, sealed and stored at 4°C for visualization.  
 
For direct visualisation of cells and tissues expressing GFP, the cells and tissues slides fixed in 4% 
PFA were mounted with VectaShield® containing DAPI, sealed and stored at 4°C. The slides were 
then analysed under an Olympus IX70 Fluoro microscope and analysed by the Fluoroview v. 1.6A 
software. 
 
Data analysis and statistics 
Statistical analysis was performed in GraphPad Prism® version 5.0 with multiple comparisons by 
ANOVA, using Tukey’s post hoc test. Comparisons of two groups utilized an unpaired student t-
test. 
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Transmembrane Domain 
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Introduction 
Given that a conformational change in ECD induced by ligand binding activates Jak2 (Brown et al, 
2005), these structural changes must be transmitted through the transmembrane domain and 
intervening sequences from the extracellular domain to the Box1 motif. The constitutive 
dimerisation of GHR (Brown et al, 2005) and EPOR (Constantinescu et al, 2001) is mediated 
predominantly through interactions in the TMD; however, other regions such as the ECD may also 
play a role in the dimerisation process or provide specificity to homodimer formation (Yang et al, 
2007). Unlike the ECD (Clackson et al, 1998; de Vos et al, 1992), there has not been any direct 
structural data about the TMD or ICD of the GHR. Comparison of the unliganded and GH-bound 
GHR ECD structures revealed that the orientations of the main chain, including residues in the 
dimerisation interface, are almost identical in both (Brown et al, 2005). The lack of major difference 
between the structures of the unliganded and GH-bound ECDs led to the hypothesis that GH 
initiates signalling by inducing rotation within the inactive preformed dimer so as to change the 
relative orientations of the cytoplasmic domains and bring Jak2 molecules bound to each GHR 
dimer partner within proximity for activation. This model suggested that both the ECD and ICD 
juxtamembrane domains of the GHR adopted a rigid conformation to allow the transmission of the 
torque force resulting from the asymmetrical binding of GH to both receptors. Furthermore, Brown 
et al. have reported that GHR can be activated in the absence of ligand by inserting a defined 
number of alanine residues within the TMD, presumably by causing a specific rotation of the 
dimerised receptor monomers relative to each other (Brown et al, 2005).  
 
Random mutagenesis experiments have revealed constitutively active mutations in the TMD of 
homologous EPOR (Lu et al, 2006) and TPOR (Onishi et al, 1996). Mutation Ser505Asn in the 
TMD of the related thrombopoietin receptor is linked to familial thrombocythemia, and this 
mutation (experimentally mutated to glutamic acid, aspartic acid or glutamine) results in 
constitutive activation of the receptor, which was proposed to be due to receptor dimerisation and 
alteration of the TMD conformation or rotation to an active form (Ding et al, 2009). Additionally, 
several non-peptide thrombopoietin mimetics interact only with residues within the transmembrane 
domain and extracellular juxtamembrane linker (Kuter, 2009), which underscores the role of the 
TMD as an important target for novel drug development to modulate cytokine receptor activation. 
 
The human GHR TMD is composed of a single 24 amino acids from F265 to S288 in a mature 
receptor (Leung et al, 1987; Waters, 1999) and is encoded entirely by exon 8 of the ghr. Numerous 
mutations in human GHR leading to loss of function attributes such as in Laron dwarfism and GHIS 
(Bronson & Lipman, 1991; Waters, 1999) have been reported. Interestingly all these mutations lie 
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in the ECD and ICD regions of the GHR and so far only a single case report with a mutation in the 
splice donor site of exon 8 that disrupts normal splicing has been reported (Woods et al, 1996). This 
resulted in the complete skipping of exon 8, producing a mutant GHR protein lacking TMD and 
ICD domains. Thus, the precise role of TMD in the initiation of receptor signalling is currently 
unknown and will be evaluated in this chapter. This chapter will discuss in detail the structural 
information generated from cysteine scanning mutagenesis studies and correlate it with downstream 
signalling in order to determine the exact role of TMD in mediating a signalling response upon GH 
binding. 
 
Materials and Methods  
Construction of full-length human GHR cysteine mutant constructs 
Truncated HA (haemagglutinin) tagged hGHR (human growth hormone receptor) with cysteine 
substitutions in pCDNA3.1 plasmid were created by site-directed mutagenesis (primers listed in 
Appendix I). Each GHR mutant created was truncated at C389 (stop codon inserted after C389) 
while cys259 was also converted to serine. Full-length HA-tagged Cys mutant hGHR constructs 
were created by carrying out AvaI partial digestion of wild-type full-length hGHR pCDNA3.1 
vector and a 2002bp fragment was isolated, purified and ligated to the dephosphorylated 5669bp 
fragment produced by AvaI digestion of truncated Cys mutant hGHR constructs. The ligation 
reaction was carried out using T4 DNA ligase at 16°C overnight and subsequently used to transform 
competent E. coli DH5α. Ampicillin resistant colonies were screened, sequenced and a correct 
clone for each construct was used for large-scale DNA preparations. Double cysteine hGHR mutant 
constructs were made by three-fragment ligations in which the wild-type vector was digested with 
EcoRI and KpnI and dephosphorylated. The vector carrying the first cysteine mutation was digested 
with EcoRI and NcoI and a 1075bp product was obtained. The vector carrying the second cysteine 
mutation was digested with NcoI and KpnI digestion and a 427bp product was obtained. The two 
products were then ligated into the dephosphorylated vector backbone and transformed into DH5α 
strain. 
 
The full-length cysteine hGHR constructs were cloned from pCDNA3.1 into viral expression vector 
pMX-IRES-GFP. This was carried out by PCR reaction along the entire length of the insert (HA-
hGHR), digestion with NcoI and finally ligation into partially digested pMX-IRES-GFP vector 
(6595bp) which expresses GFP via an Internal Ribosomal Entry Site (IRES). The correct clones 
were selected following transformation into E.coli DH5α and confirmed by restriction digestion and 
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sequencing. The pCDNA3.1-STAT5B(WT) plasmid was a kind gift from Dr. J. Barclay (Waters’ 
Group, IMB). 
 
Cell lines 
The African green monkey kidney cell line, COS-1 (purchased from ATCC) and human embryonic 
kidney cell line, HEK293 (a kind gift from Dr. F. Fontaine, Cooper Group, IMB) and retroviral 
packaging cell line, PLAT-E (Morita et al, 2000) a gift from Dr. T. Kitamura from University of 
Tokyo, Japan) were maintained in DMEM media supplemented with 10% FBS. The murine pro-B 
Ba/F3 cell line were chosen for the convenience of analysing GHR constructs (based on GH 
selection) as they are devoid of any endogenous GHR. Ba/F3 cells were maintained in RPMI 1640 
media supplemented with 10% SS, 2mM L-glutamine and 100units/ml IL-3 or 100ng/ml hGH 
(where indicated). All cell lines were maintained at 37°C in a humidified incubator containing 5% 
CO2. 
 
Signalling analysis with hGH treatment 
COS-1, HEK293 and Ba/F3 cell lines were starved overnight and then treated with hGH (expressed 
and purified by Waters’ Group) at 50ng/ml in reduced-serum media. The starve media (or reduced-
serum media) for COS-1 and HEK293 was DMEM supplemented with 0.5% FBS and for Ba/F3 
cell lines was RPMI 1640 supplemented with 5% FBS without IL-3 or GH. All GH stimulations 
(where indicated) were carried out for 10 minutes at 25°C. Following stimulation of COS-1 and 
HEK293, the media was aspirated and the cells were washed twice with chilled PBS. Treated Ba/F3 
cells were collected by centrifugation at 4°C and washed twice with ice-cold PBS before final pellet 
collection. The cells were then harvested in RIPA lysis buffer, the lysates quantified for total 
protein and these were subjected to reducing SDS-PAGE and immunoblotting.  
 
Cysteine Crosslinking Studies 
Crosslinking in membrane extracts 
COS-1 cells were plated at a seeding density of 4x105 cells per well (6 well plate format) and 
transfected with a series of N-terminal HA-tagged hGHR truncated cysteine mutants (L251C to 
S288C) in pcDNA3.1 backbone using lipofectamine 2000 as per manufacturer’s guidelines. Cells 
expressing receptor constructs were homogenised and diluted to give a minimal level of expression 
for clear detection with 100ng/well hGHR cys construct transfected per well. Crosslinking was 
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performed 24hrs after transfection. Briefly, to obtain membrane extracts wells were washed with 
ice-cold phosphate-buffered saline (pH 7.4) and scraped in 1ml of cold Buffer A (25mM sodium 
phosphate, 5mM MgCl2, 2mM Na3VO4, pH 7.4 with 1×Complete Protease Inhibitor Cocktail 
(Roche) and homogenised using handheld Kinematica Polytron homogenizer (Fisher Scientific) at 
full speed for 10sec. Membrane extracts were then centrifuged at 17000g for 20min, and 
resuspended in 100µl of buffer A. The extracts were subjected to crosslinking by disulfide bond 
formation by treatment with Cu-o-phenanthroline comprised of 0.40mM CuSO4 and 1.60mM o-
phenanthroline (Sigma Aldrich), for 10min at 37°C after addition of 500ng/ml hGH. The reaction 
was terminated with 10mM EDTA prior to SDS-PAGE on a non-reducing gel, blotted on PVDF 
membrane and probed with anti-HA antibody (Covance) to reveal monomers and dimers. Due to 
interference from crosslinking reagents protein quantification of membrane extracts by Bradford or 
BCA were not compatible and as a result equal volumes of lysates were loaded onto the gel. 
 
Crosslinking in intact cells 
For signalling analysis on intact cells, HEK293 cells were plated at seeding density of 2×105 cells 
per well and transfected next day with full-length hGHR expression constructs with cysteine 
mutations or WT GHR construct (C259). GH at 50ng/ml was then added for 10min at 37°C and Cu-
o-phenanthroline where indicated (at the concentrations indicated above). Crosslinking was stopped 
with 2mM EDTA and GH treatment was stopped with two washes in cold PBS. 
 
For signalling analysis of spontaneous cysteine dimers in the absence of hGH, 30ng of STAT5B 
pCDNA3.1 expression construct was also transfected along with 300ng of full-length hGHR 
constructs to increase sensitivity. The cells were incubated for 24-36hrs then starved overnight in 
reduced serum media (DMEM supplemented with 0.5% FBS) and harvested. STAT5 
phosphorylation and GHR levels were analysed by resolving quantified protein lysates on a 
reducing SDS-PAGE. In addition, dimerisation of full-length GHR was analysed simultaneously on 
a non-reducing SDS-PAGE gel. 
 
Production of replication defective ecotropic retrovirus  
In order to generate retrovirus for stable transduction of Ba/F3 cell line, the potent retroviral 
packaging cell line, Plat-E was used. The cells were plated at a cell density of 8.5×104 cells per well 
in a 6-well format and transiently transfected with 4µg of pMX-HA-hGHR-IRES-GFP constructs 
for each of the full-length cys mutant constructs using lipofectamine 2000 as per manufacturer’s 
guidelines. The media was replenished 24hrs post-transfection and the plates were further incubated 
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at 37°C for 24hrs. The plates were then incubated for 24hrs at 32°C and supernatant collected and 
filtered through 0.45µm (low protein binding) polyethersulfone membrane filter and used for 
transducing the Ba/F3 cell line.  
 
Stable transduction of Ba/F3 cell line 
A total of 2×105 starved Ba/F3 cells were harvested and seeded in each well of a 6-well cell culture 
plate for viral transduction with different cysteine hGHR mutants (full-length). The starved cells 
were resuspended in the harvested viral supernatant. Polybrene was added at a final concentration 
of 8µg/ml and the plates were incubated at 37°C for 1-2 hours. After incubation, an equal volume of 
RPMI growth media with twice the standard concentration of IL-3 was added and the plates were 
incubated at 37°C further for 48h. Ba/F3 cells were analysed for stable transduction by FACS 
sorted for GFP expression (via the IRES cassette) from untransduced cells (at FACS Facility, 
QIMR). These GFP expressing cells were then grown in IL-3 containing media and selected on GH.  
 
Ba/F3 proliferation assay 
For measuring proliferation of Ba/F3 cells transduced with full-length hGHR cys mutants, the cells 
were starved overnight and seeded at a cell density 2x104 cells/ml in duplicate in growth media 
supplemented with 2mM glutamine and 10% charcoal-stripped serum (Hyclone) (Day 0) and cells 
were counted daily by trypan blue (Sigma Aldrich) exclusion using a hemocytometer. 
 
Surface expression of GHR 
For analysis of the surface expression of GHR in stably transduced Ba/F3 cell lines, 107 cells were 
starved overnight in medium devoid of IL-3/GH. The cells were washed in cold PBS and treated 
with mouse anti-HA antibody (1:200) for 2hrs on ice. Note that all reactions were carried on ice and 
without any permeabilisation agent to prevent receptor downregulation and antibody internalisation. 
Following subsequent washes, cells were incubated in dark and on ice with TritC conjugated goat 
anti-mouse secondary antibody (1:50, Sigma Aldrich MO, USA) for 40 min. The cells were washed 
in cold PBS, fixed in 2% PFA and analysed at QBI FACS Facility. 
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Results 
Cysteine-scanning analysis is a valuable and established method for predicting the topology of 
membrane proteins, determining structural parameters such as distance, torsion angle and 
investigating different functional states of proteins (Friedbichler et al, 2011).  This approach has 
been expanded into Substituted-Cysteine Accessibility Method (SCAM), in which cysteine residues 
are introduced sequentially along the TMD that allows characterisation of the interacting interfaces, 
either by detection of spontaneously formed disulphide bonds or by chemical crosslinking 
(Friedbichler et al, 2011; Kubatzky et al, 2001). 
Construction of GHR cysteine mutants 
Using the WT hGHR as template, C259S and C389stop truncation were introduced sequentially, 
illustrated in figure 3.1A. The resulting PCR product was used as template to sequentially introduce 
cysteine mutants from L251 to S288 in the C259S background, truncated at residue 389. 
Modification of cys to ser is important as it provides a thiol-free background for sulfydryl 
crosslinking solely between the introduced cysteine residues in the juxtamembrane linker (L251 to 
Y264C) and the TMD (F265 to S288). Each mutant was confirmed by sequencing and transient 
expression in COS-1 cells. Using HA tag antibody revealed that all GHR truncations were 
expressed at a similar level (fig.3.1B). The same truncated constructs were later made full-length to 
assess the effect of targeted cys crosslinking on Jak2/STAT5 signalling. 
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Figure 3.1: Schematic illustration of hGHR cysteine mutant constructs and their expression. 
(A) Schematic illustration of the wildtype (WT) GHR construct and design of truncated and full-length versions of the 
hGHR Cys mutant constructs. Each juxtamembrane linker or TMD residue was sequentially mutated to cysteine in a 
C259S background, truncated at C389. (AA-amino acid; tr- truncated; ECD: extracellular domain, TMD: transmembrane 
domain, ICD: intracellular domain). (B) Similar expression levels of hGHR cys mutants by transient transfection in COS-
1 cells with lysates resolved on an reducing gel before immunoblotting with an anti-HA antibody.  
 
Spontaneous dimerisation pattern of GHR cysteine mutants 
Disulfide bond formation is possible only under oxidising conditions. This means that spontaneous 
disulfide bond formation between two cysteine residues in close spatial proximity is possible in the 
ECD but not in the ICD due to the reducing environment in the cytosol. COS-1 cells transiently 
expressing the different GHR constructs were lysed and proteins resolved under non-reducing 
conditions as shown in figure 3.2. As is evident from the blot, 6 GHRcys mutants (E260C, E261C, 
D262C, F263C, Y264C and F265C) were strongly dimerised (based on dimer to monomer ratio) 
 102 
while 4 mutants (P266C, W267C, L268C and L269C) were dimerised to a lesser extent. In addition, 
the upper linker region (L251C to T258C) above C259 did not form any detectable spontaneous 
dimers (not shown). Thus, every cysteine substitution located between E260C to L269C was able to 
form an intermolecular disulfide bond between the two GHR molecules.  
 
 
Figure 3.2: Spontaneous dimerisation pattern of the hGHR cysteine mutant. 
Transiently expressing hGHR cys truncations in COS-1 cells were lysed and protein lysates resolved on a non-reducing 
SDS-PAGE gel before immunoblotting with an anti-HA antibody (for GHR). The GHR dimers and monomers are 
indicated in comparison to full-length WT and truncated C259S. Based on the dimer to monomer ratio few residues 
(E260C to F265C) dimerised strongly in comparison to those modestly dimerised (P266C-L269C) for equal amount of 
lysate loaded, while no dimerisation was evident from I270C residue onwards. Blots representative of n=3 independent 
experiments. 
 
Cysteine crosslinking analysis of membrane extracts 
In order to overcome the limitations of crosslinker penetration into the membrane observed 
previously with MTS-2-MTS (Gardon O Masters Thesis, 2006), Cu-o-phenanthroline [Cu(II)-(1,10-
phenanthroline)3] was used. It is a zero-length crosslinker as it does not introduce any linker to 
bridge the targeted cysteines, instead copper withdraws electrons from the sulfhydryl on cysteine 
side chains creating an oxidising environment that favours disulfide bond formation between the 
sulfhydryl groups in immediate proximity. The use of Cu-o-phenanthroline (CuP) to form disulfide 
bonds is more likely to reveal minor structural changes compared to other crosslinkers such as 
MTS-2-MTS owing to the short distance of crosslink. 
 
The use of CuP on membrane extracts provided deeper access into the membrane as compared to 
the previously used crosslinkers and intact cell treatment. It was consistently observed that CuP was 
unable to crosslink the residues in the middle of the TMD (G274C-T279C) but could crosslink 
those positioned at its ends. Such an effect could be due to inability of CuP to provide an oxidising 
environment for disulfide bond formation in the middle of the TMD but since these studies were 
conducted on crude membrane extracts, the crosslinks could be formed at the ends of the TMD with 
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two-way accessibility for CuP (fig.3.3A). However, the upper linker region E260C to L269C was 
strongly crosslinked, similar to spontaneous dimerisation (fig.3.2). In addition, there was CuP 
facilitated crosslinks evident for other TMD residues (I270C to F273C) before disappearing at 
G274C and this became evident again at V280C. Note that no crosslinking was evident for C259S 
indicating that the dimers observed are solely due to the introduced cysteine residues. 
 
There were few consistent observations in the CuP-mediated crosslinking analysis with added GH 
based on the dimer to monomer ratio. Nevertheless, increased crosslinking at D262C (fig.3.3B) and 
a reduced crosslinking of V284C and F287C positions (fig.3.3C) was consistently observed 
following GH addition. Based on the helix wheel projection the V284 and F287 are on the same 
interface. 
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Figure 3.3: Effect of GH on Copper-o-phenanthroline-induced GHR dimerisation.  
Transiently transfected COS-1 with GHR cys truncated mutants were subjected to GH treatment, membrane extract 
preparation and copper phenanthroline treatment (refer methods section) and analysed on non-reducing SDS-PAGE 
gels. (A) The entire TMD and upper linker region show crosslinking from E260C to F273C and V280C to S288C. No 
crosslinking is evident for C259S and for the stretch of residues from G274C to T279C. Blots representative of n=4 
independent experiments (B) Increased CuP-mediated crosslinking in D262C subsequent to GH addition evident from 3 
independent blots. (C) Decreased CuP-mediated crosslinking in V284C and F287C (indicated with red arrows) 
subsequent to GH addition evident from 3 independent blots. The helical wheel projection indicates that both residues 
reside on same side of the interface. 
 
GHR cysteine mutant signalling analysis 
Based on the spontaneous dimerisation pattern, we also sought to determine if targeted dimerisation 
alone could induce STAT5 activation. Initially, a comparative analysis of HEK293 and COS-1 cell 
lines was carried out and HEK293 was chosen based on the fact that they have low levels of 
endogenous GHR and active STAT5 (fig.3.4). The full-length versions of each of the truncated cys 
mutant constructs were created in the current studies by removing the stop codon but retaining all 
the other mutations. All the full-length constructs were also able to activate STAT5 at similar levels 
after GH addition (not shown). 
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Figure 3.4: Choice of cell line for STAT5 activation in full-length hGHR cys mutants. 
HEK293 and COS-1 cell lines were transiently transfected with low levels of full-length GHR (WT) or empty vector (Nt) 
and subjected to GH treatment (50ng/ml) for 10 minutes and STAT5 phosphorylation was determined. For the equal 
amount of protein loaded based on β-tubulin no STAT5 phosphorylation was detectable for empty vector transfected 
HEK293 following GH treatment but this was evident in COS-1 cells. Blots representative of n=2 independent 
experiments. 
 
Based on differences in spontaneous dimer formation ability the full-length GHR cys mutants from 
L251C to I271C were analysed for STAT5 activation. Since HEK293 also have low levels of 
endogenous STAT5, small amounts of a STAT5B encoding plasmid were transfected with the GHR 
vector in order to sensitise the cells to changes induced by crosslinking of residues in JMD and 
upper TMD. By starving the transfected cells overnight in reduced serum media, any endogenous 
levels of STAT5 was reduced to basal levels and only the GHR-mediated effects on STAT5 
activation could be observed. Phosphorylation of STAT5 in the absence of GH showed considerable 
differences between the different constructs on comparison with wildtype hGHR (fig.3.5A). From 
the blot it is evident that mutants from E260C to P266C have STAT5 activity comparable to WT 
whereas the upper linker mutants L251C to T258C except S255C had significantly reduced STAT5 
activity. Interestingly, the STAT5 activity reduced to greater extent as the N-terminal distance from 
C259 increased and became comparable to that observed for C259S mutant. The only mutant with a 
high level of STAT5 activity was the double cysteine mutant (E260C, I270C). The rationale for 
using double cysteine mutant was to determine if increased helix interaction (disulfide bond 
formation) between residues on opposing face of the helix wheel could promote constitutive 
receptor activation. The corresponding dimer formation of full-length GHR cys mutants is shown in 
figure 3.5B by running the same lysate on a non-reducing gel and probing for HA-tag. In addition, 
importance of cysteine in upper linker region in GHR-mediated signalling is evident from 
significantly increased STAT5 activation relative to C259S. As shown in graph by normalising 
phospho-STAT5 to GHR expression (fig.3.5C), the entire region from C259 to P266 when 
crosslinked with a cysteine can induce STAT5 activation and that dimerisation at the N-terminal 
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juxtamembrane sequence, or the upper TMD can activate the receptor. Use of two disulfide 
crosslinks here strongly activates the receptor.  
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Figure 3.5: Signalling analysis of juxtamembrane linker and transmembrane domain residues of hGHR in the 
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absence of GH and crosslinker. 
Western Blot analysis of hGHR cys mutants transfected with STAT5B in HEK293 cells in the absence of GH stimulation 
following an overnight starve. Equal quantity of each lysate was resolved on a reducing SDS-PAGE gel and analysed 
for STAT5 activity and receptor expression. (A) Constitutive activation of spontaneously crosslinked cysteine 
substituted receptors is evident in the immunoblot (left panel) and histogram depicts ratio of active STAT5 to total 
STAT5 level normalised to receptor expression and statistical significance relative to WT (C259) (right panel). (B) GHR 
dimerisation for full-length GHR cys mutants (from the same lysates represented in panel above) shown in a non-
reducing SDS-PAGE gel. (C) Histogram depicting ratio of active STAT5 to total STAT5 level normalised to receptor 
expression with statistical significance relative to C259S mutant (thiol-free background) shown. Data representative of 
n=3 independent experiments (mean ±SEM; ****:P <0.0001, ***:P <0.001, **:P <0.01, *:P <0.05) by ANOVA. 
 
Crosslinker treatment on live cells 
Because crosslinking studies on membrane extracts have been quite informative, we sought to 
analyse if there was a difference in the GH-induced signalling on crosslinked receptor at various 
positions in the TMD. In this experiment, five set of treatments were carried out on HEK293 cells 
transiently transfected with cys hGHR constructs. These treatments included; addition of GH alone, 
addition of CuP alone, no treatment and addition of CuP and then GH and vice versa. The 
crosslinking reaction in all the treatment regimes was stopped using EDTA while washing the cells 
in PBS twice stopped the GH stimulation. All the TMD mutants were subjected to these methods 
but due to difficulty of crosslinker to penetrate the TMD only the upper region at the N-terminal 
TMD was tractable. 
 
There were significant differences in GHR activation when the receptor had been previously 
crosslinked previously indicative of a positional preference of activation due to positional difference 
in crosslinking. There was a ‘ON’ position evident at residue L268 as shown in figure 3.6. When 
this residue was crosslinked and subjected to GH treatment, the STAT5 activation was of similar 
intensity as observed with the addition of GH alone or with GH first and then CuP. Such an 
observation indicates that crosslinking at L268 position is conducive to GHR activation or occurs 
naturally during GHR activation. This observation was in complete contrast from I270 where there 
was no GHR activation observed if GHR is previously crosslinked at this position before GH 
addition. This represented a ‘OFF’ position at I270 that if crosslinked could inhibit GH-induced 
activation.  
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Figure 3.6: Helical wheel representation of the residues indicating ‘ON’, ‘OFF’ and intermediate positions in the 
upper Transmembrane domain region of GHR.  
Transiently transfected HEK293 cells indicating phosphorylated-STAT5 on reducing gel (indicating GHR activation) and 
HA blot on non-reducing gel (indicating crosslinking and dimer formation) from L268C to I271C residues are shown. 
Following CuP and GH treatments (refer text), a helical interface is evident for these residues that matches the helical 
wheel projections. Blots representative of n=3 independent experiments. 
 
Signalling analysis in Ba/F3 cells stably transduced with GHR cysteine 
mutants  
In order to support the above findings from transient transfection, the stably expressing Ba/F3 cell 
lines were created by retroviral transduction with the hGHR cys constructs. Since all these 
constructs have been shown to be GH responsive, stable cell lines were selected in GH. For 
signalling analysis, cell lines were starved overnight in low serum media to reduce level of 
phospho-STAT5 and the cell lysates were analysed for pSTAT5, total STAT5 and GHR expression. 
From figure 3.7A it is evident that there is significant activation observed in the constructs E260C, 
E261C, D262C, F265C, L268C and the double cysteine mutants PM1 (E260C, I270C) and PM2 
(F263C, I270C).  
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Figure 3.7: Analysis of the effects of full-length hGHR cys mutants in stably transduced Ba/F3 cell line in the 
absence of GH.  
(A) Western Blot analysis of different cys hGHR mutants in retroviral transduced Ba/F3 cell lines without GH stimulation 
following an overnight starve (in IL-3/GH lacking media). Equal quantity of each lysate was run on a reducing SDS-
PAGE gel and analysed for STAT5 activity evident in few juxtamembrane linker sequences. (B) Representative graph 
indicating surface expression of GHR of some hGHR cys mutants in Ba/F3 cell lines stained using anti-HA antibody 
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and TritC-labelled secondary antibody, then analysed by FACS. Note the shift in gating set using Ba/F3 as negative 
control and WT hGHR (B2B2 clone) as positive control. Two cell lines E261C and PM2 (F263C, I270C) are shown to 
express receptor at the surface. (C) Proliferation analysis of stably transduced Ba/F3 cells in charcoal-stripped serum 
containing media in the absence of IL-3 and GH indicates that PM2 mutant (F263C, I270C) is the most constitutively 
active. Data representative of n=2 independent experiments in two separate population studies and clonal lines from 
two independent transductions. 
 
All the Ba/F3 cell lines stably expressing the different hGHR cys constructs were analysed for 
surface expression of GHR by FACS using mouse anti-HA primary antibody and a TritC-labelled 
secondary anti-mouse antibody. Parental Ba/F3 cells were used as negative control while WT-
hGHR expressing Ba/F3 (B2B2 clone) (Rowland et al, 2002) served as a positive control for setting 
the gating channel. In addition, care was taken in choosing the gating so that it did not interfere with 
the GFP channel since the stable Ba/F3 mutants were selected for IRES driven GFP expression. For 
the entire set of hGHR cys mutant cell lines significant surface expression of GHR was observed 
and data for two such cell lines is shown (fig.3.7B). All the stable cell lines were subjected to 
proliferation analysis in growth media with routine FBS replaced with charcoal stripped serum to 
avoid effects from other cytokines. From these analysis the double cysteine PM2 (F263C, L268C) 
appears to be the most active hGHR construct although low level constitutive proliferation was also 
seen in other juxtamembrane residues (fig.3.7C) that showed STAT5 activation in the absence of 
GH.  
 
Conservation of GHR TMD and upper linker region sequences 
The GHR sequences from species across varied genus were analysed for evolutionary conservation 
since conservation can be correlated with functional importance of a particular amino acid specific 
to that position. The cysteine and acidic residues in the juxtamembrane linker region and potential 
TMD initiating residues FPW were highly conserved along with the GxxG motif in the TMD. 
Towards the end of the TMD, the terminal FS residues were also preserved across the species 
analysed here (fig.3.8). 
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               Juxtamembrane Linker     Transmembrane Domain 
 
Human            L P Q M S Q F T - - C E E D F Y F P W L L I I I F G I F G L T V M L F V F L F S  
Macaque      L P Q M N Q F T - - C E E D F Y F P W L L I I I F G I F G L T V M L F V F L F S  
Baboon      L P Q M N Q F T - - C E E D F Y F P W L L I I I F G I F G L T V M L F V F L F S 
Rhesus monkey    L P Q M N Q F T - - C E E D F Y F P W L L I I I F G I F G L T V M L F V F L F S  
Squirrel monkey  L P Q M S Q F T - - C E E D F Y Y P W L L I I I F G I S G L T V M L F V F L F S  
Dog       L P Q M S P F A - - C E E D F Q F P W F L I I I F G I F G L T M I L F L F I F S  
Giant panda      L P Q M S P F A - - C E E D F Q F P W F L I I I F G I F G L T M I L F L F I F S  
Guinea pig      L P Q S S P F T - - C E E E F Q F P W F L I M I F G I F G L T V M L L V V M F S  
Rat       F P Q M D T L A A - C E E D F R F P W F L I I I F G I F G V A V M L F V V I F S  
Mouse       F P Q T N I L E A - C E E D I Q F P W F L I I I F G I F G V A V M L F V V I F S  
Rabbit      L P Q M S P F T - - C E E D F R F P W F L I I I F G I F G L T V M L F V F I F S  
Pig       L P Q M S P F A - - C E E D F R F P W F L I I I F G I F G L T V I L F L L I F S  
Cow       F P Q M N P S A - - C E E D F Q F P W F L I I I F G I L G L A V T L Y L L I F S  
Sheep       F P Q M N P S A - - C E E D F Q F P W F L I I I F G I L G L T V T L F L L I F S  
Chicken      F T Q A G I E F V H C A E E I E F P W F L V V V F G V C G L A V T A I L I L L S  
Pigeon      F S Q A D I E F V H C A E E I E F P W F L V V I F G A C G L A V T V I L I L L S  
Turtle      L S S I S S V L — - C D E E I Q F P W L L V I V F G T F G L I V V M F L I L F S  
 
Figure 3.8: Multiple Alignments of GHR juxtamembrane linker and transmembrane domain amino acid 
sequences from various species. 
Sequence alignments of GHR TMDs and upper linker region shows key conserved residues (underlined in red) 
including the GxxG motif and CEED (or CDEE) gating across species. 
 
Discussion 
The main aim of using SCAM here was to demonstrate that GHR, which exists as a pre-formed 
dimer is activated by a ‘movement’ of its subunits rather than by dimerisation alone. In order to test 
this hypothesis, cysteine-scanning mutagenesis and crosslinking analysis of the TMD was 
undertaken in truncated and full-length GHR and the latter was compared with the downstream 
GHR-mediated STAT5 activation.  
 
Initial studies were undertaken in truncated GHR to determine if cysteine mutants in and around the 
TMD revealed a dimerisation pattern and if GH addition had any affect on that pattern. Indeed these 
GHR mutants were able to form dimers in the absence of GH consistent with the previous reports 
that GHR is a pre-formed dimer (Brown et al, 2005; Gent et al, 2003). However after GH addition 
few obvious differences in dimerisation pattern were evident. This lack of periodicity in the 
dimerisation pattern of the juxtamembrane linker region indicates that this sequence is not helical 
but unstructured. However, there was an increase in the ratio of dimers to monomers after GH 
addition at D262. It can be assumed that the 4 substitutions from P266 that undergo dimerisation to 
a lesser extent may be located at the interface between the JMD and the TMD and this is indicative 
that the TMD would actually start with the P266. Other SCAM studies have indicated that cysteine 
substitutions which are either completely buried in the membrane or at the cytosolic surface cannot 
form disulfide bonds because these residues are not exposed to enzymes such as protein disulfide 
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isomerase that catalyse disulfide bond formation in the ER lumen (Lu et al, 2006). This would 
explain why the spontaneous crosslinking is only evident for the first 3 or 4 residues in the TMD.  
 
The unpaired cysteine at position 259 in the extracellular domain has been reported to be critical for 
GH-induced disulfide linkage of GHR molecules (Zhang et al, 1999). In our system, the C259S 
mutation had no effect on GH-induced signalling but in the absence of GH no spontaneous dimers 
were observed, which is consistent with the findings reported by Gent et al. (Gent et al, 2003). This 
is suggestive that cysteine may just serve to stabilise the GH-induced GHR binding. The relevance 
of disulfide bridge formation at this position is now clear from the recent studies in Waters’ Group. 
In particular, removal of the conserved acidic sequence (EED) which caps the TMD and replacing it 
with non-repulsive alanine residues in jun zipper chimera resulted in lowering of FRET ratio 
indicative of receptor monomers coming close together (Brooks et al, 2014). In addition, when WT 
GHR (containing EED) was co-transfected with a mutant receptor containing KKR sequence 
(charge reversal) this resulted in constitutive activation and a decreased FRET ratio (Brooks et al, 
2014). It appears that these acidic residues act as a gating mechanism for receptor activation, where 
the electrostatic repulsion must be overcome by ligand-induced proximity of the surrounding upper 
TM residues and the cysteine disulfide bond.  
 
The MTS-2-MTS crosslinker analysis of TMD residues plotted onto a helix wheel projection 
indicated that one side of each helix is in contact. This was used to define the relative orientation of 
the two helices in the basal state and provided not only further evidence for constitutive 
dimerisation. This information provided the orientation of the basal state in molecular dynamics 
simulations of the two helices as they approached in lipid membranes. In addition, the spontaneous 
crosslinking of the introduced cysteines in the upper helix and juxtamembrane sequence down to 
I271 showed that this was associated with STAT5 activation in full-length GHR, which supported 
the view that increased receptor proximity in the upper TM/juxtamembrane sequence results in 
receptor activation. Activation was even stronger when two cysteine residues (at least 2 helix turns 
apart) were crosslinked (intermolecular) as in the case of double cysteine mutant (PM2), evident in 
constitutive activation both transiently in HEK293 and stably in Ba/F3 cells. 
 
The STAT5 activation associated with GHR full-length TM mutants determined in this study 
supports the findings from the related EpoR where two such mutations in the first two residues in 
the TMD (L226C and I227C) were shown to confer-ligand independent activation (Lu et al, 2006). 
Our data therefore indicates that activation of pre-dimerised GHR by ligand binding is achieved by 
reorientation of the TMDs and their juxtamembrane ICDs and that certain disulfide bonded dimers 
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recapitulate the activated dimeric conformation, constitutively activating downstream signalling. 
Based on our data and the previously determined structure of GHR ECD bound to GH, this provides 
useful information on structure-function aspects of receptor.  
 
The CuP treatment of intact cells indicated that L268 residue is present on the interaction interface 
between the two TM helices. This evidence was further supported by the fact that neighbouring 
residues to both ‘on’ and ‘off’ positions, L269C and I271C, give intermediate intensity of STAT5 
activation if crosslinked before GH addition. The experiment indicates that there could be a 
potential ‘rotation movement’ in the α–helix that provides residue positions with on and off effect, 
separated by residues with intermediate effects on GHR activation. Considering the TMD to be α–
helical, it is expected there will be a similar outcome every 3.6 residues from L272 onwards. 
However, no ‘on’ and ‘off’ positions were found lower into the membrane which was indicative 
either of the inability of CuP to crosslink further into the TMD due to the hydrophobic conditions 
within the membrane or a ‘fork’ like positioning of the helix. The inability of CuP to reach within 
the membrane seems more plausible since the CuP treatment of membrane extracts was able to 
form dimers for the TMD residues adjoining the ICD. In support, a previous study by Guo et al. on 
G-PCRs has reported decreased CuP-induced crosslinking in the middle of membrane (Guo et al, 
2005). The lack of consistent disulfide bond pattern on membrane extracts in the presence or 
absence of GH suggests that there is some flexibility in the TMDs making it difficult to determine 
the precise movement. However, in the case of V284C and F287C there was decreased CuP-
mediated dimer formation while in D262C there was an increased dimer formation following GH 
treatment suggestive of separation of lower TM helices and proximity of upper linker region for 
activation of GHR.  
 
In order to further validate these findings, in silico molecular dynamics modeling of the TM helices 
in lipid membranes were performed in collaboration with M. Doxastakis (University of Houston). 
To obtain the free energy profile as a function of distance (PMF) between two transmembrane 
domains (TMDs), exhaustive Monte Carlo simulations using 128 replica pairs were performed for a 
range of separations between the centers of mass of the helices as they approach. The fact that this 
profile has a deep minimum at a separation of 0.7-0.8nm supports the finding that the two TMDs 
interact strongly. The simulations showed that as the two helices approached, they first interact at 
their C-termini as a result of repulsive interactions at the N-termini (especially the EED sequence). 
Subsequently, the TMDs follow a path that maximises interactions between the Phe residues and 
Thr-Thr hydrogen bonding. This initially led to an essentially parallel dimer (State 1) corresponding 
to the crosslink pattern seen in the absence of hormone. Closer approach of the helices (as could 
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result from hormone binding) leads to a close-packed structure (State 2) with increased tilting and 
TMD rotation, resulting in a left handed cross over dimer with increased separation at the C-
terminus. Both State 1 and 2 were within the identified energy minimum, indicating a relatively 
facile State1-State2 transition. The GHR TMDs form the active left hand crossover dimer by 
rotating F276 and F283 out of the interface. Importantly, when the inactive State 1 is compared with 
the left-handed crossover form, separation between the C-termini had increased substantially. This 
parallels the finding that activity correlates with higher separation of the C-termini as monitored by 
FRET (Brooks et al, 2014). In the proposed active State2 form the N-terminal W267 sits favourably 
at the upper membrane interface, facing outward to favour association, while the C-terminal K289 
is in an unfavourable configuration for helix interaction. This model can therefore also explain how 
alanine substitution of K289 promotes the left-handed dimer form, correlating with the increased 
activation as seen in the mutation K289A GHR (Brooks et al, 2014) and can be extended to TPOR. 
It is important to note that these helix movements are essentially sequence independent, so can be 
applicable to other Class I receptors.  
 
Evidently the receptor activation mechanism does not have a specific sequence requirement for the 
TMD helix, but rather the ‘tilt and twist’ movement observed is a function of helix dynamics in a 
lipid membrane contingent on close apposition of the N-terminal end of the paired helices.  
 
Interestingly, the only known variant in the TMD sequence was identified by quantitative trait locus 
(QTL) mapping of the bovine TMD (Blott et al, 2003) as Phe279Tyr (corresponding to F283Y in 
humans), and this was associated with a major change in the milk yield and composition. The 
molecular basis of this alteration was shown not to be STAT5-dependent (Zhou & Jiang, 2006). 
Therefore it seems that another signalling pathway is affected for the strong effect on milk yield and 
composition. There may be a possibility that similar to the conformational change in F’G’ loop in 
ECD, resulting in induced biased signalling to SFK/ERK (Rowlinson et al, 2008), certain TMD 
residues may be involved in the same. A similar observation has been reported in the same study 
where perturbing the relative orientations of the two TM helices with glycine and proline 
substitutions resulted in changed ratio of Jak2/STAT5 to ERK signalling (Rowlinson et al, 2008). 
Based on these results it would be worthwhile to determine if any of the hGHR cysteine mutants 
upon crosslinking can signal via other pathways. 
 
Determining the oncogenic potential of GHR 
The constitutively active jun zipper GHR constructs (Brown et al, 2005; Brooks et al, 2014) as well 
the double cysteine arising from this chapter will be used to determine the oncogenic role of GHR 
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and define cellular location of any transformation ability. The leucine zipper domain from the 
transcription factor jun has been employed for functional replacement of GHR ECD and used to 
confer ligand-independent growth when transfected into Ba/F3 cell line by clamping the receptor 
together from the top and resulting in continuous downstream signalling (Behncken et al, 2000). 
This construct has been used to make transgenic zebrafish in vivo and was reported to double the 
size (and IGF-1 levels) in comparison to overexpression with GH, GHR or both together (Ishtiaq 
Ahmed et al, 2010). Eventually by utilising the TVA system, these constructs will be used to 
investigate the in vivo effects of constitutively active GHR and nuclear-targeted GHR, in a tissue-
specific manner.  
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Introduction 
The Growth Hormone Receptor (GHR) is a member of Class I cytokine receptors superfamily that 
exists as a dimer on the cell surface of virtually all cells of the body (Brooks & Waters, 2010). 
Upon binding of growth hormone (GH) to GHR, Janus kinase 2 (Jak2) which is associated within 
the intracellular domain at a conserved box1 motif is activated and downstream signalling cascades 
are triggered (Argetsinger et al, 1993). GHR can also activate Src family kinases (SFK: c-src, lyn, 
fyn, yes, hck) independently of Jak2 but the exact receptor binding region is yet unknown 
(Rowlinson et al, 2008). Numerous signalling pathways activated by GH have been identified, 
including those for STATs (signal transducer and activator of transcription), MAPK (mitogen 
activated protein kinase), and the PI3-K (phosphatidylinositol-3-kinase). Interestingly these 
pathways can be activated independently in a cell dependent manner (Rowlinson et al, 2008). Apart 
from promoting longitudinal body growth, GHR signalling regulates post-natal metabolism and 
cellular functions of proliferation and differentiation (Chhabra et al, 2011). A substantial body of 
evidence supports a role for the growth hormone (GH)–IGF-1 (Insulin like growth factor-1) axis in 
organomegaly and cancer incidence and progression (Miquet et al, 2008). This includes 
epidemiological evidence relating elevated plasma IGF-1 to cancer incidence as well as a lack of 
cancer in human GHR mutations resulting in IGF-1 deficiency (Gunnell et al, 2001), (Guevara-
Aguirre et al, 2011). Moreover, rodent models lacking GH or its receptor are strikingly resistant to 
the induction of a wide range of cancers (Ikeno et al, 2009; Miquet et al, 2008), and treatment with 
the GH antagonist pegvisomant slows tumour progression (Divisova et al, 2006). While GH 
receptor expression is elevated in many cancers, autocrine GH is present in several types, and 
overexpression of autocrine GH can induce cell transformation (Chhabra et al, 2011).  
 
GHR signalling is tightly regulated at numerous levels via different mechanisms. These involve the 
regulation of cell surface receptor level by internalisation and degradation and attenuation of 
receptor signalling by negative feedback mechanisms, following a GH secretory pulse. In addition, 
GHR displays a rapid turnover in the absence of GH (van Kerkhof et al, 2007). This constitutive 
turnover of GHR is probably cell type-dependent and is fast in most cell types: in rat adipocytes 
(T1/2= 45minutes) (Gorin & Goodman, 1985), in rat liver (T1/2= 40 minutes) (Donaghy et al, 
2002) and in mouse fibroblasts (T1/2=75minutes) (Murphy & Lazarus, 1984). GH-induced GHR 
endocytosis/degradation requires an intact ubiquitination system and depends on the ubiquitin-
dependent motif (UbE: DDSWVEFIELD) present in the juxtamembrane cytoplasmic sequence 
(Strous et al, 2004). Mutations in the UbE motif lead to a dramatic decrease in endocytosis and 
lysosomal degradation, rendering the cells more GH-sensitive. Protein ubiquitination involves the 
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sequential action of three classes of enzymes; E1 activating enzymes, E2 conjugase and the E3 
ligases that introduce the substrate specificity (da Silva Almeida et al, 2013). 
 
Recently, Beta-transducin repeat-containing protein (β-TrCP) has been reported to be (van Kerkhof 
et al, 2007) necessary for GHR endocytosis where it serves as the substrate recognition subunit for 
the SCF(β-TrCP) ubiquitin ligase (van Kerkhof et al, 2007). After GH binding, the serine residues 
of the DSGxxS motif get phosphorylated and SCF(β-TrCP) is recruited, mediating its ubiquitin-
dependent endocytosis. However, it has been recently demonstrated that the DSGxxS motif of GHR 
is not involved in ligand-mediated, but rather in GH-independent, basal GHR endocytosis and 
degradation (da Silva Almeida et al, 2012). In addition the GHR UbE motif regulates endocytosis 
and degradation, in both the presence and the absence of GH stimulation. β-TrCP interacts with its 
substrates through its WD40 domain and nuclear magnetic resonance studies have characterized the 
interaction of β-TrCP with classical phosphorylated degrons DSG(x)2+nS in several other substrates 
(Evrard-Todeschi et al, 2008). For the binding of the GHR DSGxxS motif to β-TrCP, the same 
residues in the WD40 domain are involved. However, in the case of UbE motif sequence, which 
differs substantially from the classical DSGxxS motif this interaction is unconventional and has a 
lower affinity (da Silva Almeida et al, 2013). Although β-TrCP ubiquitinate specifically 
phosphorylated substrates, in the case of GHR, ubiquitination was shown to be dispensable, since β-
TrCP silencing was shown to decrease the degradation of GHR mutant with all lysine residues 
mutated (in cytosolic tail) as efficiently as wildtype GHR (van Kerkhof et al, 2007). Functionally 
the SCF-ubiquitin ligases have been shown to play a pivotal role in the regulation of cell division 
and various signal transduction pathways (Fuchs et al, 2004).  
 
The GHR is synthesized as a precursor protein in the endoplasmic reticulum where it dimerises 
(Gent et al, 2002) and becomes glycosylated at five potential sites (Asn-X-Ser/Thr) in the Golgi 
before being transported to plasma membrane (Leung et al, 1987). Cell surface GHR availability is 
a key determinant of GH responsiveness. Regulation of GHR abundance include factors that 
regulate receptor gene expression (Edens & Talamantes, 1998; Schwartzbauer & Menon, 1998) as 
well as those that govern receptor protein stability, such as the propensity of Jak2 to chaperone 
nascent receptor to the cell surface and therefore provide stability to the mature receptor from 
constitutive endocytosis and degradation (Deng et al, 2007) (Schwartzbauer & Menon, 1998). 
Susceptibility of the surface receptor to inducible metalloproteolytic processing by 
TACE/ADAM17 is another factor that determines surface availability (Zhang et al, 2000; He et al, 
2003). GH-induced Jak2 activation markedly reduces surface receptor; such that a catalytically-
inactive Jak2, a Jak2 mutant incapable of associating with GHR, or a receptor mutant deficient in 
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Jak2 binding are far less able to promote receptor downregulation compared with expression of 
wild-type receptor and Jak2 (Deng et al, 2007). In addition, a receptor mutant with all intracellular 
tyrosine residues changed to phenylalanine allowed acute GH-induced Jak2 activation, this tyrosine 
phosphorylation-defective receptor underwent markedly less GH-induced ubiquitination and was 
only modestly downregulated (Deng et al, 2012). This indicates the importance of downstream 
phosphorylation of tyrosine residues in receptor turnover, suggesting that they serve as docking 
sites for not only transcription factors but also negative regulators of GHR signalling.  
 
Activation of GH-dependent signalling pathways is based on protein phosphorylation on tyrosine, 
serine or threonine residues. The mechanism for deactivation of these phosphorylations is the action 
of protein phosphatases (PP) and suppressors of cytokine signalling (SOCS). Pasquali et al. 
(Pasquali et al, 2003) have identified four protein tyrosine phosphatases (PTPs): PTP-H1, PTP1B, 
Sap1, and TC-PTP with binding affinity towards GH-induced phosphorylated GHR. Of the 4, PTP-
H1 has strong affinity for Y534, Sap1 only but strongly for Y487, TC-PTP for Y332, Y87, Y534, 
and Y595, and PTP1B for Y487 and Y332 as determined by substrate recognition by trapping 
mutants. In addition, SHP2 has been shown to negatively regulate GHR-mediated Jak2/STAT5 
signalling by binding to Y595 (Stofega et al, 2000). PTP-H1 knockout mice are larger with the 
difference being particularly significant for males (Pilecka et al, 2007). Although PTP1B has been 
strongly linked to some aspects of GHR signalling, PTP1B knockout mice are in fact smaller than 
wild type animals because of their lower fat content, which is linked to increased energy 
expenditure (Klaman et al, 2000). 
 
SOCS proteins are negative regulators of Jak/STAT signalling (Wormald & Hilton, 2004) that have 
been shown to modify cytokine action through a classic negative feedback loop. Normally, SOCS 
protein levels are constitutively low, but their expression increases rapidly following cytokine 
stimulation (Fujimoto & Naka, 2003). GH has been shown to induce the expression of several 
SOCS proteins in vitro (Adams et al, 1998; Paul et al, 2000) and in vivo (Tollet-Egnell et al, 1999). 
Generally, SOCS1, SOCS3 and CIS expression is rapidly induced following GH stimulation but is 
transient, whereas SOCS2 expression increases steadily with time (Flores-Morales et al, 2006). 
Each SOCS member has a different mechanism of action on GH signalling. SOCS1 and 3 can 
directly bind within the Jak2 activation loop blocking kinase activity and promoting its proteasomal 
degradation (Nicholson et al, 1999; Endo et al, 1997). SOCS2, SOCS3 and CIS have been shown to 
bind to tyrosine phosphorylated GHR. Strong evidence indicates that binding to Y487 and Y595 is 
required for SOCS2-mediated inhibitory actions (Greenhalgh et al, 2002). Since both tyrosines are 
known STAT5 binding sites (Wang et al, 1996), SOCS2 can competitively inhibit STAT5 binding 
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to the receptor. Vesterlund et al. (Vesterlund et al, 2011) have recently reported the mechanistic 
importance of phosphorylated Y487 rather than Y595 on GHR for its regulation by SOCS2. Not 
much is known about CIS interaction on GHR but phosphorylated Y487 and Y595 have been 
predicted as binding sites using mammalian two-hybrid method (Uyttendaele et al, 2007). 
Functionally only SOCS2 knockout mice are 40% larger compared to wild type mice (Metcalf et al, 
2000). Evidence also indicates that growth factors (e.g., insulin), xenobiotics (e.g., dioxin, statins), 
and estrogens, can induce SOCS2 expression (Leong et al, 2004; Rico-Bautista et al, 2006). 
Consequently, regulation of SOCS2 protein expression provides a mechanism for crosstalk where 
multiple factors can regulate the activity of GH.  
 
The loss of GH signalling evident in Laron dwarfism is due to lack of a functional receptor. These 
mutations reported for GHR include 153T, Q154P, and V155G that mainly affect intracellular 
trafficking and binding affinity of the receptor, whereas the D152H mutation affects receptor 
expression, dimerisation, and signalling (Wojcik et al, 1998). In addition membrane bound 
cytoplasmically truncated splice variants of GHR have also been reported. These variants can form 
heterodimers with full-length GHR and inhibit the downstream signalling due to lack of Jak2 and 
STAT5 binding sites, and generate large amounts of GH binding proteins (Ross et al, 1997). The 
most important manifestation of loss of GHR activity, as evident in the Ecuadorian cohort was a 
lack of cancer incidence in individuals with GHR deficiency as compared to their normal relatives 
(Guevara-Aguirre et al, 2011) highlighting the fact that altered GH signalling can alter cancer risk. 
Besides loss of function mutations a number of naturally occurring variants, alternatively spliced 
transcripts of GHR have been reported with no functional implications as yet. There are at least 13 
alternatively spliced human GHR mRNAs generated in the 5` untranslated exons all of which splice 
into a common acceptor site upstream of the translation initiation site of exon 2. This results in 
generation of full-length receptor polypeptide but with expression levels varying in a spatial-
temporal manner (Wei et al, 2006). 
 
A widely expressed GHR variant is the exon-3 deleted GHR isoform in humans. It lacks amino 
acids 7-28 in the extracellular domain which does not affect GHR binding or internalisation 
(Urbanek et al, 1992; Mercado et al, 1994). However it does influence the sensitivity to GH 
activation and is associated with enhanced responsiveness to GH in children (Wassenaar et al, 
2009) and reportedly altered GH pharmacogenetics (Dos Santos et al, 2004; Filopanti et al, 2011). 
Recently the first mutation for GHR that was associated with lung cancer risk in a Chinese 
population was identified (Cao et al, 2008). A base substitution from C to A on 1526nt of cDNA of 
ghr resulted in an amino acid change at position 495 from proline to threonine. The subjects 
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heterozygous and homozygous for the A allele at Pro495Thr polymorphism had a higher risk for 
lung cancer (OR= 2.02, P= 0.007, 95% CI: 1.20–3.41) with significant risk of small cell and 
squamous cell lung cancer (OR= 2.59, P= 0.006, 95% CI: 1.35–4.95) but not adenocarcinoma, 
which suggests a potential interaction between this polymorphism and pathological pathways 
related to smoking. Further analyses revealed P495T variant was more significantly associated with 
lung cancer in the male subpopulation, still-smokers subpopulation and the subpopulation with 
familial history of cancer. A similar correlation of this GHR variant was reported in a large-scale 
genome-wide association studies in UK Caucasians with an odds ratio of over 12 (Rudd et al, 
2006). This chapter characterises the P495T GHR variant in regards to its effect on the downstream 
signalling from GHR in different cell lines and determine the molecular basis for it. 
Materials and Methods 
Materials 
Fetal Bovine Serum (FBS) and Serum Supreme (SS) were purchased from Lonza Group Ltd (Basel, 
Switzerland). Lipofectamine, Bovine serum albumin (BSA) fraction V, IgG free, L-glutamine, 
Hygromycin B in PBS, RPMI 1640 media, and LHC-9 media were purchased from Invitrogen Life 
Technology (NY, USA). Human fibronectin was purchased from Becton Dickinson (NJ, USA). 
Collagen solution and puromycin was purchased from Sigma Aldrich (NSW, Australia). Complete 
Protease Inhibitor Cocktail Tablets were purchased from Roche (NSW, Australia). Immobilon 
Western Chemiluminescent HRP substrate and mild Re-blot stripping buffer were purchased from 
Millipore (MA, USA). Chemicals: DAPT, MG132 (Z-Leu-Leu-Leu-al), clasto-Lactacystin beta-
lactone were obtained from Sigma Aldrich (NSW, Australia). Brefeldin A (BFA) was kindly 
provided by Prof. Jenny Stow (IMB). Human growth hormone was expressed and purified within 
the Waters lab (IMB). 
 
Construction of plasmids  
The P495TGHR coding sequence was derived from wild type GHR by site directed mutagenesis 
and PCR amplified with KOD Hot Start polymerase (Roche) with primers containing attB 
sequences. The PCR products were cloned into two different destination vector backbones pMX 
and pQCXP using a modified Gateway cloning based on the previously described protocol by 
(Loftus et al, 2001). Haemagglutinin A (HA) tag was introduced N-terminal to GHR coding 
sequence for ease of detection during immunoblotting. The integrity of the cloned GHR vectors 
were confirmed by DNA sequencing using a set of 8 different primers to provide clear overlapping 
sequencing results spanning the entire GHR coding sequence. DNA sequencing was performed by 
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AGRF and sequence data was analysed. The pCMV-SOCS2 plasmid was purchased from Origene 
(Maryland, USA).  
 
Cell culture  
Murine pro-B cell lines (Ba/F3) were cultured in RPMI 1640 medium supplemented with 2mM L-
glutamine, 10% SS, 100units/ml interleukin-3 (IL-3) and 900µg/ml hygromycin B. For serum 
starvation, Ba/F3 cells were washed and maintained in RPMI 1640 media containing10% FBS and 
2mM glutamine but devoid of IL-3 or GH for 16hrs.  
 
Transformed normal bronchial epithelium cells (BEAS-2B) were maintained in LHC-9 medium 
(Life Technologies) with 50µg/ml hygromycin B. Flasks were pre-coated with a mixture of 
0.01mg/ml fibronectin, 0.03mg/ml collagen and 1µg/ml bovine serum albumin dissolved in LHC-9 
medium overnight at 37oC. Excess coating mixture was removed and flasks/plates were dried 
overnight at 37oC. Pre-coated flasks were subjected to three PBS washes prior to addition of cells. 
For serum starvation, BEAS-2B cells were kept in RPMI 1640 supplemented with 2mM L-
glutamine and 0.5% BSA medium for 16hrs. 
 
The androgen independent DU145 cell line was cultured in RPMI 1640 medium supplemented with 
10% FBS, 2mM L-glutamine and 250µg/ml hygromycin B. Cells were starved in 2mM L-glutamine 
and 0.5% BSA-RPMI 1640 medium for 24 hours. HEK293 and HEK293T cell lines were cultured 
in DMEM supplemented with 10% FBS. Cells were starved in DMEM with 0.5% FBS for 16hrs. 
All cells were maintained in 37oC and 5% CO2. 
 
Production of replication incompetent ecotropic retroviruses 
For generation of cell lines stably expressing wild type or the variant P495TGHR, Platinum-E 
(PLAT-E) cells were transfected by Lipofectamine as per manufacturer’s instructions. Supernatant 
was collected 3 days post-transfection, centrifuged at 400g for 5min and filtered with 0.4 µM PDVF 
filter. Murine (Ba/F3) cells were incubated in growth media containing 50% filtered PLAT-E 
supernatant in the presence of 4µg/ml polybrene. Cells were then selected for hygromycin B 
resistance three days post infection.   
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Production of replication incompetent pantropic viruses 
Pantropic retrovirus production was performed in a similar manner to ecotropic retroviruses. Lenti-
X cells (derived from 293T cells; Clontech) were transfected with pVPack-GP, pVPack-VSVG, and 
the expression vector; pQCXP-HA-GHR-IRES-hygromycin. The virus containing supernatant was 
harvested, filtered and used to transduce BEAS-2B, HEK293 and DU145 cells lines as above. The 
transduced cells were selected for GHR on puromycin. 
 
Proliferation assay 
For measuring proliferation of Ba/F3 cells transduced with WT and P495TGHR, the cells were 
starved overnight and seeded at a cell density of 1×104 cells/mL in duplicates in growth media 
supplemented with GH at 100ng/mL instead of IL-3 (Day 0). The cells were counted everyday by 
trypan blue exclusion using a hemocytometer. 
 
Time course assay for GH signalling 
Cells were serum starved as described above on attaining 80% confluency and stimulated with 
50ng/ml GH in reduced-serum medium for 15minutes. GH was removed by two PBS washes. 
Washed cells were maintained in reduced-serum medium at 37oC until harvested by scraping (for 
adherent cell lines) or centrifugation (for suspension cell lines) at different time points as described 
in the results section.  For Brefeldin A experiment starved cells were pretreated with 1µg/ml BFA 
for 1hr prior to GH treatment and BFA was added again when the media was replaced. Protein was 
extracted in cold RIPA buffer (radio immunoprecipitation assay): 150mM NaCl, 50mM Tris pH7.5; 
0.5% SDS, 1% NP-40, Sodium Deoxycholate supplemented with Protease inhibitors (Roche, 
EDTA-free), 10mM Sodium Fluoride, 1mM Sodium Pyrophosphate, 2mM Sodium Orthovanadate. 
For co-immunoprecipitation, HEK293 stable cells were transfected with 2µg of SOCS2 plasmid 
(Origene) for 24hrs. The cells were starved for 16hrs prior to GH stimulation for 15 minutes 
(50ng/ml). Cells were harvested in buffer containing 150mM NaCl, 50mM Tris pH7.5, 5mM 
EDTA, 0.5% Triton and supplemented with 100mM Sodium Fluoride, 2mM Sodium orthovanadate, 
Protease inhibitor (EDTA-free) and 1mM PMSF. For animal studies, pieces of liver tissue were 
homogenised in RIPA lysis buffer, cleared by centrifugation. Equal amounts of quantified protein 
lysates were boiled in sample buffer (15mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 10mM 
DTT) at 100°C for 5 minutes and resolved on SDS-PAGE gels. The gels were transferred on to 
PVDF membranes and subjected to specific antibodies (listed in Appendix VI). 
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Co-Immunoprecipitation and Western blot analysis 
HEK293 stably expressing WT and P495TGHR were plated in T-75 flask format at equal seeding 
density and transfected next day at 50% confluency with 2µg SOCS2 expression plasmid or 2µg 
CIS expression plasmid using lipofectamine 2000 (Invitrogen) as per manufacturer’s conditions. 
For CIS and SOCS2 comparison, equal amount of CIS and SOCS2 plasmid were added (1µg each). 
For co-immunoprecipitation (co-IP), transfected cells were starved 16hrs before harvest in serum 
reduced media (DMEM with 0.5% FBS). On the subsequent day, cells were stimulated with 
200ng/ml human GH for 12minutes at 37ºC. The cells were washed in cold PBS and harvested by 
scraping into cold lysis buffer comprising 150mM NaCl, 50mM Tris pH7.5, 5mM EDTA, 0.5% 
Trition-X-100 supplemented with 1x complete EDTA-free protease inhibitor tablets, 10mM 
Na3VO4, 30mM NaF, 10mM Na4P207. Protein lysates were spun at 12000g for 10minutes at 4ºC 
and quantified using a BCA Assay kit (Pierce). Equal amount of protein lysates were pre-cleared 
using Protein G sepharose beads (GE Healthcare) for 30minutes at 4ºC. The pre-cleared lysate was 
used for immunoprecipitation.  
 
For SOCS2 co-IP, anti-SOCS2 antibody at (1:100 dilution) and for CIS co-IP, CIS antibody (1:100 
dilution) (Cell signalling) were added to protein lysates and mixed gently on a rotating wheel at 
4ºC. After 2hours, Protein G sepharose beads were added in the antibody-lysate tube which was 
then mixed gently on a rotating wheel at 4ºC for another 2hours. The beads were washed in lysis 
buffer (lacking Triton) twice and spun at 6000rpm for 1minute each time between washes and the 
supernatant was removed. Finally, the washed beads were boiled in SDS sample buffer with 0.1M 
DTT for 5minutes and spun at 12000g for 5minutes. The supernatant was removed and subjected to 
SDS PAGE gel electrophoresis. 
 
Quantitative real time PCR (qPCR) 
Liver tissue was homogenised in Trizol Reagent (Invitrogen, USA) and RNA extracted as per 
manufacturer’s instructions. RNA was then further purified and DNase treated using the RNeasy 
Mini Kit clean up protocol (QIAGEN, Maryland, USA). RNA was reverse transcribed using 
Superscript III (Invitrogen, USA) and used for qPCR with Sybr Green Technology (ABI, CA, USA) 
in the 7500 Real Time Cycler (ABI, CA, USA). Analysis was performed by calculating the change 
in Ct between the gene of interest normalised against the housekeeping gene, β-2 microglobulin 
(B2M) using primers listed in Appendix V. 
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For HEK293 cells in the time course experiment, cells were washed in PBS and RNA extracted as 
per manufacturer’s instructions. RNA was then further purified and DNase treated using RNeasy 
Mini Kit clean up protocol (QIAGEN, Maryland, USA). RNA was reverse transcribed using 
Superscript III (Invitrogen, USA) and used for qPCR with Sybr Green Technology (ABI, CA, USA) 
in the 7500 Real Time Cycler (ABI, CA, USA). Analysis was performed by calculating the change 
in Ct between the gene of interest normalised against the housekeeping gene, glyceraldehyde-3-
phosphate (Gapdh) (listed in Appendix IV) and expressed as a fold change relative to wild type 
control. 
 
Sequencing of Prostate Cancer slides 
Prostate cancer formalin-fixed, paraffin-embedded tissue sections were obtained from Australian 
Prostate Cancer BioResource (APCB) after Human ethics approval from the UQ Ethics Committee. 
These slides were subjected to hematoxylin and eosin staining and subsequently graded and marked 
by a histopathologist. These marked slides were scanned on a NanoZoomer (Hamamatsu Photonics, 
Japan) and using as reference, the paraffin-embedded tissue (in unstained slides) was carefully 
scraped using a scalpel blade and collected in an eppendorf tube. Each tissue section (from a total of 
40 sections) was scraped for corresponding ‘cancerous’ and normal region as marked by the 
histopathologist. The DNA and RNA were extracted simultaneously using AllPrep® DNA/RNA 
FFPE kit (Qiagen) as per manufacturer’s guidelines. The DNA was sent to Dr. Sean Grimmond at 
Queensland Centre for Medical Genomics (at IMB, UQ) for sequencing while the RNA was reverse 
transcribed using Quantitect® Reverse Transcriptase kit (Qiagen) as per manufacturer’s guidelines 
and subjected to qPCR using specific sybr and/or Taqman primers. 
 
Results 
P495TGHR enhances GHR signalling in Ba/F3 cells 
To characterize the effect of the P495T variant on downstream signalling, the well-characterised 
murine pro-B cell line (Ba/F3) was used. This cell line is IL-3 dependent and does not express 
endogenous GHR. After retroviral transduction of the variant (P495T or 495) and wild type (WT) 
GHR into these cells they can proliferate in response to GH. The GHR expression was selected by 
hygromycin B and verified by western blot.  
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Figure 4.1: Time course analysis of GHR downstream signalling in WT and P495T Ba/F3 cells.  
Cells were serum starved overnight and stimulated with 50ng/ml of GH for 15 minutes followed by PBS washes. Cells 
were returned back into serum starvation medium and harvested at the indicated time points. Enhanced P-STAT5 
signalling was observed in P495T Ba/F3 compared to WT (post 90 minutes). (A) The immunoblot of the time course 
experiment, comparing P-STAT5 level in WT and P495T Ba/F3 cells. (B) P-STAT5 level was quantified and normalized 
to β-tubulin. The fold change of P-STAT5 levels in P495T Ba/F3 relative to WT is represented graphically. (C) P-STAT5 
levels were quantified and normalised to respective GHR level. The fold change of P-STAT5 levels in P495T Ba/F3 
relative to WT is represented graphically. (D) Proliferation assay of WT and P495T in growth medium containing GH 
(100ng/mL) over a period of 5 days starting at a seeding density of 104cells/mL. Data representative of n=3 independent 
experiments confirmed in three separate population studies and clonal lines from three independent transductions (mean 
± SEM; ****: P <0.0001, **: P < 0.01, *:P<0.05) analysed by student t-test. 
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As shown in figure 4.1A, the initial response to GH was similar for both GHR expressing cell lines. 
The P-STAT5 levels normalised to beta-tubulin was enhanced in P495T Ba/F3 cells from 60 
minutes and peaked at 135 minutes, when there was 4 fold more P-STAT5 in the P495T Ba/F3 
relative to WT. 
 
After serum starvation, P495T was found to have a higher basal GHR expression level than WT 
GHR. In order to determine if this was a clonal artifact, stably transduced cells were created by 
retroviral transduction in three independent experiments, and in each of the three rounds the P495T 
mutant exhibited higher GHR expression than WT after serum starvation. This suggested that the 
mutant receptor (P495T) had an inherent ability to enhance receptor expression in this cell line. 
However, the level of P495T and WT GHR became similar after 105 minutes following a GH pulse, 
which indicates that P495T GHR Ba/F3 retains the ability to downregulate in response to GH 
stimulation. Notably, activated STAT5 levels in P495T cells were still significantly higher than that 
in WT even when both the receptor levels became similar (fig.4.1A). The higher P-STAT5 level at 
the later time points despite the same level of GHR in both Ba/F3 lines is indicative that this GHR 
polymorphism hindered the termination of the Jak/STAT5 pathway. 
 
As GHR levels determines the sensitivity to GH stimulation as well as the strength of P-STAT5 
signalling, we sought to determine if the enhanced P-STAT5 level was solely due to the higher 
GHR expression in P495T Ba/F3 or an effect of polymorphism in enhancing the P-STAT5 level. 
This was achieved by normalising the levels of P-STAT5 to the respective GHR level as 
represented in figure 4.1C. Significantly, the P-STAT5 level was 4 fold higher in P495T Ba/F3 at 
105 to 120 minutes. This suggested that the difference in the active STAT5 level is only partially a 
result of the enhanced GHR expression of P495T in Ba/F3 cells, and that this variant was 
intrinsically able to signal for a longer time following a GH pulse, as occurs in vivo. In addition, the 
proliferation assay on Ba/F3 cells indicated a significant increase in cell number of P495T Ba/F3 
cells analysed over a period of days starting at the same cell density (fig.4.1D). 
 
P495TGHR is a potential driver for lung tumourigenesis 
According to the two GWAS studies, P495TGHR is strongly associated with lung tumourigenesis. 
To study the action of this mutant in lung cells, stably transduced human bronchial epithelial cells 
(BEAS-2B) with P495T and WT GHR were used. Similar to the Ba/F3 model, P495T BEAS-2B 
showed prolonged GHR downstream signalling and therefore a similar prolonged P-STAT5 
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signalling as observed in Ba/F3 cells was expected, but we found the STAT5 signal was weak and 
dropped to an undetectable level within 45 minutes (data not shown). 
 
However, GHR activation of the PI3-K pathway was altered in BEAS-2B P495T line. The P-Akt 
response to GH was significantly stronger in P495T BEAS-2B at 45-60 minutes before falling to a 
similar level by 90 minutes suggesting that P495T BEAS-2B signalling via Akt was enhanced 
(fig.4.2B). This was more evident for P-Akt Thr308 than for P-Akt Ser473 and correlated with 
mature GHR levels (the upper band) representing the receptor on cell surface (fig.4.2A). 
 
Figure 4.2: Time course of GHR downstream signalling in WT and P495T BEAS-2B.  
Cells were serum starved overnight followed by acute GH (50ng/ml) stimulation for 15 minutes. The cells were washed 
and harvested at the indicated time points. (A) P495T BEAS-2B showed an enhanced P-Akt signalling particularly 
between 30-75 minutes. (B) P-Akt Thr308 levels were quantified and normalised to β-tubulin and represented as fold 
change of P-Akt levels in P495T BEAS-2B relative to WT. (n=3 independent experiments, mean ± SEM) **:P<0.01 
analysed by student t-test. 
 
Furthermore, P-Akt Ser473 followed the same trend as that of P-Akt Thr308 but with lower 
amplitude and did not reach statistical significance. 
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The difference in GHR level at early time points was not as significant in the BEAS-2B cells 
compared to that observed in Ba/F3 cells. Nonetheless, the GHR level of 495 BEAS-2B at 60 
minutes was clearly higher. Again receptor levels came back to similar levels by 75 minutes, which 
implies the degradation mechanism of GHR in P495T BEAS-2B might be impaired leading to a 
delay in GHR downregulation. It is important to note that this result was consistent with the 
observation that we obtained in Ba/F3 cells where the GHR level in P495T mutants was higher than 
the WT.  
 
To further demonstrate that the variant P495T has an altered GHR degradation system, the time 
course assay was repeated with a second dose of GH at 60 or 120 minutes where the GHR level 
differed to the greatest extent in the previous time course assays. Figure 4.3 shows the receptor level 
of WT and P495T BEAS-2B after this second acute GH stimulation. Similar to the above result, 
P495T was more resistant to GHR degradation as these cells had a higher GHR level after the 
second GH stimulation (indicated as 60+ and 120+) particularly of the mature, cell surface level. 
This indicates that the GHR P495T has a negative effect on the GHR degradation mechanism.  
 
 
Figure 4.3: Time course of second acute GH stimulation at 60 and 120minutes following the first GH removal in 
WT and P495T BEAS-2B cells. 
The GHR receptor level in P495T BEAS-2B cells was higher at 60 minutes and after 120minutes following the initial 
acute GH stimulation. After a second GH treatment at 50ng/ml for 15minutes (indicated as +), cells were harvested after 
10 minutes indicated as (60+10 and 120+10 time point), WT BEAS-2B showed degradation of GHR level as compared to 
P495T BEAS-2B, which seems to be impaired as evident from the level of mature receptor (m) and precursor (p). 
 
P495TGHR enhances GHR surface cells in DU145 cells 
Although the outcome of P495TGHR polymorphism has only been analysed in context with lung 
cancer, there is a possibility that this polymorphism can have an impact on prostate tumourigenesis. 
Therefore, GHR were retrovirally transduced into DU145 (human prostate cancer cell line) and time 
course analysis was carried out as for the two other cell lines described above. 
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Figure 4.4: Time course analysis of GHR downstream signalling in WT and P495T DU145 cells. 
WT and P495T DU145 cells were serum starved for 24hrs and subjected to acute (50ng/ml) stimulation followed by 
subsequent washes and harvested at indicated time points following GH removal. (A) The representative immunoblot for 
shows the level of signalling molecules. (B) Fold change of P495T GHR relative to WT normalised to β-tubulin. (n=3 
independent experiments, mean ± SEM) ****:P<0.0001, ***:P<0.001 analysed by student t-test. 
 
Similar to Ba/F3 and BEAS-2B, P495T DU145 showed a higher level of mature GHR upon 
stimulation, suggesting that P495T has an impaired GHR regulation system. Consistently, the GHR 
levels of P495T DU145 were higher at 45-60 minutes (fig.4.4B) but no distinct effect on the P-
STAT5 and P-Akt signalling was observed at these time points. This may be due to the low 
endogenous levels of total STAT5 and Akt. Since DU145 is primarily an ERK-driven cancer cell 
line, we analysed the levels of active ERK. However, no statistical significance was achieved.  
 
Impaired SOCS2 binding on P495T GHR 
The Tyrosine at 487 has been shown to be the binding site for SOCS2 (Vesterlund et al, 2011). Due 
to the close proximity of the P495T polymorphism to this tyrosine we hypothesised that SOCS2 
binding to this variant might be impaired due to steric hindrance. This was analysed by co-
immunoprecipitation (co-IP) studies on HEK293 stables expressing WT and P495T GHR. As 
evident in figure 4.5A, SOCS2 binds to the mature glycosylated GHR (m) present on the cell 
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surface after GH stimulation in both cell lines but this is significantly less in the case of P495T 
GHR (fig.4.5B). Since CIS has been shown to bind to Y487 there is a possibility that CIS binding to 
the GHR might also be impaired in P495T but has yet to be analysed. In addition, the level of 
SOCS2 transcript in HEK293 stables was determined following a time course assay to evaluate if 
P495T had any effect on SOCS2 at transcriptional level. No difference in SOCS2 mRNA was 
observed at matching time intervals between WT and P495T (fig.4.5C) but there was a clear 
induction of Socs2 transcription following GH treatment at all the time points analysed. 
 
 
C 
 
Figure 4.5: SOCS2 induction and impaired binding of SOCS2 to P495TGHR in HEK293 cells.  
Parental cells (no GHR) and cells stably expressing WT and P495T GHR were transfected with 2µg SOCS2 for 24hrs 
and starved for overnight before GH stimulation (100ng/ml) for 15 were minutes. Cells were harvested in co-
immunoprecipitation buffer (refer materials and method) and lysates subjected to SOCS2 antibody pull down and with 
antibody coated on sepharose beads. The protein complex was boiled and resolved on a gradient gel. (A) The 
immunoblot for SOCS2 pull down was probed for GHR using HA antibody. m refers to the mature glycosylated form, p is 
the precursor or unglycosylated form and SOCS2 was used as input along with GHR expression in total cell lysates. (B) 
The GHR pull down was quantified for WT and 495 relative to the SOCS2 input (corrected for GHR expression) and 
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represented as densitometry units. (C) SOCS2 mRNA levels in HEK293 WT and P495T stables following a time course 
experiment are similar (mean ± SD) ****:P<0.0001, ***:P<0.001,**:P<0.01, n=4 independent experiments analysed by 
student t-test (in B) and ANOVA (in C). 
 
CIS is not a direct binding partner of GHR 
Based on MAPPIT analysis, phosphorylated Y487 and Y595 on GHR have been predicted to be 
binding sites for CIS ubiquitin ligase as well (Uyttendaele et al, 2007). To date, no direct interaction 
of CIS with GHR has been shown. In order to determine if P495T hinders the CIS interaction as for 
SOCS2, a co-IP analysis was performed. HEK293 cells stably expressing WT GHR was transfected 
with equal amounts of SOCS2 and CIS expression plasmids. The same lysate was divided in to two 
parts and subjected to CIS and SOCS2 co-IP. However, no CIS interaction was detectable in 
comparison to SOCS2 as shown in figure 4.6. Other experiments of CIS co-IP in the absence of 
SOCS2 in HEK293 stable or transiently transfected WT GHR levels did not reveal any detectable 
interaction with GHR (data not shown). It is evident from the blot (fig.4.6) that the CIS interaction 
with GHR is not direct like that of SOCS2.  
 
 
Figure 4.6:  CIS protein does not interact strongly with GHR as compared to SOCS2. 
HEK293 cells stable for WT GHR were transfected with CIS and SOCS2 plasmid (1µg each) simultaneously for 24hrs 
and starved overnight before GH stimulation (100ng/ml) for 15minutes. Cells were harvested in co-immunoprecipitation 
buffer and lysates were divided into two equal parts and subjected to SOCS2 or CIS antibody pull down separately and 
simultaneously and complexed on sepharose beads. The protein complexes was boiled and resolved on a SDS-PAGE 
gel. The blot shows clear pull down of GHR by SOCS2 indicating direct binary interaction whereas no such interaction 
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was seen in CIS. The blots are representative of n=2 independent experiments. 
 
Continuous turnover of SOCS in vivo 
In order to determine the physiological levels of SOCS2 and CIS with regards to GHR status in 
liver, both qPCR and western blot was carried out in tissues from WT and GHR KO (GHBP/GHR 
null) mice. As expected there was a decline in SOCS2 and CIS mRNA in GHR KO owing to lack of 
GHR activated STAT5. Interestingly, the protein levels for both of these were in contrast to their 
mRNA levels, with more SOCS2 protein in GHR KO and no significant change in CIS as compared 
to WT mice (fig.4.7). The latter result is consistent with impaired turnover of SOCS2 protein as a 
result of lack of GHR-mediated proteolysis, unlike CIS. Even though CIS transcript was higher in 
WT mice no change was observed at the protein level when compared to GHR KO confirming that 
CIS does not directly interact with GHR. 
 
 
Figure 4.7: SOCS2 and CIS level in livers of WT and GHR KO mice.  
(A) SOCS2 and CIS mRNA hepatic levels from age-matched male mice (age 12weeks) represented as relative to B2M. 
(B) Immunoblot of SOCS2 and CIS in the liver of the same mice shows contrasting levels of protein as compared to the 
transcript. (n=4/genotype, mean ± SEM) ***:P<0.001,**:P<0.01 analysed by student t-test. 
 
Effect of Brefeldin A on P495TGHR 
In order to ensure that the difference observed in mature GHR isoform between WT and P495T is 
due to delay in GHR degradation rather than increased synthesis, Brefeldin A (BFA) was used. 
BFA is an inhibitor of protein transport from Endoplasmic Reticulum (ER) to Golgi therefore 
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decreasing surface GHR incorporation. A similar time course experiment was carried out on 
HEK293 stable cells that were continuously treated with BFA (1µg/ml) starting 1hr before GH 
stimulation until harvesting at indicated time points.  
A 
 
B 
 
Figure 4.8: Effect of Brefeldin A treatment on HEK293 WT and P495T GHR.  
Cells stably expressing WT and P495T were starved overnight and treated with BFA starting 1hr before the GH 
stimulation (50ng/ml) of 15 minutes and subjected to time course analysis described earlier with continuous BFA 
treatment till harvest. (A) Immunoblot depicting the effects of BFA treatment. Before the addition of GH there is a clear 
difference between the levels of mature (m) GHR in WT and P495T that is maintained through the different time points 
analysed. With subsequent BFA treatment the ratio of mature GHR to precursor GHR decreases. (B) Graph representing 
the downregulation of mature GHR levels (m) in WT and P495T HEK293, following BFA and acute GH treatment, 
normalised to β-tubulin. (n=4 independent experiments, mean ± SEM) *:P<0.05 analysed by student t-test. 
 
The addition of BFA resulted in a decrease in the level of glycosylated mature GHR (m) and an 
increase in precursor (p) levels in both WT and P495T. There is however a clear difference between 
the levels of mature GHR isoform (m) suggesting less receptor on the surface of WT as compared 
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to P495T before and after a GH pulse as shown in figure 4.8. This is consistent with increased cell 
surface GHR (m) observed in three different P495T cell lines. 
 
Altered receptor turnover in P495T GHR 
Further analysis of P495T HEK293 stable revealed undetectable bands that were otherwise evident 
at 60kDa and 43kDa for GHR remnants (indicated by arrows) in WT cell lysates. These bands were 
only observed in HEK293 stables for the WT receptor (as opposed to transiently transfected) 
indicating that it was part of routine receptor endocytosis (or turnover) that occurs in vitro. Another 
observation (fig.4.9A) was that the generation of these bands was independent of GH treatment. In 
order to determine if these bands were an outcome of reduced endocytosis owing to decreased 
proteolytic or γ–secretase activity, specific inhibitors were used. A potent 26S proteasomal 
inhibitor, MG132 pre-treatment at 10µM for 2hrs on HEK293 stables did increase the mature GHR 
form but had no effect on the two remnants in WT or P495T as compared to treatment of the cell 
lines with DMSO alone (control). A similar effect was seen following treatment with another 
irreversible proteasomal inhibitor clasto-lactacystin β-lactone at 10µM for 4hrs. Finally, a γ–
secretase inhibitor, DAPT was used and no difference was observed evident with higher dose up to 
10µM for 4hrs. These analyses with inhibitors were indicative that the remnants seen in WT appear 
not to be due to proteasomal degradation.  
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Figure 4.9: Appearance of remnants in WT GHR and the effect of proteasomal and γ–secretase inhibitors on WT 
and P495TGHR in HEK293. 
(A) HEK293 WT and P495T stables were starved overnight and stimulated with GH (50ng/ml) for 15 minutes and 
harvested. The lysate were subjected to SDS-PAGE. There were 2 remnant bands observed at 60kDa and 43kDa 
(indicated with arrows) only in WT and undetectable in P495T. Blots representative of n=10 independent experiments. 
(B) HEK293 WT and P495T were subjected to MG132 (2hrs), DAPT (4hrs) and clasto-lactacystin β-lactone (4hrs) at 
10µM each, harvested and analysed on SDS-PAGE. No effect of these inhibitors was evident on the WT remnants while 
none were detectable in P495T. Blots representative of n=4 independent experiments. 
 
Conserved P495 and surrounding residues of GHR 
To determine if P495 (highlighted in red fig.4.10) and the residues surrounding it were conserved in 
other species, a multiple alignment analysis was performed using ClustalW2 program (EMBL-EBI) 
as shown in figure 4.10. Intriguingly, besides proline at 495 a stretch of amino acids upstream and 
downstream of it was also conserved. The distinctive cyclic structure of proline's side chain gives it 
an exceptional conformational rigidity compared to other amino acids and since there is no known 
structure of the GHR intracellular domain, it can only be postulated that the proline to threonine 
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conversion might cause significant structural changes since patients heterozygous for the variant 
GHR allele were also susceptible to lung cancer (Cao et al, 2008). 
 
 
Figure 4.10: Multiple sequence alignment of the GHR polypeptide around P495. 
The residue Proline at 495 is highlighted in red and is conserved all through the species along with ~8 residues both 
upstream and downstream to it. 
 
Sequencing of Prostate Cancer slides 
To determine if other GHR polymorphism similar to P495T as well as variants in GH1, GH2, 
STAT5A and B, and Jak2 occurs in prostate cancer, the extracted genomic DNA was sent for 
sequencing. The analysis was not completed at the time of writing the thesis. However, the RNA 
extracted from the same specimens, although clean was not amenable to amplification by PCR for 
house keeping gene-specific primers (Ct values over 32) and therefore not pursued further.  
 
Discussion 
Lung cancer is frequently cited as a malignancy solely attributable to environmental exposure. 
However, it has long been postulated that individuals may differ in their susceptibility with 
increasing evidence from epidemiological studies for a familial risk (Matakidou et al, 2005). Direct 
evidence for a genetic predisposition is evident from the increased risk of lung cancer associated 
with a number of rare Mendelian cancer syndromes, such as carriers of tumour protein p53 (TP53) 
(Hwang et al, 2003) and retinoblastoma (Sanders et al, 1989) gene mutations. The impact of 
alterations of GH-induced signalling on the development and progression of lung neoplasia is not 
fully understood although elevated levels of IGF-1 have been associated with lung cancer (Wang et 
al, 2013). The P495TGHR polymorphism has been associated with a 2-12-fold increase 
susceptibility to lung cancer (Rudd et al, 2006; Cao et al, 2008) and is the first GHR mutation that is 
directly linked to cancer development. We sought to identify the pathway that might be involved 
and examine its role in cancer development. Three different cell lines were transduced with the WT 
or P495T GHR expression constructs and subjected to GH-stimulated time course experiments. We 
identified that the affected signalling pathway was cell line-dependent and hypothesised that 
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negative regulators of GHR signalling like SOCS and Phosphatases as well as GHR turnover might 
be impaired and can thus prolong the signalling rather than the P495T receptor being constitutively 
active. 
 
We found that Ba/F3 cells transduced with P495T GHR have a prolonged active STAT5 signal 
following a GH pulse as well as a higher basal receptor expression than WT. Although the receptor 
levels were higher the increase in active STAT5 was statistically significant when normalised to 
GHR levels. STAT5 activation has been reported in cancers of the breast, prostate, lung, and 
leukaemia while there is evidence for increased oncogenicity when its constitutively activated 
(Xiong et al, 2009; Chhabra et al, 2011). Direct evidence comes from constitutively active STAT5 
transgenic mice that show a 22% increase incidence of developing mammary tumours (Iavnilovitch 
et al, 2004). STAT5 can also induce production of reactive oxygen species (ROS) and DNA 
damage, requirements for cancer initiation (Mallette & Ferbeyre, 2007), however the underlying 
mechanisms are not clear. In addition, enhanced proliferation of P495T following GH stimulation in 
Ba/F3 cells suggests that the expression of this mutant in a hematopoietic cell lineage may promote 
oncogenesis in a similar manner to the Jak2V617F or thrombopoietin receptor MPLW515L/K 
(mutation in the cytoplasmic domain), which can result in constitutively active Jak/STAT 
myeloproliferative disorders (Constantinescu et al, 2008). 
 
In BEAS-2B cells there was a significant increase in active Akt(Thr308) and GHR levels evident in 
P495T compared to WT. Importantly the increase in GHR levels was further exacerbated following 
a second GH pulse indicating that GH-induced degradation is impaired in P495T GHR. The role of 
PI3-K/Akt pathway in cancer progression is still emerging as many of the underlying mechanisms 
are not well understood but a recent finding has indicated that active Akt at Thr308 is a better 
prognostic indicator for non-small cell lung cancer (Vincent et al, 2011). Interestingly, the same 
cancer modality was found to be significant in the GWAS studies associated with P495TGHR 
polymorphism (Cao et al, 2008). In ERK-driven DU145 prostate cancer cell line the signalling 
molecules analysed failed to reach significance but GHR levels were clearly elevated in P495T 
compared to WT cells.  
 
STAT-mediated negative feedback via SOCS and phosphatases have been studied to a considerable 
extent with evidence that GH induces expression of SOCS1-3 and CIS. It has been shown that 
SOCS1-3 terminate GHR signalling largely by ubiquitination through binding at specific tyrosine 
residues on the GHR (Adams et al, 1998; Tollet-Egnell et al, 1999; Vesterlund et al, 2011). Since 
the binding of SOCS1 and 3 is either on Jak2 or the tyrosine residues upstream of P495 we analysed 
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the effect of P495T on SOCS2 and CIS binding as it has been shown to bind to Y487 on GHR by 
co-IP and MAPPIT studies respectively (Vesterlund et al, 2011; Uyttendaele et al, 2007). Definitive 
experiments have proven difficult at this stage, at least in part, because endogenous ubiquitinated 
complexes are expressed at low levels and are short lived and secondly SOCS abundance from 
ligand induction to protein level takes time. As a consequence, the majority of experiments have 
been performed by overexpression of SOCS molecules. On similar lines, in HEK293 cells stably 
expressing WT and P495T and overexpressing SOCS2 we found significantly decreased SOCS2 
binding to P495TGHR after GH stimulation. This observation may be attributable to steric 
hindrance and can explain the increase in STAT5 and Akt signals observed in P495T Ba/F3 and 
P495T BEAS-2B as a result of delayed degradation of GHR at a given time point by SOCS2. 
Interestingly, no direct interaction of GHR with CIS has been shown to date and with Y487 and 
Y595 on GHR predicted as binding site for CIS, it was important to confirm the effect of this 
variant on CIS binding. Essentially, both CIS and SOCS2 protein are expressed in wide range of 
tissues with highest expression in lung, liver, heart and skeletal muscle. But we were not able to 
detect any physical interaction between CIS and GHR as compared to SOCS2 even when the 2 co-
IPs were performed on the same lysate (containing both SOCS2 and CIS) simultaneously.  
 
Another important attribute of SOCS2 and CIS is their turnover rate in vivo. Both SOCS2 and CIS 
are maintained at low levels but increase steadily after a GH pulse (Flores-Morales et al, 2006). As 
a result in the GHR KO mice one would expect less SOCS2 and CIS protein as compared to WT 
due to complete absence of GH-mediated STAT5-induction of SOCS expression evident from the 
mRNA transcript analysis. On the contrary we observe more protein levels of SOCS2 and equal 
level of CIS in mice livers. This highlights two important observations; firstly SOCS2 and CIS 
transcript expression are dependent on GHR function. Secondly, SOCS2 actions may be exclusive 
to GHR unlike CIS, as the level of CIS protein does not change between WT and GHR KO unlike 
the transcript. However, absence of GHR allows SOCS2 protein to accumulate to high levels in 
liver implying that extent of SOCS2 binding to GHR is important in regulating its action. In relation 
to the P495T polymorphism in vivo, the steady state levels of SOCS2 should be enough to show a 
prolonged signalling after a GH pulse and secondly due to the pulsatile nature of GH secretion there 
is a stronger correlation between P495TGHR and lung cancer susceptibility with males over 
females (Cao et al, 2008). The role of SOCS2 in growth is evident from the fact that SOCS2 KO 
mice are giant (Greenhalgh et al, 2002) and idiopathic short stature (ISS) patients express high 
levels of SOCS2 transcripts under basal condition as compared to controls (Ocaranza et al, 2012). 
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In order to confirm that increased signalling in P495T cells is a surface phenomenon BFA 
experiments were carried out. Pre-treatment with BFA prior to GH stimulation results in a 
significant decrease in WT receptor on cell surface (as indicated by mature glycosylated form) 
compared to P495T in HEK293. This increase in GHR level in P495T is maintained throughout the 
time course analysis although the rate of decrease appears similar with WT. An important analysis 
would be to carry out a similar experiment but in the presence of SOCS2 to determine the 
difference in kinetics due to decreased SOCS2 interaction with P495T GHR. This would give a 
better idea of the scenario in vivo. 
 
The 43kDa and 60kDa bands WT GHR cell lysates differ from the one reported earlier as a 
consequence of ERAD (endoplasmic reticulum-associated degradation) mechanism (Loesch et al, 
2007). The ERAD mechanism occurs in precursor form due to inefficient protein folding and is 
pronounced in cells where GHR and Jak2 interaction is hindered or absent. Since HEK293 cells 
express Jak2 and activate STAT5 downstream following GH stimulation in both WT and P495T 
stable cell lines indicates the remnants we observed are not due to Jak2 and GHR interaction. 
Additionally, these bands differ from the metalloproteolytic cleavage-induced remnant since that 
occurs in region (242EED244) proximal to the extracellular domain of the GHR while the residue at 
495 position is close to the C-terminal of the intracellular domain. The treatment of HEK293 stables 
with 26S proteasomal inhibitors; MG132 and clasto-lactacystin β-lactone at high concentrations 
was unable to reduce these remnants in WT or make them appear in P495T cells. Similar effects 
were observed with γ–secretase inhibitor, DAPT suggesting that these remnants are not generated as 
a part of metalloproteolytic or secretase activity since the bands were observed using an anti-HA 
antibody against the HA-tag present on the N-terminus of the GHR. The effect of lysosomal 
inhibitors on WT and P495T cells has not yet been analysed. 
 
The existing literature on GHR structure and function have featured mainly on tyrosine 
phosphorylation which only forms 2.8% of total GHR polypeptide as compared to serine and 
threonine phosphorylation which form 9% and 6% respectively. It is unknown which of the serine 
and threonine residues are phosphorylated and the kinases that may be involved especially those in 
the absence of GH (van Kerkhof et al, 2007). In the case of PRLR, GSK-3β (glycogen synthase 
kinase-3β) was shown to be the bona fide kinase that phosphorylates the receptor on Ser349 and is 
required for the recognition of PRLR by β-TrCP, as well as for its ubiquitination and degradation 
(Plotnikov et al, 2008). The same residue was reported to enhance the stabilisation of PRLR in 
breast cancer cells (Li et al, 2006) due to reduced phosphorylation by GSK-3β (which itself is 
inactivated due to inhibitory phosphorylation by ErbB2 and Ras) (Plotnikov et al, 2008). 
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As observed earlier there was an increase in the level of GHR in P495T stable cells following serum 
starvation suggesting differential GHR turnover that is GH independent. Based on the 
unconventional interaction reported for GHR with β-TrCP in the absence of the GH there is no 
ruling out the possibility of involvement of other E3 ubiquitin ligases that can bind to this well 
conserved serine/threonine rich sequence. Indeed the potential binding site of cdc4 (cell division 
control protein 4) contains phosphorylated serine or threonine followed by a proline and a basic 
amino acid (Orlicky et al, 2003). Although no functional interaction of cdc4 with GHR has been 
analysed yet it is possible that such an interaction would be impaired in P495T variant (lack of 
consensus motif due to proline to threonine mutation). Intriguingly another such consensus motif 
for cdc4 lies 7 residues downstream to 495 and therefore suggests that the variant P495T does not 
completely inhibit the GHR ubiquitination and degradation but only delays it, enough to prolong the 
downstream signalling as seen earlier. Cdc4 has been shown to be an important molecule with cdc4 
KO mice being embryonically lethal (Tsunematsu et al, 2004) and has been shown to control levels 
of c-myc, Notch, cyclin E (Teng et al, 2012).  
 
This chapter highlights the attributes associated with the first gain of function variant in GHR and 
shows that it prolongs signalling in a cell line context owing to delayed degradation of the GHR. 
This delay can occur in a GH dependent manner due to decreased SOCS2 binding or in the absence 
of GH by alteration of the GHR turnover due to alteration in degradation, synthesis and/or transport 
to the surface. The interaction of the variant with other ubiquitin ligases that control the level of 
receptor at the surface cannot be ruled out. Finally, the increase in susceptibility to cancer by 
activation of specific signal transduction molecules to GHR can be tissue-specific and ultimately 
depends on protein abundance of signal activators and suppressors in those tissues. Therefore it 
remains to be determined if P495TGHR polymorphism is associated with other cancers. 
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Introduction 
Need for an appropriate animal model 
Current research on tumourigenesis seeks to understand the molecular events driving tumour 
initiation and progression. Gene knockout and transgenic mice have yielded important insights into 
the contribution of specific mutations to tumourigenesis. However these models carry germline 
mutations with an inherent potential to affect tissue development and predispose all the cells or 
tissue to neoplasia. In contrast, the majority of cancers occur somatically due to multiple, 
heterogeneous mutations in a single cell (Hanahan & Weinberg, 2011). In addition, most transgenic 
models can be used to study only one or two genetic lesions, but practically several mutations are 
likely required to produce most tumours. Furthermore, studying interactions of germline mutations 
requires extensive, expensive, and time-consuming breeding protocols. Previous attempts of 
generating one such transgenic murine model, over-expressing the NLS-GHR have proven 
unsuccessful probably because of embryonic lethality as the only transgenic mice produced from 
this strategy carried a severely truncated GHR gene (Wooh JW PhD thesis, 2008).  The recent 
studies (reviewed in (Chhabra et al, 2011) have provided significant data on the proliferative and 
tumourigenic effects GH/GHR in addition to its forced localisation into the nucleus. However this 
data was generated in GHR knockout or GH transgenic mice and athymic nude mice with 
xenografts, which is not an adequate representation of long-term tumourigenesis. Therefore, in 
order to define the in vivo effects resulting from nuclear localisation of GHR or a constitutively 
active GHR or cancer associated variant P495TGHR, a tissue-specific gene delivery system is 
required which allows restriction of expression to a particular cell or tissue. We have therefore 
sought to establish a strategy to circumvent some of the limitations of a typical transgenic model. 
This strategy is based on use of the receptor for subgroup-A Avian Sarcoma Leukosis Virus, TVA 
that allows multiple genes to be introduced somatically into a single transgenic mouse strain. 
 
The RCAS/TVA technology 
The RCAS/TVA system (Replication-Competent ASLV long terminal repeat (LTR) with a Splice 
acceptor) is based on the use of the receptor for subgroup-A of avian sarcoma leukosis virus, TVA 
that allows genes to be delivered in a tissue specific manner into small animal models (Federspiel et 
al, 1994). TVA-based systems rely on tissue-specific or generalized expression of a transgene 
encoding TVA; the expression of TVA on the surface of mammalian cells is sufficient to mediate 
retroviral infection by subgroup-A Avian Sarcoma Leukosis Viruses (ALSV-A) (Hughes, 2004). 
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This serves as an important tool for a cell and developmental stage specific delivery of the gene(s) 
of interest (Orsulic, 2002).  
 
Different retroviral envelopes have been shown to recognise different receptors on the host cell 
surface (Fisher et al, 1999). The ALSV family, which includes ALSVs, RSV and RCAS vectors 
have a variety of envelope subtypes, designated from A-J, where A to E have been used in 
laboratories (Gilbert et al, 1994). The tva gene was first cloned from chicken and quail DNA based 
on its ability to allow infection of mammalian cells by ALSV-A (Bates et al, 1993). The mRNA 
transcribed from the avian tva gene is alternatively spliced to produce at least two proteins- a 
transmembrane and a GPI-anchored isoform that have identical 83 amino acid ECD, and both are 
sufficient to permit infection of mammalian cells. While there is no recognised mammalian 
homolog, a 40 amino acid region ECD is related to a cysteine-rich element found in low density 
lipoprotein receptor (LDLR) (Rong & Bates, 1995). The role of TVA in avian biology, other than 
acting as a receptor for subgroup ASLV-A retroviruses, is unknown. The TV-B, D and E receptors 
recognise aspects of a single receptor, TVB, which is a membrane protein of fas ligand receptor 
family (Adkins et al, 2000; Brojatsch et al, 1996). The receptor for envelope C has not yet been 
identified. There is evidence that ALSV envelopes mediate viral entry into cell and fusion to host 
cell membrane only after receptor binding at low pH (Melikyan et al, 2004; Mothes et al, 2000). 
 
Development of the RCAS system 
A molecular clone of the DNA genome of the SR-A strain of Rous Sarcoma Virus was modified to 
delete the src oncogene and a unique restriction site (ClaI) was inserted in place of the deleted src 
gene (Hughes & Kosik, 1984; Hughes et al, 1987).  In RSV, the src gene is expressed from a 
spliced mRNA; the splice acceptor that is needed to generate the src message is derived from the 
cellular src gene.  The src gene is flanked by 100 bp long repeats known as direct repeats (DR). 
ALVs have one copy of the DR sequence, as only one copy of DR is both necessary and sufficient 
for viral replication (Sorge & Hughes, 1982). The RCAS vectors contain the downstream copy of 
DR while the upstream copy of DR was deleted to reduce the loss of inserted genes by a 
recombination event (Hughes, 2004).  
 
Although one copy of DR substantially reduces the rate at which inserted genes can be removed, 
inserted sequences still can be lost. This is probably the result of reverse transcriptase jumping 
between fragments that have no homology. In general, viruses with smaller genomes (RCAS 
vectors that have lost the inserted gene) replicate more rapidly than those that retain an inserted 
sequence (Hughes, 2004). However, it is understandable that with every viral passage (reverse 
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transcription) there occurs a loss of inserted sequences. Unlike the RSV, the ALSV-derived viruses 
can take up to 2.5kb insert, which is a little larger than the src gene (Greenhouse et al, 1988). 
However, in some cases inserts larger than 2.5kb have been successfully cloned in RCAS vectors 
and some inserts smaller than 2.5kb have not worked well. A simple, plausible explanation is that 
the key issue is not the length of the RNA genome but the volume it occupies when it is optimally 
folded. As a result, sequences that interfere with the expression of the full-length viral genome 
(sequences containing polyadenylation signals) or those containing direct repeats should be 
avoided.  
 
Upon viral infection, reverse transcriptase produces a linear viral DNA that is subsequently 
integrated into the host genome. However, in the nucleus of infected cells, a portion of the linear 
viral DNA is circularized by host enzymes to produce either one-LTR circles (by homologous 
recombination within the LTRs) or two LTR circles (by end to end joining of the linear viral DNA) 
(Butler et al, 2002). These circular forms have no direct role in the viral life cycle, but are extremely 
useful because they are easy to clone and provide information about mutations and the process of 
reverse transcription in vivo. 
 
In the RCAS vectors, the inserted genes are expressed from the LTR promoter and therefore the 
LTR completely controls the expression of the insert. There are two key elements that govern the 
LTR promoter efficiency; the enhancer and the sequence of pol gene. The ALV LTR contains a 
strong enhancer while the mechanism governing the pol gene expression is not very clear. But, it 
has been demonstrated that the substitution of the pol gene by Bryan high-titre strain of RSV results 
in an increase of the infectious titre with enhanced LTR promoter activity by 5-10 fold (Petropoulos 
& Hughes, 1991). The Bryan strain of RSV was selected for its rapid growth and the resultant 
RCAS derivatives containing Bryan pol gene are called RCASBP (RCAS-Bryan Polymerase). The 
main advantage of using RCASBP vector is that it does not alter the tissue specificity of the internal 
promoter (Petropoulos et al, 1992). The original RCAS vectors have two ClaI sites, of which one is 
used to insert foreign gees and the other site is non-functional due to Dam methylation when 
propagated in the majority of common E. coli strains used for cloning (fig.5.1). Hence, the insertion 
of a DNA segment into the RCAS vector requires their conversion into a ClaI fragment using 
adaptors (Hughes et al, 1987).  
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Figure 5.1: Comparison of RSV, ALV and RCAS genomes.  
The diagram shows the organisation of viral DNA genomes, the location of the genes (gag, pol, and env), the direct 
repeats (DR), the splice donor (SD) and splice acceptor (SA) sites. The src gene of RSV carries a splice acceptor (SA) 
that leads to the production of a separate spliced src message. The src gene also contains its own initiator ATG. The 
upstream DR has been deleted from RCAS; src has also been deleted and replaced by a ClaI site. There is a small 
segment of the src gene in RCAS; this segment carries the src splice acceptor (Adapted from (Hughes, 2004)). 
 
RCAS Vector Propagation 
The RCAS vectors are propagated in cells of avian origin. Originally, chicken embryo fibroblasts 
(CEFs) were prepared from chicken embryos. Like other primary cells, CEFs have a limited 
lifespan in culture, usually 20-30 passages. However, due to the presence of inherent endogenous 
proviruses (closely related to ALSV virus and RCAS vectors) leading to recombination between the 
vectors and endogenous viruses, a line of chickens, called EV-0, were developed that lacked any 
endogenous proviruses closely related to the ALSVs. This further led to development of a 
permanent, non-transformed chicken fibroblastic cell line DF-1 from an EV-0 embryo now 
routinely used to propagate the RCAS vectors (Himly et al, 1998; Schaefer-Klein et al, 1998). 
 
ALSV viruses do not infect mammalian cells because mammalian cells lack the cognate receptors 
that recognise one of the standard envelope subgroups (A-J) expressed on the virus envelope. 
Secondly, even if the entry barrier is overcome, the virus is incapable of producing infectious 
progenies, thereby making these ALSV viruses doubly-defective in mammalian cells (Young et al, 
1993). These problems can be overcome by firstly, using envelope genes from the viruses that are 
capable of infecting mammalian cells. An example of this strategy is the replication-competent 
RCAS vectors that use either the ecotropic or the amphotropic envelopes from the murine 
leukaemia virus (MLV) (Barsov et al, 1996; Barsov et al, 2001). Alternatively, VSVG protein can 
also be used to prepare viral stocks; however these viruses are replication-defective and other 
attempts to make replication-competent VSVG/RCAS derivatives have failed as VSVG is too toxic 
for the host cells to support the spread of a replication-competent retrovirus (Hughes, 2004).  
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Another solution to overcome the barrier is to express an ALSV receptor (tva for subgroup A) in a 
mammalian cell (or a transgenic animal); this allows efficient infection with RCAS derivatives that 
have the cognate envelope TVA (fig.5.2) (Federspiel et al, 1994; Fisher et al, 1999; Orsulic, 2002). 
This concept has been used to generate strains of mice that can be infected in specific cells or 
tissues.  
 
Figure 5.2: Generation of Replication competent retroviral particles  
Chicken DF-1 cells are transfected with a plasmid encoding the replication-competent, subgroup-A avian viral vector 
RCAS which contains the viral genes gag, pol and env and a gene of interest (gene X). The virus is produced in high titre 
and can infect avian cells through the attachment of its surface glycoproteins to the extracellular domain of the TVA 
receptor on the cell surface. Mammalian cells do not encode the TVA receptor and therefore are not susceptible to virus 
infection. However, mammalian cells engineered to express tva cDNA under a tissue-specific promoter are susceptible to 
the viral infection. Unlike avian cells, mammalian cells do not produce infectious RCAS. Only the protein encoded by 
gene X is efficiently produced in mammalian cells. The lack of viral envelope protein production leaves the TVA receptor 
unoccupied, permitting repeated infection of mammalian cells with different RCAS viruses from chicken producer cells 
(Fisher et al, 1999). 
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Replication Defective Lentiviral Vector 
During the past decade, gene delivery vehicles based on HIV-1, the best characterised of the 
lentiviruses, have been developed. Lentiviral vectors, a subclass of retroviruses, offer unique 
versatility and robustness as DNA delivery vehicles as they can transduce a wide range of cell types 
and integrate into the host genome in both dividing and post-mitotic cells, resulting in long-term 
expression of transgene both in vitro and in vivo (Tiscornia et al, 2006). Since they are replication-
deficient they reduce the risk of insertional mutagenesis and oncogene activation as they lack 
overlapping sequences of the retroviral genome (Delenda, 2004).    
 
The HIV-1 genome contains 9 open reading frames encoding at least 15 distinct structural and 
regulatory proteins that are involved in the infectious cycle. In addition, there are a number of cis-
acting elements required at various stages of the viral life cycle. These include long terminal repeats 
(LTRs), the TAT activation region (TAR), splice donor and acceptor sites, packaging and 
dimerisation signal (ψ), Rev-responsive element (RRE) and the central and terminal polypurine 
tracts (PPT) (Trono, 2002). The general strategy for the production of the viral particles involves 
elimination of all the dispensable genes from HIV-1 genome and separating the cis-acting 
sequences from trans-acting factors that are absolutely important for viral production, infection and 
integration (Delenda, 2004).  
 
In vitro, these vectors are produced by transient transfection or stable integration of the replication 
defective vector genomes in a packaging cell line containing stably integrated retroviral genome 
trans- sequences (gag, pol, env) but lacking the packaging signal sequence necessary to encapsidate 
them. One of the latest improvements in the lentiviral vector design has been the development of 
self-inactivating lentiviral vectors (SINs) (Zufferey et al, 1998). This is carried out by deletion in 
the 3`-LTR which reduces homologous recombination between the transfer vector and packaging 
constructs and also reduces the competition between the 5`-LTR promoter and internal promoter 
(Sclimenti et al, 2001; Zufferey et al, 1998). A second modification in the lentiviral utility is the 
envelope substitution which is achievable by transfecting an envelope negative packaging cell line 
with a heterologous env expression construct (Sakalian & Hunter, 1998) (fig.5.3). After efficient 
incorporation, these pseudotyped lentiviral particles reflect the host range of the virus from which 
the envelope protein has been derived.  
 
The second generation systems were the most commonly utilized viral generation plasmids which 
separate packaging and gene transfer functions into three distinct plasmids and lacking certain viral 
accessory genes (Stewart et al, 2003). In general, lentiviral vectors with a wild type 5' LTR need the 
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second-generation packaging system because these vectors require TAT for activation. In contrast, 
the third generation systems go even further by using three helper plasmids: a packaging construct, 
an envelope construct and a Rev construct, along with a Tat-independent gene transfer vector, 
providing 4 separate plasmids in all. This lentiviral transfer vector is made TAT-independent by 
constructing a chimeric 5' LTR in which HIV-1 promoter is replaced with a CMV or RSV. This 
generation packaging system offers maximal biosafety (Dull et al, 1998; Klages et al, 2000). 
Although both 2nd and 3rd generation vectors are generally self-inactivating by virtue of promoter 
disabling mutations engineered into the U3 region of the 3’ LTR, the elimination of the accessory 
gene Tat provides an additional level of safety. 
 
 
Figure 5.3: Schematic representation of generation of lentiviral vector. 
The main elements of the four plasmids co-transfected into 293T cells are depicted. pMDLg/pRRE, the packaging 
construct, provides most of the viral structural proteins but the envelope. The viral genes are expressed from the CMV 
promoter and the polyadenylylation site. Proviral 5' leader and P sequences have been deleted together with a large 
portion of the env gene. A translation stop codon was inserted upstream of the remaining env segment. The major 5' 
splice donor site (SD) has been conserved. pRSV-Rev provides the Rev protein for nuclear export of RNA. pCS-CG-
GFP, the transducing vector encoding for GFP, provides the vector genome. The viral long terminal repeats (LTRs) and 
the P sequence are indicated. The gag gene is truncated after 350bp and is out of frame (x), and it follows the Rev 
responsive element (RRE) and a splice acceptor site (SA). The position of a CMV-driven expression cassette for the 
GFP cDNA is shown. pCB6WTA encodes the ALSV-A envelope that pseudotypes the virus for binding specifically to the 
TVA receptor. (Adapted from (Naldini et al, 1996).  
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TVA in Animal Models 
As indicated above, mammalian cells are not susceptible because of a lack of suitable cell surface 
receptors for viral entry and infection. This has however changed with the cloning of the tva gene, 
which encodes for the TVA receptor. It was shown that ectopic expression of tva gene in 
mammalian cells allows for viral entry and chromosomal integration by ALSV-A (Bates et al, 1993; 
Young et al, 1993). This discovery has enabled the generation of mammalian cell lines and 
transgenic mouse lines that express the TVA cell surface receptor, thus rendering the cells 
susceptible to infection with RCAS viruses or ALSV-A pseudotyped lentiviruses.   
 
The TVA transgenic mice have an added advantage that TVA receptor can be expressed under the 
control of a specific promoter in order to develop a system for cell- or tissue specific gene targeting 
(Dunn et al, 2000; Federspiel et al, 1994).  Therefore, only mice cells that are engineered to express 
the TVA receptor can be infected, while mouse cells that do not express the tva gene homolog are 
resistant to ALSV-A infections. After the viral entry into TVA-positive mammalian cells, a newly 
synthesised DNA copy of the viral genome integrates into the host DNA, and the viral LTR 
promotes a high level of transcription of the integrated provirus (Orsulic, 2002).  
 
In contrast to replication-defective vectors, RCAS vectors do not need a packaging cell line and 
high titre viral stocks can be generated by transfecting the vector into a chicken fibroblast cell line 
(Himly et al, 1998; Schaefer-Klein et al, 1998). RCAS infection does not, however result in 
infectious progeny in mammalian cells (Federspiel et al, 1994) thereby preventing the spread of 
cell-to-cell infection and also limiting any cellular immune response by the host (Pinto et al, 2000). 
Another important consideration for using TVA mice is the fact that the expression of RCAS env 
gene is quite low in mammalian cells, therefore, the TVA receptor is not occupied by the viral 
envelope protein and is susceptible to multiple rounds of infection with RCAS vectors carrying the 
same or different inserts. This gives the added advantage of introducing multiple genes sequentially 
into specific cells of a single transgenic mouse strain (Federspiel et al, 1994; Holland & Varmus, 
1998; Orsulic, 2002).  A few strategies employed for retroviral vector-mediated gene delivery are 
highlighted below.  
 
Utility of RCAS/TVA based gene delivery system 
The first demonstration of expression of a tva transgene in specific mouse tissues in combination 
with recombinant ALSV-A for introducing the gene of interest (alkaline phosphatase) was 
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implemented with a tva transgene under the control of chicken αsk-actin promoter (Federspiel et al, 
1994). These mice expressed TVA in skeletal and cardiac muscle and proved that the tva based 
retroviral system was a viable means of introducing foreign genes in mice in a tissue-specific 
manner. 
 
Cooperative oncogenesis 
Cancer is thought to arise from an accumulation of multiple genetic alterations. Each genetic 
alteration contributes additional capability for progression from normal to a metastatic state 
(Hanahan & Weinberg, 2011) as evident in the case of colorectal carcinoma, where about seven 
sequential genetic alterations occur during the tumour development (Kinzler & Vogelstein, 1996).  
The most common approach for studying cooperative tumourigenesis has been the use of tumour-
prone transgenic and or knockout mice to evaluate the acceleration of tumour development. This is 
particularly complex while analysing more than two genetic perturbations and therefore requires 
analysis of synergistic combination of mutations.  
 
In the TVA system, a number of genetic lesions can be introduced simultaneously or sequentially 
into individual cells in a TVA transgenic mouse, thus allowing for the study of numerous 
combinations of genetic alterations (gain of function or loss of function) in specified cell types. This 
strategy has been employed to study cancer models of glioma by mimicking the genetic alterations 
that occur in human gliomas by rendering glial cells specifically susceptible to infection by viral 
vectors (Holland, 2000; Holland & Varmus, 1998). Using this approach in TVA mice, it was 
demonstrated that simultaneous activation of RAS and Akt pathways (Holland, 2000) or BRAF and 
Akt (Robinson et al, 2011) in progenitor cells was sufficient to induce formation of glioblastomas. 
Individually, neither RAS or BRAF or Akt pathways were able to induce glioblastoma suggesting 
the requirement for combined effects of two pathways. Additionally, Holland et al. have 
investigated the role of EGFR mutation in glioma pathogenesis using transgenic mice that 
expressed the TVA receptor under the control of the astrocyte specific glial fibrillary acidic protein 
(GFAP) promoter (Holland et al, 1998). Infection of GFAP–TVA transgenic mice with the virus 
encoding a constitutively active mutant EGFR did not result in glioma development. However, 
coinfection of GFAP–TVA transgenic mice with viruses carrying CDK4 and mutant EGFR or 
infection of GFAP–TVA transgenic mice deficient in INK4a–ARF with the mutant EGFR virus 
triggered gliomagenesis, suggesting that genetic alterations of EGFR and INK4a–ARF are two 
crucial genetic events in gliomagenesis (Holland et al, 1998). 
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Trace cell lineages and developmental processes 
TVA-based systems have also proved useful in developmental studies as the infection by RCAS 
viruses are restricted to cell lineages due to replication defects in mammalian cells, the descendants 
of infected progenitors can be traced during development. In case of GFAP-TVA transgenic mice it 
was demonstrated that the GFAP-positive astrocytes of the sub-ventricular zone (SVZ) act as neural 
stem cells (Doetsch et al, 2002). Other studies have been conducted to investigate the 
megakaryocyte lineage (Murphy & Leavitt, 1999) and neural crest development (Dunn et al, 2000). 
 
Generate transgenic animals 
Retroviruses stably integrate into the genome of cells and therefore can be used as gene delivery 
vehicles to introduce experimental genes into blastocysts. So far there has only been one study in 
this regard, in which transgenic mouse line expressing tva under the control of β–actin promoter 
were used. This line therefore expresses the TVA receptor in the majority of adult tissues and in 
early embryonic tissues (Federspiel et al, 1996).  New transgenic lines expressing chloramphenicol 
acetyl transferase (CAT) in all, or specific tissues were generated by infection of susceptible 
blastocysts (expressing tva) with retroviral vectors carrying the CAT gene under the control of 
constitutive viral promoter or an internal tissue-specific promoter (Federspiel et al, 1996). 
 
Besides the examples listed in the Table 5.1 below, the TVA system is being utilized for extensive 
studies on development, receptor signalling and gene knockdown using RNA interference 
(Foppiano et al, 2007). Recently, the Cre-loxP-based system has been incorporated in conjunction 
with TVA system for conditional somatic gene expression and knockdown. In this method, a lox-P 
flanked stop cassette was used for conditional activation of TVA in a Cre-recombinase-dependent 
manner both in vivo and in vitro (Seidler et al, 2008). Combined with the growing number of Cre 
expression models, the tva gene expression and knockdown systems provide promising perspectives 
for analysing gene functions in a spatial-temporal manner. Finally, there have been recent 
modifications to the RCAS vectors to expand the repertoire of their applications. These include 
modifications to allow gene knockdown experiments by RNAi via expression of short hairpin 
RNAs (shRNAs), and drug regulated gene expression by utilisation of the tetracycline (tet)-
dependent transcriptional regulation (Politi & Pao, 2011). 
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Table 5.1: RCAS/TVA system utility.  
Some published studies conducted using RCAS/TVA system utilising replication competent retroviral vectors 
(RCAS/RCASBP) and EnvA-pseudotyped lentiviral vectors. 
 
This chapter details the establishing of the TVA based avian retroviral and pseudotyped lentiviral 
gene delivery system both in vitro and in vivo with a methodological approach. Emphasis will be 
given on development, testing and significance of the system to generate more information on 
GHR-mediated oncogenesis in vivo.  
Mice or Model  Viral Construct Delivery/ Technique Fate Reference 
Chicken αskactin-TVA 
(Skeletal muscle)  
RCASBP-AP 30-50µl retrovirus 
2×105 DF-1 cells/leg injected intra-
muscular in neonates 
Culled after 7 
days and muscle 
stained for AP 
(Federspiel et 
al, 1994) 
β-actin TVA 
(Ubiquitous expression) 
RCASBP-AP 4×100mm DF-1 confluent plates in 
1ml, 50µl injected intra-muscular in 
neonates 
Analysed 14, 28 
and 42 days 
post-injection 
(Pinto et al, 
2000) 
β-actin TVA embryo 
derived fibroblasts (EF) 
RCAS-KrasG12D 106 EFs (retroviral transduced) 
injected sub-cutaneous into nude 
mice 
Tumours formed 
in 8 weeks 
(Pao et al, 
2003) 
MiaPaCa2TVA 
(Orthotopic Pancreatic 
Cancer Model) 
RCASBP-EGFR 
RNAi 
RCASBP-p53 RNAi 
MiaPaCa2TVA cells transplanted in 
pancreas of nude mice and injected 
intra-peritoneal with 107 DF-1 
producer cells after 5 days 
Analysed after 1 
month 
(Mayr et al, 
2008) 
Nestin-TVA 
(Neural progenitor cells 
in cerebella) 
RCASBP-IGF2 
RCASBP-Shh 
RCASBP-Akt (active 
form of Akt) 
105 DF-1 producer cells injected 
intra-cranially  
Not Defined (Rao et al, 
2004) 
Scl-TVA  
(Vascular Endothelial 
Progenitors) 
RCASBP-PyMT 8-12weeks old mice injected intra-
venous with retrovirus (107IU/ml, 
300µl/mouse) 
Analysed after 3-
6 months 
(Sausville et al, 
2008) 
MMTV-TVA 
(Mammary epithelium) 
RCASBP-PyMT 
RCASBP-Neu 
 
6weeks old pubertal mice injected 
with 10µl (or 108IU) intraductal via 
teat 
7 days post-
injection 
 
(Du & Li, 
2007) 
Nestin-TVA 
(Neural progenitor cells 
in cerebella) 
 
RCASBP-Akt 
RCASBP-Braf 
RCASBP-Kras 
(Active form of Akt, 
Braf, Kras) 
 
RCASBP-Mek1  
(Active form of Erk1) 
10cm confluent dish with DF-1 
producer cells trypsinised, into total 
50µl and 5µl injected intra-cranial in 
neonates with genotype Nestin-
TVA/Ink4a/Arflox/lox 
Tumours 
analysed after 3-
5 months 
 
(Robinson et 
al, 2010) 
 
(Robinson et 
al, 2011) 
RIP-TVA 
(B cells of pancreatic 
islets) 
RCASBP-cad 
(dominant negative) 
RIP-Tag and RIP-TVA crossed mice 
given intra-cardiac injections of 
100µl (>108IU/ml) virus at 7weeks 
Tumours 
analysed after 9 
weeks 
(Du et al, 
2007) 
DCT-TVA 
(Melanocytes) 
RCASBP-NRasQ61R 10cm confluent dish with DF-1 
producer cells trypsinised, into total 
50µl and 5µl injected sub-cutaneous 
near the ear of neonates with 
genotype DCT-TVA/Ink4a/Arflox/lox  
Tumours visible 
after 4-6 weeks  
(VanBrocklin 
et al, 2010) 
Alb-TVA 
(Liver) 
RCAS-PyMT 
RCAS-c-myc 
3 day old neonates injected with 106 
DF-1 producer cells in liver 
parenchyma 
Tumours 
analysed after 
4-6 months 
(Lewis et al, 
2005) 
Keratin19-TVA 
(Epithelial cells) 
 
MMTV-TVA 
(Mammary epithelium) 
 
HIV-1 (ALSV-A)-
PyMT 
 
RCAS-PyMT 
 
10µl of concentrated lentivirus (104 
IU/ml) injected via the teat into the 
ductal lumen of mammary glands of 
7weeks old mice. 
Mice sacrificed 
30 days post-
injection and 
tumours 
analysed 
(Siwko et al, 
2008) 
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Materials and Methods 
Chemicals 
Sudan Black B, copper sulphate and sodium butyrate were purchased from Sigma Aldrich 
(Australia). Ultraculture™ Serum-free media was purchased from Lonza (USA).  
 
Plasmids 
The plasmids pCS-CG-DV, pCS-CG-GFP, pCB6WTA (VCT) and (Δ513) were gifts from Prof. 
Brian Lewis (University of Massachusetts Medical School, MA, USA) and RCASBP-Y-DV were 
purchased from Addgene (plasmid# 11478). Lentiviral packaging plasmids pMDLg/pRRE and 
pRSV-Rev were a kind gift from Prof. Alpha Yap, University of Queensland. Lentiviral destination 
vectors with PGK-driven expression (pLenti-PGK-Puro DEST) were obtained from Addgene 
(plasmid# 19068) (Campeau et al, 2009). The pMSCV-TVA-puro vector (unpublished construct) 
was a gift from Dr. Jonas Nilsson, University Umea, Sweden. pVPack-GP® and pVPPack-VSVG® 
was purchased from Stratagene. pDONR221 vector was obtained from Invitrogen. All gateway 
destination vectors were maintained in OneShot® ccdB Survival™ E. coli strain (Invitrogen, 
Australia). 
 
Construction of RCAS and ALSV-A pseudotyped replication defective lentiviral expression 
plasmids 
RCAS constructs were constructed either by standard cloning or gateway cloning strategy. For 
standard cloning, each gene of interest was PCR amplified using specific primers (listed in 
Appendix III) designed to include AclI recognition sequences. PCR reactions were carried out using 
Pfu Turbo DNA polymerase (2.5U/µl) as per manufacturer’s recommendations (Stratagene). The 
PCR conditions used were 94°C for 20sec, 60°C for 20sec and 68°C for 150sec for 35 cycles in a 
thermal cycler (MyCycler, BioRad). The RCASBP-Y vector was digested with ClaI and 
dephosphorylated with Shrimp Alkaline Phosphatase (New England Biolabs, Genesearch Ltd, 
Australia) while all the AclI site containing inserts were digested with AclI to provide overhangs 
that were compatible for ligation with ClaI digested products. The gel-extracted purified, 
dephosphorylated RCASBP-Y vector and inserts were used in an equal molar ratio for ligation 
reactions using T4 DNA Ligase (Promega) at 16°C overnight. 
 
For Gateway recombination cloning, each gene of interest was PCR amplified using attB cassette 
containing primers (listed in Appendix III). PCR reactions were carried out using Pfu Turbo DNA 
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polymerase (2.5U/µl) as per manufacturer’s recommendations (Stratagene). The PCR conditions 
used above. Two series of reactions were carried out for each Gateway Cloning procedure. The first 
reaction was between the attB flanked PCR amplified fragment and pDONR221 donor vector 
(Invitrogen) using BP Clonase® enzyme mix (Invitrogen) in a total volume of 5µl in Tris EDTA 
(TE) buffer (10mM Tris pH8.0, 1mM EDTA) at room temperature for at least 3hrs. The second 
reaction between 4µl BP reaction end product and pCS-CG-DV, RCASBP-Y-DV or pLenti-PGK-
DV plasmids (destination vectors) were catalysed by LR Clonase® enzyme mix (Invitrogen) in a 
total volume of 8µl TE buffer supplemented with 14mM NaCl, at room temperature overnight. The 
ligation end products and 1µl LR Clonase reaction were transformed into competent E. coli DH5α 
or Stbl3™ strains (Invitrogen) and plated on LB agar plates containing ampicillin (100µg/ml).  
 
Cell Culture 
Chicken embryonic fibroblast derived cell line; DF-1 (a kind gift from Prof Douglas Foster 
University of Minnesota USA via Dr. Matthias Ernst, Ludwig Institute, Melbourne) was maintained 
in DMEM supplemented with 10% FBS (Schaefer-Klein et al, 1998). The retroviral packaging cell 
line Plat-E (a gift from Dr. T. Kitamura from University of Tokyo, Japan) was also maintained in 
DMEM with 10% FBS. HEK293 derived 293T (Clontech) and 293FT (Life Technologies) cell lines 
were maintained in DMEM with 10% FBS. Human melanoma cell line MM96 and 293T derived 
Lenti-X cell line from Dr. Aaron Smith, UQ were maintained in DMEM with 10% FBS. MM96-
TVA-puro cell line was maintained in normal growth medium supplemented with 0.4µg/ml 
puromycin (concentration determined by kill curve experiments).   
 
The murine pro-B cell line, Ba/F3 was grown in RPMI 1640 media supplemented with 10% serum 
supreme, 2mM L-glutamine and 100U/ml IL-3. Ba/F3 cells expressing wildtype and nuclear 
localised GHR were maintained in 0.1ng/ml hGH instead of IL-3 to maintain the receptor 
expression. Ba/F3-TVA-puro cell line was maintained in normal growth medium supplemented 
with 1µg/ml puromycin (concentration determined by kill curve experiments).  All cell lines were 
maintained in a humidified chamber 37°C incubator with 5% CO2. 
 
Production of replication competent ALSV-A virus 
DF-1 cells were plated at a seeding density of 106 cells in a 6-well format a day prior to transfection. 
At 50% confluency, DF-1 cells were transiently transfected with 3µg of RCASBP vector with gene 
of interest per well using lipofectamine 2000 (Invitrogen) as per manufacturer’s guidelines. The 
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media was removed 3-4 hours after transfection and replenished with 2 ml of fresh complete growth 
media. The viral supernatant was collected at several time points (i.e. 2, 3, 4, 5, 6, 7, 8, 9 days post-
transfection) and centrifuged at 3000g for 5minutes. The supernatant was then filtered through a 
0.45µm (low protein binding) polyethersulfone membrane filter (Merck) and stored at 4°C, 
concentrated or used fresh to test for functional virus production. 
 
Production of replication defective ecotropic retrovirus 
The potent retroviral packaging cell line, Plat-E was plated at a cell density of 8.5×104 cells per well 
in a 6-well format and transiently transfected with 4µg of pMSCV-TVA-puro plasmid using 
lipofectamine 2000 (Invitrogen) as per manufacturer’s guidelines. The media was replenished 
24hrs. post-transfection and the plates were further incubated at 37°C for 24hrs. The plates were 
then incubated for a further 24hrs at 32°C and supernatant collected. The supernatant was filtered 
through 0.45µm (low-protein binding) polyethersulfone membrane filter and used for transducing 
Ba/F3 cell line.  
 
Generation of Ba/F3-TVA-puro cell line 
A total of 2×105 Ba/F3 cells were harvested and seeded in each well of a 6-well cell culture plate 
for each viral transduction. The starved cells were resuspended in the harvested supernatant or 
concentrated virus. Polybrene (Sigma, USA) was added at a final concentration of 8µg/ml and the 
plates were incubated at 37°C for 1-2hrs. After incubation, an equal volume of complete growth 
media with twice the standard concentration of IL-3 was added and the plates were incubated at 
37°C. 48hrs after infection Ba/F3 cells were selected on puromycin and analysed for infection.  
 
Production of replication defective pantropic retrovirus  
Lenti-X cells were plated in a 6-well format and upon attaining 50% confluency transiently 
transfected with 4µg each of pMSCV-TVA-puro plasmid, pVPPack-VSVG plasmid and pVPack-
GP using lipofectamine 2000 (Invitrogen) as per manufacturer’s guidelines. The media was 
replenished 24hrs post-transfection and the plates were further incubated at 37°C for 48hrs and 
supernatant collected. The supernatant was filtered through 0.45µm (low-protein binding) 
polyethersulfone membrane filter and used for infecting MM96 cell line in the presence of 4µg/ml 
polybrene. The cells were selected in puromycin 48hrs after transduction.  
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Harvesting and Concentration of Viruses 
The centrifuged supernatant from transiently transfected DF-1 (containing replication competent 
virus) and 293T/Lenti-X cells (containing replication defective virus) were concentrated by 
ultrafiltration of the supernatant using Amicon Centricon® centrifugal filters (Millipore) with a 
100,000 MWCO (molecular weight cut-off), at 4000rpm at 4°C. The centrifugation time can be 
increased in order to increase the concentration of the virus. Virus concentration by 
ultracentrifugation carried out in a fixed angle Beckman Coulter Optima 70Ti series rotor at 
90,000g for 2h at 4°C. The viral pellet was resuspended in PBS and concentrated virus was used 
fresh or stored at 4°C for not more than two weeks. 
 
Estimation of Viral Titre 
MM96-TVA-puro cells were plated in a 24 well format a day prior to infections. On the day of 
infection, cells close to 75% confluency were mixed with limiting dilution of viral supernatant or 
concentrated virus in the range of 1 to 1012 in duplicates and incubated for 24hrs at 37°C. No 
polybrene was added during the process. Following 24hrs, the cells are replenished with fresh 
medium and plates incubated at 37°C. The infectious titre is determined by analysing the expression 
of reporter gene (GFP or mKate2) within 48-72hrs from the time of infection and GFP expressing 
cells were counted for each dilution under a fluorescence microscope. The viral titre is estimated by 
determining the dilution range that gives at least 10 positive cells. The formula used was: 
 
Viral titre (TU/ml) = (number of GFP positive cells) x (dilution factor)  
 
Animal Experiments  
Mouse strains: α-actin TVA (expressing TVA receptor in skeletal muscles; TVM) and β–actin TVA 
(expressing TVA receptor ubiquitously; TVU) were sourced from Dr. Stephen Hughes (National 
Cancer Institute, USA) (Federspiel et al, 1994; Pinto et al, 2000). Albumin TVA (expressing TVA 
receptor in liver; TVL) was sourced from Brian Lewis, UMASS (Lewis et al, 2005). Genotyping 
was performed for TVA mice by PCR with DNA extracted from toes. The PCRs were carried out 
using Taq DNA Polymerase (5U/µl, NEB) in a thermal cycler with the following program: 95°C for 
20sec, 59°C for 30sec, 72°C for 30sec for 30 cycles with tva specific primers.  
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Viral Delivery and Tissue collection 
Retroviral Delivery: 
Based on published studies with replication competent retrovirus, neonates were injected with DF-1 
producer cells and the route of delivery was based on the tissue expressing tva. Due to volume 
constraints 106 producer cells were resuspended in minimal PBS volume of 30µL, of which 5µL 
was injected 2-day-old neonates; intra-muscularly (i.m.) into α–actin tva litters, intra-peritoneally 
(i.p.) close to liver for albumin tva litters (Lewis et al, 2005) and/or both for ubiquitous β–actin tva 
litters.  
 
Lentiviral delivery: 
Concentrated viruses (100-fold) with titre around 109 to 1011IU/ml (Naldini, 1999) were injected 
intra-muscularly and intra-peritoneally in 2-4 week old α–actin tva mice and albumin tva mice 
respectively. Equal amount of empty expression vector concentrated virus was used as control when 
injecting virus. Intra-venous viral delivery via inferior vena cava following surgery was performed 
for albumin-tva mice. The mice and neonates were monitored regularly for any signs of toxicity, 
wound, and disease. 
 
Subsequently mice were culled 2-4 weeks post-injection by cervical dislocation and liver and/or 
muscle tissues were collected and partly fixed in 4% PFA for histopathology and rest was snap-
frozen in liquid-nitrogen and stored in -80°C freezer until use. 
 
Generation of TVA expressing Zebrafish 
The TVA expressing zebrafish was made by Dr Kaska Koltowska in the laboratory of Dr. Ben 
Hogan (IMB). All experiments were approved by and performed in accordance with the guidelines 
set by the University of Queensland Animal Ethics Committee. Briefly, tol2 transposase mRNA 
was prepared in vitro by transcription from XbaI-linearised pDB600 (Balciunas et al, 2006) using 
the mMESSAGE mMACHINE® T3 transcription kit (Ambion). RNA was purified using the 
RNeasy purification kit (Qiagen) and diluted to a final concentration of 100ng/µl and stored as 2µl 
aliquots at –80°C. The TVA construct was made using the Gateway cloning system (Kwan et al, 
2007). For microinjections approximately 5µl mix was prepared with 2µl transposase, 2µl construct 
(100ng/µl) and lµl phenol red. Finally 2nl were injected in single embryo. Fish were raised to 
adulthood and screened for founders based on GFP expression in the heart (Bussmann & Schulte-
Merker, 2011). The founders were crossed to Tg(hsp70l:Gal4)1.5kca4 and larvae generated were 
given a heat shock treatment at 39°C for 1.5hrs and analysed for tva expression by qPCR using hprt 
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as an internal control. The zebrafish larvae and adults were held in E3 medium (5mM NaCl, 
0.17mM KCl, 0.33mM CaCl2, and 0.33mM MgSO4, pH 6.8–6.9) at 29°C. 
 
 Results & Discussion 
Construction of RCASBP(A) vectors  
The most commonly used or the ‘classical’ cloning method is a restriction endonuclease dependent 
strategy for insertion of transgene into the vector of interest. Using this method, RCASBP vectors 
were digested with the ClaI enzyme and dephosphorylated. Since only one ClaI site is functional in  
the RCASBP vector, the other one being methylated, the insertion of DNA segment requires their 
conversion into a ClaI fragment using adaptors (Hughes et al, 1987). Therefore, the linearised 
plasmid was ligated to transgenes (amplified using AclI specific primers and digested with AclI to 
obtain compatible overhang with ClaI) to get the desired construct. 
 
However, due to the large size of the retroviral vector (~12kb) and inherent repetitive viral 
sequences, the constructs were prone to recombination resulting in small sized plasmids (following 
the loss of gene of interest). In order to circumvent this problem the gateway® cloning method was 
employed. This cloning exploits the bacterial or viral site-specific recombinases like the 
bacteriophage P1 Cre, the Saccharomyces cerevisiae FLP or the bacteriophage lambda integrase 
(Magnani et al, 2006).  These enzymes catalyse a reciprocal double-stranded DNA exchange 
between two specific DNA sites (Loftus et al, 2001) and summarised in the figure 5.4.  
 
 
Figure 5.4: Gateway BP and LR reactions.  
(A) BP recombination of a PCR product "X" flanked by attB sites with a Gateway donor vector resulting in generation of 
a entry clone with attL sites (B) LR recombination of the entry clone bearing a DNA fragment "X" with a Gateway 
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destination vector with attR sites. This results in the final expression clone with gene of interest ‘X’ (Magnani et al, 
2006). 
 
Consistent with published work expression clones generated using recombination based cloning had 
a higher success rate as compared to standard cloning (Loftus (Loftus et al, 2001). During the 
routine process of lentiviral and retroviral plasmid isolation from E.coli DH5α it was observed that 
the isolated plasmid DNA would often lose the insert. This issue was resolved by transforming the 
retroviral and lentiviral constructs into competent Stbl3™ E. coli strain. This strain lacks recA gene 
and is designed specifically to circumvent the problem of cloning direct repeats found in retroviral 
and lentiviral expression vectors as it reduces the unwanted recombination within the LTRs. Using 
gateway cloning strategy we have made numerous GHR constructs including wildtype, nuclear-
localised and constitutively active receptor. 
 
Establishing the RCAS/TVA system in vitro 
Mammalian cells are resistant to infection by ALSV-A vectors, therefore a cell line expressing the 
ALSV-A receptor TVA was required to determine any functional viruses produced. For generation 
of such a cell line, two important questions need to be answered; the choice of cell line and the 
method to engineer that cell line of interest. Ba/F3 cells were chosen for the convenience of 
analysing GHR constructs (based on GH selection) as they are devoid of any endogenous GHR 
while an adherent human melanoma cell line MM96 was chosen for estimating the viral titre. A 
reasonable approach for generating such cell lines was the use of replication deficient retroviral 
particles that would carry the tva gene and stably integrate into the genome of transduced cells 
without any risk of viral replication.  
 
Generation of ALSV-A based replication competent retroviruses 
For the production of high titre recombinant retroviral stock, we took the advantage of a RSV-
derived replication competent vector, RCASBP and an established chicken fibroblast cell line, DF-1 
(free from any endogenous viruses). This cell line was transfected with the RCASBP vector 
carrying the desired insert. For their anticipated ease of detection, vectors containing GFP or far-red 
fluorescent protein, mKate2 were used and cloned into RCASBP vectors. 
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Figure 5.5: Generation of Replication Competent Retroviruses.  
Chicken embryonic fibroblast cell line, DF-1 was transiently transfected with replication competent vector RCASBP(A)-
HA-NLS-GFP. The DF-1 cells were analysed for nuclear GFP expression every day (24hrs interval) to determine 
transfection efficiency and viral production by DF-1 cells, which corresponds to percentage of cells expressing nuclear 
GFP and the intensity of brightness. (A) Represents day 0 of transfection, B – H represents subsequent analysis of cells 
every 24hrs till day 7. Untransfected DF-1 cells were used as a control and analysed everyday (image not shown). 
Images taken on Olympus Fluoro microscope. 
 
A number of standardisation experiments were carried out in order to determine the most optimal 
time point of supernatant harvest for maximum viral yield. Cells were replenished, 24 hours post-
transfection, with a minimal amount of media (to obtain concentrated virus). Initially the 
supernatant was collected every 24hrs and used promptly to infect MM96-TVA-puro cells to 
determine viral load. From the tests, it was also observed that Day 6-7 harvested media had the 
maximum viral load attributed to 100% DF-1 cells being transduced with the virus. As show in the 
fig.5.5, there was a gradual increase in the intensity of the GFP signal. Initially, only a few chicken 
cells express GFP, which increases subsequently as a result of multiple rounds of infections of the 
cells with the replication competent retrovirus (RCAS) being produced by the cells themselves. This 
observation corresponds to a previous study in which successful transfections of only a few DF-1 
cells was sufficient since the replication competent virus spreads throughout the DF-1 culture 
(Schaefer-Klein et al, 1998). Even though the RCASBP vectors contain one copy of DR sequence, 
there is a possibility of the reverse transcriptase jumping fragments with little or no homology every 
time the viral RNA genome gets reverse transcribed following infection of dividing cells, resulting 
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in the loss of the gene of interest (Hughes, 2004). In general, viruses with smaller genomes (devoid 
of the gene of interest) replicate more rapidly than those that retain the inserted sequences. It is 
therefore recommended to generate fresh stock of RCAS vector by transfecting cells with cloned 
viral DNA than to passage continuously.  
 
The majority of in vivo experiments with RCAS system have shown a 24 fold higher expression of 
the gene of interest by using transduced DF-1 cells instead of the virus itself (Federspiel et al, 
1994). However, because of the requirement of dividing cells for infection by replication competent 
retroviruses, the age of mice at the time of injection is important as the infectivity has been shown 
to decreases significantly upon injections in pups over 5-days old (Federspiel et al, 1994). 
Following injections, the producer cells produce high titre retrovirus (~107IU/ml unconcentrated) as 
reported by studies (listed in Table 5.1) and infect the surrounding cells expressing the TVA 
receptor. In the case of muscles, this infectivity increases until 5 weeks and becomes constant. The 
producer cells are believed to be eliminated within 3 days from the time of injection (Holland & 
Varmus, 1998) although this would be dependent on the injection site (VanBrocklin et al, 2010). 
For all the injections untransfected or untransduced parental DF-1 cells were used as controls 
wherever required.  
 
Even though the RCAS system has major advantages, the in vivo utility of this method has 
considerable limitations: firstly, there is a short bracket of 2-3 days available for injecting mice in 
order to get efficient gene delivery and at this age the mice are very vulnerable and often get 
cannibalised by parents. Secondly, the genotype of the mice is unknown at this age (unless at least 
one of the parents is homozygous, not the case for all mice models) and there is only a small 
volume of cells/virus that can be used due to size constraints. Most importantly, the replication 
competent system is not compatible in some cases where the gene of interest itself is detrimental to 
DF-1 cells such as in the case of potential oncogene (Himly et al, 1998). The RCAS system is also 
limited by the maximum size of the insert that can be incorporated which is 2.5kb (Orsulic, 2002) 
and the infection of mammalian cells with RCAS vectors can introduce genes encoding foreign 
viral proteins that can potentially elicit an immune response in the host (Orsulic, 2002). 
Additionally, the efficiency of infection depends on tissue/organ accessibility and most importantly, 
the rate of proliferation of the cells (Naldini et al, 1996). 
 
Generation of Replication Defective ALSV-A pseudotyped lentiviral vector 
The Avian leucosis sarcoma virus (ALSV) derived retroviral vectors offer potential advantages over 
their mammalian counterparts. First, they are self-sufficient as they can encode for all the proteins 
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required for assembly of infectious particles in addition to the gene of interest. Secondly, they can 
be produced in high titres in avian cells. Since the ALSV structural proteins are not efficiently 
produced (and devoid of packaging signal) in mammalian cells any chance of infectious particle 
production is rare and hence the vector cannot spread in the target cells, tissue or animal. 
 
Like other classical retroviruses, ALSV and its derived vectors require cell division to efficiently 
establish a provirus after host infection. In contrast, lentiviral vectors are capable of integrating viral 
DNA into genomes of non-dividing cells. Therefore with the intention of initiating infection 
(tumourigenesis) in resting TVA positive cells, a system for preparation of HIV-1 based lentiviral 
vectors pseudotyped with the ALSV-A subgroup envelope protein (EnvA) was developed. This 
means that HIV-1 based lentiviral vectors retain the requirement for TVA receptor on the surface of 
target cell for entry and infection. Previously VSVG (vesicular stomatitis virus glycoprotein) 
pseudotyping of lentiviral vector has been shown and it is the most common envelope protein 
utilised for studies in different cell types across species (Naldini, 1999). Subsequently, other HIV-
based pseudotypes have been utilised.  
 
The HIV-1 based lentiviral vector pseudotyped with ALSV-A have previously been shown to be 
produced at titres greater than 5×104IU/ml and found to be stable during ultracentrifugation and can 
be concentrated to titres of 107IU/ml. It has been shown to infect both dividing and non-dividing 
cells including primary cultures from multiple mouse tissues, terminally differentiated cells, that are 
resistant to ALSV infection (Lewis et al, 2001). The HIV-1 (ALSV-A) pseudotyped vector contains 
a central polypurine tract, a short purine rich sequence within the pol gene that acts to generate a 
“plus-strand” flap in the double strand viral DNA prior to integration. This flap has been shown to 
be important for efficient nuclear import of viral DNA as well increase the viral titre by five fold 
(Zennou et al, 2000). The expression vectors used for viral production is a self-inactivating (SIN) 
vector made by deleting 133bp in the U3 region of the 3`LTR including the TATA box and binding 
sites for transcription factor SpI and NF- κB (Miyoshi et al, 1998). This deletion is transferred to the 
5`LTR after reverse transcription and integration in infected cells, resulting in the transcriptional 
inactivation of the LTR in the provirus without significant decreases in titre. The expression of the 
desired gene from a SIN vector is under the control of its internal promoter (CMV or PGK) and is 
similar to the wild-type vector (with or without an internal promoter) indicating that the LTR is still 
transcriptionally active. However in some cases the LTR has been found to negatively influence the 
internal promoter. The third generation of lentiviral vectors have increased biosafety as the transfer 
vector used has a chimeric 5'LTR which means that a part of the upstream LTR is replaced by 
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constitutively active promoter sequences such as with CMV, PGK or RSV thus making it TAT-
independent (Dull et al, 1998).  
 
The steps outlined here were optimised in the context of the third–generation lentiviral vector 
packaging system and the production and handling of lentiviral vectors was carried out using 
appropriate biosafety containment. The third generation packaging system offers maximal biosafety 
but is more cumbersome, as it involves the transfection of four different plasmids in the producer 
cells. The protocol described here outlines detailed procedures to prepare, concentrate and titrate 
ALSV-A pseudotyped HIV-1 lentiviral vectors. In these third generation lentiviral packaging 
constructs the wildtype HIV-1 genome has been modified and divided into functional components 
on separate expression plasmids consisting of pMDLg/pRRE, pRSV/Rev, pCB6WTA and pCS-CG 
or pLenti. The plasmid pMDLg/pRRE contains the gag gene, coding for the virion main structural 
proteins; pol gene, responsible for the retrovirus-specific enzymes; and RRE, a binding site for the 
Rev protein. The plasmid pRSV-Rev lacks all accessory proteins and expresses the rev gene 
required for nuclear export of the viral RNA. Since the envelope protein of the virus determines its 
tropism, the commonly used VSVG envelope (that confers broad host range) was replaced with 
another plasmid that encodes for ALSV-A envelope-A glycoprotein. This ALSV-A envelope 
protein (EnvA) was expressed from the plasmids pCB6WTA/ (VCT or Δ513) and finally a self-
inactivating lentiviral vector plasmid pCS-CG or pLenti expressing the gene of interest from an 
internal cytomegalovirus (CMV) promoter or phosphoglycerate kinase (PGK) promoter 
respectively were used as a transfer vector (Miyoshi et al, 1998; Naldini, 1999). 
 
Use of altered ALSV-A envelope constructs 
The ability of EnvA to pseudotype the HIV vector is poor relative to VSVG envelope glycoprotein, 
as demonstrated by its relatively low physical and infectious titres. While VSVG pseudotyped 
vector can be generated at titres of 106 to 107IU/ml, those from ALSV-A pseudotyped were 
consistently less than 104IU/ml (Lewis et al, 2001). A possible reason may lie in the different entry 
mechanisms of VSVG which fuses directly with the membrane phospholipids whereas ALSV 
utilises glycoprotein receptors on the membrane surface. Noteworthy was that the only difference 
between the two viruses was the envelope glycoprotein and since the cytoplasm tail of the 
transmembrane segment of the envelope is the only region that contacts the HIV core, it was 
hypothesised that cytoplasmic tail of the ALSV-A envelope might be inhibiting particle formation. 
As a result Lewis et al. (Lewis et al, 2001) have generated EnvA construct with truncation at 
residue 513, just beyond the membrane spanning region (pCB6WTA-Δ513), and a plasmid 
encoding a chimera in which the cytoplasmic tail of EnvA was replaced with that of VSVG 
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(pCB6WTA-VCT). These modified envelope proteins along with cPPT sequence were able to 
increase the viral titre by five fold as determined by serial dilution. Comparison between the two 
envelope constructs has shown that the use of pCB6WTA-VCT produced a significantly greater 
number of transduced cells as compared to the use of the Δ513 envelope construct. This result was 
in agreement to that of Lewis et al. who reported a decrease in the viral yield from 6.5×104 to 
5×104IU/ml when Δ513 envelope was used (Lewis et al, 2001). 
 
Optimal time point for harvesting supernatant 
Optimisation was carried out by harvesting the media at 4 different time points; 24hrs, 48hrs, 72hrs 
and 96hrs post-transfection. The 293T cells were transiently co-transfected with the 3 helper 
plasmids along with pCS-CG-GFP or pLenti-PGK-GFP for ease of detection and titration. 
Typically 293T cells once transfected have been shown to produce virus for two to three days 
(Naldini et al, 1996). A similar finding was observed in our experiments where the viral production 
started within the first 24hrs and increased gradually over the next 24hrs, attaining a maximum 
yield by 72hrs. Around this time the 293T cells were close to confluency (fig.5.6). Media harvested 
after 72hrs had dead, floating producer cells with reduced viral titre. As a result all the supernatant 
harvesting was carried out at 72hrs post-transfection. The harvested media was used for transducing 
DF-1 or MM96-TVA-puro cell line using an appropriate control (media from untransfected 293T 
cells) and cells were analysed after 48hrs. 
 
 
Figure 5.6: Generation of ALSV-A pseudotyped replication defective lentiviral vector.  
An envelope-negative viral packaging cell line, 293T cell line was transiently transfected with third generation split vector 
plasmids and the transfer vector pCS-CG- GFP. The 293T cells were analysed for GFP expression every day starting at 
(A) 24hrs post-transfection up to 96hrs (D) to determine transfection efficiency, which directly corresponds to intensity 
and percentage of cells expressing GFP. The lower panel indicates the transduction of DF-1 cells with the 293T 
harvested supernatant for 48hrs from top panel. (E) DF-1 cells transduced with media 24hrs post-transfection from (A), 
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(F) DF-1 transduced with media from (B), (G) DF-1 transduced with media from (C). Media from untransfected 293T cells 
was used as control and used for transducing DF-1 cells (image not shown). Images taken on Olympus Fluoro 
microscope. 
 
Optimisation of amount of DNA transfected for maximum lentivirus yield 
For efficient viral yields, the relative amount of expression, packaging and envelope constructs 
were optimised on a case-by-case basis. The amount of DNA to cell ratio is critical to ensure a high 
level of transfection. A high ratio can lead to excessive cell death and barely detectable functional 
virus. Consequently, a number of experiments with different concentrations of the 4 plasmids were 
performed and the optimal plasmid concentration was determined to be a ratio of 1:2:3:4 which 
tallied to 8µg of pCB6WTA: 16µg of pRSV-Rev: 24µg of pMDLg/pRRE: 32µg of pCS-CG or 
pLenti for a 75cm2 culture flask. This ratio resulted in the maximum viral titre that was higher than 
the one reported by Lewis et al. for unconcentrated virus (Lewis et al, 2001). Any scale up done 
using the same plasmid ratio has produced consistently high titres. Emerging studies have indicated 
that CMV promoter, even though constitutive, can be subjected to epigenetic regulation and become 
silenced in vivo (Brooks et al, 2004; Loser et al, 1998; Mehta et al, 2009). As a result expression 
vectors with murine PGK promoter (pLenti plasmid) to drive the gene expression were therefore 
used. 
 
Optimisation of transfection method for maximum lentivirus yield 
Another set of experiments were carried out to determine the best method and mode for transfecting 
DNA into the producer cells. Transient transfections provide flexibility in the method that can be 
used for introducing DNA into the cells. For optimising this process two methods of transfection; 
lipofectamine 2000 and calcium phosphate-BES (N,N-bis(2-hydroxylethyl)-2-
aminoethanesulphonic acid) were compared along with the forward and reverse modes of 
transfection for both reagents. Calcium phosphate-DNA precipitate in BES has been widely used to 
produce herpes simplex virus (Tognon et al, 1996) and lentiviral vectors (Sakoda et al, 1999) with 
reports indicating it to be more efficient than Hepes Buffered Saline (HBS) (Tognon et al, 1996). 
Therefore, in this optimisation a comparison was carried out between lipofectamine and calcium 
phosphate-BES. 
 
Using forward co-transfection calcium phosphate-BES we achieved a more uniform expression in 
the cells (70% cells transfected) as compared to lipofectamine 2000 (60%). This was in contrast to 
the reverse co-transfection method, where 90% cells were transfected with lipofectamine 2000 as 
compared to calcium phosphate-BES (60%). In these transfections the cells transfected with 
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lipofectamine showed higher intensity of GFP expression. The supernatant from all four cases were 
titred by serial dilution and a significantly higher titre was obtained for reverse transfection method 
using lipofectamine, than for transfection using calcium phosphate-BES.  
 
Optimisation of packaging cell line and effect of sodium butyrate on lentivirus yield 
The choice of packaging cell line was based on experiments done on 3 different cell lines, selecting 
the one that gave maximum viral production based on a functional titre estimation. The cell lines 
tested were 293T, 293FT and Lenti-X. These cell lines are derived from the parental HEK293 cell 
line and contain SV40 large T antigen. 293FT (Invitrogen) and Lenti-X (Clontech) cell lines are two 
fast growing variants of 293T and are commonly used for lentiviral production for their ease of 
transfection and high temporal expression. In our study we found that lentiviral production from the 
Lenti-X cell line gave a five fold higher titre as compared to using 293FT or 293T cell lines. 
 
Sodium butyrate is an inhibitor of histone deacetylase (Lea & Randolph, 1998). In the presence of 
sodium butyrate, histones are hyper-acetylated which promotes a chromatin structure permissive for 
transcription and has been previously shown to increase expression of transfected DNA (fig.5.7) 
(Workman & Kingston, 1998). A one time treatment with 10mM sodium butyrate for 8hrs before 
harvesting has been shown to increase the viral titre by three fold in experiments conducted by 
Karolewski et al. (Karolewski et al, 2003). The experimental data suggests an increase in titre by up 
to six fold upon treatment with sodium butyrate in Lenti-X cells.  
 
 
Figure 5.7: Effect of Sodium Butyrate treatment on Lenti-X expression. 
Lenti-X cells transfected with pCS-CG-mKate2 and lentiviral packaging plasmids. (A) Untreated (B) Treated for 8hrs at 
10mM Sodium Butyrate. Images taken using Olympus Fluoro microscope. 
 
Lentivirus concentration 
In the above studies, the estimated viral titre was considerably lower as compared to replication 
competent retrovirus. For in vitro cell transduction, crude (unconcentrated filtered) vector stocks are 
often sufficient whereas concentrated vector stocks are much needed for in vivo applications 
(Naldini et al, 1996). Concentrations of the lentiviral stocks were typically performed using two 
approaches. The harvested supernatant was subjected either to ultracentrifugation at high speed or 
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to ultrafiltration by passing it through a low protein binding cellulose filters with a 100,000 MW 
cut-off, then centrifugation at a low speed, to concentrate the virus by 100 fold. This concentrated 
suspension was then used for titre estimation in the absence of polybrene. Lewis et al. have 
demonstrated that the EnvA-pseudotyped lentiviral vectors are stable upon ultracentrifugation to 
yield a titre of 107IU/ml after a 100-fold reduction in volume (Lewis et al, 2001). Based on limiting 
dilution titre estimation from the 100 fold concentrated supernatant, a higher functional titre of 
108IU/ml was obtained by ultracentrifugation in our experiments which was 10 fold higher as 
compared to the one reported by Lewis et al. (2001).  
 
However, upon comparison it was evident that the viral concentration achieved using filters was 
much greater as it improved the transduction efficiency from ~20% to >90% in all the cell lines 
tested with viral titre estimated at 1010IU/ml. It has been postulated that ultrafiltration can bypass 
resuspension problems that are encountered with virus stocks concentrated by ultracentrifugation 
and hence gives a higher titre (Reiser, 2000). An issue in this approach was that at the end of 
concentration, the retentate on the filter was a viscous soup containing viral particles and 
aggregated protein and serum components. For ease of injections, it was important to reduce the 
viscosity of virus-enriched suspension, and this was affected by replacing the normal growth media 
with Ultraculture™ Serum-free media. In addition, the lack of aggregating proteins allowed a much 
faster and manifold concentration of the supernatant resulting an estimated titre of 1011IU/ml, which 
is considerably higher than the one reported for EnvA-pseudotyped lentivirus. 
 
Lentiviral storage  
A final experiment was performed to determine the stability of EnvA-pseudotyped lentivirus 
concentrated by ultrafiltration or ultracentrifugation during long-term storage at -80°C. There was a 
drastic decline in the viral titre after cold storage by nearly 5000 fold as compared to fresh virus. 
This meant that pseudotyping plays an important role in determining the stability of virus particles 
and unlike VSVG-pseudotyped virus that are stable for a long time at -80°C these EnvA ones need 
to made just prior to use. 
 
Establishing the RCAS/TVA system for gene delivery in vivo 
Currently there is no commercially available antibody for TVA receptor therefore we sought to 
detect tva transcript levels in different tissues (mainly liver, skeletal muscle and skin) of the three 
mouse models. The cDNA reverse transcribed from RNA was used as template to determine the tva 
expression using specific primers (listed in Table 5.2). It is evident in figure 5.8 that there was a 
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clear tissue-specific expression of tva gene depending on the promoter driving the tva gene with no 
leaky expression at least in the tissues analysed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Detection of tva transcript in tissues of TVA mouse models. 
Reverse-transcriptase PCR for tva gene and STAT5 (control) from RNA extracted from 
tissues of different TVA mice (TVU: β-actin tva, TVM: α-actin tva, TVL: alb-tva). Genomic 
DNA from TVU mice was used positive control and from a wildtype mice (non-transgenic for 
tva) as a negative control with water used as template in the blank. The reaction was run on 
a 1.7% agarose gel, stained with sybr safe and visualised under a UV transilluminator. 
 
Detection of viral-mediated gene delivery in mice 
For the ease of detection all the virus standardisation experiments in vitro were carried out using 
fluorescent markers such as GFP and mKate2. It was thought that the in vivo analysis for viral-
mediated gene delivery to muscle and liver could be analysed in a similar way by putting a thin 
tissue section directly under the microscope. However it was proven otherwise when the tissue 
sections (paraffin or OCT embedded) were observed under the microscope. What seemed like GFP 
fluorescence was actually a false positive due to autofluorescence visible even in the control tissues 
sections. 
 
Natural fluorescence in tissues is mainly due to the presence of endogenous flavins, reduced 
NAD(P)H, lipofuscins, reticulin fibres, collagen and elastin. Flavins and NAD(P)H are co-
enzymatic redox carriers that play important role in most metabolic pathways (Andersson et al, 
1998). These molecules increase and accumulate with age, therefore while embryo and neonates do 
not have significant background, the older mice have high natural fluorescence. Collagen/elastins, 
which are typical constituents of blood vessels, are also a source of autofluorescence (Billinton & 
Knight, 2001). Reticular fibres similarly are prone to autofluorescence, the degree of which depends 
on the tissue type (Viegas et al, 2007). In our case the two tissues that we were most interested in 
were liver and muscle. Liver has a high metabolic rate with constant NADP-NADPH turnover with 
high accumulation of flavins and lipofuscins. Being highly vascularised it contains large amounts of 
Lane Sample 
1 Muscle wt  
2 Muscle TVL 
3 Muscle TVM 
4 Muscle TVU 
5 BLANK 
6 Skin TVU 
7 Skin TVM 
8 Skin TVL 
9 Liver TVM 
10 Liver TVU 
11 Liver TVL 
12 Skin TVM 
13 Liver wt 
14 Genomic DNA 
wt 
15 Genomic DNA 
TVU 
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collagen and elastin, and its parenchyma is rich in reticular fibres. Skeletal muscle on the other hand 
is rich in NAD(P)H and flavins (Jackson et al, 2004). 
 
 
Figure 5.9: Autofluorescence detection in virus injected liver and muscle tissue of TVA mice.   
PFA fixed muscle (A, B, C) and liver (D, E, F) tissue sections (7µm thickness) from mice injected with concentrated 
EnvA-pseudotyped lentivirus carrying GFP (of 107IU/ml titre, A, B, D, E) and empty vector (C, F) observed under two 
different filters on a Olympus Fluoro microscope. All the sections were subjected to similar parameters of fixation and 
treatment. 
Tissue fixatives, which are used for preservation of morphological details, may further augment 
background fluorescence. Fixative-induced fluorescence occurs when aldehyde fixatives react with 
amines and proteins in the tissue to generate fluorescent products. This auto-fluorescence is fairly 
uniform, non-punctately distributed across the tissue, but may be brighter in some cells depending 
on the presence of the biogenic amines. One solution to this problem is performing aldehyde 
blocking by incubating the tissue with bland amino groups such as those provided by glycine post-
fixation (Viegas et al, 2007). However, this treatment of tissue sections did not show any significant 
decrease in background autofluorescence. Such treatment also reduces the intensity of 
immunofluorescent labelling, which demands a compromise between autofluorescence reduction 
and antigen visualisation. Other chemical strategies using Sudan Black B and Copper Sulphate 
treatment of tissue sections have been tried with limited success. 
 
The emission spectra of natural fluorescence or fixative-induced fluorescence is very broad 
compared to the spectra of any particular dyes, probes and proteins, making it difficult to separate 
wanted from unwanted fluorescence by traditional filtering methods of image acquisition. We 
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therefore tried separating the spectra of GFP/mKate2 from autofluorescence using confocal laser 
scanning microscopy but since the desired signal intensity from the tissue was fairly weak it was 
difficult to separate the two spectra.   
 
Analysis of in vivo gene delivery by immunofluorescence detection 
In order to circumvent the problem caused by autofluorescence in muscle and liver sections an 
antibody against GFP was used. This strategy can amplify weak signals and hence can be easier to 
analyse. A few different primary antibodies against GFP and HA-tag were used with combinations 
to different secondary antibodies. For these experiments corresponding tissues obtained from non-
transgenic (WT) and GFP expressing mice (autosomal GFP expressing mice provided by Dr. Jo 
Bowles, Koopman Group, IMB) have been used as positive controls (Hadjantonakis et al, 2001; 
Hadjantonakis et al, 1998). The antibody was first tested out in cells for its ability to detect GFP 
(data not shown). This was however not the case in tissue sections from adult mice (as opposed to 
cells and embryo sections) indicating that it was not feasible to analyse the tissue sections by 
immunofluorescence (IF) due to inherent backgrounds for reasons mentioned earlier. 
 
Since the main aim of this experiment was establishing the TVA system using viral delivery in vivo, 
we did not expect a widespread expression from viral-mediated delivery and because of the high 
autofluorescence it was not possible to conclusively determine viral-mediated gene delivery. For 
direct or indirect GFP expression analysis in tissue sections, observation of sections under any filter 
(on the fluorescent microscope) resulted in significant autofluorescence, which made it difficult to 
distinguish between control and lentiviral/retroviral injected tissue. In order to alleviate this issue 
immunohistochemistry (IHC) was performed on the tissue sections. 
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Figure 5.10: Indirect Immunofluorescence analysis of tissue sections from autosomal-GFP and WT mice. 
7µm sections of muscle (A, B) and liver (C, D) tissue were subjected to anti-GFP primary antibody overnight in a 
humidified chamber and probed with Alexa Fluor conjugated secondary antibody 647 (A, C) and 488 (B, D). The slides 
were mounted in DAPI and visualised under Olympus Fluoro microscope. There was no evident difference between GFP 
expressing (A, C) and WT (B, D) tissues in terms of GFP detection following immunofluorescence.  
 
Analysis of in vivo gene delivery by immunohistochemical detection 
Immunohistochemical analysis was performed against GFP in tissue sections (muscle and liver) 
injected with EnvA GFP pseudotyped lentivirus (108-1010IU/ml) for transduction with GFP (driven 
by PGK promoter) and positive (autosomal GFP mice tissue) and negative controls (empty vector 
injections). For IHC, the same anti-GFP antibody that was used for IF analysis was used on muscle 
sections that were subjected to prior blocking for endogenous peroxidase and biotin as both muscle 
and liver are rich in biotin (Wang & Pevsner, 1999).  
 
The comparison of brown pigmentation (because of DAB staining) between the control and injected 
sample clearly shows there is significant detectable infection in muscle tissue with not much 
success in liver tissue (data not shown). Besides constraints imposed by the different routes of 
delivery, a possible reason for easier, prolonged detection of infection in muscle than liver can be 
attributed to lower CD8+ T cells that can recognise transgenic protein and clear it from the system 
(Pinto et al, 2000).  
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Figure 5.11: Immunohistochemical analysis of muscle sections injected with EnvA-pseudotyped lentivirus. 
7µm muscle sections injected with EnvA-pseudotyped lentivirus for GFP using anti-GFP primary antibody and 
biotinylated secondary antibody incubated with diaminobenzidine (DAB) substrate (brown pigmentation) and counter-
nuclear stained with hematoxylin (blue). Muscle sections from autosomal GFP mice (A and B) were used as controls and 
empty virus injected muscle section was used as negative control (C).  Muscle section with no primary antibody is 
indicated in (B). Muscle sections injected with GFP virus (108-1010IU/ml) at different concentrations show GFP reactivity 
as evident from brown pigmentation (D, E, F). All images visualised under Olympus Fluoro microscope. 
 
Analysis of in vivo gene delivery by qPCR  
In order to validate the gene delivery, quantitative PCR reaction was carried out on injected tissue 
samples, negative and positive controls (GFP-adenovirus injected mice liver, available in the 
Waters Group) using GFP and Gapdh (as internal control) primers. It is evident from the figure 5.12 
that there is detectable infection occurring in most of TVA positive virus delivered tissues. 
Although detected at variable levels nevertheless expression was higher than the negative control 
especially in muscle. Liver samples on the other hand do not show a high level of expression 
(shown as fold change) compared to the positive control (liver tissues analysed 4 days after GFP 
adenovirus injected via tail vein). A high level of infection was achieved in mice injected with 
pLenti-PGK-GFP via inferior vena cava vein directly in the liver. No success was achieved with the 
GFP transduced DF-1 delivery in the liver (via i.p) but further experiments to improve delivery of 
concentrated viral supernatant by other routes are warranted. 
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Figure 5.12: Detection of viral delivery in muscle and liver tissue in vivo by qPCR.  
Fold activation of GFP gene expression in retroviral/lentiviral injected tissues. Gene expression was normalised to Gapdh 
and fold activation is reported relative to empty vector (EV) injected control. DF-1 control: Parental DF-1 injected, M1-2: 
Retroviral DF-1 GFP injected TVA muscles; M3-4: PGK-GFP lentivirus injected TVA muscle; Positive control: Autosomal 
GFP tissues; L1: Retroviral DF-1 GFP injected in liver intra-peritoneally L2-5: PGK-GFP lentivirus injected TVA liver via 
inferior vena cava injections; Positive control: adenovirus encoding GFP injected by tail vein.  
 
Lentiviral Delivery in Zebrafish 
Zebrafish larvae expressing the tva gene driven by a heat shock promoter (evident from GFP 
expression in the heart) were incubated at 39°C for 1.5hrs and transferred into E3 media containing 
PGK-GFP concentrated EnvA-pseudotyped lentivirus (1:5000 dilution). The larvae were analysed 
for GFP expression 2 days post-infection and are shown in fig5.13. As a control, non-transgenic 
zebrafish larvae (data not shown) and tva-transgenic zebrafish larvae without heat shock treatment 
were used and no virus-mediated GFP expression was detectable as compared to TVA expressing 
larvae following heat shock. Interestingly, we observed that the lentivirus was stable at the low pH 
of 6.8 (in E3 medium) and since the larvae generated were ubiquitously expressing TVA (after heat 
shock) GFP was detected all along the length of the larvae.  
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Figure 5.13: EnvA-pseudotyped lentivirus transduction of TVA transgenic zebrafish. 
Zebrafish larvae transgenic for TVA receptor (evident from GFP expression in heart) were infected with PGK-GFP 
lentivirus (109IU/ml) at 1:5000 ratio in E3 medium. (A) TVA transgenic larvae infected with virus without heat shock 
treatment. (B) TVA transgenic larvae infected with virus following 1.5hrs of heat-shock treatment at 39°C. The live larvae 
were visualised 2 days post-infection under the Olympus Fluoro microscope. 
Conclusion 
Although the RCAS system has been established in vivo, we had limited success in our lab. One 
possible reason could be the amount of producer cells we injected into the mice was lower than 
what has been shown recently to achieve sufficient infection (von Werder et al, 2012). 
 
We therefore decided to move focus from the use of retrovirus to a safer lentiviral delivery with the 
ability to transduce non-dividing cells. This has allowed efficient delivery in both liver and muscle 
tissues with a higher success rate as compared to retrovirus and most importantly can be utilised to 
transduce non-dividing cells in older animals. We have been the first to optimise the protocol for 
lentivirus pseudotyped for EnvA with the ability to produce titres in the range of VSVG envelope.  
 
In addition, in conjunction with Dr Ben Hogan’s laboratory, we have generated ubiquitously 
expressing TVA transgenic fish founders and shown that these can be transduced with EnvA-
pseudotyped lentivirus. This approach can be used to generate fish with tissue-specific TVA 
expression and will be used to study the effect of various constitutively active GHR constructs 
(outlined in Chapter 6) associated with increased downstream signalling. This should allow a much 
faster and easier method to determine the direct oncogenic potential of GHR in cancer initiation, 
progression and maintenance.  
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EnvA-pseudotyped Lentivirus production protocol 
The conditions that produced the highest titre for each of the standardisation experiments 
(mentioned earlier) were combined into one protocol detailed below. This protocol is now used by 
other labs in IMB for pseudotyping with VSVG envelope. 
• Day 1: Make up cocktail of plasmids in OPTI-MEM (6ml) 
24µg of pMDLg/pRRE,  
16µg of pRSV-Rev,  
8µg of pCB6WTA (VCT or Δ513) and  
32µg pCS-CG/pLenti-PGK-GFP  
Scale up depends on culture dish and also the size of the insert 
Simultaneously incubate lipofectamine 2000 in 6ml of OPTI-MEM as per manufacturer’s 
guidelines. Mix both the DNA and lipofectamine and incubate for at least 30 min at room 
temperature. 
Trypsinise Lenti-X cells from a confluent (not over-grown) T-75 cell culture flask and 
resuspend in 36ml of DMEM media with 10% FBS. Mix the resuspended cells with 12 ml 
of DNA-lipofectamine mix (reverse co-transfected with 4 plasmids) and plate into 4xT-75 
flasks with total volume of 12ml per flask. 
Incubate at 37°C in humidified incubator with 5% CO2 overnight (16hrs). 
• Day 2: Change media in the morning for all the flasks replacing with 12ml of Ultraculture™ 
Serum-free media supplemented with L-glutamine (2mM), D-glucose (5.5mM) and sodium 
pyruvate (1mM). 
• Day 3: Collect virus supernatant and store at 4°C and replace with 12ml of fresh media (as 
above) with 10mM sodium butyrate. 
• Day 4: Harvest the virus supernatant and pool with the one collected on Day2. Centrifuge at 
2000rpm for 5min at 4°C. Filter the supernatant containing the virus using 0.45um low 
protein binding PVDF filter before proceeding with virus concentration. Concentrate the 
supernatant using Amicon Ultra column (100,000 MWCO) by centrifugation at 4000rpm at 
4°C by 100 fold.  
• Day 5: Estimate the functional titre of the concentrated virus on a TVA positive cell line in 
triplicates by making a serial dilution of the virus by microscopy (based on a marker) or 
PCR analysis from DNA of transduced cells. 
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Chapter 6 
Autocrine Growth Hormone and Growth Hormone Receptor-
mediated Oncogenesis in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 180 
Introduction 
GHR-mediated cancer 
The GHR is expressed in almost all cells, and its expression is subject to control by nine alternate 
first exons in humans. The GHR transcript has been found to be overexpressed in a range of 
cancers, notably prostate carcinoma, glioblastoma, neuroectodermal tumours, adult T-cell 
lymphoma, kidney clear cell carcinoma and parathyroid adenoma (reviewed in (Chhabra et al, 
2011)) In addition, immunohistochemical and quantitative PCR studies have reported GHR 
overexpression in a high proportion of invasive breast ductal carcinoma, adrenal cortical neoplasms 
and in colorectal cancer. Moreover, elevated serum GH-binding protein is associated with a 
threefold increase in breast cancer incidence (Pazaitou-Panayiotou et al, 2007). 
Immunohistochemical assessment has also revealed GHR overexpression in melanoma (Lincoln et 
al, 1999) and prostate carcinoma (Weiss-Messer et al, 2004). This has been supported by a high 
level of GHR transcript expression reported in the NCI60 (National Cancer Institute) cancer cell 
lines (Sustarsic et al, 2013), Oncomine database (Chhabra et al, 2011) and more recently the 
development of the Cancer Cell Line Expression (CCLE) database (Barretina et al, 2012) (fig.S.1 in 
Appendix VII). To date, there are no reports of constitutively active GHR mutations but a coding 
mutation (Pro495 to Thr) has been reported to confer increase lung cancer susceptibility in GWAS 
studies (Cao et al, 2008; Rudd et al, 2006).  
 
Humans deficient in GHR or harbouring a dysfunctional GHR have no reported deaths due to 
malignancy as compared to their relatives with functional receptor that die from malignancies 
(Shevah & Laron, 2007; Guevara-Aguirre et al, 2011). The animal models with lack of a functional 
GHR (GHR KO) have lower tumour burden and delayed incidences of fatal neoplastic lesions, 
particularly lymphomas and pulmonary adenoma/carcinomas as compared to WT mice (Ikeno et al, 
2009). This was supported by other GH/IGF-1 axis deficient animal models that fail to signal 
efficiently via GHR (reviewed in (Chhabra et al, 2011). It is therefore no surprise that the level of 
endogenous GHR expression may be a critical target, which influences the tumourigenic effect of 
recombinant hGH (rhGH). This has recently been shown in gastric cancer xenograft model where 
rhGH was shown to activate tumour angiogenic factors mainly through the Jak2/STAT3 pathway 
(Lin et al, 2011). GHR may therefore be the key factor in determining if rhGH can be used in 
patients with a history of cancer. 
 
The current view of GHR signalling requires activation of GHR at the cell surface by GH available 
exogenously (endocrine manner) or following synthesis/secretion by cells themselves (autocrine) or 
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from extracellular fluid following secretion by neighbouring cells (paracrine). This activates 
numerous signal transduction cascades in a cell-dependent manner resulting in transcription of 
specific genes in the nucleus that regulate cellular proliferation, differentiation, motility and other 
cellular functions. It is now apparent that several growth factors, cytokines, and their receptors 
become nuclear-localised, with nuclear localisation in many cases being necessary for full function, 
including cell proliferation (Lin et al, 2001; Johnson et al, 2004; Giri et al, 2005). The presence of 
GHR in the nucleus is a common feature of tissues and cells demonstrating a high proliferative 
status; examples include the chondrocytes of the epiphysial growth plate (Gevers et al, 2002), the 
gastrointestinal tract (Lobie et al, 1990b), placenta (Garcia-Aragon et al, 1992), and preimplantation 
embryos (Pantaleon et al, 1997). Nuclear-localised GHR and high GHR expression have also been 
reported in a number of cancers, including breast cancer (Mertani et al, 1998), colorectal carcinoma 
(Lincoln et al, 2000), hepatocellular carcinoma (Garcia-Caballero et al, 2000), cervical cancer 
(Dehari et al, 2008), and melanoma (Lincoln et al, 1999). Despite this, rigorous correlation with 
nuclear GHR, no correlated proliferative status had been reported before the study from Waters’ 
Group indicating nuclear targeting of GHR to result in dysregulation of cellular proliferation and 
tumourigenesis (Conway-Campbell et al, 2007). 
 
It was proposed that the normally limited period of nuclear localisation of GHR after GH addition 
(1h), which coincides with cell cycle initiation, might prevent cell transformation. However, during 
excessive nuclear uptake or extended residence time of GHR in the nucleus could result in 
oncogeneic transformation as shown in Ba/F3 cells with forced nuclear localisation using a nuclear 
localisation coding sequence (NLS) preceding the GHR cDNA sequence. Once transformed, these 
Ba/F3-NLS-GHR had more GH-responsive STAT5, GH-autonomous proliferation and rapid 
tumour formation in vivo in SCID mice, whereas Ba/F3-WT GHR were reported not to form a 
single tumour (Conway-Campbell et al, 2007). Microarray analysis revealed genes differentially 
expressed between Ba/F3-WT-GHR and Ba/F3-NLS-GHR cell lines. The constitutive transcripts 
upregulated in BaF-NLS-GHR were increased 2.5–4 fold in GHR-WT cells 1h after GH addition. 
These transcripts included those associated with highly proliferating normal tissues (regenerating 
liver) Phgdh, F2r, and Ctsc, and in cancers, Phgdh, F2r, Ctsc, Mybbp1a, Eif5a, and dysadherin. In 
addition, a majority of these (Phgdh, Ctsc, Mybbp1a, and Survivin) were shown to remain elevated 
during the entirety of the experiment in nuclear localised GHR Ba/F3 cell lines (Conway-Campbell 
et al, 2007). However, a majority of GH-regulated genes, including metabolic enzymes, did not 
show differential regulation in the forced nuclear GHR vs surface GHR expression cell lines, 
suggesting that nuclear targeting of the GHR did not influence the basic metabolic functions of GH. 
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A striking observation of this study was that nuclear localised rabbit GHR Ba/F3 cells exhibited 
increased STAT5 activation and proliferation as compared to the nuclear localised human GHR, 
independent of any exogenous GH addition. This was attributed to endogenous GH (autocrine) 
synthesised by the murine pre-B cell line that can selectively bind to rabbit receptor but not human 
GHR (Conway-Campbell et al, 2007). This result indicates clear clinical implications for nuclear 
GHR in cell lines and tumours expressing high levels of GHR. A large number of studies on 
tumours and cancer cell lines have indicated the higher expression and/or polymorphism of GHR 
and associated elevated signalling molecules but failed to study the origin of this signalling (GHR 
localisation) inside the cell.  
 
Autocrine GH and Cancers 
Mammary and endometrial cancer 
The GH is expressed in normal and neoplastic mammary glands of cats and dogs (Mol et al, 1995b) 
as well as humans (Mol et al, 1995a). The GH mRNA in humans was demonstrated to be identical 
to pituitary GH and expressed by normal, benign (tumour) and malignant mammary tissue, although 
the immunoreactive hGH was restricted to epithelial cells (Mol et al, 1995a). Intriguingly, the 
pituitary and mammary gland GH transcripts originate from the same transcription start site but 
undergo differential regulation since mammary gland GH transcription occurs independently of Pit-
1 (Lantinga-van Leeuwen et al, 1999; Harvey et al, 2000). In addition, GHR mRNA and protein 
have also been detected in the mammary gland epithelia of rodents (Lincoln et al, 1990; Ilkbahar et 
al, 1995), bovine (Glimm et al, 1990), and humans (Mertani et al, 1998) as well as human 
mammary stromal and endothelial cells (Raccurt et al, 2002). In dogs, locally produced GH has 
been suggested to play a paracrine role in progesterone-induced proliferation and differentiation of 
mammary epithelium where the maximum expression occurs during the proliferation of epithelial 
cells, linking progestin-induced mammary GH synthesis to this proliferation (van Garderen et al, 
1997). Intra-tumoural GH and IGF-1 concentrations are associated with malignant tumours in dogs 
and these canine mammary tumours closely resemble those observed in humans owing to clinical 
and molecular similarities (Queiroga et al, 2011). Together with the reported GHR expression, this 
is indicative of an autocrine or paracrine action of GH in canine mammary tumours (Rijnberk et al, 
2003), independent of plasma GH and/or IGF-1 (Waters & Conway-Campbell, 2004). There is 
increasing evidence that the local mammary progestin/GH-axis is also operational in human breast 
cancer (Rijnberk et al, 2003). GH and PRL expression has been demonstrated in neoplastic human 
breast tissues (Wu et al, 2011) and progesterone is capable of promoting GH expression in human 
breast cancer cell lines (Gregoraszczuk et al, 2001). GHR expression in human breast cancer 
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correlates positively with progesterone receptor expression (Gebre-Medhin et al, 2001). In human 
breast tissue, increased GH expression is associated with increased epithelial proliferation and 
metastatic mammary carcinoma cells have the highest level of GH expression (Raccurt et al, 2002; 
Wu et al, 2011). In addition it has been shown that tissue overexpression of IGF-1 stimulates 
mammary tumourigenesis in vivo in transgenic mice (de Ostrovich et al, 2008). Both endocrine GH 
and autocrine (and paracrine) generated GH therefore possess the capacity to exert a direct effect on 
the development and differentiation of mammary epithelia in vitro and in vivo (Feldman et al, 
1993). The Pit-1 gene was reported to be expressed at both transcript and protein levels in normal 
and cancerous human breast tissue, where it regulates GH secretion and cell proliferation (Gil-Puig 
et al, 2005). Intriguingly, it may also be significant that vitamin D, a known inhibitor of mammary 
carcinogenesis, inhibits hGH expression at transcription level in human mammary carcinoma cells 
(Seoane et al, 2002) by repressing the transcription of Pit-1 by recruitment of HDAC1 (Seoane & 
Perez-Fernandez, 2006). 
 
Autocrine GH has also been shown to enhance the in vitro oncogenic potential of endometrial 
carcinoma and colorectal cells while its forced expression in immortalised endometrial carcinoma 
and breast cancer cell lines increased their cell number through enhanced cell cycle progression and 
decreased apoptotic cell death while promoting anchorage-independent growth and increased cell 
migration and invasion (Jenkins & Bustin, 2004; Pandey et al, 2008; Zhu et al, 2005). Both GH and 
GHR are expressed in immune cells and are implicated in the development of leukemia and 
lymphoma (Hooghe et al, 1998) along with IGF-1 and its receptor (Weigent & Arnold, 2005). The 
overexpression of GH and GHR in lymphoma cells have been shown to have anti-apoptotic effects 
(besides increasing IGF-1) by decreasing the production of superoxide and associated expression of 
bax, Bad and caspases 3,8 and 9 (Arnold & Weigent, 2003). A high mRNA level of GHR and GH1 
transcripts have been reported in not only mammary cancer but numerous other cancer cell lines 
(including NCI60 panel (Sustarsic et al, 2013). An intriguing observation comes from the transcript 
data of GH2 gene that is selectively expressed in higher levels in most cancerous cell lines but is 
barely detectable in their normal tissues of origin (fig.S.1 and S.2 in Appendix VII). 
 
A model system to study the role of autocrine human GH-N (hGH) in mammary carcinoma by 
stable transfection of either the GH gene or a translation-deficient gene into cell lines has been 
developed by Lobie’s Group (Kaulsay et al, 1999). The autocrine hGH producing cells display a 
marked IGF-1-independent increase in cell number in both serum-free and serum-containing 
conditions as well as a specific increase in STAT5-mediated transcription (Kaulsay et al, 1999). The 
same model system has been extended to endometrial cancer (Pandey et al, 2008). The increase in 
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mammary carcinoma cell number as a consequence of autocrine production of hGH is a result of 
both increased mitogenesis and decreased apoptosis and is dependent on the activities of both 
ERK1/2 and p38 MAPK that are mediated solely by its action on GHR (Kaulsay et al, 2001). Also, 
autocrine hGH production was shown to promote enhancement of the rate of MCF-7 cells spreading 
on a collagen substrate (Kaulsay et al, 2000).  
 
The study by Mukhina et al. provides a clear demonstration that forced autocrine production of 
hGH confers an invasive phenotype on mammary carcinoma cells due to epithelial–mesenchymal 
transition (Mukhina et al, 2004). As shown in figure 6.1, this phenotypic conversion is associated 
with a loss of expression of plakoglobin, (γ-catenin), together with a relocalisation of E-cadherin to 
the cytoplasm. Notably, an increased secretion of matrix metalloproteases (MMPs) 2 and 9 along 
with increased cell migration and invasion was also evident. Migration and invasion were both 
blocked by specific Src-kinase inhibitors. The in vitro evidence for invasive phenotype is supported 
by studies in immune-compromised mice showing diffuse infiltration of autocrine GH-secreting 
MCF-7 breast cancer cells into mammary gland stroma, together with islands of tumour cells 
removed from the main tumour mass. The proliferative effects of GH (autocrine and endocrine) are 
also maintained in primary culture of mammary carcinoma cells (Chiesa et al, 2011).  
 
 
Figure 6.1: Endocrine hGH versus forced autocrine hGH actions on mammary epithelial cells.  
The figure illustrates the differential effect of GH when administered exogenously or in an endocrine manner as opposed 
to synthesised by itself (Waters and Conway-Campbell, 2004). 
BPs, binding proteins; ECM, extracellular matrix. 
 
Autocrine production of GH in immortalised human epithelial cells enhances proliferation and 
protects against apoptosis and promotes abnormal mammary morphogenesis with oncogenic 
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transformation and tumour formation in vivo (Liu et al, 1997). Exogenous GH cannot, however, 
mimic these actions and this is supported by microarray analysis of 19,000 human genes that 
identified a subset of 305 genes that were differentially responsive to exogenous and endogenous 
GH, as well as 167 genes that were regulated in common (Xu et al, 2005). The differential actions 
of endogenous and exogenous GH could be attributable to differences in GH concentration and 
secretion, since endocrine GH is secreted episodically whereas endogenous GH is released 
continuously at low concentrations (Perry et al, 2008; Vouyovitch et al, 2008). Moreover, 
endogenous GH is released in closer proximity to GHR and potentially at higher microenvironment 
concentrations than exogenous GH, allowing it to bind with the available intracellular receptors (in 
compartments not readily accessible to exogenous GH) directly following synthesis in the ER (van 
den Eijnden & Strous, 2007). This GH-GHR complex is then transported to the plasma membrane 
where exogenous GH is unable to bind these receptors. This mechanism explains why GHR 
antagonists have been reported as ineffective in blocking the actions of autocrine GH (Tallet et al, 
2008) at least in an overexpression autocrine system. The autocrine GH can also act through nuclear 
localised GHR, which is upregulated in cancerous tissues (Waters & Conway-Campbell, 2004; 
Brooks et al, 2008). 
 
The mechanistic basis for these observations is not yet fully defined, but there are other studies 
from Lobie’s Group that shed light on the subject. First, autocrine hGH upregulates the expression 
of HOXA1, a potent mammary oncogene that is required for increased c-myc, cyclin D1, and Bcl-2 
expression (Zhang et al, 2003). Second, autocrine GH upregulated gadd153 (CHOP), which has 
been reported to provide enhanced protection from apoptosis (Mertani et al, 2001), and 
downregulated the expression of transcripts for p53-regulated placental transforming growth factor 
β (PTGF-β). The latter is known to inhibit GH-stimulated cyclin D1 expression and promote 
apoptosis (Graichen et al, 2002). More recently, it has been reported that autocrine hGH increases 
telomerase catalytic subunit (TERT) transcript levels by stabilising the mRNA (Emerald et al, 
2007), and increased TERT is known to immortalise human mammary epithelial cells. The means 
used by the activated GHR to elicit these changes in gene expression has been shown to be via 
Jak2-mediated STAT3 (Tang et al, 2010a) and STAT5A/B activation (Tang et al, 2010b), activation 
of src kinases (Bougen et al, 2012), and transactivation of the ErbB-2 receptor (Yamauchi et al, 
1997). These pathways have been shown to associate with ERK1/2 and p38 MAPK activation, 
which are known to promote carcinogenesis (Aguirre-Ghiso et al, 2003). Indeed, inhibition of this 
pathway with MEK inhibitor abrogates the increased proliferation seen in autocrine hGH expressing 
cells (Kaulsay et al, 1999). These studies are indicative that autocrine hGH by carcinoma cells can 
promote cancer progression and this can have an impact on the clinical prognosis. 
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Prostate cancer 
The binding of exogenous GH to GHR in the human prostate cancer cell line LNCaP and the 
concomitant activation of GHR-associated signal transduction pathways has been reported, but no 
effect of exogenous GH on LNCaP cell proliferation was observed (Weiss-Messer et al, 2004). This 
report contrasted with an earlier study that demonstrated an increase in LNCaP cell proliferation 
upon treatment with exogenous GH (Untergasser et al, 1999), illustrating the need for clarification 
of the role of GH in prostate cancer cell function. The ectopic expression of GH has also been 
observed in prostate cancer cell lines and tissue, indicating the possibility of autocrine signalling in 
prostate tumours that could affect tumour progression (Chopin et al, 2002; Slater & Murphy, 2006). 
It has also been reported that hGH can stimulate/modulate IGF-1 and β-estradiol receptor (ERβ) 
gene expression in PCa cancer cell lines and interact with IGF-1 and β-estradiol (E2) to stimulate 
androgen-dependent LNCaP cell proliferation (Bidosee et al, 2011). In addition, cell type-
dependent, GH-mediated differential regulation of IGF axis gene expression was observed and 
increased cell proliferation was evident only when GH and IGF-1 were administered for 96hrs 
(Bidosee et al, 2011). GH also appeared to exert a synergistic effect on E2-stimulated LNCaP cell 
proliferation. However, the functional significance of autocrine GH in prostate cancer cells and the 
possible mechanistic distinction from the effects of endocrine GH has only recently been reported. 
The study by Nakonechnaya et al. have reported distinct actions of exogenous and autocrine GH in 
LNCaP cells, accompanied by differences in the involvement of GHR-associated signal 
transduction pathways, which paralleled an alteration in the subcellular localisation of GHR, in 
which autocrine GH appeared to sequester GHR in the Golgi and ER (Nakonechnaya et al, 2013). 
While the exogenous GH was proliferative, autocrine GH was shown to be more apoptotic and 
decreased cell proliferation. These findings indicate that the activity of autocrine GH may be 
distinct from that of endocrine GH in prostate cancer cells.  
 
This chapter analyses the different GHR constructs (constitutively active vs wildtype) in prostate 
cancer cell lines to determine the molecular pathway downstream of GHR that may be involved in 
oncogenesis. In addition, based on the established model of autocrine GH as an oncogene in MCF7 
breast cancer cell line we seek to evaluate the recent conflicting study by Nakonechnaya et al. 
indicating autocrine GH to be non-tumourigenic in LNCaP prostate cancer cell line and determine if 
the level of endogenous GH expression (and/or a particular signalling pathway) can explain this 
discrepancy.  
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Materials and Methods  
Construction of plasmids 
The pMT and pCDNA3.1 vectors containing hGH-N (GH1) gene as well as empty vectors were 
provided by Dr. Jo Perry (Liggins Institute, University of Auckland). The pMT-hGH vector drives 
the expression of hGH by a Metallothionein promoter while in pCDNA-hGH expression is under 
the control of Cytomegalovirus (CMV) promoter. CMV-driven expression has been shown to be 
much higher as compared to MT promoter in vitro and in vivo (Cheng et al, 1993). The empty 
pCDNA3.1 vector was digested with SpeI to remove the 700bp CMV promoter and ligated with an 
EcoR1 digested 4.1kb fragment from pMT-hGH containing the MT promoter and hGH fusion 
cassette to generate a vector containing MT-hGH in a pCDNA3.1 vector backbone with G418 
selection. This was carried out since the original pMT-hGH vector was devoid of any selection 
marker. For a control plasmid in similar backbone, hGH was selectively removed by BamH1 
digestion and the resultant plasmid was re-ligated. All the plasmids were checked by restriction 
digestion and confirmed by sequencing at AGRF. 
 
For construction of WT, nuclear localised (NLS), and the active GHR constructs (Jun3A-rGHR, 
PM2-hGHR) with co-expression of GFP in a single ORF, a self-cleaving 2A peptide bridge was 
encoded between the GHR and GFP sequences. Cloning was carried out using PCR-mediated 
overlap extension as detailed in Results section. Following the construction of ORFs, the joined 
fragments were gel extracted and used as template for Gateway Cloning (outlined in Chapter 5) into 
pLenti-PGK-Puro DEST (plasmid# 19068, Addgene). This lentiviral destination vector drives the 
expression of the gene of interest via the PGK promoter. All PCR reactions were carried out using 
Phusion DNA polymerase (Thermo Scientific). GFP was used as a reporter in all the GHR 
constructs with all of them expressing a HA tag at the N-terminus of the GHR for the ease of 
detection by immunoblotting or immunofluorescence. 
 
Cell line and transfections 
Murine Ba/F3 cells expressing the human GHR (Ba/F3-B2B2 clone) (Rowland et al, 2002) were 
passaged in RPMI 1640 medium supplemented with 10% (v/v) Serum Supreme (Biowhittaker, 
Walkersville, MD, USA), 105 units/l of IL-3 (or 100µg/l hGH). Prostate cancer cell lines; LNCaP-
androgen dependent and DU145-androgen independent cell lines were maintained in RPMI 1640 
containing 10% FBS supplemented with 2mM L-glutamine and were obtained from ATCC (USA). 
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The human mammary carcinoma cell line, MCF-7 cell lines was a kind gift from Dr. Jo Crawford 
(laboratory of Dr. Ryan Taft, IMB, UQ). These cells were maintained in DMEM supplemented with 
10% FBS. The cell lines were stably transfected with the two expression vectors containing the 
entire hGH-N gene-driven via the CMV promoter (CMV-GH) or MT promoters (MT-GH) and their 
respective empty vectors as controls designated as CMV-EV and MT-EV using lipofectamine 2000 
as per manufacturer’s guidelines. The pooled stable transfectants were selected in 500µg/ml G418 
(Life technologies, Australia) and analysed for expression. All cell lines were maintained in a 5% 
CO2 humidified incubator at 37°C. 
 
Generation of TVA transgenic cell lines 
For making the mammalian cell lines susceptible to ALSV-A-pseudotyped lentivirus, the cell lines 
were made to express the avian tva gene (avian receptor that allows susceptibility to ALSV-A 
viruses) by using by using MSCV-TVA-IRES-PURO (a kind gift from Dr Jonas Nilsson, 
University of Gothenburg and Sahlgrenska University Hospital, Sweden) to produce replication 
defective pantropic retroviruses and selection with puromycin. A dose-dependent kill curve was 
established for all the cell lines that were made TVA positive (referred as LNCaP/tva and 
DU145/tva). The presence of functional TVA receptor was checked by infecting with ALSV-A 
pseudotyped virus with GFP and/or by RCASBP-GFP. 
 
Infection of normal and cancer prostate cell lines 
The two TVA+ prostate cell lines: LNCaP and DU145 were infected with concentrated ALSV-A-
pseudotyped replication defective lentivirus carrying constructs 1 to 9 (fig.6.2). Three days post-
infection, cells were expanded and cells were sorted for GFP expression at QIMR FACS Facility.  
The sorted cells were confirmed for receptor expression by immunoblot and used for experiments. 
 
Anchorage-independent growth assay 
For the soft-agar colony formation assay, 2×103 cells of DU145 stables and control cells in 2ml of 
RPMI 1640 media containing 10% FBS and 0.36% agar (Noble Agar Difco) were plated on a layer 
of 2ml of the same medium containing 0.7% agar. The plates were fed weekly with 0.5ml of 
RPMI/10% FBS. Three weeks after plating, the colonies were stained with 0.005% crystal violet, 
and photographed using an Olympus inverted microscope. 
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Cell morphogenesis on Matrigel.  
Tissue culture dishes were coated with Matrigel (BD Bioscience, NJ) as per manufacturer’s 
guidelines at 37°C for 30 minutes before adding 1×105 vector- or hGH1-transfected MCF-7 cells, 
which were then overlaid with a dilute solution of Matrigel (in growth media) in triplicates and 
incubated at 37°C. Images were recorded after 48hrs using Nikon inverted microscope. 
 
GH assay  
An equal number of MCF-7 stably expressing cells and parental line were seeded in a 6-well format 
and grown till confluence. The following day these cells were subjected to serum-free media for 
24hrs and media was collected for GH secretion measurements. Simultaneously, the cells were 
washed in PBS and harvested in 25mM Tris–HCl, pH 7.4. The supernatant and cell lysates were 
diluted and assayed on murine Ba/F3 cells stably expressing the human GHR (Ba/F3-B2B2 clone) 
as previously described (Rowland et al, 2002) with an MTT formazan dye endpoint. 
 
Preparation of total RNA and quantitative PCR (qPCR) 
Total RNA was isolated from MCF-7 parental and stable cell lines using RNeasy Kit (Qiagen) as 
per manufacturer’s guidelines. 1µg of total RNA was reverse transcribed to cDNA using 
Superscript III (Invitrogen, USA) and used for qPCR with Syber Green Technology (ABI, USA) 
using specific primers (listed in Appendix IV) in the 7500 Real Time Cycler (ABI, USA). Analysis 
was performed using Ct comparison for the gene of interest normalised against beta glucuronidase 
(GusB).  
 
GH treatment and Western Blot Analysis 
Before GH treatment the cells were subjected to 24hrs of serum starvation in their respective 
growth media devoid of 10% FBS then stimulated with 100ng/ml hGH for 12minutes. The cells 
were washed in cold PBS and harvested in RIPA lysis buffer. For normal growth medium analysis, 
the cells were left in growth medium and harvested after a cold PBS wash in RIPA lyis buffer. 
Protein quantification of lysates was performed using bicinchoninic acid (BCA) protein assay 
(Thermo Scientific) as per manufacturer’s instructions. Equal amounts of protein were boiled in 
sample buffer (15mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 10mM DTT) at 100°C for 5 
minutes and proteins were resolved on a 7% SDS PAGE gels followed by transfer on to 
polyvinylidene difluoride (PVDF) membranes using a semi-dry transfer apparatus (BioRad) 
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according to manufacturer’s guidelines. Blocked membranes were then incubated overnight at 4oC 
in primary antibodies (listed in Appendix VI) and washed in Tris Buffered Saline with 0.1% Tween 
(TBST) before the addition of appropriate secondary antibodies diluted 1:10000 in blocking buffer 
for 1hour. After TBST washes, immunoblots were visualised using Immobilon Western 
Chemiluminescent HRP substrate (Merck Millipore) and X-Ray films were developed by X-
OMAT. Blots were reprobed with different antibodies after stripping with Re-blot mild stripping 
buffer (Merck Millipore) according to manufacturer’s guidelines. 
Sphere-forming Assay 
To determine colony-forming efficiency, 120 single MCF-7 cells were seeded per well of a 6-well 
plate in triplicates in 2ml growth medium (DMEM with 10% FBS) and incubated for two weeks 
until macroscopic colonies were visible. Before counting, the colonies were washed with PBS and 
fixed and permeabilised using cold methanol for 10min. The colonies were stained for 1h with 
crystal violet solution (0.1% crystal violet, 20% methanol). Images were captured using a camera. 
 
Bromodeoxyuridine (BrdU) Incorporation Assay  
Cells were plated in duplicate in 6-well plates containing 3 cover slips at 2×104 cells/well complete 
growth media. The next day, complete media was removed, cells were washed with PBS, and 
serum-free media was added for 24hrs. After 24hrs, either normal growth medium or fresh reduced-
serum medium (DMEM supplemented with 0.5% BSA) was added and cells were given 20µM 
BrdU treatment for 2hrs. The cells were then washed and fixed in PFA and subjected to 
immunofluorescence with BrdU specific antibody (Chemicon) and counterstained with DAPI 
(Vector Labs) for nuclei. The coverslips were mounted and analysed under the Olympus Fluoro 
microscope. A total population of over 400 cells was analysed in several arbitrarily chosen 
microscopic fields to determine the BrdU labelling index. 
 
Results 
Creation of GHR constructs using 2A peptide  
In order to determine the effect of GHR in prostate cancer cell lines, various constructs (fig.6.2) 
were designed to be expressed under the control of murine phosphoglycerate kinase (PGK) 
promoter, based on ALSV-A-pseudotyped lentiviral system. The PGK promoter is less prone to 
silencing in stem cells and in vivo as compared to the cytomegalovirus (CMV) promoter (Qin et al, 
2010). 
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For creating GHR constructs using 2A peptide (fig.6.3A), two individual PCRs were carried out. 
The first fragment was generated by attB1 sequence linked to a pig signal peptide (Fwd primer1) 
and with the reverse complement of half of a 2A peptide sequence linked to reverse complement of 
GHR C-terminus without the stop codon (Rvs primer1). The second fragment was generated by 
using half of 2A peptide linked with GFP start codon (Fwd primer2) and attB2 sequence linked 
with reverse complement of GFP C-terminus sequence with a stop codon between attB2 and GFP 
(Rvs primer2). Most importantly, a portion of DNA sequence of 2A peptide was kept overlapping 
between the two PCRs while designing the Rvs primer1 and Fwd primer2. This common region 
between the 2 PCR products was on the same principle as overlap extension PCR cloning (Bryksin 
& Matsumura, 2013) (fig.6.3B).  
 
 
Figure 6.2: List of GHR constructs made containing the 2A peptide using overlap extension PCR cloning.  
The different combinations of cDNA for the insert as well the resulting proteins are indicated 
CDK4*- CDK4(R24C), hGHR- human Growth Hormone Receptor, rGHR- rabbit GHR, WT- wildtype, GFP- Green 
Fluorescent Protein. 
 
As mentioned, the 2A peptide sequence is a self-processing viral peptide bridge that can separate 
different protein coding sequences in a single ORF transcription unit (Ryan et al, 1991). Using these 
2A peptide constructs it has been shown that quantitative co-expression of heterologous proteins, 
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driven by one promoter is possible for both in vitro and in vivo analysis (Tang et al, 2009). The in 
vitro expression using 2A peptide sequences are shown in figure 6.3C by immunoblotting of whole 
cell extracts of transiently transfected HEK293T cells with a set of GHR constructs containing the 
2A peptide. The first 8 constructs (fig.6.2) were used in the first round of transduction. The vector 
with GFP alone was used as a lentiviral transduction control. 
 
 
Figure 6.3: GHR constructs made using 2A peptide. 
(A) Peptide sequence of 2A region with cleavage or ribosomal skip site (B) Representation of the 2A peptide containing 
ORF driven via a PGK promoter in a self-inactivating lentiviral construct. (C) Immunoblot showing expression of 2 
heterologous proteins (GFP and GHR; GFP and CDK4) made using 2A peptide by transient transfection of HEK293 cells 
(20ug protein loaded). The GHR was probed against the N-terminal HA-tag. The expression of both proteins is evident 
as two separate molecules based on their respective molecular weights rather than a fusion protein.  
PM2-hGHR- (C259S, F263C, I270C)-hGHR  
  
The 2A elements used for the study were codon optimised for human expression and owing to the 
small size of only 66bp, they can be easily introduced between 2 or more genes, thus making them 
an ideal choice for lentivirus production since there are no size constraints with 2A peptide as 
opposed to IRES (internal ribosome entry sites) (~ 600bp). This approach therefore allows a single 
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virus particle to carry a set of genes into single cell. The precise mechanism of how 2A peptides 
bring about the expression of two separated proteins is not well understood but ultimately, a 
ribosomal-skip mechanism has been proposed, and 2A and 2A-like sequences are now referred to as 
CHYSELs (cis-acting hydrolase elements) rather than self-cleaving peptides (Donnelly et al, 2001). 
The rationale for the use of 2A peptide is the fact that oncogenesis is a multi-step process and 
requires accumulation of a number of genomic ‘hits’ leading to complete transformation and/or 
survival of partially transformed cells with one or a few hits (Hanahan & Weinberg, 2011). Using 
the RCAS/TVA system we can introduce desired genes with gain or loss of function that are 
hypothesised to cause neoplasia from our in vitro studies. 
 
Immunoblot analysis for function GHR in prostate cancer cell lines 
The two prostate cell lines stably transduced with lentiviral GHR constructs were FACS sorted for 
uniform GFP expression since 2A peptide results in proteins in equimolar ratio. Due to time 
constraints, only DU145 cell lines were analysed to determine the effect of the constitutively active 
and nuclear localised GHR constructs with respect to WT-GHR. The cells were subjected to three 
conditions before protein harvest: Cell supplemented in normal growth media (Normal Media), 
cells starved for 24hours in serum-free media (Serum-free media) and cells starved for 24hours in 
serum-free media then given an acute GH stimulation (GH+) for 12minutes. The resulting 
immunoblots on DU145/tva stably expressing GHR constructs are shown in figure 6.4. The lysates 
were initially probed with HA antibody to check for GHR expression and the two bands 
corresponding to mature (glycosylated) and immature forms of the receptor are evident.  
 
 Following exogenous GH stimulation (GH+), a clear STAT5 activation signal was observed in all 
GHR stables. No changes in ERK1/2 activation and a decrease in STAT3 activation were also 
evident following GH stimulation in all GHR constructs compared to GFP control. The Jun3A-
rGHR construct lacks the receptor extracellular domain and is therefore not amenable to GH-
mediated activation or degradation. In addition, the NLS-hGHR construct has been known to be 
poorly expressed as compared to WT-hGHR (Wooh JW PhD thesis, 2008). Under normal growth 
conditions, an activated STAT5 signal was observed for the constitutively active Jun3A-rGHR and 
PM2-hGHR as well as all the rGHR constructs. The rGHR constructs can bind to the bovine GH 
present in the serum and became activated. The P-STAT3 signal was selectively reduced in NLS 
cell lines. In the absence of GH stimulation and under starved condition, activated STAT5 was only 
detectable for Jun3A-rGHR cell line and P-ERK signals were elevated in WT-GHR and PM2-
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hGHR specifically while P-STAT3 signal was quite weak. For subsequent experiments normal 
growth media conditions were chosen based on these signalling attributes. 
 
 
 
Figure 6.4: Immunoblot of DU145/tva cell lines stable for GHR constructs under different media conditions. 
The DU145 stably expressing various GHR constructs and GFP control were subjected to three media conditions. GH+: 
24hrs serum starvation and GH stimulation at 100ng/ml for 12minutes. Normal media: Complete growth media without 
serum starvation. Serum-free media: 24hrs serum starvation and no GH stimulation. The protein lysates were probed for 
downstream signalling molecules P-STAT5, P-STAT3 and P-ERK1/2 while β–tubulin was used as a loading control. 
Blots representative of n=2 independent experiments in three separate clonal lines made from three independent 
transductions. 
 
Anchorage-independent growth assay 
In order to determine a direct functional outcome of differential signalling in DU145 stables, soft-
agar assay was performed. No change was evident in any of the GHR constructs in comparison to 
GFP control (fig.6.5). As a positive control c-myc DU145 stables were used. 
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Figure 6.5: Anchorage-independent growth in DU145/tva cell lines stably expressing GHR constructs in normal 
growth media 
There was no evident difference in soft agar colonies in any of the GHR constructs as compared to GFP control. 
DU145/c-myc stables were used as positive controls. Equal number of DU145 cells were layered in agarose and 
incubated for 3 weeks. The colonies were stained using crystal violet (0.005%) and images were taken on an inverted 
microscope. Images representative of n=3 independent experiments on two separate transduction derived clones. 
 
Cell proliferation assay 
The DU145/tva stables for GHR were analysed for proliferation under normal growth conditions 
based on BrdU incorporation in the nuclei, a marker for DNA synthesis. No significant change in 
proliferation was observed in any GHR stable cell lines (fig.6.6). 
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Figure 6.6: BrdU incorporation in DU145/tva cells cell lines stably expressing GHR constructs in normal growth 
media 
Percentage of BrdU positive cells to total number of cells for GFP and GHR constructs in 10% Serum containing normal 
growth media counted in 8 random fields is represented graphically. No difference in proliferation is evident in any of the 
GHR constructs as compared to GFP control. Data pooled from three independent experiments was quantified and 
represented as mean ±SEM of n=2 independent experiments.  
 
Since no differences were observed in DU145 cells we sought to test the GHR constructs in MCF7 
cells since it is a well-characterised system of forced GH expression (Kaulsay et al, 1999). Our 
strategy initially was to evaluate and compare the downstream signalling in autocrine GH vs 
constitutively active GHR constructs in MCF7 cells. However, while generating the MCF7 stables 
for autocrine GH we observed opposing results to what has been published by Lobie’s group and 
that was pursued instead. The GHR constructs were therefore not tested in MCF7 due to time 
constraints. 
Generation of MCF-7 stables for GH expression: Two models of 
differential level of GH secretion 
MCF-7 cell lines stably expressing the GH1 gene under CMV and MT promoters were analysed for 
GH expression by qPCR relative to parental (untransfected) as shown in figure 6.7A. This was 
supported by western blot analysis using GH-specific antibody in stable clones. As expected CMV 
promoter-driven GH expression was significantly higher than MT promoter (fig.6.7B). In addition, 
to determine the functional concentration of GH secretion and production in the lysate, MTT assay 
was carried out with Ba/F3 cells expressing hGHR (Ba/F3-B2B2) following incubation of these 
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cells with MCF-7 supernatants and lysates at different concentrations. No detectable functional GH 
was evident in the any of the empty vector controls and parental cells even at the lowest dilution. 
The estimated value of GH secreted when driven via MT promoter was 95ng/ml ± 10 and in the 
lysate (inside the cell) was 45ng/ml ± 20 in preliminary studies. Consistent with qPCR and western 
blot these were lower than the CMV-driven autocrine GH expression, which resulted in secreted 
levels of GH in the range of 165ng/ml ± 22. 
 
Figure 6.7: Growth Hormone expression in MCF-7 cell lines. 
MCF-7 cell line stable clones for GH1 gene expression using two different promoters CMV (CMV-GH) and MT (MT-GH) 
and the respective empty vectors (CMV-EV and MT-EV) were analysed for GH expression. (A) qPCR analysis 
representing fold change in GH expression normalised to GusB relative to parental cell line and (B) western blotting 
using GH-specific antibody indicates high levels of GH protein expression by CMV-driven GH gene as compared to MT. 
No GH protein was detectable in parental or empty vector stable cell lines. β–tubulin was used as loading control. Data 
representative of n=3 independent experiments confirmed in three separate clonal lines made from three independent 
transfections. (Mean±SEM). MT: metallothionein, CMV: cytomegalovirus, EV-empty vector. 
 
GHR signal transduction in autocrine GH MCF-7 cell line 
In order to determine the impact of different signalling molecules downstream of GHR, 
immunoblot analysis was undertaken for MCF-7 cells made stable for GH expression as well empty 
vector controls. These were starved for 24hrs and treated with and without exogenous GH at 
100ng/mL for 12 minutes at 37°C. The cells were then harvested and probed with specific 
antibodies and represented in fig.6.8. 
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Figure 6.8: Immunoblot analysis of MCF-7 autocrine GH cell lines and controls. 
Representative blot of signalling molecules in MCF-7 stables autocrine for GH under the control of MT and CMV 
promoters as well as empty vector (EV) and untransfected parental. All cell lines were starved for 24hrs and stimulated 
with GH at 100ng/ml for 12minutes where indicated (+). Refer to text for explanation of results. Blots representative of 
n=3 independent experiments. 
 
A strong activated STAT5 signal was evident in parental and empty vector stables upon GH 
stimulation, reduced in MT-driven GH and completely undetectable in CMV-driven GH. In 
contrast, basal level of STAT5 activation was evident in MT-driven GH, which was absent in all 
other stables and parental in the absence of GH (fig.6.8A and 6.8C). A similar signalling pattern 
was observed for ERK1/2 with the highest level evident in controls (EV and parental) on GH 
stimulation. No ERK activation was seen in CMV-GH following exogenous GH stimulation and 
this level was independent of exogenous GH. The levels of active Src (Y416) was higher in CMV-
GH as compared to MT-GH and parental cell line and was independent of GH. In contrast, the 
levels of active Akt (T308) were higher in MT-GH and EV as compared to CMV-GH and 
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independent of GH. Active p38 MAPK were highest in CMV-GH and parental cell lines and lowest 
in MT-GH. In addition, cell division protein kinase, CDK4 was downregulated and cyclin-
dependent kinase 1-inhibitor (p21) was elevated selectively in CMV-GH stables (fig.6.8B). No 
change in CDK4 was observed between MT-GH and controls. However, p21 levels were lowest in 
EV as compared to MT-GH and parental. No changes in E-cadherin and vimentin protein levels 
were evident in any of the cell lines. 
Increased proliferation in MCF-7 with lower levels of autocrine GH 
Nuclear BrdU incorporation was carried out for MCF-7 cell lines and there was significantly 
increased proliferation under normal growth medium (10% Serum) and serum free media conditions 
selectively for MCF-7 cells with lower autocrine GH production via the MT promoter. In contrast, 
CMV-driven GH expression decreased cell proliferation as compared to parental cell lines or empty 
vector (fig.6.9). 
 
Figure 6.9: BrdU incorporation in MCF7 cell lines  
Graphical representation of percentage of BrdU positive cells to total number of cells for parental, empty vector (EV) and 
MT and CM-driven GH MCF-7 cell lines in 10% Serum containing normal growth media and serum-free media (starved 
conditions) counted in 6 random fields (~400cells). Increased proliferation was evident in MT-driven GH while 
proliferation was reduced in CMV-driven GH as compared to parental cell line in both conditions of media 
supplementation. There was no evident difference in proliferation in EV under both conditions in comparison to the 
parental cell line. Data pooled from three independent experiments was quantified and represented as mean ±SEM of 
n=3 independent experiments. Statistical analysis performed using ANOVA (***, p< 0.001; **, p<0.01, NS = not 
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significant). 
 
Increased colony formation in MCF-7 with lower levels of autocrine GH 
The colony formation assay is an in vitro cell survival assay based on the ability of a single cell to 
grow into a colony. The colony is defined to consist of at least 30 cells and it essentially tests every 
cell in the population for its ability to undergo "unlimited" division bearing in mind that only a 
fraction of seeded cells retain the capacity to produce colonies. The colonies with greater than 
30cells/colony were counted and broadly classified as holoclones, meroclones and paraclones 
depending on the morphology (fig.6.10). Holoclones are large with smooth edges and consist of 
small tightly packed cells at high density. Meroclones are smaller, have an irregular outline and 
consist of a mixture of small tightly packed cells and much larger loosely packed cells, particularly 
around the edge, with an average. Paraclones are small and diffuse and consist mainly of loosely 
packed enlarged cells. The highest number of clones for the same seeding density was observed in 
MT-driven GH MCF-7 cells as compared to the EV while no change was evident in any stable cell 
line driven via CMV promoter (fig.6.10). 
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Figure 6.10: Increased Clonogenic ability of MCF-7 cell line autocrine for low levels of GH. 
MCF-7 cells were plated at low seeding density and incubated for 2weeks, the generated colonies were stained with 
crystal violet (pink/purple) and only colonies greater than 30 were counted. Representative images of clones observed in 
MCF-7 cell lines for holoclone, meroclone and paraclone are shown. (A) Percentage of holoclones to the total number of 
clones is plotted for each cell line. An increase trend is evident in MT promoter driven GH cell line but did not reach 
significance. (B) Increased total numbers of clone were observed in MCF-7 stables with MT-driven GH as compared to 
EV control and no change was evident in CMV-driven GH as compared to parental cell line. Data representative of n=5 
independent experiments (Mean±SEM). NS: not significant analysed by ANOVA. 
 
Oncogenic transformation of MCF-7 cells with lower levels of autocrine 
GH 
MCF-7 empty vector and CMV-GH cells organised into small colonies when cultured on Matrigel 
(fig.6.11). In contrast, MCF-7 MT-hGH cells adopted a very rapid stellate organisation within 
48hrs. 
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Figure 6.11: Phase contrast microscopy of MCF-7 stables on 2D-Matrigel  
MCF-7 stables were seeded in equal numbers on a layer of Matrigel and overlayed with a dilute solution of matrigel (‘On-
Top’ Assay). CMV-driven GH expression and Empty vector (EV) morphology formed small aggregates of cells while MT-
driven GH had a more stellate organisation. Images representative of n=2 independent experiments. 
 
Discussion 
For this project prostate cancer was chosen as a suitable model for analysing GHR-mediated 
oncogenesis. While it is known that androgens play a central role in prostate cancer development 
and progression, other hormones and growth factors are also involved in prostate growth in both 
stages of androgen-dependent and independent neoplasia (Feldman & Feldman, 2001; Marques et 
al, 2010). IGF-1 plasma levels have been associated with prostate cancer risk, and GH/GHR axis, a 
major factor regulating IGF levels, also is able to prostate cancer cell proliferation and viability, 
with high expression of GHR reported in prostate cancer tissue (Chhabra et al, 2011). In addition 
active phosphorylated STAT3 and 5, key downstream molecule of GHR and PRLR signalling 
pathway are associated with high-grade (Gleason score) prostate tumours (Gu et al, 2010; 
Dagvadorj et al, 2007). 
 
The action of GH/GHR has been associated with an increased incidence of several types of cancer, 
including those of epithelial origin. Several lines of evidence have suggested a specific correlation 
between endocrine or autocrine hGH-mediated signalling and prostate cancer. However, only a few 
published studies have directly tested the effect of hGH on prostate cancer cell function, and 
conflicting findings have been reported. An initial report indicated increased LNCaP cell 
proliferation in response to hGH (Untergasser et al, 1999). However, a second study failed to 
recapitulate this effect, although GHR binding and the activation of the STAT5, MAPK, and PI3-K 
signal transduction pathways by exogenous hGH was observed (Weiss-Messer et al, 2004). The role 
of these pathways in exogenous hGH-stimulated LNCaP cell proliferation has only recently been 
addressed and reported to be stimulatory (Nakonechnaya et al, 2013). 
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Due to time constraints we were only able to carry out analysis on DU145, an androgen-
independent PCa cell line to investigate the effect of GHR activation in promoting prostate 
tumourigenesis. The preliminary studies with different GHR constructs driven via a PGK 
constitutive promoter have revealed no effect on cell proliferation by BrdU incorporation or 
anchorage-independence. There was no change in cell morphology even though a persistently 
activated STAT5 signal was evident in all rGHR constructs (WT, NLS and Jun3A) in the presence 
of complete growth media. Although no tests have been performed as yet in our study to determine 
the effect of exogenous GH, there seems to be no evident effect of autocrine GH on DU145 cells. 
This is supported by the fact that DU145 have no detectable GH transcript (Sustarsic et al, 2013). 
These reports do not discount for the fact that instead of proliferation, GHR-mediated signalling 
may increase cell survival by decreasing apoptosis as has been reported by exogenous GH 
administration in LNCaP cells (Nakonechnaya et al, 2013). In addition, the effect of these GHR 
constructs in the LNCaP cell line may provide more significant results as STAT5 has been reported 
to be a transcription-activator of androgen receptor (Tan et al, 2008) while SOCS2 (induced by 
STAT5) has recently been reported to mediate the cross-talk between the androgen and GH-
mediated signalling (Iglesias-Gato et al, 2014). 
 
Earlier studies have shown that activated Stat3 stimulates metastasis in human PCa cells in vitro 
and in vivo, while Stat5B preferentially promotes cell viability and tumour growth (Gu et al, 2010). 
This is supported by reports where STAT5 knockdown was shown to delay the progression of 
castration-resistant PCa (Ahonen et al, 2003; Thomas et al, 2011). The STAT5 overexpression 
studies have been carried out using an adenovirus system that results in very high expression of the 
downstream signalling molecules and therefore may not be similar to GHR or active GHR 
overexpression and most importantly would be cell line-dependent. It is important to highlight that 
Gu et al. have concluded that Stat5A/B activity related to metastatic behavior of human prostate 
cancer cells (DU145) is mediated by Src kinases rather than by Jak2 (Gu et al, 2010). In another 
study from the same laboratory it was reported that autocrine prolactin promoted PCa cell growth 
via Jak2/STAT5 signalling pathway (Dagvadorj et al, 2007). 
 
Other reports have highlighted that both STAT5 and its promoter undergo increased methylation in 
PCa cell lines as compared to normal epithelial cell lines and this aberrant methylation has been 
correlated with a loss of gene expression and function (Mishra et al, 2010). On the contrary, the 
STAT5 locus has been shown to undergo amplification in clinical PCa specimen (Haddad et al, 
2013), while other studies have emerged highlighting an opposite role of STAT5 isoforms during 
tumour progression (Shchelkunova et al, 2013). 
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Level of autocrine GH determines oncogenic ability 
There is no doubt that GHR-mediated signalling by GH via an autocrine/paracrine manner promotes 
cell proliferation in numerous cancer models (Chhabra et al, 2011; Perry et al, 2013; Sustarsic et al, 
2013) and results in a phenotypic conversion of others, especially human mammary carcinoma 
cells, into a more invasive phenotype as shown by elegant studies from Lobie’s Group (Mukhina et 
al, 2004). However, these have been disputed with two independent studies indicating autocrine GH 
to be growth-inhibitory (Nakonechnaya et al, 2013) and the other implying that autocrine GH 
producing cells may be insensitive to GH antagonist (van den Eijnden & Strous, 2007).  
 
We have utilised 2 model systems of autocrine GH in order to bridge the gap between the 
conflicting findings from Strous’s Group, Lobie’s Group, and Nakonechnaya et al. (2013). Using 
the MCF-7 cell line, the most widely published cell line exhibiting cancer-promoting autocrine GH 
effects we have made stably expressing lines in a similar manner to the previously reported studies 
using lipofectamine 2000 for transfection and pCDNA backbone to drive GH1 expression via MT 
or CMV promoters and their respective empty vector controls, all with a selection marker. 
Consistent with the observation by Liu et al. (Liu et al, 1997) we also found that cytoplasmically 
localised GH (devoid of signal peptide) was not able to activate GHR (data not shown). We 
observed very contrasting effects in regards to ‘cancer-like’ features between the two promoters. 
There was a significant increase in cell proliferation under normal growth media (10% serum) and 
serum-free conditions for low level autocrine GH (MT-GH) whereas proliferation was dramatically 
reduced when a high level GH was expressed (CMV-GH) (Table 6.1). The former has been 
reported in vast majority of publications from Lobie’s Group and the latter was used in the LNCaP 
cell line. Additionally, the level of GH reported by ELISA in these studies does not necessarily 
correspond to functional GH as opposed to our methods of bioactive GH measurement using the 
GH-responsive Ba/F3-B2B2 cell line. It is important here to note that some of the publications from 
Lobie’s Group have used CMV to drive GH expression but the level of GH expression reported in 
their endometrial carcinoma cell line (Pandey et al, 2008) was significantly lower relative to the 
promoter-matched cell line in our study over a 24hour period. In comparison, the study of autocrine 
GH in the LNCaP cell line has only calculated GH levels over an 8hour period (Nakonechnaya et al, 
2013) but based on the published graph it can be expected to strongly increase with time.  
 
The model proposed by the Strous Group (van den Eijnden & Strous, 2007) is based on relatively 
high expression levels of GH and GHR in CHO cells and is valid for situations wherein the molar 
ratio of expression levels (GH/GHR) exceeds 0.5 in any given cell. In physiological systems 
however, the cellular levels of autocrine GH and GHR can vary widely between individuals (Hattori 
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et al, 2001). Strous’s model proposes that the relative protein levels of GH and GHR synthesised 
will determine the fraction of receptor occupied by GH before arriving at the cell surface where 
high levels of autocrine GH would imply low levels or complete lack of unoccupied GHR as 
observed in some studies (van den Eijnden & Strous, 2007; Nakonechnaya et al, 2013). In line with 
the GH/GHR ratio as a factor, Segard et al. have reported enhanced proliferation and inhibition of 
differentiation in C2C12 myoblasts due to autocrine GH being observed only when the cells were 
forced to express GHR (six fold) even though they express low levels of endogenous GHR (Segard 
et al, 2003). A similar scenario exists in our study where the level of GH expression is much higher 
in cells expressing GH under a CMV promoter as compared to MT. This model can also explain the 
growth promoting effects of exogenous GH and growth-inhibitory effect by GH agonists reported in 
studies by Lobie’s Group (Kaulsay et al, 1999) as opposed to lack of growth-promoting effects of 
exogenous GH reported by others (van den Eijnden & Strous, 2007; Nakonechnaya et al, 2013). 
This model also explains the disparity in growth inhibitory effects of pegvisomant treatment in GH-
producing xenograft tumours (Divisova et al, 2006; Dagnaes-Hansen et al, 2004) and is illustrated 
in figure 6.12. Interestingly, the level of GH produced by non-invasive ductal carcinoma (DCIS) is 
higher than invasive ductal carcinoma (Table 6.1) (Raccurt et al, 2002), which suggests that high 
GH levels may prevent metastasis and that the GH secreted by them is actually used by surrounding 
cells (paracrine manner) that lack or secrete very low amounts of autocrine GH.  
 
A similar phenomenon was observed in the case of PRL, where forced autocrine PRL-producing 
T47D cells displayed lower proliferation rate with reduced PRLR levels as compared to control 
cells but their conditioned medium (containing secreted PRL) promoted proliferation of lactogen-
dependent Nb2 cells and control T47D cells (Nitze et al, 2013). Autocrine hGH has been shown to 
increase the sensitivity of the MCF-7 cell line (under CMV promoter but secreted GH levels not 
reported) to arsenic trioxide (ATO)-induced apoptosis (Zekri et al, 2013). In the light of the current 
data, this effect would likely be an additive effect of ATO on CMV-hGH driven apoptosis. 
 
Interestingly, immunoreactivity for hGH was reported to be of variable intensity in different cells 
within the same primary culture of human mammary carcinoma cells established from malignant 
biopsies (Chiesa et al, 2011). Based on this observation, the pMT-GH model of autocrine GH 
(Kaulsay et al, 1999) would closely resemble the scenario found in vivo since MCF-7 made using 
the plasmid that does not contain a selection marker of its own. This is suggestive that one needs to 
examine the amount of unliganded receptors at the cell surface before an antagonist is administered. 
The same explanation holds for autocrine GH-producing cells that upon exogenous GH 
administration are insensitive (Segard et al, 2003; Nakonechnaya et al, 2013). This was also 
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supported by the fact that MCF-7 and MCF-10A cell lines stably transfected with human GH, 
showed reduction in anchorage-independent growth with exogenous GH (Zhu et al, 2005) while 
other studies from the same group have reported inhibition of ‘cancer-like effects’ when antagonists 
were used (Kaulsay et al, 1999; Kaulsay et al, 2001). Such a discrepancy can be attributed to the 
two different model systems used in these studies with MT promoter (Kaulsay et al, 1999) used in 
one and CMV in the other (Zhu et al, 2005) to drive the GH expression. We have shown here for 
the first time that the level of autocrine GH expression is the key to determining the oncogenic 
ability. 
 
The significant inhibition of autocrine hGH–stimulated oncogenic transformation by exogenous 
hGH may simply be due to shift of the bell-shaped hGH dose-response curve. It has been shown 
that GH and GHR interact in the ER and that this association results in higher quantities of mature 
GHR (van den Eijnden & Strous, 2007). A remaining question is whether GH directly serves as a 
ligand chaperone or is dependent on Jak2 for assisting in folding of the GHR in the ER. In the 
experiments described by Strous’s Group it was shown that since GHR gets folded relatively 
quickly, the role of GH in this process might be marginal. Additionally, the exogenously added GH 
or antagonist had no effect but the transiently transfected, CMV-driven autocrine GH-producing 
cells have minimal levels of activated STAT5, possibly a result of balance between activating 
factors, such as the Jak and STAT molecules and downregulating factors, like phosphatases and the 
SOCS proteins (van den Eijnden & Strous, 2007). Raccurt et al. have reported that SOCS gene 
expression is elevated in breast carcinoma, which may be a response to autocrine/paracrine GH 
(Raccurt et al, 2003). An alternative scenario as seen in the case of CIS, a member of the SOCS 
family and inhibitor of STAT5 signalling is its role in tumour promotion. CIS has been reported to 
correlate well with cell proliferation and colony formation with high expression level of CIS 
observed in proliferative areas corresponding to high level of GH synthesis in human breast 
cancers. CIS has been hypothesised to work via a negative feed back loop in MCF-7 cells stably 
transfected with the hGH gene (MCF-hGH) resulting in strong activation of MAPK pathway and 
inhibition of the cellular differentiation mediated through the Jak/STAT pathway (Borges et al, 
2008; Raccurt et al, 2003). 
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Table 6.1: Autocrine GH secretion in cancer cell lines and breast cancer tissue based on published literature 
Tissue/cell 
sample 
Plasmid  Transfection 
reagent 
GH levels in 
media 
secreted by 
cells  
GH levels in 
protein 
extracted 
from cells 
Reference 
Normal breast 
tissue 
n.a n.a n.a 69±21.5pg/m
g lysate 
(Raccurt et al, 
2002) 
Fibroadenoma 
tissue 
n.a n.a n.a 99.5±12.5pg/
mg lysate 
(Raccurt et al, 
2002) 
DCIS 
(Intraductal 
carcinoma 
tissue) 
n.a n.a n.a 195.5±12.5pg
/mg lysate 
(Raccurt et al, 
2002) 
Invasive ductal 
carcinoma tissue 
n.a n.a n.a 102±13pg/m
g lysate 
(Raccurt et al, 
2002) 
Human 
mammary 
carcinoma cells 
(HMCC) 
derived from 
malignant 
biopsies 
n.a n.a n.a 30 to 150 
pg/ml 
Normalised 
to cell count: 
1.5 to 6.5 
pg/ml/million 
cells 
In some cells 
hGH was 
undetectable 
(Chiesa et al, 
2011) 
Breast cancer 
explants 
n.a n.a 0.061±0.1 
ng/mg tissue 
Secreted into 
media 
n.a (Milewicz et al, 
2011) 
MCF-7  pMT-GH 
(No 
selection 
marker) 
DOTAP 2pg/ml 
 
1100pg/mg 
cell lysate 
(Kaulsay et al, 
1999) 
MCF-7 pCDNA-
GH 
(Selection 
marker 
present) 
SAINT-MIX Not shown Not shown  (Brunet-
Dunand et al, 
2009) 
MCF-10A pCDNA-
GH 
(Selection 
marker 
present) 
Effectene 100nM 
(2200ng/ml) 
(24hr end 
point)  
n.a (Zhu et al, 
2005) 
RL95-2 pCDNA-
GH 
(Selection 
marker 
present) 
SAINT-MIX 37.5ng/ml 
(1.7nM)  
(24hr end 
point) 
 
n.a (Pandey et al, 
2008) 
LNCaP Prostate 
cancer cell line 
pCMV1-
hGH 
(Selection 
marker 
present) 
Lipofectamine 
2000 
15ng/ml (8hr 
end time 
point) 
24hr levels 
undetermined 
n.a (Nakonechnaya 
et al, 2013) 
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The ability of MCF-7–MT-GH to form an increased number of clones in the clonogenic assay 
supports increased proliferation and cell viability. In addition a significant increase in the number of 
holoclones generated from single cells was evident in our studies. This finding is consistent with the 
report that holoclones harbour cancer stem cell and are highly proliferative with self-renewal 
capacity as well as being serially tumourigenic (Beaver et al, 2014). In contrast, CMV-GH had no 
significant change in total number of clones or holoclones.  Another point of difference between 
high and low levels of GH was morphology of cells on 2D-matrigel with close resemblance to in 
vivo assembly in low GH-driven cells as opposed to a more differentiated one seen in CMV-GH.  
 
In regards to signalling, the autocrine GH has been shown to signal via Jak2/STAT3/5 (Kaulsay et 
al, 2001; Tang et al, 2010a; Tang et al, 2010b). The increase in mammary carcinoma cell number as 
a consequence of autocrine production of hGH is a result of both increased mitogenesis and 
decreased apoptosis and is dependent on the activities of both ERK1/2 and p38 MAPK that are 
mediated solely by its action on GHR (Kaulsay et al, 2001). Autocrine GH-mediated radioresistance 
in mammary and endometrial carcinoma cells has been attributed to Jak2 and Src kinases (Bougen 
et al, 2012). Remarkably, a converse correlation has been reported in signalling between the 
autocrine hGH and exogenous hGH administration in LNCaP cells. It was shown that inhibition of 
PI3-K or STAT5 was able to overcome the negative effect of autocrine hGH on LNCaP cell 
proliferation by returning it to a wildtype level (DMSO treated) (Nakonechnaya et al, 2013), which 
implies that these pathways also have a role in mediating growth inhibitory effects of overexpressed 
autocrine hGH. Finally, while MAPK pathway signalling appears to be required for basal LNCaP 
proliferation, ERK1/2 inhibition did not alter the effects of exogenous or autocrine hGH, indicating 
that MAPK pathway signalling is not likely involved in mediating the observed stimulatory effects 
of hGH.  
 
Our results are in support with the role of STAT5 in autocrine GH-mediated proliferation as 
activated STAT5 was evident only in MCF-MT-GH both in the presence and absence of GH. The 
fact that there was more STAT5 and ERK signal following GH stimulation is indicative that low 
levels of GH in MT-GH as opposed to high levels in CMV-GH do not occupy all endogenous GHR. 
In addition, Src and p38 were higher in cells with more GH production suggesting a tumour 
suppressor role in our model. The decrease in BrdU incorporation and reduced clone numbers in 
CMV-GH are supported by reduction in CDK4 and increase in p21 protein levels. Similar to the 
earlier study by Mukhina et al. we also observed reduced plakoglobin levels in all cell lines with 
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GH indicative of a decrease in cell-cell contacts, essential for epithelial to mesenchymal transition 
(Mukhina et al, 2004). 
  
These differences in signalling can be attributed to differential modes of GHR activation. It has 
been reported that GHR can be activated only when the receptor has exited the Golgi apparatus after 
glycosylation, a prerequisite for signalling. It is possible that very high levels of GH bound GHR 
complex are amenable to rapid degradation depending on the GH and GHR ratio, before they can 
even signal. This altered localisation has been shown in LNCaP cells overexpressing GH, with 
GHR location changing from peripheral patches on plasma membrane (in empty vector control) to 
cytoplasmic perinuclear intracellular compartments. These were later identified using specific 
marker enzymes assays to be Golgi and the endoplasmic reticulum with very little localisation on 
plasma membrane. The GHR was also shown to co-localise in Golgi with GH by confocal 
microscopy (Nakonechnaya et al, 2013). 
 
The pulsatility of endocrine GH secretion does not seem to influence this difference in signalling, as 
the most extensively studied model of autocrine GH is mammary carcinoma in females that retain a 
more continuous level of GH secretion as opposed to males. This difference in signalling mediated 
through autocrine or endocrine GH may be caused by the fact that the receptors are already 
activated within the cell. Alternative signal transduction pathways might become activated through 
signalling from the Golgi system. The factors that can determine if the autocrine or endocrine will 
be promoting or inhibitory for proliferation are the signalling pathways that are differentially 
regulated as well as the concentration and location of activated receptor at that given time. 
 
MCF-7 cells express GHR and PRLR transcripts at high levels while low levels of GH transcript 
and undetectable PRL transcript have been reported (Sustarsic et al, 2013). Wennbo et al. have 
suggested that the oncogenic effects of hGH are conducted only through interaction with the 
prolactin receptor (Wennbo et al, 1997). In the context of autocrine GH studies, the effects of the 
prolactin or IGF systems were not measured but the results reported by us and others are most likely 
only due to autocrine GH activating GHR because of their high expression levels. Further studies by 
using a TET-regulated system of autocrine GH synthesis are warranted and could aid in determining 
a ‘threshold’ level of autocrine GH that is tumourigenic above which it becomes growth inhibitory. 
Use of signalling and GHR inhibitors as well as cell transformation assays are required to further 
support our hypothesis. In addition, the direct effects of GH2 in cancer progression need to be 
evaluated by autocrine and endocrine mechanisms since GH2 transcript is elevated in numerous 
cancer cells (fig.S.1 in Appendix VII) as opposed to undetectable in corresponding normal tissues. 
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It is possible that different cell types and functional end points do not share the same requirement 
for intracellular vs extracellular hormone. More comprehensive analysis is needed to determine how 
the cellular site of GH action relates to the contrasting effects seen in our study and recapitulate 
these results with differential effects of GH expression levels in the LNCaP cell line. 
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Figure 6.12: Model for endocrine vs differential autocrine GH actions on GHR in MCF-7 cells. 
Schematic representation of endocrine (left panel) and autocrine (right panel) mode of signalling. Endocrine or 
exogenous GH administration results in GH binding to the receptor on cell surface and subsequent activation of 
downstream GHR signalling pathways. The complex is then internalised and degraded in the endosomal/lysosomal 
system. In the autocrine mode, GH can bind GHR following synthesis in the ER and signal transduction can start from 
Golgi itself and may continue until it is degraded. The level of endogenous GH can decide the GHR fate. During low 
level of autocrine GH (in MT-hGH stably transduced cells), reduced levels of GH do not occupy all the GHR and 
therefore some unbound receptor is still available on cell surface to bind exogenous GH (or G120R antagonist). 
However, during increased autocrine GH production (in CMV-hGH stably transduced cells) no exogenous GH (or 
G120R) binding can take place as all the receptors are pre-occupied by GH internally. In addition, the differential signal 
transduction pathways between low and high levels of autocrine GH need to be determined such that choice of pathway 
in former is transforming while latter is inhibitory to proliferation respectively. The precise location of cellular 
transformation signal is also currently unknown. (Developed from (van den Eijnden and Strous, 2007). 
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Introduction 
Src Family Kinase Structure 
Src family non-receptor tyrosine kinases are present in essentially all metazoan cells, where their 
regulated activation by diverse growth factor, cytokine, adhesion, and antigen receptors is critical 
for generating an appropriate cellular response to external stimuli (Brown & Cooper, 1996). The 
nine members of the Src family include Src, Lck, Hck, Fyn, Blk, Lyn, Fgr, Yes, and Yrk. Src 
kinases share a conserved domain structure consisting of consecutive SH3, SH2, and tyrosine 
kinase (SH1) domains (fig.7.1). All family members also contain an SH4 membrane-targeting 
region at their N-terminus, which is always myristoylated and sometimes palmitoylated (Resh, 
1999). The SH4 region is followed by a 'unique' domain of 50–70 residues, which is divergent 
among family members. 
 
During myristoylation at the glycine residue on position 2, the terminal methionine is cleaved and a 
14 carbon-myristoyl group is attached. This serves to provide membrane localisation but does not 
guarantee it. The function of the second ‘unique’ domain is currently unknown but has been 
suggested to play a role in individualized protein contacts (Brown & Cooper, 1996). This is 
followed by a SH3 domain that is 50-60 residues in length and has a β-barrel architecture consisting 
of five antiparallel β-strands and two prominent loops, termed the RT and n-Src loops (Noble et al, 
1993). These loops lie at either end of a surface composed of aromatic and hydrophobic residues. 
An optimal Class I Src SH3 ligand has a consensus sequence RPLPPLP and a Class II ligand has 
φPPLPxR (where φ represents a hydrophobic residue and X denotes any amino acid). Therefore the 
recognition site for SH3 domain is the proline-rich sequences bearing the 'PxxP' motif (Lim et al, 
1994). However, the SH3 domain of Fyn kinase, within the SFK family, has been shown to be 
promiscuous as it can even bind the proline-independent motif RKxxYxxY found in the immune 
cell adaptor SKAP55 (Kang et al, 2000). Even quite subtle changes in the sequence of SH3 domains 
and their binding peptides can alter the specificity of the peptide binding. 
 
The SH2 domain is comprised of 100 residues and contains specific phosphotyrosine binding site. 
This phosphotyrosyl recognition site is highly conserved among SH2 domains, and contains a 
universally conserved arginine residue (Arg175 in Src) that forms requisite electrostatic interactions 
with the phosphorylated tyrosine (Waksman et al, 1993). Src-family SH2 domains bind 
preferentially to the pYEEI motif, coordinating the phosphotyrosine and isoleucine residues in the 
canonical recognition pocket. Polar and electrostatic interactions favour glutamic acid residues at 
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the pY +1 and +2 positions, but many other residues can be accommodated in these positions in Src 
SH2 domains (Songyang et al, 1993). 
 
 
Figure 7.1: Schematic illustration of SFK structure. 
At the N-terminal, SFK is myristoylated at the glycine residue on position 2 which lies in the SH4 domain (not shown 
here) and is followed by a unique domain of unknown function. The SH3 domain has a preferential binding for proline-
rich sequences while the SH2 domain binds to phosphorylated tyrosine. The SH2 domain is connected to the 
Kinase/SH1 domain via a linker that allows SH3 domain to attach with the N-lobe. The activating phosphorylation site, 
Tyr 416 lies in the catalytic region of the SH1 domain while the inactivating phosphorylation site (Tyr527) lies outside 
the kinase domain on the C-terminal tail (Boggon & Eck, 2004). 
 
The SH1 or Kinase domain is composed of 253 residues and follows the SH2 domain. The SH1 
domain consists of a small N-terminal lobe and a large C-terminal lobe. The SFKs share the bilobal 
protein kinase fold that is a characteristic feature of all tyrosine kinases and ser/thr kinases. The N-
terminal (or small) lobe is composed of five β-strands and a single α-helix, termed the C helix, 
which is an important component of the regulatory mechanism employed in Src kinases. The C-
terminal (or large) lobe is predominantly α-helical, and contains the regulatory activation loop, 
which is the site of activating tyrosine phosphorylation in Src and other kinases (Boggon & Eck, 
2004). Nucleotide binding and phosphor-transfer (via ATP) have been shown to occur in the cleft 
between the two lobes. The adenine moiety of the bound nucleotide is coordinated largely by 
interactions with the N-lobe and a short hinge segment that connects the two lobes. Bound 
nucleotide phosphates are in part coordinated by the glycine-rich G-loop (also termed the P-loop, 
for phosphate binding) (Taylor et al, 1992; Hubbard & Till, 2000). The activating tyrosine 
phosphorylation site at 416 is present in the catalytic site. There is a linker between SH2 and N-lobe 
that has prolines at positions 246, 250 and 263 whereby the SH3 domain attaches to the N-lobe. 
Towards the end of the kinase domain is an inhibitory phosphorylation site at Tyr527, which when 
phosphorylated allows it to attach to the SH2 domain and close the catalytic cleft. The proposed 
mechanism of its activation is described in figure 7.2. 
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Figure 7.2: Illustration of proposed regulation of Src Family kinase 
Generally SFK have an auto-inhibitory closed confirmation (left panel). This occurs as a result of stabilisation of SH3 
domain by binding to the linker, which provides packaging of the N-lobe, while the SH2 domain attaches to the 
phosphorylated Tyr527 at the C-terminus. The ordered Activation "A" Loop forms a helix, stabilising the inactive 
conformation of the kinase domain while simultaneously blocking the peptide-substrate binding site and preventing 
phosphorylation of Tyr416. Following an activation stimuli (right panel), the SFK undergoes 3 steps: (i) unlatching where 
Tyr527 is dephosphorylated (by SHP1, PTPs) and detached from the SH2 domain. In addition to growth factor binding 
and Tyr527 dephosphorylation, a variety of SH2 and SH3 competitors may serve to alter SFK structure, leading to its 
activation (ii) unclamping where an opening and closing of the cleft between N-lobe and C-lobe is created (iii) switching 
where Tyr416 undergoes autophosphorylation (Bjorge et al, 2000; Boggon & Eck, 2004). 
 
GHR and Src Family Kinases 
Jak2 has been regarded as the classical GHR signalling kinase but there is strong evidence that 
indicates activation of the GHR also results in direct activation of SFKs (Zhang et al, 2006) 
(Rowlinson et al, 2008; Barclay et al, 2010), although the strength of the relative Jak2 and SFK 
signals is dependent on cell type (Jin et al, 2008). Activation of SFKs by ligand binding has already 
been shown for the related TPOR, EPOR, and PRLR (Lannutti & Drachman, 2004; Tilbrook et al, 
1997; Chin et al, 1998; Fresno Vara et al, 2000). The activation of SFK by GH does not require 
Jak2 activation (Rowlinson et al, 2008) as is also the case for prolactin-mediated activation of 
PRLR (Fresno Vara et al, 2000). In addition, GH-driven SFK was shown to activate ERK1/2 
through a phospholipase Cγ–Ras pathway (Rowlinson et al, 2008) similar to EPOR (Boudot et al, 
2003). 
 
Barclay et al. have described targeted knockin mutations to the Box1 sequence of GHR in mice, 
which completely abrogated Jak2 activation by GH in vivo, but did not decrease activation of 
hepatic ERK via SFK. These mice displayed an mRNA expression profile different from that of 
mice harboring a complete deletion of ghr gene, especially the transcripts regulated by ERK 
(Barclay et al, 2010). Relevant to the receptor activation mechanism, perturbing the relative 
orientations of the two transmembrane helices of the growth hormone receptor with glycine and 
proline substitutions changed the ratio of Jak2/STAT5 to ERK signalling (Rowlinson et al, 2008). 
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This has raised the possibility that some hGH analogues are able to activate ERK, but only weakly 
compared to STAT5, as reported for the I179M hGH mutant associated with deficient growth 
(Lewis et al, 2004). This residue sits next to W169 in receptor site 1. Moreover, a specific 
conformational change in the loop between the β-strands F’ and G’ of the lower fibronectin module 
of the GHR ECD was identified in the crystal structures, which differs between agonist-bound and 
antagonist-bound forms of the receptor, and mutating this loop markedly decreased ERK signalling 
but not Jak2/STAT5 signalling i.e. induced-biased signalling. 
 
Of interest is the conserved YGEFS motif adjacent to the F’G’ loop in the lower fibronectin 
module, which is equivalent to the WSXWS motif in the ECD of all Class 1 cytokine receptor 
family members. Mutations within this sequence have been shown to cause GH insensitivity and 
Laron syndrome (Brooks & Waters, 2010). Supporting the duality of GHR signalling, studies on the 
EPOR using numerous ECD conformations in conjunction with alanine insertions, at the boundary 
between transmembrane domain and cytoplasmic domain, which introduces helical rotations, 
showed differential STAT5 to ERK activation (Liu et al, 2009). These data clearly support that 
conformational changes in the ECD and rotation of the TMD are critical activation mechanisms for 
these receptors. Waters’ Group has shown both in vitro in the Jak2-deficient cell line γ2A and in 
vivo in mice with mutated Box1 motif (alanine substitutions of the four prolines) that ERK can be 
activated by GHR independent of Jak2. These Box1 mutated mice (GHR K4) were similar to GHR-
null mice in that they display severe growth retardation and lack Jak2/STAT5 phosphorylation in 
response to GH administration; however, they were able to activate ERK and a set of transcripts 
associated with SFK/ERK signalling (Barclay et al, 2010) (Thompson et al, 2000). 
 
Further evidence that GH signalling utilises a Src family tyrosine kinase independently of Jak2, has 
come from Lobie’s Group (Ling et al, 2003; Zhu et al, 2002). In NIH-3T3 cells it has been shown 
that GH activates c-Src, which in turn can activate ERK1/2 via a pathway involving the activation 
of the Ras-like small GTPases RalA and RalB, leading to Elk1-mediated transcription (Zhu et al, 
2002). Further studies showed that both Jak2 and c-Src activate the additional Ras-like small 
GTPases Rap1 and Rap2 that acts to inhibit RalA-mediated activation of ERK1/2 (Ling et al, 2003). 
This chapter aims to determine the precise region of GHR to which Lyn kinase (and other SFK 
member) binds and vice versa as well if this binding is constitutive in nature. In addition, we seek to 
determine if there exists a competition between SFK (using Lyn kinase) and Jak2 binding on GHR 
and its functional consequence in terms of downstream signalling. 
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Materials and Methods 
Construction of GHR mutants and truncations 
Full-length human ghr encoded within a pQCXP plasmid was used as a template for the 
construction of GHR truncations and Box1 mutants with N-terminal HA tag. GHR truncations were 
made using specific primers with stop codon for early termination of receptor cDNA. The primers 
were designed to contain flanking attB sequence and are listed in Table 7.1. PCRs were carried out 
using Phusion® DNA polymerase (Thermo Scientific). For creation of the Box1 mutant in which all 
four prolines (PPVPVP) were mutated to alanine (AAVAVA), PCR-mediated overlap cloning 
(Bryksin & Matsumura, 2013) was used where two separate PCR products were ligated together 
(outlined in Chapter 6). All the mutants (represented in fig.7.3) were cloned into pQCXP-CMV-
Puro DEST (plasmid# 17386, Addgene) by Gateway Cloning. The resulting clones were analysed 
by restriction digestion and sequencing. The pCMV-Lyn(WT)-myc tag vector was a kind gift from 
Prof. E. Ingley at Western Australian Institute of Medical Research, Perth Australia. The pCMV-
Jak2 construct was made by Dr. A.J. Brooks (Brooks et al, 2014). 
 
Table 7.1: Primer sequences used for construction of GHR truncation and Box1 mutants. 
Primer Sequence 
hGHR 270tr 
stop attB2 Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTAAGAAAATAAGAAT
ACAAATAGCATCACTGTTAGCCCAAATATTC 
hGHR 280tr 
stop attB2 Rvs 
5’GGGACCACTTTGTACAAGAAAGCTGGGTCTACAGAATCAGCATTT
TAATCCTTTGCTGTTTAGAAAATAAG 
hGHR 289tr 
stop attB2 Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTATTTAATCTTTGGAA
CTGGAACTGGGGGCAG 
hGHR 312tr 
Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGT C 
hGHR 339tr 
stop attB2 Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTAAGTCTTTTCATCTG
GCTCATCAATATCTAGCTCAATAAATTC 
hGHR 364tr 
Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGT C 
hGHR 
Y314A/389tr 
Fwd 
5’CCATTCATGATAGCGCTAAACCCGAGTTCCACA 
hGHR 
Y314A/389tr 
Rvs 
5’TGTGGAACTCGGGTTTAGCGCTATCATGAATGG 
hGHR 389tr 
stop attB2 Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTAACCCTCATGTATGT
CATTGGCATTGAAATCAG 
hGHR 439tr 
stop attB2 Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTATTGTGGTTTGTTTT
TCTCTGCTTGGATAACACTG 
hGHR Box 1 
mut Fwd: 
5’TGGCCGCAGTTGCAGTTGCAAAGATTAAAGGAATCGATCCAGATC
TCCTC 
hGHR Box 1 
mut Rvs 
5’CTTTGCAACTGCAACTGCGGCCAGAATCAGCATTTTAATCCTTTGC
TGTTTAGAA 
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attB1 pGHR 
sig Fwd 
5’GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGATCTCTGGCAGC
TTCTGTTGACC 
hGHR attB2 
Rvs 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTCTAAGGCATGATTTTG
TTCAGTTGGTCTGTG 
 
Construction of Lyn mutants and truncations 
The Lyn constructs were designed based on the earlier study by Chin et al. evaluating Lyn binding 
to EPOR (Chin et al, 1998). More constructs have been designed to analyse the effect of Lyn kinase 
domain on GHR binding. These constructs were created by overlap PCR extension method 
(Bryksin & Matsumura, 2013). The primers used are listed in Table 7.2. 
 
Table 7.2: Primer sequences used for generating Lyn constructs 
Primer Sequence 
pCMV-Tag 
Rev 
5’GCTCCAGCTTTTGTTCCCTTTAGTGAGGG 
pCMV-myc 
Fwd 
5’GAGCAGAAACTCATCTCTGAAGAGGATCTGTAGGT 
pCMV-Lyn1 
Fwd 
5’CCCTCACTAAAGGGAACAAAAGCTGGAGCATGGGATGTATTAAATC
AAAAAGGAAAGACAATCTCA 
Lyn119-myc 
Rvs 
5’ACCTACAGATCCTCTTCAGAGATGAGTTTCTGCTCGGCCACGTAGTT
GCTGGGGATGAAG 
pCMV-
Lyn67 Fwd 
5’CCCTCACTAAAGGGAACAAAAGCTGGAGCATGATTGTGGTGGCCTTA
TACCCTTATGATGGC 
pCMV-
Lyn120 Fwd 
5’CCCTCACTAAAGGGAACAAAAGCTGGAGCATGAAGGTCAACACCTT
AGAAACTGAAGAGTGGTTCTTC 
Lyn230-myc 
Rvs 
5’ACCTACAGATCCTCTTCAGAGATGAGTTTCTGCTCTTTGGGACTGATG
CATGCCTTCTCCA 
myc tag1 Rvs 5’ACCTACAGATCCTCTTCAGAGATGAGTTTCTGCTC 
pCMV-
Lyn234 Fwd 
5’CCCTCACTAAAGGGAACAAAAGCTGGAGCATGCCATGGGATAAAGA
TGCCTGGGAGATCC 
Lyn-E260G 
Fwd 
5’GGGCAGTTTGGGGGAGTCTGGATGGGTTAC 
Lyn-E260G 
Rvs 
5’GTAACCCATCCAGACTCCCCCAAACTGCCC 
Lyn323-myc 
Rvs 
5’ACCTACAGATCCTCTTCAGAGATGAGTTTCTGCTCAGCCATGAACTC
GGTGATGATGTAGATGG 
pCMV-
Lyn322 Fwd 
5’CCCTCACTAAAGGGAACAAAAGCTGGAGCATGGCTAAGGGTAGTTT
GCTGGATTTCCTCA 
 
Cell lines  
Human embryonic kidney HEK293 cell line (a kind gift from Dr. F. Fontaine, Cooper Lab, IMB) 
and 293 derived HEK293T cell line together with African green monkey kidney COS-7 cell line (a 
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kind gift from Dr. M. Sweet, IMB) were maintained in DMEM supplemented with 10% FBS and 
maintained at 37ºC in a 5% CO2 humidified incubator.  
 
Signalling analysis 
For signalling analysis, HEK293 and COS-7 cells were seeded at 1×105 cells per well and 
transfected using lipofectamine 2000 (Invitrogen) as per manufacturer’s conditions with GHR 
expression constructs (300ng/well) or Lyn construct (100ng/well) where indicated. A total of 400ng 
of DNA was transfected per well with the residual quantity made up with pCMV-empty vector. 
Transfected cells 36hrs after transfection were starved in serum-reduced media (DMEM containing 
0.5% FBS) and exposed to GH treatment at 200ng/ml hGH for 12minutes at 37ºC.  
 
Co-Immunoprecipitation and Western Blotting 
HEK293T cells were plated in T-75 flask format at equal seeding density and transfected next day 
at 50% confluency with 12µg GHR plasmid, 8µg Lyn plasmid or 8µg Jak2 plasmid using 
lipofectamine 2000 (Invitrogen) as per manufacturer’s conditions. For Jak2 and Lyn competition 
assays, equal amount of Lyn and Jak2 plasmid were added (4µg each) with 12µg of GHR 
constructs. For co-immunoprecipitation (co-IP), transfected cells were starved 16hrs before harvest 
in serum reduced media (DMEM with 0.5% FBS). On the subsequent day, cells were stimulated 
with 200ng/ml human GH for 12minutes at 37ºC. The cells were washed in cold PBS and harvested 
by scraping into cold lysis buffer comprising 150mM NaCl, 50mM Tris pH7.5, 5mM EDTA, 0.5% 
Trition-X-100 supplemented with 1x complete EDTA-free protease inhibitor tablets, 10mM 
Na3VO4, 30mM NaF, 10mM Na4P207. Protein lysates were spun at 12000g for 10minutes at 4ºC 
and quantified using a BCA Assay kit (Pierce). Equal amount of protein lysates were pre-cleared 
using Protein G sepharose beads (GE Healthcare) for 30minutes at 4ºC. The pre-cleared lysate was 
used for immunoprecipitation.  
 
For Jak2 co-IP, anti-Jak2 antibody at (1:100 dilution) and for Lyn co-IP, Lyn antibody (1:50 
dilution) or myc-tag (at 1:100 dilution) (Cell signalling) were added to protein lysates and mixed 
gently on a rotating wheel at 4ºC. After 2hours, Protein G sepharose beads were added in the 
antibody-lysate tube which was then mixed gently on a rotating wheel at 4ºC for another 2hours. 
The beads were washed in lysis buffer (lacking Triton) twice and spun at 6000rpm for 1minute each 
time between washes and the supernatant was removed. Finally, the washed beads were boiled in 
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SDS sample buffer with 0.1M DTT for 5minutes and spun at 12000g for 5minutes. The supernatant 
was removed and subjected to SDS PAGE gel electrophoresis. 
 
Results 
Construction of GHR truncations and signalling analysis 
A series of GHR truncations illustrated in figure 7.3A were constructed and verified for expression 
ability by transient transfection in HEK293 cells by immunoblotting for the HA tag (fig.7.3B). All 
GHR constructs excluding 364tr and 339tr expressed well (as compared to WT), and show two 
bands, a higher molecular weight representing mature glycosylated monomer and lower band 
representing the precursor form. The 339tr and 364tr failed to express even in the presence of 
proteasomal inhibitor, MG132 (data not shown) indicating that the decreased expression was 
independent of proteasomal degradation and may be the outcome of an unstable mRNA that 
undergoes rapid degradation. Most GHR truncations were expressed at higher levels as compared to 
full-length receptor owing to smaller size and reduced degradation especially 289tr and 270tr 
lacking both UbE motif and DSGxxS motif important for proteasomal degradation (da Silva 
Almeida et al, 2012). In addition, owing to lack of Box1 motif, no Jak2 binding could be expected 
with these constructs which would also reduce Jak2-mediated degradation. 
 
As shown in figure 7.3B, STAT5 activation was only evident for WT GHR following GH 
stimulation. There are some endogenous GHR in the HEK293T cell line accounting for low level of 
STAT5 activation seen in all other mutants. However no difference in ERK activation was evident 
even in the presence of GH (data not shown). To establish a cell line to analyse Lyn-mediated ERK 
signalling HEK293 and COS-7 cells were tested by transient transfection of mutants. The STAT5 
activation in HEK293 cells was similar to HEK293T but with increased ERK activation evident 
after GH stimulation (fig.7.4A). However, ERK activation was also evident in Lyn only transfected 
wells indicating that GH-mediated ERK pathway is already predominant in these cells due to 
endogenous GHR. It is also important to note that GHR truncations express at a higher level as 
compared to full-length constructs (fig.7.3B). The poorly expressed constructs (364tr and 339tr) 
have since been excluded from signalling analysis. 
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Figure 7.3: Construction of GHR mutants and signalling analysis in HEK293T. 
(A) Schematic representation of GHR Box1 mutant and GHR truncations used for Lyn co-IP analysis. The WT hGHR is 
represented with extracellular domain (ECD), transmembrane domain (TMD) and intracellular domains and with Box1 
(red box), Box2 (green box), UbE: ubiquitin motif, DSGxxS motif (black box) indicated.  Each truncation is represented 
with the last three amino acids in the sequence followed by a stop codon (#). The box1 sequence with the prolines 
mutated to alanines is indicated in blue. HEK293T cells transiently transfected with GHR truncations, Box1 mutant 
(refered to as Box1) and WT receptor were immunoblotted for GHR (for HA tag) and represented on a molecular weight 
scale. (B) Western blot analysis of transiently transfected GHR mutants in HEK293T cell lysates using HA-tag for 
receptor expression and STAT5 activation after GH stimulation (+) at 200ng/ml for 12minutes. All GHR constructs except 
339tr are expressed more efficiently than full-length WT and Box1 for an equal amount of protein loaded based on β–
tubulin. Activated STAT5 after GH stimulation is strongest for WT GHR as compared to Lyn alone transfected control. 
Blots representative of n=3 independent experiments. 
 
In the case of COS-7 cell line, GH-mediated STAT5 activation although weak was evident only 
when GHR was transfected. In addition, following GH stimulation there was increased ERK 
activation when GHR was transfected and it increased further upon Lyn transfection and was not 
evident in Lyn only control (fig.7.4B).  
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Figure 7.4: Downstream signalling from GHR mutants following GH stimulation. 
Transiently transfected GHRtr and Box1 mutants with Lyn were analysed in HEK293 and COS-7 cell lines for 
downstream signalling after GH stimulation (+) at 200ng/ml for 12minutes. (A) HEK293 cells transfected with WT gave a 
strong activation of STAT5 that was not evident for other GHR constructs while ERK activity was detectable in all 
mutants and control cells following GH stimulation. Blots representative of n=2 independent experiments (B) COS-7 cells 
show STAT5 activation after GH stimulation that was only evident in WT transfected cells. Increased ERK activation was 
observed when both WT and Lyn were transfected as compared to WT alone and no GH-mediated ERK activation was 
observed in Lyn only control. Blots representative of n=2 independent experiments. 
 
Co-immunoprecipitation of GHR truncations 
The GHR truncations were subjected to co-IP following transient transfection in HEK293T. Since 
these cell lines have low endogenous SFKs, therefore based on the Waters’ Group results of Lyn (a 
SFK member) interaction with GHR (Rowlinson et al, 2008), Lyn was transfected along with GHR. 
For co-IP, different buffers were standardised (to amount of Triton-X-100) to get maximum pull 
down of GHR and Lyn, without disrupting their interaction. The harvested protein lysate was pulled 
down with Lyn antibody and the blots were probed for HA tag. The immunoblot is shown in figure 
7.5A and an interaction between full-length WT and Box1 mutant with Lyn is evident. In addition, 
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Lyn interaction was also observed for the truncations 439tr and 389tr. No interaction was evident in 
289tr and 270tr even at higher level of expression of GHR in total cell lysate (fig.7.3) and also in 
the case of 339tr, which was shown to have reduced receptor expression (fig.7.4A).  Following the 
first round of co-IP analysis further truncations were made between residues 364 and 289. In 
addition to truncation at 312, the tyrosine at 314 was mutated to alanine in the 389tr background 
and both were found to interact with Lyn (fig.7.4B). These co-IP results were confirmed using an 
anti-myc tag antibody (to detect C-terminal myc tag in Lyn) and gave similar results (data not 
shown). 
 
A 
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Figure 7.5: GHR interaction with Lyn in HEK293T cells 
GHR mutants were subjected to co-IP analysis (refer materials and methods) to determine the region on GHR where Lyn 
binds. (A) Lyn binding is evident in full-length WT and Box1 mutant as well 439tr and 389tr. No binding was evident in 
the case of 339tr (issues with expression), 289tr and 270tr. Blots representative of n=3 independent experiments. (B) Lyn 
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binding to 312tr and Y314A/389tr is also evident. Blots representative of n=2 independent experiments. 
 
Effect of Jak2 on Lyn GHR interaction  
In order to determine if there was an effect of Jak2 on Lyn binding to GHR, HEK293T cells were 
transfected with WT GHR and both Jak2 and Lyn subjected to co-IP pull down simultaneously with 
Jak2 and Lyn antibody. Jak2 co-IP was first performed as a proof of principle to confirm if this 
binding was specific to Box1 motif. As evident from immunoblot in figure 7.6A Jak2 interaction 
with WT GHR was constitutive but required an intact Box1 motif as no interaction was evident in 
Box1 mutant. In addition, there was increased activation of Jak2 following GH addition in WT 
receptor as evident from the P-Jak2 immunoblot (fig.7.6A). The Lyn co-IP immunoblot (fig.7.6B) 
revealed two observations. Firstly, there was a decrease in Lyn interaction with WT receptor 
following GH stimulation when Jak2 was transfected. This was in contrast to the observation in 
Box1 mutant where the binding of Lyn to Box1 mutant was facilitated upon GH stimulation and 
was constitutive when no Jak2 was added (fig.7.6B, 7.5A). Interestingly, addition of Jak2 and its 
concomitant binding at Box1 motif in WT receptor resulted in an increase in mature GHR isoform 
in comparison to the precursor (fig.7.6B) as shown previously (He et al, 2005). 
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Figure 7.6: Effect of Jak2 on Lyn interaction with GHR. 
Jak2 and Lyn constructs were transfected with WT and Box1 mutant GHR in combination or with Lyn alone in 
HEK293T cells and subjected to co-IP analysis (refer materials and method section). (A) Jak2 interaction with WT and 
Box1 mutant indicates that Jak2 binds only to the Box1 motif in the GHR and gets activated after GH stimulation 
evident from P-Jak2 blot. (B) Lyn co-IP was carried out to determine the effect of Jak2 on Lyn binding to GHR for WT 
and Box1 constructs. The remaining lysate left after using the half for the Jak2 co-IP above was used for Lyn co-IP 
and matched with lysate lacking exogenous Jak2. There was decrease in Lyn binding following GH treatment in the 
presence of Jak2 while no binding difference was evident in the absence of GH stimulation for WT GHR. In contrast 
Lyn binding to Box1 mutant increased after GH stimulation when Jak2 was transfected. Note the increase in mature 
receptor isoform following Jak2 transfection with WT GHR. Blot representative of n=2 independent experiments. 
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Lyn Constructs 
Similar to the strategy used to determine Lyn interaction with EPOR (Chin et al, 1998), several Lyn 
constructs were made to determine the region on Lyn (fig.7.7) that interacts with GHR. Numerous 
constructs with different domains deleted and others mutated such as kinase dead (E260G) were 
made. These are currently being analysed for expression, signalling and co-IP analysis using 
antibody against its C-terminal myc tag. 
 
Figure 7.7: Schematic illustration of Lyn constructs. 
Lyn constructs were designed to determine the region on Lyn that binds to GHR. Each illustrated construct indicates the 
domain and amino acid residues based on wildtype full-length Lyn (56kDa isoform). All constructs were designed to 
contain by a C-terminal myc tag for the ease of detection. 
 
Discussion 
There is strong evidence that GHR can activate SFK independently of Jak2 both in vitro and in vivo 
(Brooks & Waters, 2010). This study has used truncated GHR constructs to determine the precise 
region on GHR where Lyn, a predominantly hematopoietic SFK member binds by co-
immunoprecipitation analysis. We report here for the first time that Lyn binds to GHR between the 
residues 312 and 289. This region lies between the Box1 motif and the Box2 motif (not inclusive) 
with no requirement for Box1 motif to bind Lyn as shown previously by Waters’ Group (Barclay et 
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al, 2010). Based on the current study, Lyn binding occurs in the region in the sequence indicated in 
figure 7.8 and alignment of this region with GHR sequences of other species highlights that this 
region is very conserved. 
                     Box1       Lyn Binding Region 
Human   PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKP 
Macaque   PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKP 
Baboon    PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKP 
Rhesus monkey       PPVPVPKIKGINPDLLKEGKLEEVNAILAIHDSYKP 
Squirrel monkey     PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKP 
Dog     PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDNYKP 
Giant Panda   PPVPVPKIKGIDSDLLKEGKLEEVSTILAIHDNYKP 
Guinea Pig   PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDNSKP 
Rat     PPVPVPKIKGIDPDLLKEGKLEEVNTILGIHDNYKP 
Mouse    PPVPVPKIKGIDPDLLKEGKLEEVNTILGIHDNYKP 
Rabbit    PPVPVPKIKGIDPDLLKEGKLEEVNTILAIQDSYKP 
Pig     PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDNYKH 
Cow     PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDNYKH 
Sheep    PPVPVPKIKGIDPDLLKEGKLEEVNTILAIHDNYKH 
Chicken    PPVPVPKIKGIDPDLLKKGKLDEVNSILASHDNYKT 
Pigeon    PPVPVPKIKGIDPDLLKKGKLDEVNSILASHDNYKT 
Turtle   PPVPAPKIKGIDPDLLKKGKLDEVNSILASHDSCKP 
 
Figure 7.8: Multiple alignment of potential Lyn binding amino acid sequence on GHR from various species. 
Based on the co-IP results the Lyn binding region on human GHR was aligned to the corresponding GHR sequence of 
various species and appears conserved all along the Lyn binding region as well as proximal sequences. 
 
The consensus sequence stated by earlier studies for SFK binding via its SH2 domain (Songyang et 
al, 1993) or SH3 domain (Lim et al, 1994) are not evident in GHR although numerous non-
consensus binding regions have been reported for both domains. SFK binding to GHR does not 
appear to require a tyrosine residue for binding, since the mutation Y314A (in 389tr) did not affect 
GHR and Lyn binding but in fact increased the GHR expression compared to 389tr. An earlier 
study by Manabe et al. have reported that treatment of F-36P human leukemia cells with a Src 
inhibitor resulted in reduced GHR phosphorylation to the same extent as that of Jak2 inhibition 
(Manabe et al, 2006). However, with barely detectable levels of endogenous receptor 
phosphorylation evident from GHR immunoprecipitation, this study failed to determine subtle 
differences between Src and Jak2-mediated GHR phosphorylation. In addition, the level of tyrosine 
phosphorylation of GHR in COS-7 cells co-transfected with WT-Src was shown to be of a similar 
extent when Jak2 was transfected (Manabe et al, 2006). This study however failed to consider that 
the level of endogenous Jak2 in COS-7 cells would be enough to phosphorylate GHR independent 
of exogenous Src. Thus, it remains to be determined if SFK bound to GHR can phosphorylate the 
GHR. Previous studies on the closely related PRLR using immunoprecipitate kinase reactions have 
not been able to show any involvement of c-Src activity in PRLR tyrosine phosphorylation. 
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Moreover, in cells co-expressing PRLR (Box1 mutant) and c-Src, addition of PRL, although 
induced activation of c-Src, did not result in receptor phosphorylation (Fresno Vara et al, 2000). 
 
GHR-mediated SFK activation has been implicated in mediating the autocrine actions of GHR 
(Tang et al, 2010a) with increased cancer cell attributes associated with SFK signalling (Bougen et 
al, 2012). Numerous reports of GH/GHR expression in immune system also suggest that GH acts on 
various types of immune cells, especially B-lymphocytes, monocytes and macrophages (Hattori et 
al, 2001) with Lyn kinase being predominantly expressed in hematopoietic lineage and SFK 
implicated in an array of signalling networks regulating metabolism, viability, proliferation, 
differentiation and migration within different immune cells (Parsons & Parsons, 2004). In contrast, 
it has been demonstrated that thrombopoietin-stimulated SFK inhibits cellular proliferation and 
megakaryocyte differentiation (Lannutti & Drachman, 2004). Engagement of the B-cell antigen 
receptor (BCR) initiated by the Lyn has been shown to trigger signalling cascades, leading to 
proliferation, differentiation or growth arrest of B cells (Wang et al, 2007) indicating that SFK can 
perform distinct roles in different cell types and cytokine receptor systems. 
 
An interesting observation made by Chin et al. has been the binding of the Lyn SH2 domain to 
tyrosine-phosphorylated Jak2 in vitro although no in vivo binding could be demonstrated by co-
immunoprecipitation in the same study (Chin et al, 1998). Similarly, Uddin et al. have reported that 
Fyn, another member of the Src family, associates via its SH2 domain with Tyk2 or Jak2 in cells 
stimulated with interferon IFNα or IFNγ, respectively (Uddin et al, 1997). More recently, it has 
been shown that SFK can control Jak2 activation in response to PRL through a tyrosine kinase-
independent mechanism (Garcia-Martinez et al, 2010). PRLR was shown to utilise Src SH2 and 
SH3 domains for Jak2 signalling in W53 lymphoid cells and by using non-catalytic Src mutant, 
SrcK295M/Y527F, whose SH3 and SH2 domains are exposed, these workers could control 
Jak2/Stat5 activation. In contrast, the kinase inactive SrcK295M mutant, with inaccessible SH3 and 
SH2 domains, could not control Jak2 activation. These mutants were also shown to attenuate 
PRLR-induced Akt and p70S6K activation (Garcia-Martinez et al, 2010). Finally, Jak2/Stat5 
pathway has been shown to be downregulated in Src-/- mice mammary glands in the same study.  
 
Earlier study in F-36P leukemia cells has shown Src depletion using siRNA did not affect Jak2 
expression or its tyrosine phosphorylation after GH stimulation although GH-mediated STAT5 
activation was shown to be reduced in the absence of Src (Manabe et al, 2006). The same study also 
reported that when WT GHR, Jak2 and Src were co-transfected together, Jak2 and Src co-
immunoprecipitated with GHR and this association was seen when non-catalytic Src mutants were 
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used, indicating that Src association with GHR does not require its tyrosine kinase activity (Manabe 
et al, 2006). Other studies have emerged that reporting that Jak2 inhibition can deactivate Lyn 
kinase (Samanta et al, 2009), further strengthening Jak2 and SFK association. However, studies 
from Waters’ Group have indicated that both binding and activation of Lyn are independent of Jak2. 
These studies were carried out in both Jak2-deficient cell line and in Box1 mutant mice (GHR K4) 
where no activation of Jak2 was evident (Rowlinson et al, 2008). It is to be noted that there was 
increased ERK activity in vivo between in Box1 mutant’s hepatic tissue with (no GH-mediated 
STAT5 activity) but this may have been a consequence of elevated plasma GH (Barclay et al, 
2010). This result indicates that SFK-mediated STAT5 activation via GHR is either cell line-
dependent or an artefact of overexpression system. 
 
In the current study we have presented preliminary results indicating a reduction in Lyn binding to 
WT receptor after GH stimulation. It remains to be evaluated if this is a direct effect of Jak2 on Lyn 
or mediated due to rapid GHR degradation owing to the higher level of Jak2 (transfected) and GHR 
on cell surface. In contrast, a Box1 mutant that cannot interact with Jak2 showed increased Lyn 
binding following GH stimulation. It may be speculated that Lyn and GHR compete with each other 
for Jak2 binding and when Jak2 is unable to bind GHR (as in the case of Box1 mutant) this will 
facilitate Lyn binding to GHR either directly or via another signalling molecule such as PLCγ or 
FAK. As a result, these co-IP studies need to be performed in Jak2-deficient γ2A cell line to 
evaluate the effect that lack of endogenous Jak2 might have on SFK association with GHR.  
 
SFK members have been shown to associate through their SH2 domains with several receptor-type 
tyrosine kinases (e.g. EGFR), resulting in the mutual stimulation of catalytic activity and enhanced 
phosphorylation of downstream targets of these tyrosine kinases (Parsons & Parsons, 2004) (Arbet-
Engels et al, 1999). It may thus be speculated that the Lyn-Jak2 interaction may activate or stabilise 
the catalytic activity of both tyrosine kinases and mediate GHR crosstalk with other receptors. In 
vitro and in vivo binding studies have previously shown that Lyn also binds to Cbl, Shc, PI3-K, 
PLCγ, MAPK, and GAP47 most of which have also been implicated in signalling mediated through 
GHR (Brooks & Waters, 2010). Therefore, Lyn may also directly phosphorylate these signalling 
molecules involved in GHR-mediated signalling or indirectly potentiate their tyrosine 
phosphorylation.  
 
Further studies are currently in progress to determine the precise binding region of Lyn binding to 
GHR and to investigate Lyn-mediated tyrosine phosphorylation of GHR (in the absence of Jak2). 
These findings will be re-evaluated in FDC-P1 cell lines (used in (Rowlinson et al, 2008) made 
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stable for GHRtr to evaluate the extent of Lyn activation in this SFK-dependent line. It should be 
noted that some GH-dependent ERK activation also occurs from Jak2 via Ras (Choi et al, 2006) in 
FDCP-1 cells evident from the residual activity in the presence of SFK inhibitors. This situation 
may be reversed in other cell types, so the relative extent of these alternate pathways (Jak2 or SFK) 
would depend on the relative expression levels of these two kinases. Since binding alone is 
necessarily not a measure of activation, the GHR truncations will be analysed for ERK1/2 
activation in the COS-7 cell line, which has now been established as a suitable system for GH-
stimulated Lyn-mediated ERK activation. 
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Introduction 
Numerous cancers, including breast, prostate and colorectal, increase with advancing age, with the 
vast majority of cancer cases reported in people over 60 years of age (Ahmad et al, 2009). The risk 
of cancer mortality increases in an age-dependent manner, although both incidence and mortality 
rate apparently plateau and subsequently decline after 90 years of age (Smith, 1996). The increased 
incidence of cancer as a function of ageing has long been interpreted to suggest that multiple 
genetic changes are required for carcinogenesis to occur. Cancer is the primary cause of death in 
most mouse strains, although tumour type appears highly strain-specific (Anisimov, 2001). 
Hypophysectomy or surgical removal of the pituitary gland was the most common form of 
endocrine therapy used to reduce hormone action before the development of specific chemical 
agents and monoclonal antibodies for the treatment of cancer, diabetes and hypertension (Saglam et 
al, 1970). Reduced levels of endocrine hormone/growth factors have also been associated with anti-
ageing effects that contribute to extend lifespan in nematodes, fruit flies, and rodent models (Tatar 
et al, 2003), supporting the link between cancer and longevity. This chapter will highlight some of 
the common attributes that may lead to reduced cancer incidences and in turn promote longevity 
based on the genetic murine models of altered GH/GHR signalling.  
 
Mutant and genetically modified animal models, characterised by shortening or extension of the 
lifespan, provide an opportunity to evaluate the role of ageing genes in the mechanisms of 
carcinogenesis and vice versa. The most well characterised murine models in regards to longevity 
are the Ames and Snell dwarf mice. On an average, Ames mice live 69% and 49% longer (in Ames 
genetic stock background females and males, respectively), whereas Snell dwarfs live nearly 42-
26% longer (DW/J Pit1dw X C3H/HeJ Pit1dw-J genetic background females and males, respectively) 
than wildtype littermates (Flurkey et al, 2002), these differences being largely a result of genetic 
background rather than differences in pituitary function (Brown-Borg et al, 2012). Both of these 
mice models have embryonic developmental arrest in the anterior pituitary arising from autosomal 
recessive mutations in Prop-1 and Pit-1 genes respectively, resulting in undetectable circulating 
GH, PRL and thyrotropin levels (Sornson et al, 1996; Magkou et al, 2007). Despite having a similar 
endocrine profile as Snell dwarf mice, old Ames dwarf mice exhibited a high incidence and burden 
of cancer at the time of death (Ikeno et al, 2003). Necropsy at the time of death revealed malignant 
lesions in 72% of Ames dwarf mice, in comparison to 95% of control mice where as in the case of 
Snell dwarf mice the cancer deaths accounted for only 18% as compared to 82% in control mice 
(Alderman et al, 2009). 
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Since these mice lack at least three hormones it was difficult to establish the exact role of GH 
and/or IGF-1 levels to lifespan extension until the generation of GHR/GHBP knockout (GHR KO) 
mice by targeted disruption of murine ghr (Zhou et al, 1997b; Coschigano et al, 2000). The GHR 
KO have been made in two different genetic backgrounds: 129Ola X BalbC with lifespan extension 
of 55% and 38% (females and males, respectively) (Coschigano et al, 2000) and C57Bl/6 with 
lifespan extension of 26 and 16% (females and males, respectively) (Coschigano et al, 2003). 
Although the GHR KO mice can synthesise GH normally they are GH insensitive and show 
deficiency in endocrine IGF-1 levels as well as retarded post-natal growth, similar to Laron patients 
(Coschigano et al, 2000). Owing to low IGF-1 levels (and therefore lack of negative feedback on 
GH synthesis) as well as reduced GH clearance these mice have high levels of circulating GH as 
compared to wildtype. Additionally plasma PRL levels that normally increase with age in wildtype 
mice were shown to decline in GHR KO males, and did not differ between aged GHR KO and 
controls (Chandrashekar et al, 2007). GHR KO have decreased levels of thyroid hormones (T3 and 
T4) (Hauck et al, 2001) and testosterone in males (Chandrashekar et al, 2007). 
 
Ikeno et al. have reported reduced incidence (and burden) from 83% in C57Bl6 littermate controls 
to only 42% and delayed occurrence of neoplastic diseases as well as a decrease in the severity of 
non-neoplastic diseases in both male and female GHR KO mice of 129Ola X BalbC genetic 
background (Ikeno et al, 2009).  These mice exhibit a pathological profile similar to mice subjected 
to calorie restriction (Bronson & Lipman, 1991) and consequently live longer than age and gender 
matched wildtype littermates (Coschigano et al, 2003). Similarly Lit/Lit mice harbouring a mutation 
in Ghrhr have reduced GH levels owing to lack of GH synthesis by pituitary somatotrophs and 
therefore a secondary reduction in IGF-1 levels (Lin et al, 1993), exhibit significantly reduced 
growth of breast cancer xenografts relative to controls (Yang et al, 1996). Since the common 
endocrine denominator between Lit/Lit, GHR KO, Ames, Snell dwarf mice and CR mouse models 
is the suppressed levels of GH/IGF-1, it is clear that low levels of GH and IGF-1 are unfavourable 
to tumourigenesis.  
 
Human studies are in complete accordance with the results in mice models as indicated by non-
existent tumour incidences (and diabetes) in patients with Laron syndrome (Steuerman et al, 2011; 
Guevara-Aguirre et al, 2011). In contrast to the dwarf animal models GH transgenic (GHtg) mice 
exhibit gigantism characterised by increased longitudinal body growth owing to increased IGF-1 
levels in circulation as compared to wildtype littermates (Wolf et al, 1993). Increased inflammation, 
hepatocellular carcinoma and premature death have been reported in two different models of GHtg 
mice (Wanke et al, 1991; Friedbichler et al, 2011). Dysregulation of several oncogenic pathways 
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and signalling mediators were reported in the liver of GHtg mice of both genders as compared with 
normal controls, including Akt2, NF- κB, GSK3β, β-catenin, cyclin D1, cyclin E, c-myc, c-jun and 
c-fos (Miquet et al, 2013). Also, acromegalics have been reported to have a higher incidence of 
colon and thyroid cancers (Chhabra et al, 2011) while other increased tumour incidences have not 
been confirmed due to small sample size.  
 
Potential cancer resistance mechanisms in dwarf mice 
The observations highlighted above should be considered in the context of several aspects of 
GH/IGF-1 signalling such as inhibition of insulin signalling, promotion of inflammation, 
mitochondrial and oxidative pathways that correlate directly with longevity and are particularly 
relevant to tumour development.  
 
Mitochondrial function 
The mitochondria plays a central role in energy metabolism through oxidative phosphorylation 
(OxPhos), apoptosis, modulation of redox status, control of cytosolic Ca2+ levels and generation of 
free radicals as byproducts of the electron transport chain (Wallace, 2012). Changes in these 
elements can interrupt biosynthetic pathways, cellular signal transduction pathways, transcription 
factor action and even chromatin structures in order to shift the cell from a quiescent, differentiated 
state to an actively proliferating one (Wallace, 2012). A progressive decline in physiological 
function occurs with ageing that is associated with accumulated damage in DNA, RNA and protein 
resulting in loss of cellular function (Salvioli et al, 2001). Mitochondrial DNA (mtDNA) is 
characterized by high variability, maternal inheritance, and absence of recombination and can affect 
rate and quality of ageing. Differences in mitochondrial function arising from mtDNA germline 
inherited variants have been associated with extended ageing profile in an Italian population (de 
Benedictis et al, 2000) while other mitochondrial gene variants have been reported at higher 
frequencies in Japanese centenarians than in controls (Tanaka et al, 1998). In addition, mutations in 
genes encoding key mitochondrial enzymes such as succinate dehydrogenase (SDH), fumarate 
hydratase (FH), and isocitrate dehydrogenase (IDH1 and 2) arising in cancer cells are well 
established (Wallace, 2012). 
 
The five-multimeric enzyme complexes that drive OxPhos and cellular respiration are contained 
within the inner mitochondrial membrane. Complex I (NADH dehydrogenase) forms the largest of 
the multimeric electron transport chain (ETC) proteins and contributes significantly to the 
generation of free radicals, respiration rate and overall control of ETC (Brown-Borg et al, 2012). 
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Inhibition of complex I alone by as little as 25% has been shown to negatively impact energy 
metabolism and production (Brown-Borg & Bartke, 2012) and is also reported to be a naturally 
occurring process during ageing (Ventura et al, 2002). Complex II or succinate dehydrogenase is a 
second entry point to the electron transport chain and is the only enzyme that is part of both the 
citric acid cycle and the electron transport chain (Cecchini, 2003). It is believed to be important in 
decreasing production of reactive oxygen species while it oxidises succinate to fumarate and 
reduces ubiquinone (Yankovskaya et al, 2003). The maintenance of succinate levels within the cells 
is important as it can serve as a metabolic signal in inflammation and has been shown to stabilise 
the transcription factor hypoxia-inducible factor-1α (HIF-1α) in specific tumours (Mills & O'Neill, 
2013). 
 
Q-cytochrome c-oxidoreductase or complex III is involved in the oxidation of one molecule of 
ubiquinol and the reduction of two molecules of cytochrome c, a heme protein loosely associated 
with the mitochondrion. This protein has been associated with oncogene-induced senescence and 
found to be upregulated in breast cancer cells and primary breast tumours (Owens et al, 2011). 
While complex I and II exert great control over the respiratory chain flux, complex IV (Cytochrome 
c oxidase) is the final and rate-limiting step of the ETC and along with complex I and III is 
responsible for ROS generation (Huttemann et al, 2012; Hoehn et al, 2009). Use of GHRH 
antagonists in the prostate cancer cell line LNCaP has been shown to prevent ROS generation by 
inhibition of Complex IV activity (Barabutis & Schally, 2008).  
 
Age matched Ames mice liver has increased complex I and IV activity and protein levels as 
compared to wildtype with greater decline observed in wildtype tissues with age (Brown-Borg et al, 
2012). This is also complemented by data obtained from fruit flies, rats and human livers (Salvioli 
et al, 2001). ATP synthase (Complex V) couples proton flow from the inter-membrane space back 
to the matrix with conversion of ADP and inorganic phosphate to ATP (Yoshida et al, 2001). This 
complex is key to energy availability and is not co-regulated with OxPhos proteins (Brown-Borg & 
Bartke, 2012). This is important because energy deficits are common in diseases with low ATP 
synthase protein or due to mutations in the genes encoding the ATP synthase complex, which 
results in increased membrane potential, delay in ETC and higher ROS production (Jonckheere et 
al, 2011).  
 
PGC1α (peroxisome proliferator-activated receptor γ co-activator1α) has been identified as a key 
regulator of mitochondrial biogenesis and plays an important role in utilisation of fatty acids as a 
metabolic fuel, thereby controlling lipid homeostasis (Wu et al, 1999). Enhanced PGC1α expression 
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at transcript level in liver has been reported in GHR KO and Ames mice although this did not result 
in greater mitochondrial numbers per se (Al-Regaiey et al, 2005; Brown-Borg et al, 2012). Other 
factors involved in the regulation of mitochondrial biogenesis include AMP-activated protein kinase 
(AMPK), Sirtuins, endothelial nitric oxide synthase (eNOS), nuclear respiratory factor1 (Nrf1), 
mitofusin2 (MFN2) and calorie restriction (CR) (Pfeifer et al, 2001). Disturbances in mitochondrial 
biogenesis affect oxidative stress resistance, energy production and metabolism and may result in 
the development of age-associated degenerative diseases as evident in the case of GHtg mice that 
have markedly decreased level of complexes I, II and IV and shortened lifespan (Brown-Borg & 
Bartke, 2012). 
 
During carcinogenesis cells shift their metabolism from aerobic energy production to glycolysis. 
This shift can take place even in the presence of oxygen and is therefore referred to as aerobic 
glycolysis, and it is known as the Warburg effect (Hanahan & Weinberg, 2000). Since 2000, 
considerable work has been done on the role of mitochondria in neoplastic transformation. 
Generally, two primary mitochondrial cancer promoting factors have been linked to cancer, i.e. 
metabolic switching to provide building blocks for the growing cells (Weinberg & Chandel, 2009), 
and/or increased mitochondrial ROS production resulting in the emergence of cells with oncogenic 
mutations (known as ‘mitochondrial malignancy’) (Ralph et al, 2010). This indicates that 
examination of changes in individual OxPhos components and mitochondrial enzymes due to 
differences in circulating levels of hormones in mice models has the potential to uncover areas of 
altered function relating to cancer.  
 
Free Radicals and Reactive Oxygen Species 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) can induce oxidative 
stress/damage but at lower levels are physiologically important for regulating cellular and stress 
signalling, integrating energy state, and survival (Hamanaka & Chandel, 2010). It has been 
proposed that oxidative damage due to excessive free radical generation by mitochondria as a by-
product of OxPhos contributes to cancer, neurodegenerative disorders, diabetes, and inflammation 
(Ralph et al, 2010). Mitochondrial redox regulation is crucial for mitochondrial function and 
NADPH is used for reduction of mitochondrially generated H2O2 and other peroxides by 
glutathione and GPx. When ROS production is too high it will induce cellular apoptosis that if 
prevented can contribute to neoplastic transformation (Burdon, 1995). Recent investigations have 
suggested that during uncontrolled proliferation in cancer cells oxygen depletion in the tumour core 
stimulates mitochondria to elaborate increased ROS, with subsequent activation of signalling 
pathways, such as hypoxia inducible factor 1α (HIF-1α), that promote cancer cell survival and 
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tumour growth by increased inflammation and metabolic reprogramming (Semenza, 2010). 
Mitochondrial ROS from complex III has been shown to be essential for stabilising HIF-1α during 
hypoxia (Chandel et al, 2000). Additionally AMPK, a pro-survival kinase was reported to be highly 
sensitive to ROS/RNS and shown to function as a physiological repressor of NADPH oxidase 
(Nox) to maintain NADPH levels (Wang et al, 2010a). 
 
Despite intensive investigations in this field, current antioxidant therapeutics (vitamin A, E and β-
carotene) have not been clinically effective in combating the pathological conditions arising from 
oxidative stress, but rather promote mortality (Bjelakovic et al, 2014). There is clear evidence that 
demonstrates the GH/IGF-1 axis plays a role in antioxidative defense as in the case of GHtg mice 
that succumb to cancer early in life. These have increased superoxide radical and reduced 
antioxidant enzymes levels such as superoxide dismutase (SOD), catalase and GPx (Brown-Borg et 
al, 1999). In contrast, GH deficiency in dwarf mice results in enhanced antioxidative defense 
capacity in Ames mice but not GHR KO. Ames mice have been reported to harbour elevated 
transcripts of catalase, SOD and GPx in multiple tissues (Brown-Borg et al, 1999) (Brown-Borg & 
Rakoczy, 2000) which can be suppressed by exogenous GH administration (Brown-Borg & 
Rakoczy, 2003). In the case of GHR KO however, a lack of free radical scavenging in the liver and 
kidney has been reported (Hauck et al, 2002). Recently Marty et al. have reported a role for ROS in 
Jak2V617E mediated progression of myeloproliferative neoplasm (Marty et al, 2013) while STAT3 
and 5 transcription factors downstream of GH signal cascade have been implicated in cross-
regulation of oxidative metabolism/ROS generation in cancer cells (Bourgeais et al, 2013). 
 
Stress resistance: Ability to deal with ROS 
Increased stress resistance against cytotoxic and metabolic stresses can contribute to differential 
neoplastic disease occurrence. Indeed, human mammary epithelial cells cultured in the serum of the 
GHR-deficient (GHRD) Ecuadorian cohort were protected from oxidative DNA damage, compared 
with cells cultured in the serum of their relatives (Guevara-Aguirre et al, 2011). In the setting of 
oxidative stress, increased cytotoxicity was also observed in the cells cultured in the serum from the 
GHR mutant patients, while the addition of IGF-1 to this serum or culturing cells in the serum from 
controls reduced the rate of cell death (Guevara-Aguirre et al, 2011). GHD/GHR mutation therefore 
appears to protect cells from oxidative damage while simultaneously increasing cytotoxic pathways 
for removing mutated/damaged cells.  
 
Snell dwarf mice are resistant to chemically induced cancers and exhibit reduced growth of 
transplanted tumours compared to control mice that are either homozygous or heterozygous for the 
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wildtype Pit1 allele (Flurkey et al, 2001). This resistance is also evident in cells derived from these 
dwarf mice. The skin-derived fibroblasts from Snell mice were resistant to multiple forms of 
oxidative and non-oxidative cellular stress (Murakami et al, 2003). Significant increases in LD50 
values were observed in dwarf mice over those of wild-type mice following exposure to UV 
irradiation (45%), hydrogen peroxide (H2O2; 147%), paraquat (53%), cadmium (180%), and heat 
(102%).  Similar studies were performed on other long-lived dwarf mice (Ames, GHR KO) and 
revealed increased resistance against UV, H2O2 and paraquat (Salmon et al, 2005). More recently it 
has been shown skin-derived fibroblasts from both Snell and GHR KO have diminished 
phosphorylation of mTOR, S6K and 4EBP1 after amino acid deprivation (in GHR KO and Snell 
fibroblasts), H2O2 (Snell fibroblasts), and paraquat (Snell fibroblasts), consistent with the higher 
levels of autophagy in these cells following a stress stimulus (Wang & Miller, 2012) Additionally it 
has been suggested that stress resistance might be dependent on developmental changes (hormone-
dependent) that occur during the first few months after birth since no differences were observed in 
fibroblasts derived from neonates of dwarf mice and littermate controls (Salmon et al, 2005). 
 
A different approach to studying oxidative stress in Snell dwarf mice challenged with 3-
nitropropionic acid (OxPhos Complex II inhibitor) showed decreased activation in the MEK-Erk 
cascade and a lack of c-Jun (Ser63) phosphorylation as compared to wildtype, suggesting altered 
management of oxidative stress in the Snell dwarf (Madsen et al, 2004). Although antioxidative 
defence enzymes have not yet been systematically examined in the GHR KO mice (C57Bl/6 
background), an overall enhancement of this system is likely responsible for increased resistance to 
oxidative insult as found in Ames and Snell dwarf mice.  
 
The results above can be attributed to increase in Nrf2 (Nuclear Factor-erythroid 2-related factor 2) 
expression. Nrf2 is the master controller of oxidative and xenobiotic stress response that has been 
shown to influence oxidative stress-related physiological and pathological processes such as cancer, 
diabetes, and inflammation (Kensler et al, 2007). Snell dwarf mice derived skin-fibroblasts have 
been shown to maintain a steady-state level of Nrf2 as compared to control, which further increases 
transcription of antioxidant response element (ARE)-responsive genes in dwarf mice (Leiser & 
Miller, 2010). Gene expression array data from GH deficient mice models have revealed elevation 
in phase I enzymes which can also be attributed to Nrf2 activation in vivo, a hallmark of long-lived 
(Steinbaugh et al, 2012) and CR mice (Martin-Montalvo et al, 2011). 
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Glucose deprivation 
Cancer cells are dependent on glycolysis for ATP production rather than OxPhos and so have a 
requirement of high levels for glucose for energy production (Matoba et al, 2006). Glucose 
deprivation (and starvation) has been shown to cause rapid cancer cell death as compared to healthy 
cells in vitro and in vivo (El Mjiyad et al, 2011; Shim et al, 1998). Accordingly, elevated circulating 
glucose increases the risk of cancer and reduces the effectiveness of medical treatment in cancer 
patients (Stattin et al, 2007; Malin et al, 2005). Importantly, Ames and Snell dwarfs, GHR KO, and 
non-transgenic calorie-restricted mice have reduced levels of glucose in peripheral circulation 
(Brooks et al, 2007; Alderman et al, 2009; Dominici et al, 2002; Liu et al, 2004; McCarter et al, 
2007). The decrease in plasma glucose was proposed to not be an important factor in the action of 
calorie restriction on longevity (McCarter et al, 2007) although lower glucose by calorie restriction 
is inversely correlated to cancer incidence (Rondini et al, 2011). It is relevant that p53, one of the 
most frequently mutated genes in cancers, modulates the balance between the utilisation of 
respiratory and glycolytic pathways (Matoba et al, 2006).  
 
IGF-1/IGF-1R in Cancer Promotion 
IGF-1 has been shown to act in vitro as a tumour promoter by increasing proliferation and 
decreasing apoptosis, and by promoting angiogenesis and metastasis (Samani et al, 2007). Indeed, 
local expression of IGF-1 in mouse mammary tissue resulted in spontaneous mammary tumours in 
30% of mice (de Ostrovich et al, 2008). Some conclusions have been drawn from mouse models 
with lower levels of circulating IGF-1 but with normal/elevated tissue expression as a result of 
selective knockout of hepatic IGF-1 expression (liver IGF-1-deleted or LID mice). These mice had 
approximately 50% of normal circulating IGF-1, which resulted in a 40% significant decline in 
azoxymethane-induced colon adenocarcinoma number, largely due to increased apoptosis (Olivo-
Marston et al, 2009). An earlier study with orthotopically transplanted colon-38 adenocarcinomas 
has reported that the circulating IGF-1 in LID mice to be approximately 25% of normal, and this 
was associated with a substantial decrease in the number of mice with palpable colon tumours from 
57% to 31% with a significant increase in tumour latency from 23 to 27 days (Wu et al, 2002). 
Hepatic metastases were also significantly decreased from 44% to 31%, and these improvements 
were reversed with IGF-1 administration. Generation of mammary tumours by chemical or genetic 
means is also decreased in LID mice (Wu et al, 2003). Besides IGF-1, GH has been shown to 
directly regulate the transcription of igf2 in human liver (von Horn et al, 2002) and increased 
expression of IGF-2 has been reported in a variety of cancers, including geriatric malignancies such 
as brain tumours, mammary carcinoma, gastrointestinal cancer including pancreatic carcinoma and 
ovarian carcinoma (Pollak, 2008).  
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Similarly increased IGF-1R expression has been reported in numerous cancers and cancer cell lines 
and though not all data is consistent, it is generally associated with worse prognosis (Railo et al, 
1994; Law et al, 2008; Ludovini et al, 2009). This elevated expression and/or increased activation 
of IGF-1R is mainly associated with pro-survival signalling pathways (Kurmasheva & Houghton, 
2006) and can therefore tip the balance between apoptotic cell death versus survival of damaged 
cells towards survival and consequently favour the emergence of a malignant clone. Additionally, 
the IGF axis has been implicated in the maintenance of cancer stem cells and induction of EMT 
(Bodzin et al, 2012; Graham et al, 2008). This has been demonstrated in stem cell niches generated 
in hypoxic microenvironments that trigger the stabilisation and activation of hypoxia inducible 
factors (HIF) (Keith & Simon, 2007). Constitutive IGF-1R levels have been reported to be elevated 
in chemoresistant cell lines relative to parental cell lines (Dallas et al, 2009). 
 
Disruption of an intracellular substrate of the IGF-1 receptor, p66Shc, provides a 30% increase in 
lifespan and increased resistance to hydrogen peroxide, UV-irradiation, and paraquat toxicity 
(Migliaccio et al, 1999). Low circulating levels of IGF-1 obtained by liver-specific IGF-1 
inactivation (lv-IGF-1−/−) (Svensson et al, 2011) or brain-specific IGF-1R knockout (Croce et al, 
2014) also extend lifespan in mice. Holzenberger et al. have demonstrated that the longevity effect 
of IGF-1R on 129/SvPas genetic background was sexually dimorphic with female heterozygotes 
(IGF-1R+/-) exhibiting 33% increase in longevity and resistance to oxidative stress (paraquat), while 
the effect was not significant in males (IGF-1R+/-) (Holzenberger et al, 2003). However, Bokov et 
al. have reported only 5% extension of lifespan in female IGF-1R+/− mice on C57BL/6 genetic 
background and unchanged lifespan in mutant males (Bokov et al, 2011). Similarly, the modest 
longevity effect of low IGF-1 in lv-IGF-1−/− mice (on C57BL/6 genetic background) was seen in 
females, but not in males (Svensson et al, 2011). Indeed, it is now established that the longevity 
effect of IGF-1R hetrozygosity is dependent on the genetic background of the mice (Xu et al, 2014). 
 
Insulin /Insulin Receptor in Cancer Promotion 
Epidemiological studies have demonstrated a clear association between T2DM and cancer (Ko & 
Chaudhry, 2002; Calle & Kaaks, 2004; Noto et al, 2011). This association between diabetes and 
cancer is mediated in part by chronic hyperinsulinemia acting via IR as well as the effects that 
elevated insulin levels have on the IGF system (Calle & Kaaks, 2004). Elevated IR expression has 
been reported in cancers of the breast, lung, ovary, thyroid, and colon and associated with larger, 
higher-grade tumours as well as higher estrogen receptor concentrations (Cannata et al, 2010). 
Elevated insulin levels have been shown to promote activation of STAT5 inducing IGF-1 (Le et al, 
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2002) and elevated insulin levels have been shown to hinder IGFBP-1 and 2 expression therefore 
increasing IGF-1 availability locally (Lukanova et al, 2004). In addition, elevated insulin levels (as 
in the post-prandial surge in insulin-resistant subjects or after insulin injection) are likely to bind to 
IGF-1R, which has increased mitogenic potential as compared to IR (Vigneri et al, 2009). 
Experiments with insulin-deficient (diabetic) animals have shown that insulin promotes tumour 
growth and development in xenograft models and in chemical models of carcinogenesis (Cocca et 
al, 1998) and finally adipocyte-specific deletion of the IR gene (FIRKO mice) was shown to lower 
plasma insulin levels by more than 30% and increases lifespan by 15% to 18% in male and female 
mice, respectively (Bluher et al, 2003) while mutants with inactivation of its downstream signalling 
molecules like IRS-1 (Selman et al, 2008; Selman et al, 2011) and S6K1 (S6 Kinase1) have been 
(Selman et al, 2009) shown to have extended lifespan. 
 
Hyperinsulinemia is directly associated with GH deficiency as evident in obesity, but with normal 
circulating IGF-1. Conversely, GH excess in the liver of GHtg mice was associated with a decrease 
in insulin receptor (IR) with simultaneous increase in the basal activity of IR/IRS-1 and PI3-K 
pathway, although these are unresponsive to exogenous insulin stimulation (Dominici et al, 1999). 
In skeletal muscle of GHtg mice, decreased levels of IR protein and decline in insulin-mediated 
signalling with increase in p85 (negative regulator of insulin signalling) are thought to be key 
element in promoting insulin resistance (Barbour et al, 2005). Additionally, prolonged exposure to 
GH is associated with hyperinsulinemia, insulin resistance and cardiomegaly due to persistent 
stimulation of PI3-K/Akt and p38 pathways in GHtg mice (Miquet et al, 2011; Izzard et al, 2009). 
Enhanced oxidative stress in the serum and tissues of GHtg rats (particularly heart) and serum of 
acromegalics has been reported by Nishizawa et al. but attributed to increased IGF-1 levels rather 
than GH in C2C12 myocytes (Nishizawa et al, 2012). Acquired metabolic alterations, such as 
hyperglycemia and hyperinsulinemia, can also promote the production of ROS, which damage 
mitochondria in insulin-responsive tissues (Szendroedi et al, 2012). Conversely, insulin resistance 
has been proposed to be a cellular antioxidant defense mechanism, one that is preceded by 
mitochondrial oxidative stress (Hoehn et al, 2009).  
 
Conversely, GH deficient long-lived dwarf mice have reduced insulin levels and enhanced insulin 
sensitivity (Dominici et al, 2002) that can be reversed by exogenous GH administration (Masternak 
et al, 2009). Essentially, reduction in GH levels has been demonstrated to affect not only IGF-1 
secretion but also that of insulin as evident in the case of GHR KO mice that have reduced 
pancreatic islet size (Liu et al, 2004) and in Ames dwarf mice that contain decreased islet number 
along with impaired secretory response to glucose (Parsons et al, 1995). The decrease in islet 
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growth in GHR KO was restored by pancreatic islet-specific expression of IGF-1 at least partially 
through cell hypertrophy (Guo et al, 2005). GH replacement can exacerbate insulin resistance in 
GHD patients associated with induction of p85 subunit of PI3-K and a switch from glucose 
metabolism to lipolysis (Bramnert et al, 2003). Additional GH-mediated indirect mechanisms for 
negatively regulating insulin sensitivity, such as reduction in adiponectin, enhanced mTOR 
signalling and alterations in serum lipid profile as well as fat accumulation, have also been reported 
(Bartke & Westbrook, 2012). Additionally, disruption in the expression of klotho gene, which 
encodes a circulating hormone that inhibits intracellular insulin and IGF-1 signalling, was 
demonstrated to extend lifespan and reduce age-related pathologies (Kurosu et al, 2005).  
 
Inflammation 
Cancer incidence increases with age and there is a decline in immune system function leading to 
chronic low-grade inflammatory activity that can lead to long term tissue damage and even 
mortality (Vasto et al, 2007). On the other hand calorie restriction has been shown to enhance 
immune function and ameliorate inflammation (Fernandes et al, 1997).  
 
A body of evidence suggests the presence of low-grade inflammation in obesity, with altered levels 
of several circulating factors such as an increase in the plasma levels of C-reactive protein (CRP), 
tumour necrosis factor α (TNFα), interleukin-6 (IL-6), and other biological markers of inflammation 
(Olefsky & Glass, 2010). In addition, there is a correlation in healthy individuals between body 
mass index (BMI) and CRP levels (Choi et al, 2013). IL-6 has been reported to increase liver CRP 
production and is positively associated with oxidative resistance (Park et al, 2013). TNFα has been 
shown to exert its effects on metabolism through serine-phosphorylation of IRS-1, which inhibits its 
interaction with the β-subunit of the insulin receptor and blocks insulin signalling resulting in 
obesity-linked insulin resistance (Hotamisligil et al, 1993; Kern et al, 1995). In addition to in vitro 
studies daily GH injections for three weeks in healthy individuals was shown to increase pro-
inflammatory cytokines TNFα and IL-6 in circulation that was not observed in pegvisomant-
injected individuals (Andreassen et al, 2012). 
 
Obesity and Adipokines 
Obesity is linked to increased cancer risk and impacts the secretion of hormonal factors regulating 
tissue homeostasis and metabolism (Calle & Kaaks, 2004). Adult GHtg mice have increase in lean 
mass and reduction in fat mass consistent with the lipolytic action of GH while GHR KO are obese 
and accumulate excess subcutaneous fat independent of gender and age implying subcutaneous fat 
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is GH sensitive (Berryman et al, 2004). The lipid profile between the two mouse models is also 
altered with high levels of cholesterol, high-density lipoproteins (HDL) and low-density 
lipoproteins (LDL) in GHtg and opposite levels in GHR KO (Frick et al, 2001; Egecioglu et al, 
2006). Additionally, Ding et al. using proteomics approach have identified biomarkers differentially 
secreted in plasma between GHR KO and GHtg mice (Ding et al, 2011; Ding et al, 2012).  
 
Adiponectin is an adipocyte-secreted, circulating hormone with pleiotropic functions in lipid and 
glucose metabolism, and beneficial roles in cardiovascular functions and inflammation (Brooks et 
al, 2007). Adiponectin was shown to be negatively associated with GH activity in GHtg and GHR 
KO mice, regardless of age. Interestingly exogenous GH excess, but not IGF-1 could decrease 
circulating adiponectin levels (Lubbers et al, 2013).  Acromegaly has also been shown to inhibit the 
expression of endothelial adhesion molecules and vascular smooth muscle cells proliferation, 
suppressing the transformation of macrophages and inducing production of anti-inflammatory 
factors like IL-10 (Vielma et al, 2013). Adiponectin is also known to suppress the secretion of 
TNFα (Park et al, 2008). Adipose tissue in obese subjects has been shown to be infiltrated by a 
large number of macrophages that secrete several chemokines that result in the recruitment of even 
more macrophages leading to a continuous low-grade inflammatory state (Makki et al, 2013).  
Resistance to cancer and increased insulin sensitivity in dwarf mice has been attributed to the 
elevation of circulating adiponectin (Brooks et al, 2007; Berryman et al, 2004). Although its role in 
cancer remains controversial adiponectin has been shown to inhibit endogenous glucose production 
(Brooks et al, 2007) in the liver through the suppression G6Pase and PEPCK, the rate-limiting 
enzymes in hepatic glucose production and associated with improved insulin sensitivity (Berg et al, 
2001). Numerous epidemiologic studies have suggested that cancer risk is decreased by elevated 
circulating adiponectin (Vansaun, 2013). Additionally, it stimulates fatty acid utilization through its 
intracellular target, AMP activated protein kinase (AMPK) (Brooks et al, 2007; Yamauchi et al, 
2002).  Elevation in adiponectin levels and increase in AMPK activation are important features of 
GH-deficient patients and dwarf mice and has been shown to reduce inflammatory NF- κB 
signalling (Salminen et al, 2011; Meazza et al, 2013).  
 
Metabolic regulation by Sirtuins 
Cancer cells meet their needs for energy by consuming high levels of glucose and rewiring 
metabolism to support continuous growth and metastasis. Since many metabolic intermediates that 
support cell growth are provided by mitochondria it is instructive to determine the factors that 
regulate these mitochondrial pathways. Sirtuins, a well conserved family of NAD-dependent 
enzymes have been implicated in the regulation of mitochondrial pathways as well as stress 
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responses and longevity in model organisms (Haigis & Sinclair, 2010). Sirtuins are known to 
possess diverse enzymatic activities that include ADP-ribosylation, desuccinylation, 
demalonylation, depropionylation and debutyrylation, in addition to deacetylation (Haigis & 
Sinclair, 2010; Du et al, 2011; Peng et al, 2011).  
 
Acetylated proteins are found in the nucleus, cytoplasm and mitochondria, and the seven 
mammalian Sirtuins (Sirt1-7) are similarly distributed throughout the cell (Haigis & Sinclair, 2010). 
In particular, mitochondrial proteins appear to be acetylated dynamically and at the highest 
frequency at multiple lysine residues (Kim et al, 2006). This serves as an important mechanism of 
regulation in mitochondria by altering protein-protein interaction, protein stability, mitochondrial 
localisation or modulating enzymatic activity. Sirt1 targets a number of substrates that regulate 
DNA damage, stress response, mitochondrial biogenesis, and glucose and lipid metabolism 
(Houtkooper et al, 2012). Sirt2 controls cell cycle and glucose and lipid metabolism (Chalkiadaki & 
Guarente, 2012; Houtkooper et al, 2012). Sirt3, 4, and 5 regulate ATP production, metabolism, 
apoptosis, and cell signalling (Haigis et al, 2006; Michishita et al, 2005; Onyango et al, 2002). Sirt6 
is involved in genomic DNA stability and repair, and crucial in metabolism and ageing (Zhong et al, 
2010). Sirt7 is nucleolar and regulates transcription, oxidative stress resistance and inflammation 
(Vakhrusheva et al, 2008). 
 
Dynamic mitochondrial acetylation is regulated by changes in nutrient status and calorie restriction, 
high fat diet, and ethanol feeding, as well as fasting and re-feeding that can all cause dramatic shifts 
in global mitochondrial protein acetylation in vivo (Schwer et al, 2009; Hirschey et al, 2011).  These 
alterations in protein acetylation are kept in check by deacetylating sirtuins that respond to the 
changes in energy expenditure as well as exercise, and adiponectin (Ruderman et al, 2010; Shaw et 
al, 2005). Importantly, Sirt1 and Sirt3 can activate AMPK by deacetylating its upstream liver kinase 
B1 (LKB1), which promotes LKB1 translocation from the nucleus to the cytosol, where it is 
activated and in turn phosphorylates and activates AMPK (Palacios et al, 2009; Hou et al, 2008; 
Price et al, 2012). Conversely, AMPK has been shown to activate Sirt1 by increasing the 
NAD/NADH ratio or the expression/activity of NAMPT (Canto et al, 2009). Collectively, these 
findings suggest the existence of an AMPK-Sirt1/3 cycle that links the cell’s energy and redox 
states (Ruderman et al, 2010). In addition, AMPK and SIRT1 (and other sirtuins) act on common 
transcriptional activators and coactivators, including the mitochondrial master regulator PGC1α and 
members of the FoxO family, most of which are negatively regulated by GH/IGF-1 signalling 
directly or indirectly (Pfeifer et al, 2001) except Sirt1 which was reported to be elevated in GHtg 
mice at protein level (Al-Regaiey et al, 2005). 
 245 
  
There seems to be little doubt that sirtuins are involved in carcinogenesis but owing to complexity 
and diversity of effects, the mechanisms involved have remained elusive and there is as yet no 
consensus on role of each sirtuin in cancer (Bosch-Presegue & Vaquero, 2013). Overall, it appears 
that Sirt2 and Sirt6 may be tumour suppressors, whereas Sirt1 and 3 depending on the context, can 
either be a tumour suppressor or an oncogenic factor. Knockout mice models for five Sirtuins 
(Sirt1–4 and 6) have clearly shown increased levels of genome instability, as indicated by high 
levels of DNA damage, defective DNA repair and chromosomal aberrations (Bosch-Presegue & 
Vaquero, 2013). Furthermore, four of these five KO’s undergo spontaneous tumourigenesis (the 
exception being Sirt1 KO mice, as Sirt1 functions appear to be more complex).  
 
Sirt1 overexpression has been reported in several types of human tumours including breast, 
prostate, hepatocellular, and pancreatic cancer (Morris, 2013) where it could serve to silence tumour 
suppressors rather than being an oncogene itself. It is not known if Sirt1 overexpression causes or is 
a consequence of tumourigenesis (Morris, 2013). A possible mechanism of Sirt1 elevation in cancer 
could be loss of transcriptional repressors evident in the case of one such repressor, HIC1. Mice 
knocked out for H1C1 are prone to cancer and exhibit Sirt1-dependent resistance to apoptosis 
during DNA damage (Chen et al, 2005). Tumour suppressor p53 has been shown to bind to Sirt1 
proximal promoter and inhibit its expression (Nemoto et al, 2004). Since p53 is the first to be lost in 
most cancer, it can increase Sirt1 expression in tumours. Additionally, Sirt1 has been shown to 
inhibit p53 activity by deacetylation and block p53-dependent apoptosis (Luo et al, 2001).  
 
On the other hand there is also a large body of evidence highlighting a tumour suppressor role for 
Sirt1. It has been shown to suppress growth of intestinal, colon, liver, ovarian, and bladder cancers 
(Morris, 2013) as well as breast cancers in various animal models (Wang et al, 2008a). Mice 
transgenic for Sirt1 exhibit a global decrease in carcinomas and sarcomas, but not lymphomas 
(Herranz & Serrano, 2010). Additionally, these mice are less prone to DNA damage and 
inflammation by deacetylating and inhibiting NF- κB (Yeung et al, 2004). Sirt1 has been shown to 
suppress tumours by deacetylation and inactivation of HIF-1α and the genes targeted by HIFs (Lim 
et al, 2010).  
 
Numerous studies have supported a role for Sirt2 as a tumour suppressor (Bosch-Presegue & 
Vaquero, 2013) mainly because of its function as mitotic checkpoint during mitotic stress (Dryden 
et al, 2003). In gliomas, Sirt2 expression was found to decrease while in some cases the locus itself 
was lost (Hiratsuka et al, 2003). Sirt2 expression was also reduced in oesophageal, breast, 
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hepatocellular carcinoma and gastric adenocarcinomas (Peters et al, 2010; Kim et al, 2011) while in 
melanoma, an inactivating mutation has been identified in the catalytic domain of Sirt2 (Lennerz et 
al, 2005). Further evidence for its role as tumour suppressor comes from Sirt2 KO mice, which 
develop hepatocellular carcinoma in males and mammary tumours in females (Kim et al, 2011). 
Additionally cancer cells have been shown to display hyperacetylation of the lysine 53 of histone 
H3, a known target of Sirt2 (Das et al, 2009). In one reported study of acute myeloid leukemia cells, 
however, Sirt2 was upregulated and involved in the aberrant proliferation and survival of leukemic 
cells (Dan et al, 2012). 
 
The mitochondrial Sirt3 has been shown to regulate metabolism and oxidative stress (Bell et al, 
2011) and there is some evidence that Sirt3 acts as a mitochondrial tumour suppressor (Kim et al, 
2010). Loss of Sirt3 expression can result in elevation of ROS that increases stabilisation of HIF-1α 
and thereby increase expression of HIF-dependent genes and metabolic reprogramming towards a 
cancer phenotype (Finley et al, 2011a; Bell et al, 2011). Adenovirus-mediated overexpression of 
Sirt3 inhibited hepatocellular carcinoma cell growth and induced apoptosis (Zhang & Zhou, 2012). 
This was reported to be associated with NAD+ suppression, reduction in Erk1/2 and activation of 
Akt signalling, and downregulation of Mdm2, resulting in increased p53 levels due to reduction in 
p53 degradation (Zhang & Zhou, 2012). Sirt3 also has the ability to protect cells from oxidative 
stress that is dependent on inhibition of the mitochondrial matrix protein IDH2, which is mutated in 
majority of cancers (Yu et al, 2012). Sirt4 has been found to be elevated along with Sirt1 in photo-
damaged skin cells (Benavente et al, 2012).   
 
Sirt6 is the only member of the sirtuin family that has been shown to regulate mammalian lifespan 
conclusively especially in males by lowering the IGF-1 levels (Kanfi et al, 2012). It has been shown 
to have a tumour suppressor role and it deacetylates histones H3K9 and H3K56 (Michishita et al, 
2008; Michishita et al, 2009) and is involved in DNA repair at double-stranded breaks (Kaidi et al, 
2010). H3K56 is hyperacetylated in skin, thyroid, breast, liver, and colon cancers (Das et al, 2009). 
Induction of SIRT6 overexpression in cancer cell lines selectively resulted in massive apoptosis 
(Van Meter et al, 2011) that was dependent on its mono-ADP-ribosyltransferase activity rather than 
its deacetylase activity, leading to activation of p53 apoptotic signalling cascades (Van Meter et al, 
2011).  
 
Sirt7 levels were reported to be elevated in breast cancer, including node-positive breast cancer 
(Ashraf et al, 2006) and thyroid cancer (Bosch-Presegue & Vaquero, 2013). It seems to be 
important for maintaining the cancer phenotype (Martinez-Redondo et al, 2012) by deacetylating 
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acetylated histone H3K18 (Barber et al, 2012). The action of Sirt7 was shown to promote 
anchorage-independent growth, consistent with progression of tumours to aggressive phenotypes 
while its depletion was shown to markedly impede tumour development (Barber et al, 2012). 
 
GHR knockin and knockout mouse models 
GHR KO mice are devoid of any/all GH-mediated signalling and therefore inconclusive in 
determining the exact downstream molecule/pathway that can be attributed to cancer resistance. In 
order to overcome this issue, Waters’ Group have generated mice with truncated or mutated GHR 
cytoplasmic domain. These GHR mutant mice have previously enabled the identification of 
STAT5B as essential for igf-1 expression and post-natal growth (Rowland et al, 2005b), since loss 
of the terminal 260 residues of GHR (GHR K2) resulted in concomitant loss of STAT5 activation 
ability and IGF-1 expression in addition to dwarfism. This phenotype was however absent in 569 
truncation mutant (GHR K1) mice that retained 30% of residual STAT5 activity (Rowland et al, 
2005b). In addition, these mutants allowed identification of key Phase I and Phase II xenobiotic 
metabolising enzymes that were STAT5-dependent (Rowland et al, 2005b; Barclay et al, 2011). 
Another mutant with the inability to activate Jak2 (Box1 or K4 mutant) has allowed identification 
of Jak2-independent but SFK/Erk activated factors involved in GH action (Barclay et al, 2010).  An 
important point to note here is that all the GHR knockin mice have an intact UbE motif, not 
allowing the GHR to accumulate at the cell surface and therefore the heterozygous mice do not 
harbor a dominant negative receptor and have only a partial impairment of post-natal growth 
(Rowland et al, 2005a) and closely resemble wildtype. 
 
The other features common to GHR K2, K4 mutant and KO mice include small body size due to 
decreased IGF-1 concentration and increased adiposity with age (Barclay et al, 2010; Rowland et al, 
2005b). Additionally, these mutant mice have increased GH concentration in serum (due to lack of 
IGF-1-mediated feedback inhibition) and lack STAT5 pulsatility resulting in feminising effects on 
males. This chapter seeks to determine the effect of lack of GHR-mediated signalling (absence of 
GH-mediated STAT5 activation and circulating IGF-1) on longevity and cancer incidences in male 
and female animal models of GHR and provides a more descriptive mechanism based on the 
measurement of transcript and protein levels of key genes.  
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Materials and Methods  
Longevity Study 
Animals in the longevity study were housed in pairs of same sex and kept under a 12hr light/dark 
cycle at 20±2°C with environment enrichment. Water and food (Meat-free rat and mouse diet, 
Specialty Feeds, Australia) was available ad libitum. Solid pellets were replaced with wet mash of 
the same composition when mice were old. All experiments were approved by and performed in 
accordance with the guidelines set by the University of Queensland Animal Ethics Committee. The 
animals were checked daily for health and survival and were handled for cage changes only. 
Animals that appeared to be near death (listless, unable to walk, and cold to the touch) or had large 
tumours or neoplastic growth approaching 10% of body weight were euthanised, and the date of 
euthanasia was considered as the date of death. Initial evaluation for the cause of death was based 
on any evident gross morphology changes (palpable tumours, lesions etc.) and classified into one of 
three categories: tumour, sick, and found dead as the cause of death. After death or euthanasia, all 
mice were fixed in 10% formalin as near as possible to the time of death and sent to Dr. Helle 
Bielefeldt-ohmann at School of Veterinary Science, University of Queensland Gatton campus for 
histopathological analysis to determine the exact cause of death.  
 
Circulating GH estimation 
The serum from old GHR mutant female mice was used for estimation of circulating GH levels 
based on the method described by Steyn et al. (Steyn et al, 2011). Briefly, a sensitive sandwich 
ELISA was carried out in a 96-well plate format (Corning Inc., NY, USA) that was coated with 
50µl capture antibody (anti-ratGH-IC-1; a kind gift from Dr. F. Steyn) at a final dilution of 1:40,000 
and incubated overnight at 4°C. To reduce non-specific binding, each well was subsequently 
incubated with 200µl blocking buffer (5% skim milk powder in 0.05% PBS with Tween-20 
(PBST)). A standard curve was generated using a 2-fold serial dilution of mouse GH (mGH) in 
PBST supplemented with 0.2% BSA (PBST). Bound standards and samples were incubated with 
50µl detection antibody (rabbit antiserum to ratGH) at a final dilution of 1:40,000). The bound 
complex was incubated with 50µl horseradish peroxidase-conjugated antibody (anti-rabbit, IgG; GE 
Healthcare Ltd., Bucks, UK) at a final dilution of 1:2000. Addition of 100µl O-phenylenediamine 
(Invitrogen, CA, USA) substrate to each well resulted in an enzymatic colorimetric reaction. This 
reaction was stopped by addition of 50µl 3M HCl, and the absorbance was read at a wavelength of 
490nm with a Rainbow 96 monochromatic microplate reader. The concentration of GH in each well 
was calculated by regression of the standard curve. 
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Western blot analysis 
All tissues (~100mg) were homogenised in 500µl of RIPA lysis buffer using handheld Kinematica 
Polytron homogenizer (Fisher Scientific) at full speed until no chunks were visible. Tissue 
homogenates were cleared by centrifugation at full speed for 10min at 4°C. Total protein was 
quantified by BCA Assay (Pierce) and resolved on Mini-PROTEAN® Precast gradient gels 
(BioRad). The gel was immunoblotted using the semi-dry Trans-Blot® Turbo™ Transfer System 
(BioRad). Membranes were blocked with 5% Bovine Serum Albumin (BSA) or 5% skim milk in 
Tris-Buffered Saline containing 0.1% Tween-20 (TBST) for 1hr at room temperature. Blots were 
probed by incubating with specific primary antibody (listed in Appendix VI). 
 
DNA extraction and mitochondrial/nuclear ratio estimation 
DNA was extracted from liver tissue (~20mg) using the DNeasy® Blood and Tissue kit (Qiagen, 
Maryland, USA) as per manufacturer’s guidelines. The extracted DNA was subjected to qPCR 
using Sybr Green® primers specific for mitochondrial genome (mt-rnr2) and nuclear genome 
(polg2) listed in Appendix V.  
 
Lipid peroxidation measurement 
Quantification of lipid peroxidation, an indicator of oxidative injury was carried out using Lipid 
Hydroperoxide Assay kit (Cayman, Michigan, USA) as per manufacturer’s guidelines.  
 
Total antioxidant determination 
The total antioxidant capacity in mouse serum was determined using the TAC Peroxyl kit (Applied 
Bioanalytical Labs, Florida, USA) as per manufacturer’s guidelines. 
 
Results 
Waters’ Group currently has GHR mutant knockin mouse models that were created to determine the 
molecular basis for GH control of postnatal growth (Barclay et al, 2010; Lichanska & Waters, 2008; 
Rowland et al, 2005b). These comprise mice with 30% STAT5 activation ability (GHR K1), no 
STAT5 activation ability (GHR K2) and mice with an inability to activate Jak2 as well as STAT5 
(GHR K4) (fig.8.1A). In contrast, these mutants (K1, K2, K4) still retain the ability to activate SFK 
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members (Barclay et al, 2010; Rowlinson et al, 2008). Growth retardation was observed as shown 
in figure 8.1B (to a lesser extent in the K1 mutants) as was striking late onset obesity in male 
mutants with a marked increase in sub-cutaneous fat stores (Barclay et al, 2010; Rowland et al, 
2005b). These targeted knockin mice are compared with GHR KO mice (gifted by Prof. J.J. 
Kopchick), transferred to a C57Bl/6 background. 
 
To investigate the roles of pathways downstream of GHR, we sought to evaluate if the lack of GH-
induced STAT5 activation and differential signalling in these mutants can affect cancer incidence 
and longevity. Since GH secretion is sexually dimorphic it is pertinent to analyse both females and 
males to determine the sex-dependent effects associated with GH-dependent secretory pattern.  
 
A 
 
B 
 
 
 
 
Figure 8.1: Cytoplasmic Domain of Targeted Growth Hormone Receptor Mutations and their attributes with 
regards to longevity and cancer.  
(A) The cytoplasmic domains of murine WT, K1, K2 and K4 targeted GHR mutations (in red) are shown above. The K1 
mutation is truncated at proline 569 in addition to conversion of tyrosines 539 and 545 to phenylalanine. The K2 
mutant is truncated at lysine 391 while K4 mutant has four proline residues of the box1 domain converted to alanine in 
a full-length receptor. Compared to WT, GH activated STAT5 and SFK in mutant GHR receptors are indicated as 
percentage and signal intensity (+/-) respectively. (B) Male GHR mutant  and WT mice at 2 months of age with evident 
difference in body size. 
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Robustly increased longevity in all GHR mutant females, but not all 
males 
There was no significant difference in median lifespan in most male mutants except K4, with a 
median survival of 1044days vs 904days in control amounting to 15% median life extension. As 
shown in fig.8.1C, median survival of female GHR K2 (955days), K4 mutants (1104days) and 
GHR KO (909days) was increased approximately by 26%, 45% and 20% respectively relative to 
WT controls (759days). The GHR K1 female mutants with only 30% residual GH-mediated STAT5 
activity had median survival of 807days, hence a marginal 6% increase in median lifespan 
extension and were not further analysed. In addition, there is an increase in maximal lifespan 
evident in both male and female GHR K4 and female K2 mutants.  
C 
 
Figure 8.1C: Kaplan-Meier Plots for GHR knockin and knockout mice. 
Survival curves of GHR knockin and knockout models and WT mice (controls) in the same C57Bl/6 genetic 
background and subjected to similar animal husbandry conditions are represented. The mice numbers included in the 
study for each model are indicated in brackets. Increased median lifespan extension is evident in all GHR female 
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mutants but only in GHR K4 male mutants.  
 
The animals included in longevity studies were analysed for the cause of death initially based on 
gross morphology as indicated in figure 8.1D taken from 5 years of records. From the graph it is 
evident that the WT and GHR K1 males have higher incidences of macroscopic tumour as 
compared to other GHR male mutants. Interestingly, no death due to cancer was evident in GHR K4 
male mice thus far. This was in striking contrast with unexpectedly high levels of tumour incidences 
observed in GHR K4 females even though they showed maximum lifespan extension (fig.8.1C). 
Other GHR female mutants had lower incidences of tumour-related deaths as compared to WT 
females. 
D 
 
E 
  
 
Figure 8.1: Attributes of GHR knockin and knockout mice mutants with regards to tumour and cancer incidences. 
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(D) Initial cause of death was classified as macroscopic tumour, sick (no evident tumour), found dead (no evident 
pathology) and is represented as percentage of total deaths. (E) Based on number of mice shown in histogram above, 
histopathology results of tumour incidences, GHR mutants are indicated with corresponding cancer modality.  
 
After death (or euthanasia), all mice that were part of this study were sent for histopathologic 
evaluation for the exact cause of death. The chart in figure 8.1E represents the cancer modalities 
corresponding to the tumour-related cause of death. These results even though preliminary are 
indicative that lymphoma is the primary cause of death in most GHR male mutants (except GHR 
K4 males) and WT in C57Bl/6 genetic background. In the case of females, there is may be a 
reduction in lymphoma incidences across GHR KO and K2 mutants while GHR K4 are also prone 
to sarcoma and carcinoma as compared to WT mice. Since all GHR mutant females live longer than 
WT, this is suggestive of reduced lymphoma aggressiveness in female mice lacking GH-induced 
STAT5 activation.  
 
In order to better understand the molecular mechanisms that may be associated with decreased 
cancer incidences and increased survival in some GHR mutant models indicated above, qPCR and 
immunoblotting experiments were carried out on metabolically active tissue(s) of young (12weeks) 
and old (78weeks) mice.  
 
Gene expression profiles in young GHR mutant mice 
The liver controls various metabolic processes including metabolite and xenobiotic detoxification, 
glucose production serum protein synthesis and bile production. It is composed of highly 
specialised tissues that regulate a wide variety of high-volume biochemical reactions, including the 
synthesis and breakdown of small and complex molecules, many of which are necessary for normal 
vital function. Since it is the primary target for GH action and therefore an endocrine organ that 
regulates IGF-1 levels it is important to determine the molecular elements that are altered in various 
GHR mutants that associate with increased protection against cancer and/or promote survival. 
 
Elevated circulating GH levels in female GHR mutant mice 
Growth Hormone was measured in the serum of 12weeks old female GHR mutant mice fed ad 
libitum. Serum GH was significantly elevated in these mice as evident from figure 8.2. GH-induced 
STAT5 is absent in these mutants (Rowland et al, 2005b), hence the circulating IGF-1 levels are 
dramatically low as evident from hepatic transcripts (fig.8.3). The elevated GH is a direct outcome 
of lack of IGF-1-mediated negative feedback on GH secretion in the hypothalamus and pituitary 
gland of these mice as compared to WT.  
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Figure 8.2: Circulating Growth Hormone levels in GHR mutant female mice fed ad libitum. 
Circulating GH levels in are higher in all GHR mutant 12weeks old female mice compared to WT. K2 and K4 mice have 
lower GH levels than KO (n=6/genotype, mean ± SEM). ****, p<0.0001 compared to WT by ANOVA. #, p<0.05; ##, 
p<0.01 compared to KO by ANOVA. 
 
In addition to the reduction in IGF-1 levels, IGF-2 transcript although present in low copy number 
was elevated in all the mutants and achieved significance in all KO mice and all GHR male mutants 
(fig.8.3). Other GH/IGF-1 axis parameters such as IGF binding proteins (IGFBPs) were 
differentially regulated in mice models. IGFBP-1 and 2 were significantly elevated in all GHR 
mutants independent of the gender. In addition, IGFBP-3 and 4 transcripts were also elevated in KO 
while IGFBP-2 and 3 were also sexually dimorphic in expression as shown in figure 8.3. 
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Figure 8.3: Altered hepatic transcripts of Insulin like growth factor and IGF binding protein in 12weeks old 
GHR mutant mice fed ad libitum. 
Decrease in IGF-1 and increase in IGF-2 and IGFBP-1 and 2 transcripts in 12weeks old male and female mice. Other 
IGFBPs were differentially regulated while being sexually dimorphic in its expression. Data represented as mean ± 
SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 compared to WT of the same gender by 
ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared within the same genotype of different 
gender by student t-test.  
 
Altered sirtuins and mitochondrial biogenesis regulator in mice models 
The mitochondrial biogenesis and function regulator pgc1α (peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha) transcript is significantly elevated in the liver of all GHR 
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mutant models. In contrast, pgc1β transcript was only elevated in the KO and K2 males (fig.8.4). 
However at the protein level PGC1 was elevated in KO and K4 male livers (fig.8.5). 
 
 
Figure 8.4: Altered mitochondrial biogenesis regulator and sirtuins transcripts in liver of 12weeks old GHR 
mutant mice fed ad libitum. 
Mitochondrial biogenesis regulator pgc1α transcripts were significantly elevated in GHR mutants while pgc1β was 
upregulated in only GHR male mutants. Key mitochondrial sirtuin, Sirt3 transcript was elevated in all the mutants 
independent of gender while Sirt1 and 2 were elevated mostly in KO males and Sirt6 in KO and K2 males. Data 
represented as mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 compared to WT 
of the same gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared within the same 
genotype of different gender by student t-test.  
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Mammalian homologs of Sir2, the sirtuins showed gender and genotype differences at the transcript 
level in these mice models. Sirt3 transcript was consistently elevated across all genotypes and this 
was also evident at the protein level (fig.8.5A and B). Sirt1 transcript was significantly elevated 
only in the KO male mice livers while the protein was elevated across all the genotypes in male 
mice as compared to WT (fig.8.4, 8.5A and B). Both Sirt1 and 3 transcripts were elevated in males 
more than females with the exception of Sirt3 in K4 females. Sirt2 showed only a slight increase in 
transcript in KO male whereas no change was observed at the protein level. Sirt6 transcripts were 
increased in both male and female in KO livers as well as K2 and K4 males (fig.8.4) but the protein 
level was not increased in KO and K4 male livers (fig.8.5A). Additionally, protein expression of 
GCN5 (KAT2A), a ubiquitous histone acetyltransferase that promotes acetylation and inactivation 
of PGC1α (Lerin et al, 2006) was also elevated in KO and K4 male mice liver. Another observation 
seen in the liver of all three male mutant models was increased levels of phosphorylated AMPK. 
AMPK besides being an energy sensor is an important player in mitochondrial biogenesis and ROS 
detoxification in conjunction with Sirt1 and 3 (Canto & Auwerx, 2009). 
 
A 
 
B 
 
 
 
 
Figure 8.5:  Protein levels of mitochondrial and key sirtuins in liver of 12weeks old male GHR mutant mice fed 
ad libitum. 
(A) Increase in protein level of PGC1, phosphorylated-AMPK (T172), Sirt1 and 3 in KO and K4 GHR mutants. Sirt2 and 
6 both have 2 isoforms and no change was observed in both mutants. GCN5 protein was elevated in KO and K4 
mutant livers. Blots representative of n=5mice/genotype (B) Elevated phosphorylated-AMPK (T172) levels as well as 
Sirt1 and 3 protein in K2 male mutant mice as compared to WT. Blots representative of n=4mice/genotype. 
 
Increased mitochondrial function in GHR mutants 
In addition to the elevated mitochondrial biogenesis markers pgc1α and pgc1β, transcripts for 
mitochondrial oxidative phosphorylation enzymes were found to be elevated. These include Sdhb, 
mt-CO1, Uqcrc2, ATP5a, Ndufa5 that were upregulated in most of the male mutants. In the case of 
female mutants, ATP5a was elevated across all the mutants while Ndufa5 and Uqcrc2 were 
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increased only in KO and Sdhb in KO and K4 females (fig.8.6). MFN2 (mitofusin2) involved in 
regulation of mitochondria morphology and function was elevated in all male GHR mutants but not 
in females at the transcript level. NAD(P)H dehydrogenase quinone 1, Nqo1 transcript was 
significantly elevated in all the male GHR mutants, has been associated with promoting anti-
carcinogenic and insulin sensitivity effects (Pearson et al, 2008). 
 
It was important to address the question of whether the increase in mitochondrial OxPhos proteins 
observed was an outcome of increase in mitochondria number. Estimation of the ratio of 
mitochondrial DNA vs nuclear DNA by qPCR using genome-specific primers was performed to 
answer this question. It was clear that there was no change in mitochondria numbers in any of the 
GHR mutant female mice as compared to WT (fig.8.6). 
 
Supporting these results, western blot analysis revealed elevated levels of oxidative phosphorylation 
enzymes ATP5a (complex V), Uqcrc2 (complex III), Ndufb8 (complex I) in KO, K4 and K2 and 
Sdhb (complex II) in both K4 and K2 (fig.8.7A and B). mt-CO-1 (Complex IV) could not be probed 
in these blots being heat labile as the liver lysates were boiled before gel electrophoresis. One of the 
nuclear encoded catalytic core subunits of mitochondria, cytochrome C oxidase IV (Cox IV) was 
elevated in KO and K4 mice liver while mTFAM (mitochondria transcription factor A) that aids in 
transcription of mitochondrial genome did not change (fig.8.7A). No change in levels of Sdha 
protein was observed in KO and K4 male mice. 
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Figure 8.6: Altered mitochondrial oxidative phosphorylation enzymes transcripts and estimation of 
mitochondrial vs nuclear DNA in liver of 12weeks old GHR mutant mice fed ad libitum. 
Hepatic ranscripts for enzymes involved in mitochondrial OxPhos complex mt-CO1, Ndufa5 were elevated in GHR 
mutant males while ATP5a was elevated in all the mutant mice across both genders while Uqcrc2 and Sdhb were 
elevated only in KO male and female mice. Other mitochondrial function regulator genes mfn2 and nqo1 were 
elevated only in GHR mutant males as compared to WT mice. No change in mitochondrial numbers was evident in 
GHR mutant females as evident from lack of differences in mitochondrial vs nuclear genome. Data represented as 
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mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 compared to WT of the same 
gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared within the same genotype of 
different gender by student t-test. 
 
 
A 
 
 
B 
 
Figure 8.7: Protein levels of key mitochondria function regulator and oxidative phosphorylation complex 
enzymes in liver of 12weeks old male GHR mutant mice fed ad libitum. 
(A) Male KO and K4 mutant mice livers have elevated levels of COX IV, mTFAM as well as OxPhos complexes I, III 
and V. Additionally complex II was elevated in K4 mice and no change was evident in Sdha levels. Blots 
representative of n=5mice/genotype. (B) Elevated OxPhos complex components I, II and III in K2 male mutant mice as 
compared to WT. Blot representative of n=4mice/genotype. 
 
Increased insulin sensitivity in GHR mutants 
The key downstream insulin receptor signalling molecules IRS1 transcript was elevated in all male 
GHR mutants while IRS2 transcript was elevated in male and female KO and male K4 mutant mice. 
The liver-specific glucose transporter Glut2 transcript was elevated two-fold in all male GHR 
mutants and to a lesser extent in K2 female mice with significant sexual dimorphism across all the 
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GHR mutants. The phosphatase PTP1B that negatively regulates insulin signalling pathway was 
also elevated at transcript level in all the male GHR mutants and KO female livers. The fibroblast 
growth factor 21 (FGF21) is a hormone that is secreted by liver and is negatively regulated by 
PGC1α (Estall et al, 2009). The hepatic FGF21 transcript was significantly downregulated in all the 
mutants across both genders with higher levels in mutant females than males (fig.8.8). The fatty 
acid translocase gene CD36 was elevated in all the mutant GHR females and has been shown to 
play an important role in promoting tissue-specific insulin sensitivity in liver by hyperinsulinemic 
clamps (Goudriaan et al, 2003). Previous work from Waters’ Group has reported elevated CD36 at 
both transcript and protein level in KO and K2 males (Barclay et al, 2011) as well increased insulin 
sensitivity (Nelson CN PhD thesis, 2013). 
  
 262 
 
Figure 8.8: Altered hepatic transcripts involved in insulin signalling in liver of 12weeks old GHR mutant mice 
fed ad libitum. 
Increase in IRS1 and glucose transporter Glut2 transcript in all male GHR mutants and IRS2 transcript in KO male 
and female mutants while exhibiting sexual dimorphic expression. Negative regulator of insulin signalling, PTP1B is 
elevated in GHR mutants males and KO females specifically. FGF21 was downregulated across all mutants in both 
genders while CD36 was elevated in all female mutants with the former being sexually dimorphic. Data represented as 
mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 compared to WT of the same 
gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared within the same genotype of 
different gender by student t-test.  
 
An important indicator of increased insulin sensitivity is the elevation of insulin receptor β subunit 
expression in male KO and K4 liver at the protein level (fig.8.9) with decrease in levels of 
downstream signalling adapter protein IRS1 and negative regulator of IRβ and IRS1/2, PTP1B in 
KO and K4 mutants in contrast to their transcript levels above. The FGF21 protein was in 
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accordance to transcript level while HNF4A was downregulated in the mutant livers in contrast to 
the unchanged transcript (fig.8.17). 
 
 
 
Figure 8.9: Altered protein levels of key insulin signalling molecules in liver of 12weeks old male GHR mutant 
mice fed ad libitum. 
Increase in insulin receptor β protein levels in KO and K4 and reduction in insulin signalling molecule IRS-1 and 
hepatocyte nuclear factor4A in KO and K4. Negative regulator of insulin signalling, PTP1B is downregulated in KO 
and K4 as well as FGF21. Blots representative of n=5mice/genotype. 
  
Increased Oxidative stress management and ROS detoxification in GHR 
mutant mice 
The key antioxidant enzymes that catalyse the dismutation of superoxide radicals into oxygen and 
hydrogen peroxide are superoxide dismutase SOD1-3. SOD2 and SOD3 are elevated in all GHR 
mutant males while SOD1 was increased only in KO males at mRNA and protein levels (fig.8.10 
and 8.11A). In female GHR mutants SOD2 was significantly elevated in all the mutants (fig.8.10). 
In addition, all the SOD genes were sexually dimorphic across all genotypes including WT. 
Sulfiredoxin encoded by Srxn1 provides oxidative stress resistance by reducing cysteine-sulfinic 
acid formed under oxidant exposure. The Srxn1 transcripts were significantly elevated in all the 
GHR mutants in both males and females with higher expression in males than females. The 
ubiquitous enzyme encoding Catalase gene, CAT was elevated in all the mutants but reached 
significance only in KO female mutant. The catalase enzyme is involved in decomposition of 
hydrogen peroxide to water and oxygen in turn protects the cell from oxidative damage. 
Apolipoprotein E (ApoE) transcript was elevated in most GHR mutants while the flavin containing 
monooxygenase, FMO2 that catalyse oxidation of xenobiotics was elevated in all the GHR mutant 
males but downregulated in all GHR mutant females. Additionally, both male and female GHR KO 
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exhibited elevated Mt1 (metallothionein1) transcript with 3 times higher levels in males than 
females. 
 
 
Figure 8.10: Altered hepatic transcripts involved in oxidative stress management in 12weeks old GHR mutant 
mice fed ad libitum.  
Elevated transcripts of superoxide dismutase, SOD1, SOD2, SOD3 in males and SOD2 and ApoE in female GHR 
mutants. Increased Srxn1, FMO2 and ApoE in male GHR mutants and Mt1 and CAT in female GHR KO. Decrease in 
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expression of FMO2 and increase in Srxn1 in female GHR mutants. Data represented as mean ± SEM 
(n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 compared to WT of the same gender by 
ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared within the same genotype of different 
gender by student t-test. 
 
In addition to SOD’s, liver of male GHR mutant mice have increased expression of nuclear factor 
erythroid 2-related factor respiratory factors, Nrf1 and Nrf2 at both transcript and protein levels 
(fig.8.11, 8.12A and B) with the latter being sexually dimorphic. Nrf’s are important transcription 
factors that activate numerous metabolic genes regulating cellular growth and nuclear genes 
important in respiration, heme biosynthesis, and mtDNA transcription. In addition, Nrf’s are 
responsible for mediating antioxidant response during stress and under the control of Keap1 (Kelch-
like ECH-associated protein1) the transcript of which was increased specifically in KO male 
mutants. Interestingly there is a striking sexual dimorphic pattern between Nrf2 and Keap1 between 
male and female mice. 
 
 
Figure 8.11: Altered hepatic transcripts associated with reactive oxygen species detoxification in 12weeks old 
GHR mutant mice fed ad libitum. 
Elevated transcripts of Nrf1 and Nrf2 in male GHR mutants and Keap1 specifically in GHR KO males with GHR 
mutants exhibiting sexual dimorphism in Nrf2 and its inhibitor Keap1. Data represented as mean ± SEM 
(n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 compared to WT of the same gender by 
ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared within the same genotype of different 
gender by student t-test. 
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Figure 8.12: Elevated antioxidant transcription factors and enzyme in liver of 12weeks old GHR mutant mice 
fed ad libitum.  
(A) Male KO and K4 mutant mice livers have elevated levels of Nrf1 and Nrf2 antioxidant transcription factors with KO 
liver also expressing higher SOD1 at protein level as compared to WT. Blots representative of n=5mice/genotype. (B) 
Elevated Nrf2 in K2 male mutant mice as compared to WT. Blot representative of n=4mice/genotype. 
 
Dampening of signalling response in GHR mutant mice 
The main outcome of the lack of GH-induced STAT5 signalling is evident from decreased mRNA 
levels of suppressors of cytokine signalling SOCS2 and CIS across all GHR mutant mice 
(fig.8.13A). In contrast SOCS3 levels were not significantly changed in all GHR mutants.  
Interestingly, SOCS3 transcript levels were sex-dependent between males and females across all 
genotypes. The protein levels however were in complete contrast to the transcripts with higher 
levels of SOCS2, SOCS3 in KO and K4 male mutants and no change in CIS protein in comparison 
to WT (fig.8.13B) indicating a constant pool of these tumour suppressors in GHR mutant mice. 
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Figure 8.13: Altered hepatic transcripts and protein levels of suppressors of cytokine signalling molecules in 
12weeks old mice fed ad libitum. 
(A) Significant decline in SOCS2 and CIS transcripts in GHR mutant mice while SOCS3 remains unaltered but 
sexually dimorphic. Data represented as mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; 
****,p<0.0001 compared to WT of the same gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 
compared within the same genotype of different gender by student t-test. (B) Altered protein levels of suppressors 
of cytokine signalling molecules in liver of male GHR KO and K4 mice. Elevated SOCS2 and SOCS3 levels while CIS 
expression is unchanged in these mice. Blots representative of n=5mice/genotype. 
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Additionally, other key signalling elements that are elevated in cancers are downregulated at protein 
level in GHR mutant mice. Besides the decrease in IGF-1 transcript, its receptor IGF-1R is also 
downregulated in the liver as well as its downstream signalling molecule Akt2, which is also a 
putative oncogene (fig.8.14). The most frequently mutated and elevated receptor EGFR was also 
downregulated in these mutants to undetectable levels. There was an increased expression and 
activation of STAT3 in the liver potentially due to the loss of GH-induced STAT5 activation. This 
is also reflected in increased SOCS3 level at transcript and protein level (fig.8.13A and B). 
 
 
Figure 8.14: Altered protein levels of key factors involved in carcinogenesis in liver of 12weeks old male GHR 
mutant mice fed ad libitum. 
Decrease in expression of IGF-1R, Akt2 and EGFR in GHR KO and K4 mice and increase in expression of active and 
total STAT3. Blots representative of n=5mice/genotype. 
 
Decrease in pro-inflammatory factors in GHR mutant mice 
The anti-inflammatory cytokine receptor genes IL-10Rα and IL-10Rβ transcripts were elevated in 
all male GHR mutants. In addition, while IL-1β pro-inflammatory messenger did not change but 
there was increase in IL-1 receptor antagonist (IL-1RA) messenger levels that has been shown to 
bind non-productively to IL-1 receptor and inhibit binding of IL-1 inflammatory cytokine and 
thereby decreasing inflammation. The IL-1RA had an overall increasing trend in all GHR mice but 
attained statistical significance in KO males and females and K2 males. Elevated cdkn1a in KO 
males and females is associated with decreased response to mitogenic stimuli and inflammatory 
cytokine (fig.8.15).  The while IL-1β message needs to be evaluated in female GHR mutants. 
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Figure 8.15:  Altered hepatic transcripts of genes involved in inflammatory stimuli in 12weeks old GHR mutant 
mice fed ad libitum. 
Elevated transcripts of IL-10Rα and IL-10Rβ in male GHR mutant and IL-1RA, cdkn1a in GHR KO males and females. 
No change was evident in IL-1β levels. Data represented as mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; 
***, p<0.001; ****,p<0.0001 compared to WT of the same gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; 
####, p<0.0001 compared within the same genotype of different gender by student t-test. 
 
The alterations in transcripts were accompanied by decrease of other pro-inflammatory signal 
modulators at the protein level (fig.8.16). There was decline in levels of acetylated tubulin, an anti-
inflammatory signal (Wang et al, 2014) as well as that of active stress kinase p38 MAPK, indicative 
elevated stress in WT mice. This was also supported by reduction in NADPH oxidase4 (Nox4) 
expression along with p65 subunit of NF- κB, which is a potent inflammation and oxidative stress 
generator. 
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Figure 8.16: Decreased protein levels of inflammation modulators in livers of 12weeks old male GHR mutants 
fed ad libitum. 
Decrease expression of acetylated tubulin (K40), phosphorylated p38 stress kinase as well as inflammatory and 
immune response modulator NF- κB p65 subunit and oxidative stress generator Nox4 in GHR KO and K4 mice. Blots 
representative of n=3mice/genotype. 
 
Altered hepatic nuclear factors and receptor levels in GHR mutant mice 
The GHR mutant mice were analysed for alterations in nuclear receptor and hepatocyte nuclear 
factor levels, both of which are key regulators of several aspects of hepatic physiology and 
pathophysiology. Nuclear receptors play a major role in metabolic processes, drug disposition, bile 
acid homeostasis, inflammation and tumourigenesis (Wagner et al, 2011). An important family of 
nuclear receptor comprises the peroxisome proliferator-activated receptors (PPAR). These receptors 
function as transcription factors regulating cellular differentiation, development and metabolism in 
a tissue-specific manner. The transcripts of ppargamma1 were elevated in GHR mutant males and 
female GHR K2 mice while ppargamma2 were significantly downregulated in most male mutants 
but elevated in K2 and K4 female GHR mutants. The level of pparalpha transcript was unaltered in 
any mutant mice but was dramatically sexually dimorphic like ppardelta, which was elevated in KO 
and K4 males and females (fig.8.17).  
 
In addition, the hepatocyte nuclear factor HNF1A and HNF3B were elevated in all GHR mutant 
males while HNF1A was also elevated in KO and K2 females. The HNF6 was drastically 
downregulated in both male and female GHR mutants (fig.8.17) and has been shown to be a GH-
induced STAT5 dependent gene (Lahuna et al, 1997). These HNFs serve as transcription factors of 
diverse group of genes involved in glucose, cholesterol and fatty acid transport and metabolism. 
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Figure 8.17: Altered hepatic transcript levels of nuclear receptors and hepatocyte nuclear factors in 12weeks 
old GHR mutant mice fed ad libitum. 
Elevated levels of ppargamma1 and ppardelta in male GHR mutants and some female mutants. The ppargamma2 
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transcript levels are downregulated in most male GHR mutants but elevated in female mutants. HNF3B and HNF1A 
levels are increased in male GHR mutants and few female mutants while HNF6 is downregulated in all GHR mutant 
mice. Data represented as mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 
compared to WT of the same gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared 
within the same genotype of different gender by student t-test. 
 
Another family of nuclear receptor transcription factors are the liver X receptors (LXR) that are 
closely related to PPARs transcripts. The two isoforms LXR alpha and LXR beta were upregulated 
in all GHR male mutant mice and KO and K2 females respectively. The LXRs are important 
regulators of cholesterol, fatty acid, and glucose homeostasis. NCOR (nuclear receptor co-
repressor) are transcriptional co-regulatory proteins that contain several nuclear receptor interacting 
domains and recruit histone deacetylases to DNA promoter regions resulting in downregulation of 
target gene expression. The NCOR1 transcript was elevated in GHR KO males while NCOR2 
transcript was elevated in both GHR KO males and females (fig.8.18).  
 
The RAR-related orphan receptors (RORs) are also members of the nuclear receptor family of 
intracellular transcription factors that are important for lipid, bile and steroid metabolism, 
inflammation response and importantly in the regulation of genes encoding several phase I and 
phase II metabolic enzymes (Kang et al, 2007). The GHR KO and K2 male and female mice 
exhibited elevated ROR gamma transcript and was sexually dimorphic in mutant mice. On the other 
hand ROR alpha was unaltered but was dramatically sexually dimorphic in all the mice. Finally, the 
two key transcriptional repressors Rev-Erb alpha and Rev-Erb beta that play an important role in 
circadian rhythm and metabolism were altered in GHR mutant mice. The levels of Rev-Erb alpha 
and Rev-Erb beta transcripts were drastically elevated and downregulated respectively in male GHR 
mutant mice. In addition, both the transcripts were sexually dimorphic in WT mice but not in the 
mutants indicating a feminising effect of lack of pulsatile GH-induced STAT5 signalling on GHR 
mutant males (fig.8.18). 
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Figure 8.18: Altered hepatic transcript levels of nuclear receptors in 12weeks old GHR mutant mice fed ad 
libitum. 
Elevated levels of LXR alpha and LXR beta in male GHR mutants and few female mutants. The NCOR1, NCOR2 and 
ROR gamma transcript levels are upregulated in male GHR KO while NCOR2 and ROR gamma levels are increased 
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in female GHR KO females. Rev-Erb alpha and Rev-Erb beta levels are differentially regulated in all male GHR 
mutant mice while WT mice are dramatically sexually dimorphic, indicating and overall feminising effect on GHR 
mutant. Data represented as mean ± SEM (n=5mice/genotype). *, p<0.05; **, p<0.01; ***, p<0.001; ****,p<0.0001 
compared to WT of the same gender by ANOVA. #, p<0.05; ##, p<0.01; ###, p<0.001; ####, p<0.0001 compared 
within the same genotype of different gender by student t-test. 
 
Gene expression profiles in old GHR mutant mice 
Liver 
Protein levels of key mitochondrial and antioxidant proteins altered in the liver of aged (78weeks 
old) mice exhibit striking sexual dimorphism. Increased levels of active AMPK and Sirt3 were 
observed only in female GHR K2 mice and these levels remained unchanged in males. 
Additionally, antioxidant transcription factor Nrf2 and anti-inflammatory IL-1RA appeared elevated 
in female K2 mice. Nrf2 protein was undetectable in aged male mice. Mitochondrial OxPhos 
components I, II and V were increased in females as was Cox IV and Sdha with no significant 
differences observed in males (fig.8.19). Cox IV has not yet been analysed in K2 males.  
 
Lipid peroxide levels in the serum and liver tissue lysate were estimated as an indicator of free 
radical generation. No significant difference was determined as compared to WT mice. 
  
 275 
A 
 
 
B 
 
Figure 8.19: Altered hepatic levels of mitochondrial and antioxidant proteins and lipid peroxide levels in 
serum and liver of 78weeks old GHR K2 mice fed ad libitum. 
(A) Increase in Nrf2, Sirt3, IL-1RA and active AMPK as well as mitochondrial proteins Cox IV, Sdha and OxPhos 
components in K2 GHR females specifically. Blots representative of n=4mice/genotype.  
(B) Lipid peroxide levels measured as change in malonidialdehyde concentration (µM) in serum and liver tissue of 
aged female mice. Data represented as mean ± SEM (n=4mice/genotype) compared to WT by student t-test. 
 
Heart 
Similar to the trend observed in liver, there was increased expression of Sirt3 and phosphorylated 
AMPK and mitochondrial Cox IV and OxPhos components complex II, IV and V in female K2 
GHR mutant with no significant change observed in males. Antioxidant proteins Bmi1 (B cell-
specific moloney murine leukemia virus integration site1) and catalase were elevated in females 
while no catalase was detectable in males (fig.8.20). The mitochondrial uncoupling protein1 (UCP-
1) was increased in cardiac tissue of aged female K2 mutants. The UCP-1 is normally found in 
brown adipose tissue (BAT) of mammals leading to thermogenesis. It has an important role in 
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increasing energy expenditure by returning the protons pumped by the respiratory chain to the 
mitochondrial matrix, bypassing the ATP-producing return pathway through the FoF1-ATP synthase 
(Hoerter et al, 2004). Another consequence of partial uncoupling is a reduction in the membrane 
potential that can lower the mitochondrial production of superoxide radicals. UCP-1, catalase, Cox 
IV and Bmi1 have not yet been analysed in male K2 mice. 
 
 
Figure 8.20: Altered levels of mitochondrial and antioxidant proteins in heart tissue of 78weeks old GHR K2 
mice fed ad libitum. 
Increase in Nrf2, Sirt3, Bmi1, catalase and active AMPK as well as mitochondrial proteins and OxPhos components in 
K2 GHR females with no change in K2 GHR males as compared to gender-matched WT. Blots representative of 
n=4mice/genotype. 
 
Skeletal Muscle 
The skeletal muscle of female K2 mutant mice showed elevation of mitochondrial Sirt3 and OxPhos 
components I, II, IV and III including cytochrome c, UCP-1 involved in electron transport chain, in 
female K2 mice specifically. The mitochondria biogenesis regulator PGC1 levels were unaltered in 
both male and female K2 mice as compared to gender-matched WT. Reactive oxygen detoxifying 
enzyme catalase was increased while SOD1 levels remained unaffected in both male and female K2 
mutants (fig.8.21A). Other redox proteins thioredoxin1 (Trx1) and possibly sulfiredoxin1 (Srxn1) 
were elevated in K2 females as well (fig.8.21B). Antioxidant protein Nrf2 continued to be elevated 
in females and undetectable in male skeletal muscle tissue. IRβ as well as regulator of lipid 
biosynthesis regulator ACSL3 (Acyl-CoA synthetase long-chain family member 3) were increased 
in GHR K2 females selectively. Activated form of energy and ROS sensor AMPK was also 
elevated in K2 females. Finally activated STAT5 suppressor CIS levels were unaltered in K2 mice. 
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Figure 8.21: Altered levels of mitochondrial and antioxidant proteins in skeletal muscle tissue of 78weeks old 
GHR K2 mice fed ad libitum. 
(A) Elevated levels of Sirt3, Nrf2 as well as mitochondrial UCP-1, Sdha and OxPhos components in K2 female 
mutants as opposed to K2 male. Increased amount of cytochrome c, ACSL3 in K2 females and catalase in K2 males 
and females. The level of PGC1, CIS and SOD1 was unaltered in mutants. Blots representative of n=4mice/genotype. 
(B) Increased activation of AMPK and elevation of redox enzyme Trx1 and IRβ in K2 females. Blots representative of 
n=3mice/genotype. 
 
Kidney 
The protein lysates from kidney of GHR K2 and KO female mutants were found to have elevated 
Sirt3 and Gapdh protein. The K2 females also have increased catalase expression while KO females 
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had higher level of antioxidant proteins endothelial nitric oxide synthase (eNOS), SOD2 and 
mitochondrial regulator PGC1 (fig.8.22). 
 
 
Figure 8.22: Altered protein levels in kidney of 78weeks old female GHR mutant mice fed ad libitum.  
Increased expression of Sirt3, catalase and Gapdh in GHR K2 and KO female GHR mutant mice. Elevated levels of 
PGC1, SOD2 and eNOS in KO mutant mice selectively as compared to WT. Blots representative of n=3mice/genotype 
 
Key sirtuins remain elevated in aged GHR mutant mice 
In order to determine if the GHR mice retain elevated sirtuin levels with age, both young and aged 
mice livers were analysed in male GHR KO mice (fig.8.23). The GHR KO mutant mice exhibited a 
decline in the Sirt1 and 3 levels with age however their levels continued to be elevated when 
compared to age matched WT. The activated AMPK levels also remained elevated with age in GHR 
KO mice. 
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Figure 8.23: Retention of elevated expression of key sirtuins and activated AMPK in liver of GHR KO males fed 
ad libitum with age. 
Increased level of Sirt1 and 3 and active AMPK observed in 12weeks old (young) is maintained with age as seen in 
78weeks old (aged) GHR KO mice as compared to age-matched WT. Blots representative of n=3mice/genotype.  
 
Increased circulating antioxidants in female GHR K2 mutant mice 
The GHR K2 male and female mice were analysed for circulating levels of total antioxidant that 
was found to be dramatically elevated in females but no significance was attained in males 
(fig.8.24). 
 
 
Figure 8.24: Lipid peroxidation and antioxidant capacity of 78weeks old GHR K2 mice fed ad libitum. 
Total antioxidant capacity in female and male serum with significantly higher levels in female K2 mutant as compared 
to males. The antioxidant concentration is expressed as counts per second corrected for induction time and light 
production. Data represented as mean ± SEM (n=4mice/genotype). **, p<0.01 compared to gender-matched WT by 
student t-test. 
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Increased Src Family Kinase activation in the liver of GHR K4 female mice 
There occurs a modest level of sexual dimorphism in the level of activation of SFK as evident from 
P-SFK (Y416) blot in the livers (fig.8.25A) of WT males and females. This dimorphism is however 
increased dramatically in the case of GHR K4 mice. In addition, K4 males had significantly lower 
level of SFK activation as compared to WT. In addition, the total c-Src (a ubiquitous SFK member) 
was modestly sexually dimorphic in GHR K4 and may further contribute to the decrease in the 
activation of SFK. The activation of ERK1/2 was unaltered between WT and K4 females but was 
increased in K4 males, although this increase was not statistically significant (fig.8.25B). This 
increase in active SFK levels in females could be responsible for reduction in lymphoma and 
increased sarcoma and carcinoma cancer modalities as indicated in figure 8.1E. 
 
A 
 
B 
 
Figure 8.25: Altered protein levels of active ERK1/2 and sexually dimorphic levels of active SFK (Y416) and c-
Src in liver of 12weeks old WT and GHR K4 mutant mice fed ad libitum.  
(A) Western blot and (B) densitometry analysis of P-Src, P-ERK1/2 and total c-Src levels indicating enhanced sexual 
dimorphism in Src Family Kinase activation in GHR K4 as compared to WT mice. Blots representative of n=4mice for 
females and n=3mice for males. Data represented as mean ± SEM. *, p<0.05 compared to WT of the same gender 
by student t-test. #, p<0.05; ###, p<0.001 compared within the same genotype of different gender by student t-test. 
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Discussion 
GH/IGF-1 axis in aging 
Despite the numerous studies highlighting the importance of adequate levels of circulating GH and 
IGF-1 for healthy aging, the role of these potent anabolic hormones leading to aging phenotype 
remains highly controversial. Based on studies initially conducted in mutant and transgenic 
invertebrates (worms and flies), the corresponding data supports the conclusion that IGF-1 
signalling is part of a “conserved mechanism of aging” with decreased level of GH/IGF-1 signalling 
delaying the aging process (Clancy et al, 2001; Kimura et al, 1997). In C. elegans, loss of function 
mutations in genes involved in IIS (Insulin-like-signalling) such as daf-2 (homolog of mammalian 
insulin/IGF-1 receptor), age-1 (encoding catalytic subunit of PI3-K), serine-threonine kinases Pdk-
1, Sgk-1, Akt1, Akt2 as well as gain of function of daf-16 (forkhead transcription factor) has been 
shown to increase lifespan (Berryman et al, 2008). Similarly in D. melanogaster, loss of function 
mutations in InR (insulin-like-receptor), Chico (insulin receptor substrate) and PI3-K/Akt/FOXO 
components of IIS can alter lifespan, sometimes in a tissue-specific manner (Berryman et al, 2008; 
Russell & Kahn, 2007). 
 
Noteworthy was the expression and function of DAF-2 in a highly organ-specific manner in 
neuronal cells which was indicative of the central role of the nervous system in DAF-2–dependent 
regulation of animal longevity (Wolkow et al, 2000; Kimura et al, 2011) and surprisingly 
independent of the metabolic effects of insulin-like signalling in the gastrointestinal system and 
muscle tissue (Wolkow et al, 2000). However, the link between IGF-1 signalling in the brain and 
mammalian longevity had not been investigated until recently. IGF-1R levels in the brain were 
reported to be negatively associated with longevity in 16 rodent species (Azpurua et al, 2013). 
However, two disparate concepts exist; firstly the presence of normal levels of GH and IGF-1 
accelerate aging and lack of these hormones or disruption of the signalling pathways driven by 
these hormones exert anti-aging effects (as indicated above) and secondly the age-related decline in 
GH and IGF-1 levels contribute to the deterioration of physiological function while replacement of 
these hormones delay or reverse the aging phenotype (Sonntag et al, 2012).  
 
These conceptual differences have been exacerbated by numerous studies that draw conclusions 
about aging and lifespan based on a low number of experimental animals, suboptimal animal 
husbandry, and/or the absence of end-of-life pathology, generalisation of results from one gender to 
other and most importantly varied genetic backgrounds to corroborate the conclusions. This was 
evident in the case of reported longevity of IGF-1+/- mice which when corrected for genetic 
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background and animal husbandry conditions did not reach significance (Bokov et al, 2011). A 
similar outcome was evident in the case of GHR KO when the lifespan was analysed on C57Bl/6 
background rather than on a mixed background (129Ola X BalbC). The most cited longevity study 
on GHR KO mice by Coschigano et al. was carried out in sample size of under 20 
mice/genotype/gender on a mixed genetic background (Coschigano et al, 2003) when a minimum 
sample size of 30-40 mice per group (to be analysed) is required to accurately detect significant 
differences in mean lifespan (Liang et al, 2003). Therefore, using the existing GHR KO data in 
terms of longevity should be dealt with caution! Additionally, the subsequent study in C57Bl/6 
indicates a percent increase in lifespan (in a small sample size) which if analysed as percentage 
median lifespan extension was estimated to be 20.2% in females and a modest 8.7% in males 
(Coschigano et al, 2003).  
 
A later study from the same group has analysed lifespan extension this time with 37-43 mice per 
genotype but with genetic background not indicated (Bonkowski et al, 2006). This recent study has 
suggested a median lifespan extension of 28% in females and 18.8% in males as compared to WT. 
The main difference between Coschigano et al. (2003) and Bonkowski et al. (2006) is increase in 
mice numbers and also the protein content of the diet calculated as a percentage of total energy 
from proteins increased from 16% to 28.5% in the latter. In addition, the earlier (2003) study 
subjected the mice to a 14hr light/12hr dark cycle as opposed to 12hr light/12hr dark in the (2006) 
study. It is plausible that these changes increased median survival of GHR KO vs WT but remains 
inconclusive since the genetic background was not mentioned. 
 
In contrast to the previous reports, our study found no evident lifespan extension in GHR KO males 
(n= 38 vs n= 54 in WT) but a 20% median lifespan extension in GHR KO females (n= 46 vs n= 69 
in WT). Upon analysis of GHR knockin mutants with limited GH-mediated activity, the lifespan 
extension was evident selectively in females with the exception of GHR K4 where both males 
(15%) and females (45%) live longer. Yet, circulating IGF-1 levels are very low in both male and 
female mutants (Barclay et al, 2010; Rowland et al, 2005b). Therefore, our results are incompatible 
with the earlier concepts that reduction in GH/IGF-1 signalling always increases lifespan in 
mammals as was reported in invertebrate models (Kenyon et al, 1993). Therefore, it was of key 
importance to examine the pathological profile of these mutant mice by documenting their age-
related cancer incidence and type. 
 
It has been proposed that a common feature to the three models of GH/IGF-1 deficiency that 
consistently show increased lifespan across multiple studies: Ames, Snell, and GHR KO mice is the 
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resistance towards cancer (Junnila et al, 2013) (except Ames mice which only have delayed cancer 
occurrence but similar incidence and burden). The exact molecular basis of this has been unknown 
till date but credited mainly to reduced IGF-1 action. Human studies have been in accordance with 
this conclusion as in the case of Laron patients that have reduced IGF-1 levels and do not die from 
cancer compared to normal relatives (Guevara-Aguirre et al, 2011; Steuerman et al, 2011). 
However, these patients do not show lifespan extension, dying instead from convulsions, 
alcoholism and suicide.  
 
GH/IGF-1 axis and cancer incidences 
C57Bl/6 are the most commonly used strain in aging studies and are particularly prone to 
lymphomas and sarcoma (Blackwell et al, 1995; Ward, 2006; Ikeno et al, 2009) with higher 
incidences observed in females than males (Blackwell et al, 1995; Ward, 2006). In addition, overall 
spontaneous tumour incidences were reported to be double in females that also outlived males 
(Anisimov, 2001). Although calorie restriction (CR) has been shown to significantly reduce the 
lifetime tumour incidences in both and males and females, as compared to those fed ad libitum, 
there was increase in incidences of histiocytic sarcomas in females specifically (Blackwell et al, 
1995). In our study all the animals utilised were of the C57Bl/6 genetic background, subjected to 
similar animal husbandry conditions and fed ad libitum. The common attribute to all GHR mutant 
mice was complete lack of GH-mediated STAT5 induction (Barclay et al, 2010; Rowland et al, 
2005b). It is important to note here that no GH-induced STAT5 activation via SFK was observed in 
K4 mice in vivo (Barclay et al, 2010) in contrast to the in vitro studies with GH (Manabe et al, 
2006) and EPO treatment (Okutani et al, 2001).  
 
In on our studies we observed a similar percentage of spontaneous tumour-related deaths in WT 
males and females but the incidences of cancer in gender-matched mutants (GHR K2 and KO) were 
significantly reduced. In addition, no cancer death was evident for GHR K4 males which was in 
contrast with increased percentage of cancer-related deaths in K4 females. Further to this, we have 
sought to histologically evaluate the cancer modality as the cause of death in mice and from 
preliminary results it is evident that the major cause of death in these mice is lymphoma in most 
GHR mutants and WT mice. 
 
No correlation was evident between lack of GH-mediated STAT5 activity (reduced circulating IGF-
1 levels) and lymphoma incidence but there was either a delayed occurrence of cancer or reduction 
in severity of lymphoma in female mutants that allowed them to live for a longer period of time 
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especially with increase in median lifespan across all females. Even the GHR K4 female mutant that 
reported the highest level of total cancer-related deaths had reduced lymphoma but did harbour 
other cancer modalities (carcinoma and sarcoma). Excessive Jak/STAT5 signalling is well known to 
promote lymphoma in man (Marty et al, 2013). 
 
All the GHR mutants exhibited drastically reduced hepatic IGF-1 transcripts and circulating levels 
resulting in small size and reduced body growth. These mice have significantly elevated GH due to 
absent IGF-1-mediated negative feedback on GH secretion at the hypothalamus and pituitary gland. 
In contrast, GH transgenic mice show a ‘giant’ phenotype due to increased circulating IGF-1. Given 
the lipolytic and β-oxidative actions of GH, the latter mice were extremely lean throughout life 
(Palmer et al, 2009). These mice have shortened lifespan due to pathological changes that arise as a 
result of GH excess such as insulin resistance, renal sclerosis, and hepatocellular carcinoma (Bartke, 
2003). Although a negative correlation exists between body size/growth and longevity in rodents 
(Bartke, 2000), dogs (Li et al, 1996) and humans (Samaras & Elrick, 2002) there are a few 
exceptions. One such case is that of long living and stress resistant p66shc KO mice that have 
normal body size (as WT) (Migliaccio et al, 1999) with no data on cancer incidence reported. 
Additionally, 6 months of 25% CR has been shown to promote decrease in body weight as well as 
fat mass (similar to exercise) in humans (Redman et al, 2007) but it did not reduce GH or IGF-1 
levels in humans (Redman et al, 2010) unless protein intake was also reduced, which was also 
protective against cancer (Fontana et al, 2008). 
 
A more recent population-based study has revealed a relationship between circulating IGF-1 levels 
and mortality in the general population using random-effects meta-analysis and dose–response 
meta-regression (Burgers et al, 2011). Analysis of over 14,000 participants clearly demonstrated 
that in humans that there exists a U-shaped association between circulating IGF-1 levels and all-
cause mortality (including cancer) and that low and high levels of IGF-1 translate into a 
significantly increased mortality risk in the general population, predominantly due to cardiovascular 
diseases and cancer (Burgers et al, 2011; Renehan et al, 2004).  
 
Can such a U-shaped survival curve with regards to IGF-1 apply to rodents as well? 
 
By using these genetic mouse models we aim to determine the factor(s) that affect cancer 
incidences and burden in GHR mutants while selectively increasing longevity in females. We chose 
to analyse tissues in these GHR mutants at two different ages; young (12weeks old) and aged 
(78weeks old) in order to determine some of the age-related alterations due to lack of or altered 
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GHR signalling. Our GHR mutant mice exhibited elevated IGF-2 transcripts that have been linked 
to steatotic liver (Chiappini et al, 2006) and cancer progression (Malaguarnera & Belfiore, 2014). 
IGFBP-2 transcript was also elevated in all the mutants and its higher levels have been reported 
during liver cirrhosis (Wolf et al, 2000) due to decreased GH signalling caused by downregulation 
of GHR expression (Wang et al, 2003). Cirrhosis is the end outcome of non-alcoholic hepatic 
steatosis that has been reported in GHR mutant rodent models by our group (Barclay et al, 2011) 
and in adult Laron patients (Laron et al, 2008). 
 
Reductions in GH-mediated STAT5 activation and Oxidative Stress  
The current data from long-lived invertebrate and rodent genetic models is consistent with the 
observation that prolonged lifespan is associated with increased resistance to oxidative stress 
(Harper et al, 2006; Murakami, 2006). The ‘oxidative stress theory of aging’ hypothesises that free 
radicals and ROS cause cumulative damage of macromolecules, which accelerates aging (Kregel & 
Zhang, 2007). ROS are also by-products of normal metabolism generated by mitochondria that are 
necessary for cellular homeostasis at low levels. However as they accumulate with age they cause 
an increase in oxidative stress, presumably due to reduced defense against cellular stress with age. 
As a result they are closely associated with reprogramming of metabolism in cancer cells as well as 
tumour promoting inflammation, the key hallmarks of cancer (Hanahan & Weinberg, 2011). Wang 
et al. have shown that mitochondria in mammalian cells undergo quantal, stochastic bursts of 
superoxide production termed ‘mitochondrial flashes’ (mitoflashes). This mitoflash frequency is 
highly sensitive to oxidative stress and metabolic changes and can therefore be exploited as a 
readout of energy metabolism and free-radical production (Wang et al, 2008b). More importantly, 
they have demonstrated a strong coupling between mitochondrial function and ageing by in vivo 
visualization of these mitoflashes (Shen et al, 2014).  
 
We have shown the mitochondrial Mn superoxide dismutase, SOD2 was elevated in all GHR 
mutant models with males selectively expressing higher level of the extracellular Cu-Zn SOD3 
mRNA especially in KO. Mice lacking SOD2 were shown to die shortly after birth, indicating that 
unchecked levels of superoxide are incompatible with mammalian life (Li et al, 1995). However, 
mice 50% deficient in SOD2 exhibit a normal lifespan with minimal phenotypic defects but do 
suffer increased DNA damage and increased incidence of cancer (Van Remmen et al, 2003). 
Recently, CR has been shown to reduce oxidative stress by elevating SOD2 expression that is Sirt3-
mediated (Qiu et al, 2010). In contrast to the earlier study, our GHR KO male mice had increased 
Cu-Zn SOD1 expression at transcript and protein levels. Studies in mice have also shown profound 
sex-specific differences in antioxidant responses with aging, with males showing low levels of 
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antioxidant enzymes such as superoxide dismutase, catalase, and glutathione reductase (Tomas-
Zapico et al, 2006). The brains of female mice were reported to have lower oxidant and higher 
antioxidant capacity than those of males, mostly due to catalase enzyme activity (Sobocanec et al, 
2003). In our study all SODs were expressed at higher levels in all male mice than females but this 
needs to be confirmed at protein level. In addition all the GHR mutants had elevated transcripts for 
sulfiredoxin (Srxn1), Nrf2 regulated gene. Sulfiredoxin1 belongs to an in vivo gene expression 
signature of oxidative stress in mice (Han et al, 2008) and shown to be critical for redox balance 
and survival of cells exposed to low steady-state levels of H2O2 (Baek et al, 2012). Catalase was 
exclusively elevated in KO females as compared to WT females, consistent with the earlier report 
(Al-Regaiey, 2013).  
 
Based on these results it is clear that the liver of different GHR mutants may have altered gender-
specific susceptibilities to oxidative damage even though they have a common feature of lack of 
GH-induced STAT5 activity. 
 
In cancer cells unregulated cellular proliferation leads to formation of masses that extend beyond 
the resting vasculature, resulting in oxygen and nutrient deprivation. The resulting hypoxia triggers 
a number of critical adaptations that enable cancer cell survival, including apoptosis suppression, 
altered glucose metabolism, and an angiogenic phenotype with the activation of HIF-1α (Semenza, 
2010). Because mitochondria are key organelles undergoing reprogramming during cancer 
induction, the relationship between mitochondria, ROS signalling, and dampening of pro-growth 
signalling pathways needs to be determined in these GHR mutants. 
 
Reductions in GH-mediated STAT5 signalling and AMPK activation 
AMPK activation controls numerous metabolic processes, including fatty acid synthesis, 
gluconeogenesis in the liver, and glucose uptake in muscle (Mihaylova & Shaw, 2011). Under 
conditions of stress (low glucose), ATP is depleted, leading to concomitant increase in cellular 
AMP and ADP that regulate AMPK function mainly by preventing its dephosphorylation and 
inactivation. However recent data has identified ADP rather than AMP as the predominant regulator 
of AMPK phosphorylation (Oakhill et al, 2012). The major upstream kinases that phosphorylate 
AMPK are liver kinase B1 (LKB1) (Woods et al, 2003) and Ca2+/calmodulin-dependent protein 
kinase kinase beta (CaMKKβ) (Hawley et al, 2005). In addition to energy sensor role of AMPK, it 
can also be activated during cellular stress by non-canonical mechanisms that may not involve 
increases in AMP, ADP or Ca2+ levels. In cultured cells, AMPK was activated by reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) (Fujita et al, 2010). It was also reported that at 
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high concentrations of free radicals, AMPK activation might be secondary to the inhibition of 
mitochondrial ATP synthesis, with consequent rises in AMP and ADP levels (Hawley et al, 2010). 
We have shown that all the male GHR mutant mice had elevated levels of active AMPK in their 
liver. 
 
AMPK can act in coordination with NAD+-dependent deacetylase Sirt1 by increasing cellular 
NAD+ levels (Canto et al, 2009). One of the major Sirt1 targets is PGC1α, a master regulator of 
mitochondrial biogenesis (Canto & Auwerx, 2009). The biogenesis of mitochondria is a process 
that plays an essential role in energy homeostasis and metabolism, apoptosis regulation and cell 
viability (Hock & Kralli, 2009). Mitochondrial biogenesis is influenced by environmental stress 
such as exercise, caloric restriction, low temperature, oxidative stress, cell division and renewal and 
differentiation and is accompanied not only by variations in number, but also in size and mass.  
PGC1α/β are co-transcriptional regulation factors that induces mitochondrial biogenesis by 
activating Nrf1 and Nrf2, which promote the expression of mTFAM. NRFs are important 
contributors to the sequence of events leading to the increase in transcription of key mitochondrial 
enzymes, and have been shown to interact with mTFAM, which drives transcription and replication 
of mtDNA (Virbasius and Scarpulla, 1994). In the present study both Pgc1α and Pgc1β were 
elevated in the liver of most GHR mutants especially males at transcript and protein level 
confirming the earlier report in GHR KO males (Al-Regaiey et al, 2005). In contrast Pgc1α levels 
have been shown to decrease in GHtg mice (Al-Regaiey et al, 2005). Additionally, MFN2 
(mitofusin2) hepatic transcripts were also upregulated in all GHR males and are known to be 
indispensable in the maintenance and operation of the mitochondrial (Chan, 2006).  
 
Reductions in GH-mediated STAT5 activation effects on mitochondrial 
parameters 
Although the genes regulating mitochondrial biogenesis have been analysed in different tissues of 
GHR KO mice (Al-Regaiey et al, 2005; Gesing et al, 2011a; Gesing et al, 2011b), none have 
examined the OxPhos components in them. Most importantly, Cox IV, regarded as a measure of 
mitochondrial content was elevated in male GHR KO and K4 mutants at protein level. OxPhos 
components Ndufb8 (C(I)), Uqcrc2 (C(III)) and ATP5a (C(V)) were elevated in all male mutants 
while Sdhb (C(II)) was elevated only in GHR K4 and K2 male mice. Cytochrome c oxidase subunit 
I (mt-CO1) is one of three mtDNA encoded subunits of respiratory complex IV that was elevated in 
all male GHR mutants. These observations in GHR mutants were in contrast to the decrease in 
complex I, II and V reported in GHtg mice that have shortened lifespan (Brown-Borg & Bartke, 
2012). Succinate dehydrogenase complex are involved in oxidation of succinate, a step where 
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electrons are generated. If its activity is inhibited electrons that would normally transfer through the 
Sdhb subunit to the ubiquinone pool are instead transferred to oxygen to create ROS that can 
stabilise the production of HIF-1α forming an active complex, in turn leading to the induction of 
tumourigenic genes (Selak et al, 2005) and inflammation (Mills & O'Neill, 2013). Sdha levels 
however remain unaltered in GHR KO and K4 males. In this study we have also shown Sdhb 
transcript was gender-specific while mt-CO1 expression was sexually dimorphic only in the mutants 
and not WT. We also report that this increase in OxPhos complex protein or transcript was not due 
to change in mtDNA (possibly due to lack of change in mTFAM protein levels) as no statistically 
significant difference was evident in any of the female GHR mutants compared to WT, supporting a 
similar finding in Ames dwarf mice (Brown-Borg et al, 2012).  
 
Disturbances in mitochondria biogenesis affect oxidative stress resistance, energy production and 
metabolism resulting in age-associated diseases (Reznick et al, 2007) that can be regulated by 
sirtuins. In this study we have analysed the expression of sirtuins at transcript and protein levels in 
GHR mutant livers. It has been reported that CR but not lack of GHR, resulted in increased Sirt1 
protein levels in liver (Al-Regaiey et al, 2005). In contrast, our results show elevated Sirt1 transcript 
in GHR KO males only but increased protein level was evident in all male GHR mutants. 
Interestingly, Sirt1 upregulation has been shown to have no detectable impact on longevity in two 
different mouse models but it did promote healthy aging (Herranz et al, 2010). However, increased 
Sirt1 levels (~3 fold) systemically were shown to be protective against physiological damage 
produced by high-fat diet (Pfluger et al, 2008), diabetes (Banks et al, 2008), and metabolic 
syndrome associated cancer (Herranz & Serrano, 2010). 
 
Besides Sirt1, the transcript for mitochondria-localised sirtuin, Sirt3. was elevated in all GHR 
mutant mice and was confirmed at protein level in all males. Sirt3 expression is reported to be 
highest in metabolically active tissues including the brain, heart, liver, brown adipose tissue (BAT), 
and skeletal muscle (Lombard et al, 2007; Ahn et al, 2008; Gurd et al, 2012). Sirt3 is a crucial 
regulator of mitochondrial function and mTFAM targets, controlling global acetylation of the 
organelle and inducing activity of complex I and promoting oxidative phosphorylation. Sirt3 null 
mice show no obvious phenotypic changes, but succumb to age-linked diseases including metabolic 
syndrome, cancer, and cardiac failure (Hirschey et al, 2011). Sirt3 deletion in mice was shown to 
cause hyperacetylation of mitochondrial proteins and metabolic defects with 65% of all proteins in 
mitochondria having at least one lysine acetylated in liver tissue (Hebert et al, 2013). Therefore, 
loss of Sirt3 appears to decrease mitochondrial substrate oxidation and results in more intensive 
glycolysis and higher extracellular lactate levels (Finley et al, 2011a). The effect of Sirt3 deficiency 
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on ATP production is further aggravated by fasting, underlying its reliance on NAD+ (Hirschey et 
al, 2011). Expression of Sirt3 in liver has been shown to be induced by PGC1α through a 
mechanism involving estrogen-related receptor alpha (ERRα) (Kong et al, 2010). Both PGC1α and 
ERRα are induced by fasting and consequently increase Sirt3 levels. In line with these observations, 
the increased expression of OxPhos components in GHR mutants may be the outcome of enhanced 
Sirt3 and/or PGC1α in liver as shown in myotubes (Kong et al, 2010). Succinate dehydrogenase 
enzymes have been shown to be direct targets of Sirt3 with hyperacetylated levels of Sdha and Sdhb 
reported in Sirt3 null mice thereby increasing succinate accumulation and HIF stabilisation (Finley 
et al, 2011b).  In addition, Sirt3 was shown to oppose the reprogramming of breast cancer cells 
through destabilisation of HIF-1α (Finley et al, 2011a).  
 
Sirt3 may also upregulate PGC1α and control mitochondrial biogenesis through a positive feedback 
mechanism by deacetylation and activation of liver kinase B1 (LKB1) as shown in cardiomyocytes 
(Pillai et al, 2010). Active LKB1 can phosphorylate and stimulate AMPK-mediated cyclic AMP 
response element binding protein (CREB) leading to increased PGC1α expression (Thomson et al, 
2008). Moreover, AMPK has been shown to directly phosphorylate and activate PGC1α, adding 
additional stimulatory mechanisms to this pathway (Jager et al, 2007). It has been demonstrated that 
PGC1α is a suppressor of ROS generation in myotubes, hippocampus and endothelial cells by 
increasing the expression of GPx1 and SOD2 and reducing mitochondrial membrane potential 
(Kong et al, 2010; St-Pierre et al, 2006; Valle et al, 2005). Similarly, knockdown of endogenous 
Sirt3 expression led to an increase of cellular ROS level that was reversed by its overexpression, 
indicating that Sirt3, like PGC1α, acts as suppressor of ROS formation in vivo (Kong et al, 2010). 
Therefore, Sirt3 has the ability to integrate cellular energy metabolism and ROS generation 
Intriguingly, it has now been proposed that Sirt3 is a prominent regulator in CR adaptation by 
coordinately deacetylating proteins involved in diverse pathways of metabolism and mitochondrial 
maintenance (Hebert et al, 2013) and that these effects are distinct from those of Sirt1 (Tauriainen 
et al, 2011). Surprisingly whether Sirt3 transgenic mice (ubiquitous and/or tissue-specific) exhibit 
increased longevity is yet to be elucidated. Additionally, Sirt2 and 6 protein levels were not altered 
in the GHR mutants analysed. It is evident that by targeting numerous enzymes Sirt3 is perfectly 
positioned to orchestrate coordinated shifts in mitochondrial metabolism, with potential 
implications for diseases (especially cancer) that rely on mitochondrial metabolic activities. 
 
It is important to note that key mechanism by which metformin inhibits cancer progression is by 
activation of AMPK via LKB1 (Shaw et al, 2005) which then inhibits the mammalian target of 
rapamycin complex 1 (mTORC1), a central mediator of cancer cell metabolism, growth and 
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proliferation (van Veelen et al, 2011). In addition, metformin has also been shown to act 
independently of AMPK by directly elevating AMP/ATP ratio in the liver restricting the supply of 
ATP for gluconeogenesis (Foretz et al, 2010). It is believed that mitochondria is the primary target 
of metformin action where it inhibits cellular respiration by directly decreasing oxygen 
consumption and mitochondrial membrane potential through inhibiting the OxPhos complex I to 
stop ATP synthesis without altering the downstream OxPhos machinery (Owen et al, 2000). 
Metformin has also been shown to reduce Sirt3 levels as well as that of ERRα independently of 
AMPK (Buler et al, 2012). 
 
Dampening of growth signalling owing to reduction in GH-mediated STAT5 
activity. 
Dampening of growth signalling by CR or by mutational inactivation of conserved GH/insulin/IGF-
1 and mTOR signalling pathways has been shown to prolong the lifespans of eukaryotic organisms 
from yeasts to humans (Guevara-Aguirre et al, 2011). In complex eukaryotes, this inhibition of 
growth signalling also protects against age-related diseases, including cancer, cardiovascular 
disease and neurodegenerative disorders (Burhans & Weinberger, 2007). These lifespan-extending 
effects of reduced growth signalling occur in parallel with the induction of antioxidative stress 
responses that reduce levels of ROS. In line with these observations, a most striking result here was 
the contradictory levels of transcript and protein of two key suppressors of cytokine signalling; 
SOCS2 and CIS in GHR mutants. While the mRNA levels were dramatically downregulated the 
protein was upregulated, especially in the case of SOCS2, indicating that SOCS2’s ubiquitin ligase 
activity is specific for GH-induced STAT5 inhibition and GHR degradation. On the other hand, CIS 
protein levels were unaltered in mutants whereas the transcript was downregulated in these mutants 
as compared to WT, indicating that hepatic CIS does not directly degrade GHR. Nevertheless, 
increased protein levels of both these tumour suppressors (Elliott et al, 2008) in vivo ensure 
dampening of pro-growth or inflammatory signalling via STAT5. In contrast to SOCS2 and CIS, 
the SOCS3 mRNA remained unaltered but sexually dimorphic favouring the females while the 
protein was elevated in male mutants. Increased SOCS3 was in line with elevated STAT3 
expression and activation observed in these mice due to lack of STAT5 activation reported here and 
elsewhere (Barclay et al, 2011). It would be worth determining if the STAT3 activation and/or 
expression is sexually dimorphic in liver as it has been shown to be in brain (Di Domenico et al, 
2010). 
 
GHR KO and K4 mutant mice have reduced IGF-1R and EGFR levels, which are commonly 
upregulated tyrosine kinase receptors in cancers. The decrease in IGF-1R level ensures not only 
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decreased IGF-1 signalling (which is already reduced to undetectable levels) but also of insulin (at 
elevated levels). In the presence of IGF-1, cells may accumulate more DNA damage and are 
protected from apoptosis, therefore increasing the likelihood of cancer cells proliferating. These 
results thus support the concept that reductions in GH and IGF-1 with aging may be important in 
protecting against the development of cancer, by altering cellular susceptibility to DNA damage and 
apoptosis (Guevara-Aguirre et al, 2011). A decrease in EGFR activation has been previously 
reported in GHR KO (Zerrad-Saadi et al, 2011).  In addition, the downstream signalling molecule to 
IGF-1R and IR, Akt2 was reduced in GHR KO and K4 mice while its level has been reported to be 
upregulated in GHtg mice that have various hepatocellular abnormalities (Miquet et al, 2013). GHR 
KO males and females have increased transcript expression of cdkn1a that encodes for p21, 
inhibitory regulator of cell cycle progression. 
 
Reductions in GH-mediated STAT5 activation and inflammation markers 
CR has been shown to decrease inflammatory and endocrine markers that promote breast cancer 
(Harvie & Howell, 2012). A similar profile is evident in the case of GH-resistant and GH-deficient 
rodents where elevated adiponectin levels and AMPK activation reduce pro-inflammatory signals 
by inhibiting NF- κB signalling (Masternak & Bartke, 2012). This was evident by western blot 
analysis of GHR mutant liver where the protein level of p65(RelA) subunit of NF- κB were 
downregulated compared to WT. NF- κB is important in regulating cellular responses as it belongs 
to the category of "rapid-acting" primary transcription factors that are present in cells in an inactive 
state and do not require new protein synthesis in order to become activated. A few known inducers 
of NF- κB activity include ROS, TNFα, IL-1 beta. There is also antagonistic crosstalk between Sirt1 
and NF- κB. Sirt1 has been shown to directly deacetylate p65RelA subunit of NF- κB complex 
while it stimulates oxidative energy production via the activation of AMPK, PPARα and PGC1α. 
Simultaneously, these factors inhibit NF- κB signalling and suppress inflammation. On the other 
hand, NF- κB signalling can downregulate Sirt1 activity through the expression of miR-34a, IFNγ, 
and ROS (Kauppinen et al, 2013).  
 
Although, there was no change in the IL-1beta transcript levels in the male mutants there was 
increase in the mRNA levels of natural anti-inflammatory IL-1RA in both male and female GHR 
KO. Leptin, which is inherently higher in circulation in GHR KO (Al-Regaiey et al, 2005) has been 
shown to directly induce the expression of IL-1RA in monocytes (Gabay et al, 2001). Anti-
inflammatory receptor IL-10R alpha and IL-10R beta were elevated in all male GHR mutants as 
well. The level of activated stress kinase p38 MAPK was reduced in the liver of GHR KO and K4 
males and this, under physiological conditions has been shown to function as a mediator of ROS 
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signalling that can either activate or suppress cell cycle progression in hepatocytes depending on the 
level of ROS, as governed by the activation stimulus (Tormos et al, 2013). The NADPH oxidase 4 
(Nox4) has recently been identified as a Janus-faced ROS generator having mostly detrimental but 
protective function in one report (Schmidt et al, 2012). The levels of Nox4 protein was down 
regulated in male GHR KO and K4 livers. Additionally the acetylated-tubulin (K40) levels 
(unknown pathological function) were downregulated in GHR mutant livers. Thus far there are two 
known deacetylases that act on tubulin; HDAC6 and Sirt2 (Janke & Bulinski, 2011) and since the 
level of latter are not changed in the livers this might imply that HDAC6 is elevated in the livers of 
these mice. This highlights the cancer resistance of the GHR mutants since HDAC6 has been 
identified as a tumour suppressor in liver cancers by promoting autophagic cell death (Jung et al, 
2012). 
 
Reductions in GH-mediated STAT5 and resistance against stress 
Although stress resistance has been extensively studied in skin-derived fibroblasts from Ames, 
Snell and GHR KO mice (Wang & Miller, 2012; Murakami et al, 2003; Salmon et al, 2005) there is 
a lack of free radical scavenging reported in vivo in GHR KO liver and kidney with conflicting 
results from the same lab (Hauck et al, 2002; Al-Regaiey, 2013). This may be attributed to different 
genetic background of mice and the age group used between the two studies. The Laron dwarfs 
(Ecuadorian cohort) have reduced stress-induced signalling with their serum increasing SOD2 and 
decreasing mTOR levels in human mammary epithelial cells (Guevara-Aguirre et al, 2011). 
Similarly, serum from individuals on long term CR has been shown to enhance stress resistance in 
primary fibroblasts in culture by elevating SOD2 and GPx1 (Omodei et al, 2013). 
 
Transcriptional regulation of the antioxidant response element (ARE) by Nrf2 is important for the 
cellular adaptive response to toxic insults. Although there is no direct data of GH-mediated 
inhibition of Nrf2, recent data in skin-derived fibroblasts of Snell dwarf mouse indicates elevated 
levels of Nrf2 and of multiple Nrf2-regulated ARE genes (Leiser & Miller, 2010). Furthermore, 
mRNA levels for some Nrf2 regulated genes; Mt1, Gclm, Txnrd, Hmox were also elevated in at 
least some tissues of Snell dwarf mice. Sun et al. have shown elevated Nrf2 expression in cortex of 
long-lived GHRH KO mice (Sun et al, 2013).  Intriguingly, it was also reported upon comparative 
microarray analysis that liver-specific Keap1 knockout mice have a similar hepatic gene expression 
pattern to GHRH KO mice (Sun et al, 2013). Our results have revealed an elevated expression of 
Nrf1 and Nrf2 in young GHR male mutants at transcript and protein level while the transcript levels 
remain unchanged in females for both genes. The Keap1 mRNA levels were elevated in GHR KO 
males and there was a strong sexual dimorphism evident in Nrf2 and Keapl with levels of both 
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genes being inversely proportional.  
 
NAD(P)H quinone oxidoreductase 1 (Nqo1) is a prototypical Nrf2 target gene that catalyses the 
reduction and detoxification of highly reactive quinones that can cause redox cycling and oxidative 
stress. Nqo1 transcript was significantly elevated in all GHR male mutants. Additionally, the Nrf2 
regulated antioxidant gene Mt1 was dramatically elevated in GHR KO male and to a modest extent 
in KO female. Importantly, metallothionein is a negative regulator of oxidative stress-mediated 
apoptosis and buffers tissues against the initiation of inflammatory cascades following injury 
(Dutsch-Wicherek et al, 2008). Mt1 is also a part of set of genes designated as a shared signature set 
of numerous mouse models with extended lifespan (Steinbaugh et al, 2012). Augmented activity of 
Nrf2 and ARE-responsive genes may therefore coordinate many of the stress resistance traits and 
cancer protection seen in cells from these long-lived mutant mice.  
 
Despite the well-documented relationship between Nrf2 and protection from oxidative stress, 
relatively little is known about the role of Nrf2 in aging. Recent studies in C. elegans have 
suggested that the Nrf2 homologue, SKN-1, is necessary for the lifespan extension seen with dietary 
restriction (Bishop & Guarente, 2007) and insulin pathway disruption, and overexpression of SKN-
1 can increase worm life span (Tullet et al, 2008). Further work has suggested that a Keap1 
heterozygous loss of function mutation in D. melanogaster can increase Nrf2 activity, increasing 
both oxidative stress resistance and life span in male flies only (Sykiotis & Bohmann, 2008). 
Analogous studies in mice have been complicated by the lack of viability of the Keap1 knockout 
mouse (Wakabayashi et al, 2003) and have been mostly limited to observations of decreased Nrf2 
signalling with increased age (Shih & Yen, 2007) and increased Nrf2 signalling with calorie 
restriction (Pearson et al, 2008). 
 
Apolipoprotein E (ApoE) is a well-documented longevity gene in humans based on linkage studies 
of exceptionally long-lived families (Beekman et al, 2013; Brooks-Wilson, 2013). Considering liver 
is the primary organ involved in ApoE synthesis and lipid metabolism, elevated ApoE levels in 
most GHR mutants indicate decreased hepatic oxidative stress which is elevated in the case of 
ApoE−/− mice that contain increased oxidised DNA (Folkmann et al, 2007). In addition, ApoE−/− 
mice developed age-dependent morphological and biochemical alterations, including fibrosis 
(newly formed collagen), elevated pro-inflammatory cytokines (IL-6 and iNOS), and decrease of 
antioxidant enzymes (SOD and catalase) in several organs (kidney, liver and heart) thereby 
reducing survival (Bonomini et al, 2010).  
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Reductions in GH-mediated STAT5 activation and insulin signalling 
It is well established that GH decreases insulin sensitivity (Dominici et al, 2005). Physiological 
bursts of GH have clear insulin antagonistic effects, rapidly decreasing glucose uptake, an effect 
that is sustained for several hours (Moller et al, 1990). Accordingly, excess GH signalling, as seen 
in acromegalics and bovine GH transgenic mice, results in insulin resistance (Coculescu et al, 2007; 
Olsson et al, 2005). Lack of GH signalling, despite its consequent obesity and NAFLD (conditions 
usually associated with insulin resistance), is associated with higher insulin sensitivity (Dominici et 
al, 2002). Additionally GHR KO and Ames dwarf mice have been shown to be insulin sensitive 
compared to respective WT mice (Masternak et al, 2009).  Liu et al. have reported reduced insulin 
and glucose levels (increased insulin sensitivity) owing to significantly reduced pancreatic islet size 
in GHR KO mice (Liu et al, 2004). A similar low fasting glucose profile in other GHR mutants 
(Nelson CN PhD thesis, 2013) can explain the persistent activation of AMPK in these mice that are 
in a continuous state of starvation (as compared to WT) even in a fed condition. 
 
Insulin release is stimulated by a rise in blood glucose and is instrumental in glucose regulation by 
stimulating its uptake into tissues. When blood glucose decreases, the opposing process of 
gluconeogenesis is stimulated by glucagon and other counter-regulatory hormones to maintain 
homeostasis by converting pyruvate to glucose. However, abnormal elevation of hepatic 
gluconeogenesis is central to the onset of hyperglycemia in patients with T2DM.  The origin of 
insulin resistance has been difficult to elucidate in part due to diverse set of risk factors but the most 
reliable predictor is mitochondria generated superoxide radicals (Hoehn et al, 2009). Hence, genetic 
or pharmacologic strategies that can override the mitochondria generated radical can prevent insulin 
resistance. This is supported by selective induction of ROS by mitochondrial complex III antagonist 
antimycin A resulting in rapid insulin resistance that can be reversed by the mitochondrial specific 
SOD2 (Hoehn et al, 2009). 
 
Several studies have reported that Sirt1 functions to activate gluconeogenesis in response to nutrient 
signalling by deacetylating PGC1α, thus permitting interaction between PGC1α, HNF4α and 
FOXO1 which leads to the induction of gluconeogenic genes (Caton et al, 2010). Interestingly, 
Sirt1-dependent gluconeogenesis was not regulated by classical gluconeogenic regulatory hormones 
such as glucagon or insulin, but was instead mediated by changes in the levels of NAD+ and 
pyruvate (Rodgers et al, 2005). However, since HNF4A protein levels are downregulated in GHR 
mutants, gluconeogenesis is impaired in these mice. This was supported by pyruvate tolerance tests 
in these mutants (Nelson CN PhD thesis, 2013). In addition GCN5, an acetyl transferase, which is 
elevated in GHR KO and K4 male mutants, inhibits gluconeogenesis by acetylating and 
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deactivating PGC1α, also leading to the suppression of gluconeogenic gene expression (Lerin et al, 
2006). Therefore, GCN5 inhibits gluconeogenesis and thereby promotes increased insulin 
sensitivity in GHR mutants. A similar mechanism is also used by metformin to suppress hepatic 
gluconeogenesis in diabetes by induction of Sirt1 and GCN5 (Caton et al, 2010). It is relevant that, 
reduction in age-enhanced gluconeogenesis has been shown to extend lifespan in yeasts (Hachinohe 
et al, 2013). 
 
The elevated insulin sensitivity in GHR mutant mice was associated with increased insulin 
receptorβ and a decrease in phosphatase PTP1B protein. Additionally IRS1 and IRS2 mRNA were 
elevated in all male GHR mutants and male GHR KO respectively supporting the earlier literature 
in GHR KO males (Masternak et al, 2005). In contrast to their transcripts, IRS1 and PTP1B protein 
levels were reduced in GHR KO and K4 mutants. The decrease in hepatic PTP1B levels is 
associated with increased insulin sensitivity (Owen et al, 2013) and has been shown to be Sirt1-
mediated (Sun et al, 2007). Insulin sensitivity is also consistent with elevated Glut2 level in all male 
GHR mutants and female K2 mutants. In regards to longevity, CR diets apparently do not further 
increase lifespan in GHR KO mice (Bonkowski et al, 2006) possibly due to lack of increase in their 
insulin sensitivity (Masternak et al, 2009). However, there is evidence than reducing insulin 
sensitivity, provided that diabetes is not induced, has little effect on prolonging lifespan (Nelson et 
al, 2012). This is also evident in the case of long-living yet marginally insulin-resistant IGF-1R+/-, 
IRS1-/- mouse models (Junnila et al, 2013).  
 
FGF21 or starvation hormone plays an important role in eliciting and coordinating the adaptive 
fasting response and promotes similar physiological changes as CR, including decreased glucose 
levels, and increased insulin sensitivity (Potthoff et al, 2012). Overexpression of FGF21 has been 
shown to prolong lifespan in mice (Zhang et al, 2012b). Here, FGF21 transcript was downregulated 
in all GHR mutants. A plausible mechanism of low FGF21 expression is its negative regulation by 
PGC1α-mediated modulation of the heme/Rev-Erb alpha axis (Estall et al, 2009). The Rev-Erb 
alpha was elevated in all male GHR mutants, resembling a feminised pattern of expression which is 
sexually dimorphic and significantly higher in all females. Reduced FGF21 is associated with 
increased steatosis in these GHR mutants (Barclay et al, 2011) and more recently with brain 
circadian clock which coordinates nutrient homeostasis with reproduction (Bass, 2013). 
 
Reductions in GH-mediated STAT5 activation and nuclear receptor expression 
Nuclear receptors are the best-characterised regulators of Phase I xenobiotic metabolism genes 
(XMGs). Studies of GH regulation of xenobiotic metabolism have not been extensively carried out 
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except for Lit/Lit mice (Amador-Noguez et al, 2007). However, there is circumstantial evidence to 
suggest alterations of phase I XMGs expression by additional factors such as PPAR isoforms that 
are elevated in Ames and GHRKO (Masternak & Bartke, 2007). In this study we have analysed 
both isoforms of PPAR gamma and found elevated expression of ppar gamma1 in K2 females and 
all male GHR mutant mice and decreased expression of ppar gamma2 in GHR KO and K4 males. 
Both the isoforms were sexually dimorphic with ppar gamma1 favouring females and ppar 
gamma2 higher in the males indicating the feminised pattern in GHR mutant males. Additionally, 
ppar alpha expression was also gender-specific but elevation of its expression did not reach 
significance in GHR KO in our study. Besides influencing glucose homeostasis, suppression of GH 
signalling promotes β-oxidation of fatty acids in liver. Fatty acid oxidation is promoted by direct or 
indirect action of PPAR alpha, PGC1α, FGF21, adiponectin and AMPK while GH negatively 
regulates the expression or activation of each of these factors (Gesing et al, 2011b). 
 
Differences in nuclear receptor expression were observed in LXR alpha and LXR beta with higher 
mRNA levels in GHR mutant males. These nuclear receptors are associated with cholesterol and 
lipid metabolism suggesting that they may influence the development of metabolic disorders. LXRs 
have been shown to regulate fatty acid synthesis and glucose metabolism by modulating the 
expression of sterol regulatory element binding protein-1c (SREBP-1c), which is also regulated by 
insulin (Repa et al, 2000). Elevated LXRs have been proposed to promote steatosis in GHR mice 
lacking STAT5 activity (Barclay et al, 2011). 
 
Nuclear receptor co-repressors are key transcriptional co-regulatory proteins that contain several 
nuclear receptor interacting domains that have been shown to downregulate the DNA expression by 
recruiting HDACs to DNA promoter regions (Glass & Rosenfeld, 2000). Both NCOR1 and NCOR2 
were elevated in GHR KO male and GHR KO male and female mutant mice respectively but their 
physiological relevance is yet unknown. Similarly, ROR gamma transcripts were elevated in both 
male and female GHR KO and K2 mutants while ROR alpha remained unchanged but highly 
sexually dimorphic. The RORs are involved in the regulation of circadian rhythms and shown to 
bind and activate the promoter of the BMAL1 gene (Guillaumond et al, 2005), a transcription factor 
central to the generation of physiological circadian rhythms. Also, since the levels of RORs are 
rhythmic in some tissues (liver, kidney), they have been proposed to impose a circadian pattern of 
expression on a number of clock-controlled genes (Liu et al, 2008). These circadian rhythm 
functions of RORs are carried out in conjunction with another set of nuclear receptor family, Rev-
Erb comprising of two forms alpha and beta. Intriguingly, both these forms were dramatically 
altered only in GHR male mutants with Rev-Erb alpha being elevated and Rev-Erb beta 
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downregulated to a level that is expressed in the females. It would be interesting to analyse the 
‘clock’ genes in these mutants as well other genes that are bound by the circadian rhythms.  
 
From out data there is clear feminisation of male GHR mutants owing to lack of GH-mediated 
STAT5 pulsatility. In support, long-lived Ames mice have been shown to lose the sexual dimorphic 
pattern associated of gene expression in male and female rodents (Amador-Noguez et al, 2005). A 
similar finding has been reported following calorie restriction (CR) where genome-wide mRNA 
profile in male mice was feminised (Estep et al, 2009) with alteration of 32 xenobiotic metabolising 
genes (XMG) (Fu & Klaassen, 2014). The CR-induced feminisation effects interestingly correlate 
with the phenomenon that females tend to have a longer life expectancy than males in humans 
(Vina et al, 2005) and rodents (Goodrick, 1975). Gender-divergent gene expression in rodent liver 
is determined in large part by GH secretory pattern, which is continuous in females but pulsatile in 
males (Waxman & O'Connor, 2006). The survival curves of GHR mutants in our group indicate a 
similar profile with all GHR mutant females outliving the genotype-matched males. CR was also 
reported to decrease plasma GH levels in male rats (Chacon et al, 2005). Therefore, the feminisation 
effects of many XMGs by CR in males may be due to the CR-induced decrease in GH levels in 
mice. 
 
GHR knockout male mice retain key molecules with age 
An important observation in this study was the retention of active AMPK, Sirt1 and Sirt3 protein 
levels in the liver of aged GHR KO males although there was an age-associated decline; it was 
clearly elevated as compared to age-matched WT males. Based on the existing literature this would 
imply that GHR KO males should exhibit cancer resistance and lifespan extension. The latter was 
not evident indicating that separate pathways exist for protection against cancer and for lifespan 
extension. This is in contrast to the earlier report suggesting reduction in AMPK activity and 
mitochondrial biogenesis as the cause for aging (Reznick et al, 2007). Similarly, Brown et al. have 
proposed that Sirt3 upregulation in hematopoietic stem cells (HSC) of aged mice can reverse the 
aging-associated degeneration by improving their regenerative capacity (Brown et al, 2013).  
 
Why do female GHR mutants lacking GH-mediated STAT5 activation (reduced circulating IGF-1 
levels) have lifespan extension, whereas males do not? 
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Sexism in GHR K2 mutants 
In order to answer this question we had sought to determine changes in metabolically active tissue 
of old GHR K2 (lowest common denominator: both GH-mediated Jak2 and SFK activation but not 
of STAT5) male and female mice at the protein level. The results obtained in aged liver tissue were 
in complete contrast to ones observed in young mice with key antioxidants and mitochondrial 
proteins favouring only K2 female over males. The hepatic protein levels of Sirt3, Nrf2 and 
activated AMPK were upregulated in females and unaltered in males as compared to gender-
matched WT. Expression of Nrf2 was surprisingly not detectable in males for the same amount of 
lysate even though Nrf2 was elevated in young K2 mice. In addition, it could be expected that 
inflammation is reduced in K2 females due to increase in IL-1RA, Sdha levels and key OxPhos 
components (I, II, V) in females. Cox IV levels were also elevated in K2 females. However, the 
lipid peroxide levels in serum and liver tissue of K2 females were unaltered while the males need to 
be tested.  
 
A similar profile as liver was revealed in heart tissue as well, with elevated active AMPK, Sirt3, 
OxPhos components (II, IV and V) and Cox IV activity retained in K2 females and unaltered in 
males. In addition there was increased expression of antioxidant catalase in K2 females which was 
unaltered in K2 males. The antioxidant regulator specific to heart, Bmi1 was elevated in K2 females 
as compared to WT but undetectable in males in general. Uncoupling protein 1 levels were high 
indicating low ROS production and clearly better management due to elevated Sirt3 in K2 females. 
The skeletal muscle tissue of females revealed elevated levels of mitochondrial Sirt3 even though 
PGC1α were unaltered in both genders. Nrf2 and active AMPK were undetectable in males but 
were elevated in K2 females along with IRβ Sdha, Cox IV, UCP-1 and OxPhos components (I, II, 
III and IV). Numerous ROS quenchers and antioxidant enzymes such as sulfiredoxin1, 
thioredoxin1, cytochrome C were upregulated in K2 females as compared to WT. Catalase was 
upregulated in both male and female K2 mice. Interestingly, thioredoxin1 overexpression in mice 
(C57Bl/6) has been shown to prolong median lifespan by providing increased resistance against 
oxidative stress during the early part of life (Mitsui et al, 2002; Perez et al, 2011).  
 
Kidney lysates of only female K2 and KO were analysed and revealed elevated Sirt3, catalase and 
Gapdh expression in both models. However PGC1, SOD2 and eNOS were selectively elevated in 
GHR KO indicating an inhibitory effect of GH-induced Jak2/STAT3 and SFK signalling on 
expression of these genes. The elevated Gapdh could possibly be due to increased renal 
gluconeogenesis that has been shown to occur during prolonged fasting or due to impaired hepatic 
gluconeogenesis (Mutel et al, 2011), which is clearly reduced in GHR mutants (Nelson CN PhD 
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thesis, 2013). Finally, a total antioxidant analysis revealed complimentary results with significantly 
higher levels in K2 females but not in K2 males. These results clearly highlight the molecular basis 
behind lifespan extension of K2 females that were absent in K2 males. However these findings did 
not aid in determining reasons for reduced cancer incidences that is independent of the gender. The 
common attribute of GHR mutant mice is lack of GH-induced STAT5 signalling and reduced IGF-1 
levels. Hence, the Waters’ Group is investigating the lifespan and cancer incidences in mice with 
liver expressing IGF-1 on a GHR K2 background to determine if the effects reported here are 
exclusive to GHR and independent of IGF-1 levels. 
 
The feminisation of male-specific hepatic RNA expression as a consequence of lack of GH 
pulsatility involves not only differential regulation of XMGs but also other antioxidant and 
metabolism regulating genes that are differentially expressed in male and female mutant mice. In 
addition, the altered hepatic XMGs can generate different metabolites in mice on a particular diet 
that can be genotype and gender-specific (Steinbaugh et al, 2012; Waxman & O'Connor, 2006). 
With recent reports on impact of gut microbiota metabolism (Matsumoto et al, 2011), it is 
warranted that a mass spectroscopic or NMR analysis of the biological fluids (urine, stool) be 
carried out to generate a ‘metabolic fingerprint’ at different ages as shown previously by our group 
in GHR KO, K1 and K2 males (Schirra et al, 2008) as well as determine the gut flora in long-lived 
GHR mutants. In addition, the measurement of mitoflashes in metabolically active tissues at 
different ages of GHR mutants could provide information on the basis of lifespan extension in mice.  
 
Role of SFK activation in cancer incidence and longevity 
One possibility for increased cancer incidences in long-lived K4 females in comparison to WT 
females was elevated levels of GH and thereby increased GH-mediated SFK activation. However, 
this was not evident in the livers of these mice by immunoblot. On the contrary, SFK activation was 
reduced in K4 males as compared to WT, correlating with lack of tumour-related death. In addition, 
the SFK activation in liver tissue of K4 females was significantly higher than K4 males. The total 
Src levels were also reduced in K4 males further, enhancing the differential SFK activation. Thus 
far, there is only one study that has reported a sex-specific increased expression and activation of 
Src in kupffer cells of males over proestrus females following hypoxia (Zheng et al, 2006). In the 
light of existing literature and our own data it would be beneficial to determine if this sexual 
dimorphism also exists in other tissues and if certain SFK-regulated genes are differentially 
expressed (and activated) in females than males. SFKs have been shown to regulate nuclear export 
and degradation of Nrf2 to switch off antioxidant transcription (Niture et al, 2011). This could 
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explain high cancer incidences of cancer in K4 females over males even though both genders 
exhibit both median and maximal lifespan extension. Finally, the extent of sexual dimorphism in 
SFK activation in GHR KO (GH-independent) as well as GH-mediated SFK activation in male and 
female GHR K2 mutants (which can activate both Jak2 and SFK) remains to be evaluated.  
 
Another aspect of reduced lymphoma but elevated sarcoma and carcinoma in GHR K4 females may 
be attributed to estrogen receptor (ER) signalling. Reports have suggested SFK as a critical 
upstream regulator of the estrogen-stimulated PI3-K/Akt pathway in endothelial cells (Haynes et al, 
2003) while there is also amounting evidence for estrogen-mediated SFK activation in the same 
cells (Groten et al, 2005) indicating a complementary interaction between estrogen and SFK. Zhang 
et al. have reported that low concentrations of estrogen can activate SFK/ERK while high levels are 
inhibitory in breast cancer cells and proposed that Src acts as a switch in linking estrogen signalling 
with EGFR pathway (Zhang et al, 2012a). Estrogen receptor α (E2Rα)-mediated Src activation has 
been reported to promote proliferation in both E2R positive and negative cancer cells with positive 
crosstalk with EGFR (Fox et al, 2008). Importantly, estrogen regulates normal and 
pathophysiological processes differentially via its receptors E2Rα and E2Rβ (Yakimchuk et al, 
2013). While estrogen-mediated signalling via E2Rα has been reported to promote proliferation of 
the breast (Fox et al, 2008), uterus and developing prostate (Yakimchuk et al, 2013), the E2Rβ 
activation results in suppression of proliferation and stimulation of differentiation of numerous 
tissues (Wada-Hiraike et al, 2006). This dichotomy of E2Rs in addition to the opposing effects of 
estrogen treatment reported earlier further increase the complexity of its role in promoting 
carcinogenesis and may therefore shift the balance from lymphoma (primarily STAT5 driven) in 
favour of carcinomas and sarcomas (SFK and Akt driven) in GHR K4 females. 
 
Conclusion 
The cancer resistance and lifespan extension in the GHR mutant mice lacking the full repertoire of 
GHR signalling is sexually dimorphic. In female mutants, reductions in GH-mediated STAT5 
activation or circulating IGF-1 levels appear beneficial in mediating median and maximal lifespan 
extension and reducing tumour incidence and lymphoma aggressiveness. While in males, there was 
reduced cancer burden with the decrease in circulating IGF-1 levels, no effect was evident in 
lifespan extension. Therefore, instead of IGF-1, the delayed cancer occurrence or reduced cancer 
burden seen in GHR mutants could be the accumulative effect of multiple interacting mechanisms 
that include but are not limited to reduced activation of growth-promoting pathways, increased 
stress resistance, reduced inflammation markers, and increased insulin sensitivity. Interestingly 
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these changes are also common to calorie restriction mediated lifespan extension, at least in rodents 
and invertebrates. This multi-factorial involvement (illustrated in fig.8.26) is also evident in the 
recent use of the anti-diabetic drug metformin in cancer treatment (Pollak, 2012) where it has been 
shown to induce a dietary restriction-like state and protective oxidative stress response via AMPK 
and Nrf2 (Onken & Driscoll, 2010). Metformin also exerts CR-like genomic and metabolic 
responses, which were interpreted as induction of genes associated with longevity pathways in 
mice. Translation of the knowledge from these genetic models and CR may provide cancer 
prevention strategies in humans.  
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!
   Figure 8.26: Cancer resistance pathways in GHR knockin and knockout mouse models. 
The signalling pathways and molecules responsible for cancer resistance in form of reduced tumour incidence and/or aggressiveness in GHR mutants with lack of GH-mediated 
STAT5 activation are summarised.  
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Overview 
The Growth Hormone Receptor is expressed in almost all cell types (Waters & Shang, 2002) and its 
transcript and protein and therefore its actions have been reported in every physiological system 
(Lichanska & Waters, 2008). It is the most widely studied member of its family of Class I cytokine 
receptors. At the cellular level, GHR has been implicated in proliferation, differentiation and 
survival and indeed GH acting on GHR has been reported to result in over 450 different actions in 
over 80 cell types (Waters & Shang, 2002). It is therefore no surprise that GH/GHR signalling is 
associated with each of the ‘hallmarks of cancer’ (fig.9.1) either directly or via IGF-1 induction, 
indicating that dysfunctional signalling emanating from overexpression of the hormone or its 
cognate receptor can promote cancer progression. The strongest evidence for this came from 
humans with dysfunctional GHR (Ecuadorian cohort) that have no reported deaths due to 
malignancy as compared to their relatives with functional receptor (Guevara-Aguirre et al, 2011). 
This finding supported a previous report from Shevah et al. (Shevah & Laron, 2007).  
 
The risk of developing any cancer is determined by genetic elements and by environmental 
conditions including diet and lifestyle. Recent evidences have suggested that the GH/IGF-1 axis 
might provide a link between these factors and the disposition to cancer through its effects on 
normal cell proliferation, differentiation and apoptosis. The GH/IGF-1 axis influences several 
stages and aspects of cancer development and behaviour: cellular proliferation, cell survival, 
angiogenesis and metastasis, and even resistance to chemotherapy (Chhabra et al, 2011). 
 
Figure 9.1: The hallmarks of cancer. 
The complex nature of cancer has been reduced to a small number of underlying principles which dictates the common 
attributes ("hallmarks") that govern the transformation of normal cells to cancer (malignant or tumour) cells (Developed 
from (Hanahan & Weinberg, 2011)). 
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Major advances, both mechanistically and clinically, have been achieved over the past two decades 
in understanding the function of GH/IGF-1 axis. Many of its physiological roles, the genes it 
regulates and the signalling pathways used for this purpose are being determined. Moreover, a 
precise molecular understanding of how the hormone binds to its receptor and a new model for its 
activation is now available. In the last decade alone a considerable paradigm shift has occurred – 
from GH-induced dimerisation to constitutive homodimerisation, Jak-STAT specific signalling to 
recognition of additional Jak-independent pathways, receptor crosstalk signalling, autocrine mode 
of GH activation, and finally function of nuclear-localised receptor, yet much remains to be 
determined.  
 
Structure-function aspects of GHR TMD  
The GHR is a single pass constitutively dimerised receptor at the cell surface, and the existence of 
such dimers implies that a specific ligand-induced conformational change is required for signal 
transmission to the associated cytoplasmic Jak2 kinases (Brown et al, 2005). The conformational 
change/realignment in ECD induced by ligand binding activates Jak2 and these structural changes 
are transmitted through the TMD and intervening sequences from the ECD to the Box1 motif. 
However, unlike the ECD there has not been any direct structural information about the TMD and 
upper juxtamembrane linker or the ICD. GHR TMD interaction using ToxR assay have shown the 
importance of Pro266 and the first glycine (274) of the GxxG motif (both of which are highly 
conserved) in weakening the TMD helix interaction, since interaction increased on conversion of 
these residues to Ile. These results support the view that the GHR TMD helices do associate 
constitutively in a specific manner, but not so strongly as to preclude realignment as a result of 
ligand binding to the ECD (Brooks et al, 2014).  
 
This chapter provided insights into the role of GHR TMD in ligand-induced activation, notably how 
proximity of ECD and separation of ICD upon ligand binding results in GHR activation. For this, 
we analysed the effect of cysteine scanning mutations (or SCAM) by individually mutating every 
residue across the upper juxtamembrane linker from L251 through the entire TMD to S288 with 
cysteine 259 mutated to serine to get a thiol-free background for analysis of the mutants. In 
addition, these mutants were made in full-length receptor or truncated (at 389) to analyse activation 
and dimerisation. The relation between TMD association and receptor dimerisation was evidenced 
by spontaneous cysteine crosslinking of the TMD and juxtamembrane residues. Earlier crosslinking 
studies using MTS in intact cells has revealed a helical periodicity in the TMD placements evident 
in dimer formation within the TMD and when crosslinked residues were plotted on a helix wheel 
projection, an interaction interface was apparent corresponding to the basal state. This included 
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I272/F273, I275/F276, and V280 with crosslinking just visible at F283. This interface correlates 
well with the basal state configuration predicted by molecular dynamics (MD) simulations (Brooks 
et al, 2014). It was indicated that MTS has limited accessibility to residues buried deep in the 
bilayer where little reactive thiolate anion is present, as a result of which low efficiency of dimer 
formation was observed towards the cytoplasmic side (Guan et al, 2002). 
 
The truncated mutants were then subjected to Cu-o-phenanthroline (CuP) crosslinking to determine 
the extent of crosslinking in the presence or absence of GH using cell membrane extracts. We 
observed increased CuP-induced crosslinking of D262C, located in the JM region and decreased 
crosslinking of V284C and F287C, in the presence of GH, while other residues did not yield 
consistent results. This supports the view that ligand binding increases the proximity between JM 
residues in this conserved upper membrane proximal sequence while separating the lower 
juxtamembrane sequence. In addition, the observation of GH enhanced dimers at D262 is consistent 
with hGH-induced formation of disulfide dimers at the adjacent C259 residue in the native receptor 
as reported by others (Gent et al, 2003).  
 
GHR dimerisation by disulfide bond formation at the extracellular juxtamembrane and upper TMD 
resulted in constitutively active receptors. GH, like its structural homologs EPO and PRL, has two 
asymmetrically placed receptor binding sites which would change the interaction geometry between 
the two receptor subunits on binding. In order to understand the nature of this change full-length cys 
mutants were utilised since we had observed that a minor fraction of cys mutants formed dimers 
spontaneously in the absence of ligand. To determine if this dimerisation resulted in GHR 
activation, transient expression in HEK293 cells revealed that constitutive crosslinking of the GHR 
with cysteine substitutions between E260 and L269 is accompanied by receptor activation 
(measured as STAT5 tyrosine phosphorylation), while above this dimer formation and activation 
(L251-T258) is weak. No significant dimer formation or signalling was seen with Cys259 converted 
to serine, i.e. when no JM or TMD free cysteines are present to crosslink. Evidently dimerisation 
within the upper TMD or the extracellular EED sequence can initiate signalling so that close 
apposition of the upper TMD is required for signalling. Accordingly, introducing two disulfide 
bonds by cysteine substitution at F263C and I270C resulted in the strongest receptor activation and 
this was confirmed in Ba/F3 stable lines showing constitutive proliferation and STAT5 activation in 
the absence of GH. 
 
Finally, the CuP treatment on live cells transiently transfected with full-length upper TMD cys 
mutants has revealed that GHR undergoes relative rotation in the upper helices of TMD with L268 
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present on the interaction interphase while I270 is lies on the non-interacting side. When 
crosslinked at I270C with CuP, GH addition failed to induced GHR activation. These findings are 
suggestive that GHR activation involves both an optimum rotational position and the need to 
closely appose the upper JM sequences for activation, resulting in a “tilt and twist” movement of 
the TMDs. Such a mechanism may be common to other Class I cytokine receptors since the TMD 
and ICD of the G-CSFR and GHR, can be interchanged to produce signalling competent receptors 
(Ishizaka-Ikeda et al, 1993). These findings were supported by molecular dynamics modeling in 
silico to determine the 2 states of receptor TMD; basal and GH–induced (Brooks et al, 2014). This 
model of GHR activation (summarised in fig.9.2) will provide valuable insights into the design of 
new cytokine receptor therapeutics and facilitate understanding of a variety of relevant cytokine 
related genetic disorders. 
 
 
Figure 9.2: Proposed model of activation of GHR. 
Refer Appendix VIII  
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Lyn (SFK member) interaction with GHR 
The GH-induced Jak2 activation mechanism is now known but GHR has also been shown to 
activate other pathways independently of Jak2, and of these pathways have been associated with 
specific physiological roles in a cell line-dependent manner. One of these pathways is GH-induced 
SFK activation. Based on a previous study from our group there is solid evidence that GH activates 
SFK independently of Jak2 both in vitro and in vivo (Brooks & Waters, 2010) but the mechanism is 
unknown. In this study we employed truncated GHR constructs and determined a 23 residue 
conserved sequence between Box1 and Box2 motif as the Lyn binding region. The Lyn binding to 
GHR does not seem to be conventional in nature since no consensus SH2 and SH3 binding sites 
were evident in this region or for that matter within the entire GHR. The Lyn binding to GHR does 
not require a phosphorylated tyrosine since when the sole receptor tyrosine in the truncated receptor 
mutated to alanine (Y314A), the receptor was still able to bind Lyn. A similar interaction has been 
proposed in closely related PRLR where no receptor phosphorylation was evident in a Box1 mutant 
even though Src activation was reported after PRL stimulation. Another study has indicated that 
when WT GHR, Jak2 and Src were co-transfected together, this resulted in co-IP of Jak2 and Src 
with GHR and this association was also seen when non-catalytic Src mutants were used, indicating 
that Src association with GHR does not require SFK catalytic activity (Manabe et al, 2006). 
 
In this study we have presented preliminary results indicating a reduction in Lyn binding to WT 
GHR following GH stimulation. It remains to be evaluated if this is a direct effect of Jak2 on Lyn or 
occurs due to rapid GH-induced degradation. In contrast, the Box1 mutant that cannot interact with 
Jak2 showed increased Lyn binding after GH stimulation. It may therefore be speculated that Lyn 
and GHR compete with each other for Jak2 binding and when Jak2 is unable to bind (as in Box1 
mutant), it can facilitate the binding of Lyn to GHR either directly or via another molecule. Other 
studies have emerged reporting Jak2 inhibition can deactivate Lyn kinase (Samanta et al, 2009), 
further strengthening Jak2 and Lyn association. However, for GHR no Jak2 dependency of Lyn 
binding or activation to GHR was observed in vitro or in vivo (Rowlinson et al, 2008) (Barclay et al, 
2010). 
 
Determining the precise mechanism and cellular location of GHR-mediated SFK activation would 
be useful to determine its role in GH-mediated SFK activation in long-lived GHR K4 (all Box1 
motif proline mutated to alanine) male and female mutants. In addition, GHR-mediated SFK 
activation has been implicated in mediating autocrine actions of GH (Tang et al, 2010a) with 
increased cancer cell ‘hallmarks’ associated with SFK signalling (Bougen et al, 2012).  
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Autocrine GH and GHR-mediated oncogenesis in vitro 
The constitutively active constructs based on the structure and function studies of GHR along with 
the nuclear localised GHR (Conway-Campbell et al, 2007) were analysed in an androgen-
independent prostate cancer cell line (DU145) to determine the direct role of GHR in promoting 
cancer progression. Although the jun zipper based, PM2/hGHR (F263C, I270C) and rGHR 
constructs (WT, NLS) were able to constitutively signal via STAT5 under normal growth 
conditions, no increase in proliferation or soft-agar growth was evident. However, the proliferation 
assay needs to be performed in serum-free media where STAT5 activity was clearly evident only 
for jun zipper construct. In addition, it is possible that instead of promoting proliferation, GHR can 
support cancer progression by reducing apoptosis, thereby increasing cell survival. This aspect of 
cancer progression is yet to be analysed. Several attempts to generate a NLS-GHR cancer model by 
sub-cutaneous inoculation of Ba/F3-NLS-GHR cells in athymic nude mice did not result in any 
tumour formation in vivo even when the injected cell numbers (based on (Conway-Campbell et al, 
2007)) were doubled, raising the possibility of clonal artefact. 
 
Based on the established role of autocrine GH and GHR signalling in MCF7 cells by Lobie’s 
Group, we decided to investigate MCF-7 mammary cancer cell line instead. Forced expression of 
hGH has been shown to promote proliferation and phenotypic conversion of MCF-7 into a more 
invasive phenotype (Mukhina et al, 2004). However, these findings have been disputed by two 
separate groups indicating autocrine hGH to be growth-inhibitory (Nakonechnaya et al, 2013) and 
G120R-insensitive (van den Eijnden & Strous, 2007). We have utilised 2 model systems of 
autocrine hGH expression in order to bridge the gap between the conflicting studies from Strous’s 
Group, Lobie’s Group and Nakonechnaya et al. (2013). This was achieved by using two different 
promoter-driven expression models for hGH, namely strongly expressing CMV or the relatively 
weakly expressing MT promoter mainly used by Lobie’s Group. From our studies it was evident 
that MT-driven hGH promoted proliferation in both complete growth media as well as serum-free 
media while CMV-driven hGH expression was inhibitory. In support of its cancer promoting 
effects, the lower expression of hGH (by MT promoter) also significantly increased the clonogenic 
ability of MCF-7 cells as well as the number of holoclones formed. Indeed, depending on the 
autocrine GH levels we were also able to show that the cell lines behaved differently phenotypically 
in a 2D-Matrigel assay with rapid stellate organisation of MT-driven hGH cells and only small 
colonies in CMV-hGH cells. 
 
The immunoblot analysis of key downstream signalling pathways has indicated that the surface 
localisation of unbound GHR is reduced or non-functional in CMV-driven hGH MCF-7 stables as 
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no hGH-induced STAT5 or ERK activation was evident in contrast to MT-driven GH. This was 
indicative of the fact that lower levels of GH did not sequester all the available GHR and some 
unbound GHR was available at the surface to bind exogenous hGH, which could explain the 
inhibitory effects of autocrine hGH observed in LNCaP cell line (Nakonechnaya et al, 2013) and the 
inability to bind the G120R antagonist in the study by Strous’s Group since both were driven by 
CMV promoter. In addition, no constitutive activation of STAT5 was evident in CMV-hGH, unlike 
MT-hGH. Importantly, MAPKs ERK1/2 and p38 activation were already higher in CMV-hGH cell 
lines independent of exogenous GH. A high level of ERK activation has been shown to be 
inhibitory for stem cell renewal (Binetruy et al, 2007) and even emergence (Zhang et al, 2014). This 
can be extrapolated to cancer stem cell renewal and emergence. In support of reduced proliferation 
in CMV-hGH MCF-7, these stables had reduced levels of CDK4 and high levels of p21 indicating 
cell cycle arrest. Active SFK levels were also higher in CMV-hGH as compared to MT-hGH cells 
that showed an exogenous GH response. It is possible that very high levels of GH can switch the 
pathway from Jak/STAT to SFK/ERK, and this shift may depend on the site where the signalling 
actually begins since the autocrine GH bound GHR complex has been shown to localise primarily 
in Golgi and ER in LNCaP cells where it is inhibitory (Nakonechnaya et al, 2013).  
 
The Ba/F3-B2B2 proliferation assay for secreted/synthesised bioactive hGH in the media from the 
MCF-7 stables has indicated that the CMV-hGH cells secrete almost double the level of GH in 
comparison to MT-hGH stables. These levels, although higher than the levels reported in studies by 
Lobie’s and Perry’s Groups, have indicated that the lower GH levels are tumour promoting while 
higher levels are inhibitory and potentially apoptotic. A similar phenomenon was reported with high 
levels of prolactin shown to lower proliferation rate and reduce PRLR levels in forced autocrine 
PRL T47D cells (driven via a strong viral promoter), while the conditioned media was able to 
increase cell numbers of Nb2 cells and control T47D cells (Nitze et al, 2013).  
 
The most encouraging support for the autocrine hGH in cancer hypothesis comes from the study by 
Lobie’s Group (Wu et al, 2011), analysing expression of hGH in mammary carcinoma. These 
workers found autocrine hGH expression associated with lymph node metastasis, tumour stage and 
proliferative index, hence survival outcome. Hence, administering a suitable antagonist early on 
during disease progression should be clinically efficacious. Similar studies on larger population 
numbers are warranted which would allow one to establish a range for GH and also for PRL from 
cancer tissue biopsies (especially mammary and prostate of origin) and thence to compare the levels 
of these cytokine with the cancer modality and severity.  
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Molecular basis of P495TGHR associated cancer susceptibility 
This chapter highlights the molecular basis of the lung cancer associated P495T polymorphism in 
GHR which has been associated with 2-12 fold increase in lung cancer susceptibility in two 
separate GWAS studies on different ethnic populations (Cao et al, 2008; Rudd et al, 2006). We 
have determined that GHR P495T signalling for this cytoplasmic domain variant was not 
constitutive but prolonged and in a cell-line dependent manner. Using two separate cell lines, a 
murine pro-B cell line and a human normal lung epithelial BEAS-2B line, we have shown that this 
polymorphism prolonged STAT5(tyr694) and Akt(thr308) activity respectively following an acute 
GH pulse, as compared to wildtype (P495). Both of these signalling proteins have been associated 
with neoplastic progression (Magkou et al, 2007; Mallette & Ferbeyre, 2007) and shown to 
converge into major downstream networks in lung cancer (Sordella et al, 2004). The role of the Akt 
pathway in cancer progression is still emerging but recent findings have implicated Akt not only in 
survival but also in the maintenance and meeting the metabolic requirements of cancer stem cells 
(Ito and Suda, 2014). In addition, activated Akt(thr308) serves as a prognostic indicator for non-
small cell lung cancer (Vincent et al, 2011), the same modality associated with P495TGHR 
polymorphism in one of GWAS studies (Cao et al, 2008).  
 
The stably transduced Ba/F3 cell lines for WT and P495TGHR differed significantly in level of 
receptor expression, with higher levels observed in latter owing to the polymorphism itself rather 
than being an artefact of the expression system. In addition, there was increased surface receptor 
level (mature glycosylated form) in BEAS-2B and DU145 lines evident at 45-60 minutes following 
a GH pulse. A GH-independent difference on GHR degradation was also evident in HEK293 cells 
stably expressing WT or P495TGHR. No degradation product was evident in P495TGHR and this 
was proteasome-independent. GHR-induced STAT5-mediated phosphatases and SOCS expression 
serves as a key negative feedback mechanism to suppress downstream signalling and in the process 
SOCS degrade GHR. Since binding of SOCS1 and 3 occurs either on Jak2 or on GHR tyrosine 
residues quite upstream to 495, we analysed the binding of P495T to SOCS2 and CIS since Y487 
on GHR has been shown bind to SOCS2, an E3 ubiquitin ligase (Vesterlund et al, 2011), is in close 
proximity to the polymorphism. No direct interaction of GHR and CIS has been shown to date 
although Y595 has been predicted as a binding site based on MAPPIT studies (Uyttendaele et al, 
2007).  
 
Using a HEK293 system stably expressing WT and P495TGHR we found significant but equal 
induction of SOCS2 following acute GH stimulation. However, at low levels of SOCS2 expression, 
co-IP analysis revealed dramatically reduced binding of SOCS2 to P495TGHR as compared to WT 
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by transfecting small amount of SOCS2. In addition to SOCS2 we evaluated if a CIS interaction 
was impaired with P495T. However we could not detect any CIS interaction with GHR unlike 
SOCS2. Interestingly, we could confirm that the interaction of GHR was specific for SOCS2 but 
not CIS in the hepatic tissue of GHR KO since protein levels of SOCS were greater in the GHR 
KO. From the in vivo studies it was evident that GHR undergoes a continuous turnover owing to 
SOCS2. Extrapolating the current data it could be expected that P495TGHR in vivo would result in 
prolonged signal due to delayed degradation of GHR in both GH-dependent and independent 
manner and the choice of downstream signalling molecule would depend on the cell line harbouring 
the variant. This is the first time a ‘gain of function’ mutation in GHR has been linked with cancer 
development and highlights the importance of GHR turnover in cellular homeostasis. 
 
Establishing the RCAS/TVA system 
The RCAS/TVA system serves as an important tool for cell and developmental-stage specific 
delivery of the gene(s) of interest. ALSV viruses cannot infect mammalian cells efficiently because 
these cells lack the cognate receptors (TVA) that recognises the standard envelope subgroups 
expressed on the virus envelope. Even if the entry barrier is overcome by the virus it is incapable of 
producing infectious progeny, thereby making these ALSV viruses doubly-defective in mammalian 
cells (Young et al, 1993). We have successfully established the tissue-specific gene delivery system 
in vitro to deliver genes of interest using two different ALSV based viral particles by stably 
expressing the TVA receptor in cell lines or in a tissue-specific manner in vivo (using particular 
promoters).  
 
The replication competent retrovirus generated from the chicken fibroblast cell line, DF-1 was 
generated at high titre but owing to insert size constraints and the obligatory requirement of 
dividing cells, these virus particles were not the ideal for in vivo utility. This limitation was 
overcome by using relatively safer replication defective EnvA-pseudotyped lentiviral particles, 
which allowed transduction of non-dividing cells as well as transduction with large inserts. The 
pseudotyped lentiviral virus was utilised for making stables in the prostate cancer cell line DU145 
(Chapter 6). This system is a third generation lentiviral packaging system that makes it much safer, 
being Tat-independent and self-inactivating by virtue of a mutant promoter. By carrying out 
numerous standardisation experiments we have established a protocol that consistently provides 
high titre pseudotyped lentivirus that can be scaled up or down.  
 
We then successfully demonstrated delivery of EnvA-pseudotyped lentivirus encoding GFP by 
qPCR and immunohistochemistry into muscle and liver tissue expressing TVA receptor. We were 
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unable to demonstrate the same by immunofluorescence due to a high level of autofluorescence in 
these adult tissues. Interestingly, autofluorescence is now used to analyse organ functionality during 
diseased states (Croce et al, 2014) yet many published studies have used this technique to show 
gene delivery without demonstrating valid controls (Pfeifer et al, 2001).  
 
Using the TVA system we intend to introduce desired candidates that we have hypothesised to 
cause neoplasia from our in vitro studies by using the 2A peptide bridges. These peptide bridges 
have allowed expression of equimolar ratio of 2 or more heterologous genes driven via a single 
promoter (Mehta et al, 2009). The most pertinent study in this regard has shown that constitutive 
EGFR could induce gliomas only in combination with cdk4 (cyclin dependent kinase 4) but not in 
conjunction with p53 deficiency (Holland et al, 1998). Based on this strategy we intend to use the 
2A peptide bridges to make constructs with combination of GHR (constitutively active full-length 
cys mutant (Chapter 3), gain of function variant P495TGHR (Chapter 4), nuclear localised GHR 
(Conway-Campbell et al, 2007), jun zipper construct (Behncken et al, 2000) (Brooks et al, 2014) in 
combination with previously established oncogenes (cdk4, c-myc, Braf, Ras, etc), transcription 
factors (STAT1/3/5) and signalling molecules (Src/lyn, Akt, Ras) to dissect the pathway of GHR-
mediated oncogenesis in vivo.  
 
To aid in this detection, we have generated TVA system in zebrafish for the first time and shown 
that these zebrafish were amenable to EnvA-pseudotyped lentiviral infections and anticipate that 
similar to TVA mouse models, tissue specific tva-zebrafish can also be generated and used in 
future. 
 
Cancer incidences and longevity in GHR knockin and knockout mouse models 
Phenotypic and genotypic characteristics of all living organisms are determined by the interplay of 
genetic and environmental influences, and this applies to the control of aging and cancer 
development. There is solid evidence that the endocrine system plays an important role in mediating 
the impact of genetic and environmental factors on physiological processes. Mice with mutations 
causing a deficiency of GH or resistance to its actions are long-lived (Ikeno et al, 2009) (Junnila et 
al, 2013), and humans with similar mutations are protected from cancer, diabetes and other diseases 
(Guevara-Aguirre et al, 2011). A series of key observations have led to a growing convergence 
between the biology of ageing and the mechanisms that underlie cancer. It is not yet clear as to how 
and where these two processes merge and where their mechanisms diverge. However, the last few 
decades have witnessed an increase in identification of hundreds of potential cancer-related targets 
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for therapeutic development. Of note is the observation that selective anti-cancer drugs can prolong 
lifespan in Drosophila (Danilov et al, 2013).  
 
In this chapter we have explored the pathways and evaluated molecules that may provide protection 
against cancer and/or promote lifespan extension in GHR mouse models lacking the full repertoire 
of GHR signalling. For our study all animals in the same genetic background (C57Bl/6) were 
subjected to similar husbandry conditions and the common attribute to all these mutant mice was 
lack of GH-induced STAT5 activation and therefore reduced IGF-1 and high GH serum levels. We 
observed that while female mice lacking GHR-STAT5 activation have substantial lifespan 
extension (20-26%), males did not, despite having similarly low plasma IGF-1 levels. However, in 
mice with targeted mutation to the Box1 motif, hence unable to activate Jak2 but able to activate 
Src family kinases (SFK), life extension was evident in both male and females (females 45%, males 
15%).  
 
In the same study we also analysed the cause of death initially based on gross morphology, which 
was indicative of reduced macroscopic tumour incidences in most GHR mutant males and females 
with no cancer-related death in GHR K4 male and strikingly high levels in K4 females. While both 
GHR K4 mutants are long lived, the contrasting cancer incidences can be attributed to sexual 
dimorphic SFK activation evident in age-matched hepatic tissue. This finding needs to be evaluated 
on other metabolically active tissues and to determine the downstream genes that may be 
regulated/activated and responsible for common lifespan extension and differential cancer 
modalities evident in GHR K4 males and females.  
 
While no correlation was evident between lack of GH-induced STAT5 activation (reduced IGF-1 
levels in the circulation) and lymphoma incidence upon histopathological analysis of tumours, there 
was reduction in lymphoma aggressiveness in females that could therefore be responsible for 
increased median and maximal lifespan. Interestingly, increased SFK activation in GHR K4 females 
could be attributed to other cancer modalities evident in these mice. In males however, reduced 
IGF-1 levels were not responsible to lifespan but could be credited for reduced cancer incidences in 
most mutants.  
 
Upon analysis of young male mutants for determining reduced cancer incidence, we found that 
GHR mutant models have increased mitochondrial protein levels for the OxPhos complex, which 
may be the direct outcome of persistently active energy sensor kinase, AMPK, even in fed 
conditions, to maintain steady ATP levels. The elevated AMPK activity implies a continuous 
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energy deprivation state also observed during calorie restriction (Canto & Auwerx, 2009) and 
metformin administration for cancer treatment (Shaw et al, 2005). In support of elevated AMPK 
activity, these mutant models have reduced serum glucose levels and increased insulin sensitivity 
when analysed at 12weeks of age. The elevated insulin sensitivity was also associated with 
increased insulin receptor and decreased PTP1B and IRS1 protein levels.  
 
Dampening of growth signalling has been shown to protect against age-related diseases including 
cancer (Burhans & Weinberger, 2007). This was consistent with increased levels of SOCS proteins 
and reduced levels of EGFR, Akt2, and IGF-1R in hepatic tissue of GHR mutants. The elevated 
levels of total and active STAT3 as a result of reduced GH-mediated STAT5 activation has been 
associated with increased hepatic steatosis (Barclay et al, 2011) rather than cancer. During cancer 
progression, transformed cells shift their metabolism from aerobic respiration to glycolysis to meet 
increased energy requirements and create a hypoxic environment in the core, which in turn 
increases inflammation and modulates metabolic reprogramming (Semenza, 2010). The HIF-1α 
generated during hypoxia has been shown to be stabilised by ROS/RNS (Chandel et al, 2000). In 
cultured cells, AMPK was shown to be activated by ROS and RNS (Fujita et al, 2010) which might 
be secondary to inhibition of mitochondrial ATP synthesis, with consequent rises in AMP and ADP 
levels (Hawley et al, 2010). In the GHR mutants, however, while there is increased mitochondrial 
activity and AMPK activation there are also increased enzymes to reduce unwanted ROS/RNS.  
 
The GHR mutants appear able to manage oxidative stress by detoxification of ROS generated 
during physiological processes. Most young mutant mice express elevated levels of antioxidative 
enzymes SOD1 and SOD2 while all young and old GHR K2 female mutants expressed increased 
levels of Nrf2, the master regulator of antioxidant responses as well numerous Nrf2 regulated genes.  
 
While there is increased expression of mitochondrial progenitor (PGC1α) in mutants there was no 
evident increase in mitochondrial numbers. Mitochondrial Sirt3 and nuclear Sirt1 were also 
elevated in all young male mutants. The sirtuins are implicated in positive regulation of 
mitochondrial pathways as well as in stress responses and longevity (Haigis & Sinclair, 2010) 
where they deacetylate proteins to control protein-protein interaction, protein stability, cellular 
localisation or modulate enzymatic activity. Sirt3 has the ability to integrate cellular energy 
metabolism and ROS generation and has been proposed to be a prominent regulator in CR 
adaptation by coordinately deacetylating proteins involved in diverse pathways of metabolism and 
mitochondrial maintenance (Hebert et al, 2013). Moreover, GHR mutants are expected to have 
reduced inflammation based on upregulation of anti-inflammatory cytokine receptors (IL-10R) and 
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pro-inflammatory receptor antagonist (IL-1RA) as well reduced activity of p38 stress kinase in 
young male mutants. 
 
In order to determine why GHR mutants lacking GH-mediated STAT5 activation exhibit sexually 
dimorphic effects in lifespan extension, we have analysed metabolically active tissues of 78weeks 
old GHR K2 males and females with age and gender-matched WT. We have obtained contrasting 
results in comparison to young mice with key antioxidants and mitochondrial proteins favouring 
only females over males along with higher plasma antioxidant levels in female mutants only. 
Another important observation in this study was the retention of active AMPK, Sirt1 and Sirt3 
protein levels in the liver of aged GHR KO males, and although there was an age-associated 
decline, levels were clearly elevated as compared to age-matched WT males. Based on the existing 
literature this would imply that GHR KO males should exhibit cancer resistance and lifespan 
extension. The latter was not evident indicating that separate pathways exist for protection against 
cancer and lifespan extension. This is in contrast to the earlier report suggesting reduction in AMPK 
activity and mitochondrial biogenesis as the cause for aging (Reznick et al, 2007).  
 
This study suggests a universal role for IGF-1 deficiency in cancer resistance or aggressiveness but 
not in longevity. While resistance against cancer seems to be a combination of multiple factors 
(fig.9.3) such as increased insulin sensitivity, increased mitochondrial function, increased stress 
resistance, reduced inflammation markers and reduced growth-promoting pathways, none of these 
individually or in combination support the increased lifespan extension we observe in the GHR 
mutants, and we are seeking the molecular basis for this differential effect. 
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Figure 9.3: Mechanisms involved in resistance towards cancer owing to reduced/lack of GHR-mediated 
signalling  
Developed from (Bartke et al, 2013). 
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Future Directions 
Given the animal and human data supporting critical involvement of the GH/IGF-1 axis in cancer 
incidence and progression, the development of GH antagonists for use alone or in conjunction with 
IGF-1R blockers, is of key importance. While pegvisomant is partially effective in suppressing 
cancer in animal models and autocrine cancers, it is disadvantaged by high cost and likely 
impairment of its action by elevated plasma GH resulting from lowered IGF-1 feedback. Therefore, 
other means of limiting GH action are needed and would require the knowledge of the mechanism 
of activation of GHR we have provided. However, the recently proposed model of GHR-mediated 
Jak2 activation by our group has a much broader relevance and could be extended to other Class I 
cytokine receptors.  Using the cysteine crosslinking analysis, we were able to make the first 
constitutively active full-length GHR constructs that will be analysed in tva-zebrafish model to 
show their effect in vivo in a tissue-specific or ubiquitous manner. In addition, it remains to be seen 
if these cysteine mutants have the ability to activate other GH-mediated pathways such as SFK. 
Simultaneously, there is a gap in determining the precise mechanism of SFK activation and role of 
Lyn binding to Jak2 at physiological levels. More research is warranted to determine:  
1) If Lyn binding to GHR truncations can activate signalling pathways upon GH stimulation 
or requires the full downstream cytosolic region on GHR to trigger activation. 
2) If Lyn activate can phosphorylate the GHR in a Jak2-deficient (γ2A fibrosarcoma) cell 
line and stably transduced FDC-P1 cell line. 
3) The subcellular localisation where Lyn and GHR binding occurs? Is it only at the surface 
due to myristoylation of Lyn. 
4) If Lyn binds to Jak2 and the effect of GH/GHR on this binding as well as its kinase 
activity. 
5) If Lyn binding mediates STAT5 activation via GHR and if this is cell-line dependent. 
6) If GHR binding to other SFK members follows similar attributes to that of Lyn. 
 
Recent emerging findings on GHR polymorphisms in relation to GH responsiveness and disease 
susceptibilities have given significant attention on in vitro receptor signalling outcomes. Although 
over 60 loss of function mutations in GHR have been associated with deficient post-natal growth, to 
date no constitutively active GHR mutation has been reported. Our study currently in progress is 
aimed at identifying novel mutations in GHR, STAT5, Jak2, and GH in clinical prostate cancer 
tissues. In addition, we seek to determine the basis of the GH-independent receptor fragments 
observed in WT GHR lysates as compared to P495TGHR. There is also a possibility of lysosomal 
rather than proteasomal-mediated degradation that may be involved in the control of basal level of 
GHR degradation. This will be analysed by pre-treatment of the HEK293 stables with specific 
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inhibitors such as chloroquine, and leupeptin. Based on the P495 adjacent sequence analogy to the 
cdc4 recognition sequence, a physical interaction of cdc4 and GHR remains to be evaluated by co-
IP. Finally, to confirm the role of SOCS2 in decreased GH-mediated P495TGHR degradation, 
SOCS2 co-IP in Ba/F3 and Beas-2B stables at 60minutes time point (when the difference in 
receptor level is quite apparent) would be beneficial. In support of the same, surface GHR 
degradation in P495TGHR needs to be analysed using BFA in the presence of SOCS2.  
 
Although substantial evidence supports a causal role for the GH/IGF-1 axis in cancer, important 
questions remain unanswered with respect to the utility of GH antagonism in cancer. While we were 
able to show a differential effect of the level of autocrine hGH in vitro, this needs to be 
substantiated using GH antagonists in both MCF-7 stables (CMV vs MT) as well as by xenograft  
and autocrine models in vivo. In addition, cell survival assays and other typical cancer ‘hallmark’ 
assays such as invasion, migration and spheroid assays need to be performed at the differential 
autocrine GH levels. An important goal would be to determine the signalling pathways and the 
cellular localisation of signal in both these models as well as any miRNA that may be involved in 
modulating differential effects of autocrine GH or as a consequence of it. 
 
A Tet-regulated system would serve as a suitable model to confirm the ‘cancer like’ effects of low 
levels of autocrine GH, although this time the expression will be driven via the same promoter to 
reduce further variables. This would allow one to control the relative levels of GH and GHR and 
determine a threshold level of GH, beyond which it is non-tumourigenic. Finally, these experiments 
need to be performed in the other cancer cells such as LNCaP to confirm a broader applicability of 
our hypothesis and bridge the gap in knowledge between published studies. Based on our 
preliminary and anticipated future results, we would be able to explain the ineffectiveness of 
pegvisomant in treatment of certain tumours and also draw much needed attention towards the 
design and use of more antisense oligonucleotide inhibitors specific to GHR per se. These would 
directly control GHR availability as opposed to G120R-mediated reduced signalling that is actually 
dependent on unbound GHR availability in the first place. 
 
The direct oncogenic potential of GHR needs to be evaluated in different cancer models. 
Physiologically, it may involve gene amplification, activating mutations in GHR or downstream 
molecule that requires GHR for signalling (similar to Jak2V617F). While the former will be 
analysed from prostate cancer slides, we intend to evaluate the latter using constitutively active and 
nuclear-localised GHR starting with prostate cancer model (LNCaP) cell lines and extend it in vivo 
using the RCAS/TVA system that we have established. 
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Using the GHR mutant models we plan to continue the determination of cancer incidences, burden 
and modality in comparison to WT for both genders (increasing mouse number as and when 
available), in conjunction with the histopathologist. A considerable amount of work also needs to be 
done to determine the sexually dimorphic pattern of lifespan extension in GHR KO and K2 mutants 
and in contrast the sex-independent longevity observed in GHR K4. Such a task would require 
microarray analysis to determine differentially expressed transcripts (and miRNA) and protein as 
well as pertinent antioxidants and stress assays (in vivo or on fibroblasts extracted from mice). 
Specific mitochondrial activity assays and acetylation status to evaluate the role of sirtuins will be 
undertaken in metabolically active tissues from both young and old mice. In addition, the GHR K4 
mutant females will be studied in detail to determine if increased SFK activation is prevalent in 
other tissues and the probable cause of cancer modalities not common to C57Bl/6 strain. Based on 
current literature, the role of estrogen-mediated signalling will be further explored. 
 
Nevertheless, clinical trials of pegvisomant in cancer in conjunction with other adjuvant therapies 
appear warranted. The ability of GH and IGF-1 to confer resistance to radiotherapy and 
chemotherapy is a further reason for use of GH antagonists. Given the potential role of GH in 
promoting stem cell activation, one can expect to see translational studies relating GH action to 
cancer stem cells and GH. In the near future, we can expect small molecule agonists and 
antagonists, tissue-specific deletion of the receptor and many surprises to provide novel 
understandings of the physiological actions of this pleiotropic cytokine. 
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Appendix I: List of primers designed for making hGHR cys 
mutants 
 
Primer Sequence 
L251C Rvs  5’CATCTGAGGACATGTTACATAGAGCACCTCACTGAACTCGCC 
P252C Fwd  5’TGTCAGATGAGCCAATTTACATCTGAAGAAGATTTCTACTTTC 
P252C Rvs 5’AAGTGTTACATAGAGCACCTCACTGAACTCGCC 
Q253C Fwd  5’TGCATGAGCCAATTTACATCTGAAGAAGATTTCTACTTTCC 
Q253C Rvs 5’AGGAAGTGTTACATAGAGCACCTCACTGAACTCG 
M254C Rvs  5’ACACTGAGGAAGTGTTACATAGAGCACCTCACTGAACTCG 
S255C Rvs  5’TGTAAATTGGCACATCTGAGGAAGTGTTACATAGAGCACCTC 
Q256C Rvs  5’TGTAAAGCAGCTCATCTGAGGAAGTGTTACATAGAGCACCTC 
F257C Rvs  5’TGTACATTGGCTCATCTGAGGAAGTGTTACATAGAGCAC 
T258C Rvs  5’GCAAAATTGGCTCATCTGAGGAAGTGTTACATAGAGC 
Fwd a (From S255) USED 
FOR L251 to M254) 
5’AGCCAATTTACATCTGAAGAAGATTTCTACTTTCCATG  
Fwd b (From C259S) 
USED FOR S255 to T258) 
5’TCTGAAGAAGATTTCTACTTTCCATGGCTCTTAATTATTATC  
Fwd A (Common for all) 5’CTGGAGTCTGCAAAGTGTTAATCCAGGCC 
Rvs A (Common for all) 5’GATCGATTCCTTTAATCTTTGGAACTGGAACTGG 
 
Primer Sequence 
C259S Fwd 5’GATGAGCCAATTTACATCTGAAGAAGATTTCTAC 
C259S Rvs 5’GTAGAAATCTTCTTCAGATGTAAATTGGCTCATC 
E260C Fwd 5’GAGCCAATTTACATCTTGTGAAGATTTCTACTTT 
E260C Rvs 5’AAAGTAGAAATCTTCACAAGATGTAAATTGGCTC 
E261C Fwd 5’CCAATTTACATCTGAATGTGATTTCTACTTTCCA 
E261C Rvs 5’TGGAAAGTAGAAATCACATTCAGATGTAAATTGG 
D262C Fwd 5’ATTTACATCTGAAGAATGTTTCTACTTTCCATGG 
D262C Rvs 5’CCATGGAAAGTAGAAACATTCTTCAGATGTAAAT 
F263C Fwd 5’TACATCTGAAGAAGATTGCTACTTTCCATGGCTC 
F263C Rvs 5’GAGCCATGGAAAGTAGCAATCTTCTTCAGATGTA 
Y264C Fwd 5’ATCTGAAGAAGATTTCTGCTTTCCATGGCTCTTA 
Y264C Rvs 5’TAAGAGCCATGGAAAGCAGAAATCTTCTTCAGAT 
F265C Fwd 5’TGAAGAAGATTTCTACTGTCCATGGCTCTTAATT 
F265C Rvs 5’AATTAAGAGCCATGGACAGTAGAAATCTTCTTCA 
P266C Fwd 5’AGAAGATTTCTACTTTTGTTGGCTCTTAATTATT 
P266C Rvs 5’AATAATTAAGAGCCAACAAAAGTAGAAATCTTCT 
W267C Fwd 5’AGATTTCTACTTTCCATGTCTCTTAATTATTATC 
W267C Rvs 5’GATAATAATTAAGAGACATGGAAAGTAGAAATCT 
L268C Fwd 5’TTTCTACTTTCCATGGTGCTTAATTATTATCTTT 
L268C Rvs 5’AAAGATAATAATTAAGCACCATGGAAAGTAGAAA 
L269C Fwd 5’CTACTTTCCATGGCTCTGTATTATTATCTTTGGA 
L269C Rvs 5’TCCAAAGATAATAATACAGAGCCATGGAAAGTAG 
I270C Fwd 5’CTTTCCATGGCTCTTATGTATTATCTTTGGAATA 
I270C Rvs 5’TATTCCAAAGATAATACATAAGAGCCATGGAAAG 
I271C Fwd 5’TCCATGGCTCTTAATTTGTATCTTTGGAATATTT 
I271C Rvs 5’AAATATTCCAAAGATACAAATTAAGAGCCATGGA 
I272C Fwd 5’ATGGCTCTTAATTATTTGCTTTGGAATATTTGGG 
I272C Rvs 5’CCCAAATATTCCAAAGCAAATAATTAAGAGCCAT 
F273C Fwd 5’GCTCTTAATTATTATCTGTGGAATATTTGGGCTA 
F273C Rvs 5’TAGCCCAAATATTCCACAGATAATAATTAAGAGC 
G274C Fwd 5’CTTAATTATTATCTTTTGTATATTTGGGCTAACA 
G274C Rvs 5’TGTTAGCCCAAATATACAAAAGATAATAATTAAG 
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I275C Fwd 5’AATTATTATCTTTGGATGTTTTGGGCTAACAGTG 
I275C Rvs 5’CACTGTTAGCCCAAAACATCCAAAGATAATAATT 
F276C Fwd 5’TATTATCTTTGGAATATGTGGGCTAACAGTGATG 
F276C Rvs 5’CATCACTGTTAGCCCACATATTCCAAAGATAATA 
G277C Fwd 5’TATCTTTGGAATATTTTGCCTAACAGTGATGCTA 
G277C Rvs 5’TAGCATCACTGTTAGGCAAAATATTCCAAAGATA 
L278C Fwd 5’CTTTGGAATATTTGGGTGTACAGTGATGCTATTT 
L278C Rvs 5’AAATAGCATCACTGTACACCCAAATATTCCAAAG 
T279C Fwd 5’TGGAATATTTGGGCTATGTGTGATGCTATTTGTA 
T279C Rvs 5’TACAAATAGCATCACACATAGCCCAAATATTCCA 
V280C Fwd 5’AATATTTGGGCTAACATGCATGCTATTTGTATTC 
V280C Rvs 5’GAATACAAATAGCATGCATGTTAGCCCAAATATT 
M281C Fwd 5’ATTTGGGCTAACAGTGTGCCTATTTGTATTCTTA 
M281C Rvs 5’TAAGAATACAAATAGGCACACTGTTAGCCCAAAT 
L282C Fwd 5’TGGGCTAACAGTGATGTGTTTTGTATTCTTATTT 
L282C Rvs 5’AAATAAGAATACAAAACACATCACTGTTAGCCCA 
F283C Fwd 5’GCTAACAGTGATGCTATGTGTATTCTTATTTTCT 
F283C Rvs 5’AGAAAATAAGAATACACATAGCATCACTGTTAGC 
V284C Fwd 5’AACAGTGATGCTATTTTGTTTCTTATTTTCTAAA 
V284C Rvs 5’TTTAGAAAATAAGAAACAAAATAGCATCACTGTT 
F285C Fwd 5’AGTGATGCTATTTGTATGCTTATTTTCTAAACAG 
F285C Rvs 5’CTGTTTAGAAAATAAGCATACAAATAGCATCACT 
L286C Fwd 5’GATGCTATTTGTATTCTGTTTTTCTAAACAGCAA 
L286C Rvs 5’TTGCTGTTTAGAAAAACAGAATACAAATAGCATC 
F289Fwd 5’GCTATTTGTATTCTTATGTTCTAAACAGCAAAGG 
F287 Rvs 5’CCTTTGCTGTTTAGAACATAAGAATACAAATAGC 
S288C Fwd 5’ATTTGTATTCTTATTTTGTAAACAGCAAAGGATT 
S288C Rvs 5’AATCCTTTGCTGTTTACAAAATAAGAATACAAAT 
C389Stop Fwd 5’CTCTGGACGTACCAGCTGATGTGAACCTGACATT 
C389Stop Rvs 5’AATGTCAGGTTCACATCAGCTGGTACGTCCAGAG 
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Appendix II: List of sequencing primers  
 
Primer  Sequence 
hGHR426 Fwd 5’GCAGCTATCCTTAGCAGAGC 
hGHR827 Fwd 5’CTGAACGTCAGTTTAACTGG 
hGHR1439 Fwd 5’CAGACTTCTAAGCAGTGACC 
hGHR1815 Fwd 5’CAGGTGAGCGACATTACACC 
hGHR2091 Fwd 5’ACAGGAGAACATGTTCCAGG 
hGHRintron Rvs 5’CTTCAGGTGTTAATTAGTACTAGC 
hGHR709 Rvs 5’ACAATAAGGTATCCAGATGG 
hGHR1014 Rvs 5’ACTTCATATTCCTTATCCAC 
hGHR1381 Rvs 5’TCAACCCAAGAGTCATCACTG 
hGHR1706 Rvs 5’CTCTGCTTGGATAACACTGG 
hGHR2053 Rvs 5’AGTGGTAAGGCTTTCTGTGG 
 
Primer  Sequence  
rGHR102 Fwd 5’ATTCACCAAGTGCCGTTCACC 
rGHR499 Fwd 5’AAGGGATGGATAGTCTTGGAG 
rGHR908 Fwd 5’GAGGTGAACACAATCTTAGCC 
rGHR1299 Fwd 5’AGAGGAAGACAAACCGCGACC 
rGHR1700 Fwd 5’CCCCAGGTTCTGAGATGCCTG 
rGHR1501 Rvs 5’CTGGATGCGCATCACACTGAG 
rGHR1098 Rvs 5’AGAGTCGTCATCCTTTGCTGC 
rGHR701 Rvs 5’GGAAGGGTTACATAGAGCACC 
rGHR199 Rvs 5’ACAGCTGCACAGATCCTGGGC 
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Appendix III:  List of primers designed for plasmid 
construction, gene expression and genotyping in the 
RCAS/TVA system  
 
Primer Sequence Utility 
hGHR-AclI 
Rvs 
TATCAACGTTCTGGCATGATTTTGTTCAGTTGGT
CTGTG 
HA-hGHR 
HA-NLS-hGHR 
GFP-AclI-Rvs TATCAACGTTACTTGTACAGCTCGTCCATGCCG
AGAG 
HA-NLS-GFP 
AclI-HA Fwd TACTAACGTTATGGGATATCCATATGATGTTCC
AGATTACGC 
HA-NLS-GFP 
rGHR-AclI 
Rvs 
GATCAACGTTCTATGGCAAGATTTTGTTGGTCTG
TG 
HA-rGHR 
HA-NLS-rGHR 
AclI-pGHRsig 
Fwd 
TACTAACGTTATGGATCTCTGGCAGCTTCTGTTG
ACC 
HA-hGHR 
HA-NLS-hGHR 
HA-rGHR 
HA-NLS-rGHR 
attB1- 
pGHRsig Fwd 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATG
GATCTCTGGCAGCTTCTGTTGACC 
HA-hGHR 
HA-NLS-hGHR 
HA-rGHR 
HA-NLS-rGHR 
HA-Jun-3A-rGHR 
rGHR-attB2 
Rvs 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTAT
GGCAAGATTTTGTTCAGTTGGTCTGTG 
HA-rGHR 
HA-NLS-rGHR 
HA-Jun-3A-rGHR 
attB1-HA Fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATG
GGATATCCATATGATGTTCCAGATTACGC 
HA-NLS-GFP 
GFP-attB2 
Rvs 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTAC
TTGTACAGCTCGTCCATGCCGAGAG 
HA-NLS-GFP 
hGHR-attB2 
Rvs 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTAA
GGCATGATTTTGTTCAGTTGGTCTGTG 
HA-hGHR 
HA-NLS-hGHR 
mGAPDH  
Fwd 
AGCCTCGTCCCGTAGACAAAA qPCR  
mGAPDH  
Rvs 
TGGCAACAATCTCCACTTTGC qPCR  
tva Fwd GAGTGTTACCCGCAGGACTGG Genotyping 
TVA Rvs GAGTCAGGTTCCGTGGTGAGC Genotyping 
GFP Fwd CAGAAGAACGGCATCAAGGTG qPCR 
GFP Rvs GGACTGGGTGCTCAGGTAGTG qPCR 
zfTVA Fwd CACGGACAACGGCACAGA qPCR 
zfTVA Rvs AGCAAAAGATCCCTGCAGTGA qPCR 
ZfHPRT Fwd ATCAGCGAAACAGGAAAGGAG qPCR 
ZfHPRT Rvs CTGCGGTGAGCTGCACTACT qPCR 
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Appendix IV:  List of primers designed for making constructs 
comprising 2A peptide bridges  
 
Primer Sequence 
attB1-psig Fwd 5’GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGATCTCTGGCAGCT
TCTGTTGACC 
hGHR-2Ac1 Rvs 5’GTTTTCCTCCACGTCGCCGCAGGTGAGCAGGCTTCCCCTGCCCTCAG
GCATGATTTTGTTCAGTTGGTCTGTGCTC 
rGHR-2Ac1 Rvs  
 
5’GTTTTCCTCCACGTCGCCGCAGGTGAGCAGGCTTCCCCTGCCCTCTG
GCAAGATTTTGTTCAGTTGGTCTGTGCT 
2AC1-CDK4 Fwd 5’ACCTGCGGCGACGTGGAGGAAAACCCTGGCCCCGCCCCAGGATCCA
TGGCTACCTCTCGATATGAGCCAGTGGC 
CDK4-2Ac2 Rvs 5’GGGATTCTCTTCGACATCTCCACATGTCAGGAGGCTTCCCCTGCCCT
CCTCCGGATTACCTTCATCCTTATGTAGATAAGAGTGC 
2AC1-c-myc Fwd 
 
5’ACCTGCGGCGACGTGGAGGAAAACCCTGGCCCCGCCCCAGGATCCA
TGCCCCTCAACGTTAGCTTCACCAAC 
c-Myc-2Ac2 Rvs 5’GGGATTCTCTTCGACATCTCCACATGTCAGGAGGCTTCCCCTGCCCT
CCGCACAAGAGTTCCGTAGCTGTTCAAGTTT 
2AC2-GFP Fwd 
 
5’CTGACATGTGGAGATGTCGAAGAGAATCCCGGCCCTGCCCCAGGAT
CCATGGTGAGCAAGGGCGAGGAGCTG 
GFP-attB2 Rvs 5’GGGGACCACTTTGTACAAGAAAGCTGGGTTTACTTGTACAGCTCGTC
CATGCCGAGAG 
attB1-CDK4 Fwd 5’GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGCTACCTCTCGATA
TGAGCCAGTGGC 
CDK4-2AC1 Rvs 
 
5’GTTTTCCTCCACGTCGCCGCAGGTGAGCAGGCTTCCCCTGCCCTCCT
CCGGATTACCTTCATCCTTATGTAGATAAGAGTGC 
attB1 c-Myc Fwd 
 
5’GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCCCTCAACGTTAG
CTTCACCAAC 
c-Myc-2Ac1 Rvs 
 
5’GTTTTCCTCCACGTCGCCGCAGGTGAGCAGGCTTCCCCTGCCCTCCG
CACAAGAGTTCCGTAGCTGTTCAAGTTT 
2AC1-GFP Fwd 
 
5’ACCTGCGGCGACGTGGAGGAAAACCCTGGCCCCGCCCCAGGATCCA
TGGTGAGCAAGGGCGAGGAGCTG 
2Ac1 mKate2 Fwd 5’ACCTGCGGCGACGTGGAGGAAAACCCTGGCCCCGCCCCAGGATCCA
TGGTGAGCGAGCTGATTAAGGAGAACATG 
mKate2-attB2 Rvs 5’GGGGACCACTTTGTACAAGAAAGCTGGGTTCATCTGTGCCCCAGTTT
GCTAGGG 
 
 
Primer Fwd  Rvs  
GH1/2 5’GCAGTGCCTTCCCAACCA 5’ATGGGCGCGGAGCAT 
SOCS2 5’CCCGGAACGGCACTGTT 5’CTACAGAGATGCTGCAGAGATGGT 
B2M 5’CATTCGG5’GCCGAGATGTCT 5’CTCCAGGCCAGAAAGAGAGAGTAG 
GusB 5’TTCCCTCCAGCTTCAATGACA 5’CCACACCCAGCCGACAA 
GAPDH 5’GCCCCCGGTTTCTATAAATTG 5’GTCGAACAGGAGGAGCAGAGA 
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Appendix V: List of primers designed for qPCR analysis on 
mouse tissues 
Primer Sequence 
m16S Fwd 
(for genomic DNA) 
CCGAAACCAAACGAGCTACCT 
m16S Rvs 
(for genomic DNA) 
CTCGTTAGGCTTTTCACCTCTACCT 
mApoE Fwd TGGCTACCAACCCCATCATC 
mApoE Rvs TGCAGGACAGGAGAAGGATACTC 
mAtp5a Fwd CAACAAAGGATGACCCCAAA 
mAtp5a Rvs AAGCTGCAAGGATGCTGTCT 
mB2M Fwd ACTGATACATACGCCTGCAGAGTT 
mB2M Rvs CTCGATCCCAGTAGACGGTCTT 
mCAT Fwd TGGCTTTTGACCCAAGCAAT 
mCAT Rvs CGGCCCTGAAGCATTTTGT 
mCD36 Fwd TGTGTGGAGCAACTGGTGGAT 
mCD36 Rvs CGTGGCCCGGTTCTACTAATT 
mCdkn1a Fwd GAAACACCAGCACTATGATTGGA 
mCdkn1a Rvs ATTCCCGTAAACTCCCCTGTG 
mCIS Fwd TACAACATCTGTGTCGGCTAAGTCA 
mCIS Rvs TCGGAGGTAGTCGGCCATAC 
mFGF21 Fwd ATGGAATGGATGAGATCTAGAGTTGG 
mFGF21 Rvs TCTTGGTGGTCATCTGTGTAGAGG 
mFMO2 Fwd GATTTAGCTCCATGCTCCGAAA 
mFMO2 Rvs TCTGTTGTTCCATCATCCACTTG 
mGlut2 Fwd CGGAATGGTCGCCTCATT 
mGlut2 Rvs ACATTGCTTTGATCCTTCCAAGTT 
mHNF1A Fwd AAAGAGCTGGAGAACCTCAGC 
mHNF1A Rvs GACAGGTGGGACTGGTTGA 
mHNF3B Fwd TCATGTTGCTCACGGAAGAG 
mHNF3B Rvs TAAAGTATGCTGGGAGCCGT 
mHNF4A Fwd GCTGTCCTCGTAGCTTGACC 
mHNF4A Rvs TTAAGAAGTGCTTCCGGGCT 
mHNF6A Fwd TCCTTCCCATGTTCTTGCTC 
mHNF6A Rvs GGAGGATGTGGAAGTGGCT 
mIGF-1 Fwd CACTCATCCACAATGCCTGT 
mIGF-1 Rvs TGGATGCTCTTCAGTTCGTG 
mIGF-2 Fwd TGTGTGACCAGGCTGCTAGTTC 
mIGF-2 Rvs ACCATGTGGACAGGTGCTTAGA 
mIGFBP-1 Fwd TGGACAGCTTCCACCTGATG 
mIGFBP-1 Rvs TGATGGCGTTCCACAGGAT 
mIGFBP-2 Fwd CAGCAGGTTGCAGACAGTGATG 
mIGFBP-2 Rvs GCTCCTTCATGCCTGACTTGAG 
mIGFBP-3 Fwd GCTGGTGTGTGGACAAGTATGG 
mIGFBP-3 Rvs GGCAATGTACGTCGTCTTTCC 
mIGFBP-4 Fwd GCCCATCTTTGGTCAGGGTAT 
mIGFBP-4 Rvs TTTCCCACAGCAGAGATCTACCT 
mIL-10beta Fwd TGTCAAATTCATTCATGGCCT 
mIL-10heta Rvs ATCGATTTCTCCCCTGTGAA 
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mIL-10R alpha Fwd TGAGCCTAGAATTCATTGCATACG 
mIL-10R alpha Rvs GGAAAAATCTGGCTTCAAACCA 
mIL-10R beta Fwd TTCGGAGTGGGTCAATGTCA 
mIL-10R beta Rvs TGCATCTCAGGAGGTCCAATG 
mIL-1RA Fwd GCATCTTGCAGGGTCTTTTC 
mIL-1RA Rvs GTGAGACGTTGGAAGGCAGT 
mIRS1 Fwd GGAGGATTTGCTGAGGTCAT 
mIRS1 Rvs CTATGCCAGCATCAGCTTCC 
mIRS2 Fwd CCCCAGTGTCCCCATCCT 
mIRS2 Rvs TTTCCTGAGAGAGACGTTTTCCA 
mKeap1 Fwd CATCCACCCTAAGGTCATGGA 
mKeap1 Rvs CATCACGTGCAGGACACACTT 
mLXR alpha Fwd TGGAGAACTCAAAGATGGGG 
mLXR alpha Rvs TGAGAGCATCACCTTCCTCA 
mLXR beta Fwd AGAACTTGTGGGGGAAGACA 
mLXR beta Rvs GGTGCAGTCATGAGCCCC 
mMFN2 Fwd TGAAAGTCACTGTGCATTTGATAAAGT 
mMFN2 Rvs GGCGCCCATCAGTCATTC 
mMt1 Fwd GCTGTGCCTGATGTGACGAA 
mMt1 Rvs AGGAAGACGCTGGGTTGGT 
mNCOR1 Fwd CCTATTAAACCAAACCCATTGGAT 
mNCOR1 Rvs CATGGAGTGCAAGAAACCATTG 
mNCOR2 Fwd CCTTCCGTGAGAAGTTTATGCA 
mNCOR2 Rvs CACACTCAGCGACCGTCTTTC 
mNdufa5 Fwd TGGAAGAGCCGCCTGCTA 
mNdufa5 Rvs TTCCCATCCACCATCTGACA 
mNqo1 Fwd GGGTCGTCTTGGCAACCA 
mNqo1 Rvs CAGATGTTGAGGGAGGATCGTAA 
mNrf1 Fwd TCCAGTCTCTGTGGACAAAATGA 
mNrf1 Rvs CGACCTGTGGAATACTTGAGCAT 
mNrf2 Fwd TCCTTAGACTCAAATCCCACCTTAA 
mNrf2 Rvs GGGCTCTGCTATGAAAGCAGAA 
mPgc1α Fwd AGCGCCGTGTGATTTACGTT 
mPgc1α Rvs GTCTCCATCATCCCGCAGATT 
mPgc1β Fwd TCCTGTAAAAGCCCGGAGTAT 
mPgc1β Rvs GCTCTGGTAGGGGCAGTGA 
mPolg2 Fwd  
(for genomic DNA) 
CGCAGCCGAGGGACAGT 
mPolg2 Rvs  
(for genomic DNA) 
AAGAAATGCCACTAGCTGTTCCTT 
mPpar alpha Fwd AGTGCCCTGAACATCGAGTGT 
mPpar alpha Rvs CCGAATAGTTCGCCGAAAGA 
mPpar delta Fwd GGTCATAGCTCTGCCACCAT 
mPpar delta Rvs ACTCAGAGGCTCCTGCTCAC 
mPpar gamma1 Fwd GCGGCTGAGAAATCACGTTC 
mPpar gamma1 Rvs GAATATCAGTGGTTCACCGCTTC 
mPpar gamma2 Fwd AACTCTGGGAGATTCTCCTGTTGA 
mPpar gamma2 Rvs GAAGTGCTCATAGGCAGTGCAT 
mPparγ Fwd GCATCAGGCTTCCACTATGGA 
mPparγ Rvs TCCGGCAGTTAAGATCACACC 
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mPtp1B Fwd GGCGGCCCAAAGAGTGA 
mPtp1B Rvs GGAGATGCATAGCCTGAAAAGG 
mRev-Erb alpha Fwd ACGGCAAGGCAACACCAA 
mRev-Erb alpha Rvs  CTTCCCAGATCTCCTGCACAGT 
mRev-Erb beta Fwd CTGTGATGCCAACGGCAAT 
mRev-Erb beta Rvs CTGTGCGGTCACTCTTCAGAAC 
mRORalpha Fwd TGACGCCCACCTACAACATC 
mRORalpha Rvs CATCCATATAGGTGCTGAGGTCAT 
mRORgamma Fwd   GCTCATCAGCTCCATATTTGACTTT 
mRORgamma Rvs   AGGGCAATCTCATCCTCAGAAA 
mSdhb Fwd TCTGGGTCCCATCGGTAAAT 
mSdhb Rvs GCCGTTCTCGGCAGAGTC 
mSIRT1 Fwd GACACAGAGACGGCTGGAAC 
mSIRT1 Rvs CAGACCCTCAAGCCATGTTT 
mSIRT2 Fwd CCGCGGGTATCCCTGACT 
mSIRT2 Rvs  GGTACTTCTCCAGGTTTGCATAGAG 
mSIRT3 Fwd GGTTTCACAACGCCAGTACA 
mSIRT3 Rvs CAGCTACATGCACGGTCTGT 
mSIRT6 Fwd  ACCTGCCCCTTGCCACTAA 
mSIRT6 Rvs  TGGGTTGCAGGTTGACAATG 
mSOCS2 Fwd CGCGTCTGGCGAAAGC 
mSOCS2 Rvs TTCATTAACAGTCATACTTCCCCAGTA 
mSOCS3 Fwd AACTTGCTGTGGGTGACCAT 
mSOCS3 Rvs AAGGCCGGAGATTTCGCT 
mSOD1 Fwd TTTTTTGCGCGGTCCTTTC 
mSOD1 Rvs GACCAGAGAGAGCAAGACGAGAAG 
mSOD2  Fwd TCACTCACGGCCACATTGAG 
mSOD2  Rvs CAGTCATAGTGCTGCAATGCTCTA 
mSOD3 Fwd CATGCAATCTGCAGGGTACAA 
mSOD3 Rvs AGAACCAAGCCGGTGATCTG 
mSrxn1 Fwd   GCATCCACACCAGACTTGCA 
mSrxn1 Rvs   CCGGGTAGTGGTGCTGATGT 
mt-CO1 Fwd TGCTAGCCGCAGGCATTAC 
mt-CO1 Rvs GGGTGCCCAAAGAATCAGAAC 
mUqcrc2 Fwd GCGCTTCACTCTCAGGTCAAA 
mUqcrc2 Rvs CCAGCCACTTGCTTGATGCT 
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Appendix VI: List of antibodies used for immunoblotting and 
immunoprecipitation 
Antibody Vendor Dilution   Antibody dilution  
Buffer 
Acetylated tubulin 
(K40) 
Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Akt Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Akt2 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
ASCL3 Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
Bmi1 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Catalase Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
CDK4 Cell Signaling Technology 
(MA, USA) 
1:2000 5% Skim milk/TBST 
CIS Cell Signaling Technology 
(MA, USA) 
1:1000 WB 
1:100 IP 
5% BSA/TBST 
Cox IV Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Cytochrome C Abcam Inc (MA, USA) 1:1000 5% Skim milk/TBST 
E-cadherin Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
EGFR Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
eNOS Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
ERK1/2 Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
FGF21 Abcam Inc (MA, USA) 1:1000 5% BSA/TBST 
GAPDH Cell Signaling Technology 
(MA, USA) 
1:1000  
 
5% BSA/TBST 
GCN5 Abcam Inc (MA, USA) 1:1000 5% BSA/TBST 
GFP Abcam Inc (MA, USA) 1:2000 5% BSA/TBST 
GH1/2 Santa Cruz (CA, USA) 1:500 5% BSA/TBST 
Haemagglutinin 
(HA) antibody 
Covance  (NJ, USA) 1:1000 WB 
1:100 IP 
5% Skim milk/TBST 
HNF4A Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
IGF-1R Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
IL-1RA Abcam Inc (MA, USA) 1:5000 5% BSA/TBST 
IRS1 Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
IRβ Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
Jak2 Cell Signaling Technology 
(MA, USA) 
1:1000 WB 
1:100 IP 
5% BSA/TBST 
Lyn Cell Signaling Technology 
(MA, USA) 
1:1000 WB 
1:50 IP 
5% BSA/TBST 
mTFAM Abcam Inc (MA, USA) 1:500 5% BSA/TBST 
Myc-tag Cell Signaling Technology 
(MA, USA) 
1:1000 WB 
1:100 IP 
5% BSA/TBST 
NF-κB p65 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Nox4 Santa Cruz (CA, USA) 1:500 5% BSA/TBST 
Nrf1 Cell Signaling Technology 1:1000 5% BSA/TBST 
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(MA, USA) 
Nrf2 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
OxPhos cocktail Abcam Inc (MA, USA) 1:2000 5% Skim milk/TBST 
P-Akt (Ser473) Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
P-Akt (Thr308) Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
P-AMPK (Thr172) Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
P-ERK p42/p44 
(Thr202/Tyr204) 
Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
P-Jak2 
(Tyr1007/1008) 
Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST5  
P-p38 
(Thr180/Tyr182) 
Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
P-Src (Tyr416) Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
P-STAT3 (Tyr705) Cell Signaling Technology 
(MA, USA) 
1:1000 5% Skim milk/TBST 
P-STAT5 (Tyr694) Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
p21 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
p38 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
PGC1 Abcam Inc (MA, USA) 1:1000 5% BSA/TBST 
PTEN Cell Signaling Technology 
(MA, USA) 
1:2000 5% BSA/TBST 
PTP1B Abcam Inc (MA, USA) 1:1000 5% BSA/TBST 
Sdha Cell Signaling Technology 
(MA, USA) 
1:2500 5% BSA/TBST 
Sirt1 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Sirt2 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Sirt3 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
Sirt6 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
SOCS2 Cell Signaling Technology 
(MA, USA) 
1:1000 WB 
1:100 IP 
5% BSA/TBST 
SOCS3 Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
SOD1 Abcam Inc (MA, USA) 1:10000 5% BSA/TBST 
SOD2 Abcam Inc (MA, USA) 1:10000 5% BSA/TBST 
Srnx1 Santa Cruz (CA, USA) 1:1000 5% BSA/TBST 
STAT3 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
STAT5 Santa Cruz (CA, USA) 1:5000 5% BSA/TBST 
Trx1 Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
UCP-1 Abcam Inc (MA, USA) 1:1000 5% BSA/TBST 
Vimentin Cell Signaling Technology 
(MA, USA) 
1:1000 5% BSA/TBST 
β-tubulin Cell Signaling Technology 
(MA, USA) 
1:1000 5% Skim milk/TBST 
 410 
 
 
  
Sheep Horseradish 
peroxidase-
conjugated anti-
goat IgG 
Santa Cruz (CA, USA) 1:10000 5% BSA/TBST 
Donkey 
Horseradish 
peroxidase-
conjugated anti-
mouse IgG 
GE Healthcare Life Sciences 
(Dusseldorf, Germany) 
1:10000 5% Skim milk/TBST 
Donkey 
Horseradish 
peroxidase-
conjugated anti-
rabbit IgG 
Santa Cruz (CA, USA) 1:10000 5% BSA/TBST 
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Appendix VII: Gene expression analysis of key GH/IGF-1 axis 
molecules in cancerous and normal tissues 
 
Figure S.1. Expression of GHR (A), PRLR (B), GH1 (C), GH2 (D), PRL (E), IGF- 1 (F) and IGF-1R (G) 
from Cancer Cell Line Encyclopedia (CCLE).  
CCLE GHR mRNA expression levels from 947 cell lines in 36 tumour classifications. Expression levels are represented 
as box-and-whisker plots with median expression level indicated by a line, the inter-quartile range by a box, and bars 
represent 1.5x the inter-quartile range. The number of samples for each cancer type (n) is shown in parentheses. Gene 
expression data was extracted from CCLE_Expression_Entrez_2012-10-18.res and is presented as gene-centric Robust 
Multi-array Average-normalised mRNA expression levels. This data was extracted from the publicly accessible CCLE 
database (Barretina et al, 2012). 
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Figure S.2. Expression of GHR (A), PRLR (B), GH1 (C), GH2 (D), PRL (E), IGF-1 (F) and IGF-1R (G) 
from Genotype-Tissue Expression (GTEx) database (Consortium, 2013). 
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Appendix VIII: Human Growth Hormone Receptor cDNA 
sequence 
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This figure outlines the nucleotide (upper line) and amino acid (lower line) sequences of the full-
length hGHR. Nucleotide numbering is in black, blue numbers correspond to amino acids of the 
full-length transcribed protein or immature receptor (from M at the signal peptide being 1), and red 
numbers correspond to the mature protein (excluding 18 amino acids of the putative signal peptide 
sequence, M is residue number -18). Exon boundaries are indicated by arrows and numbering, eg 
5/6 indicates the boundary between exon 5 and exon 6. The residues that make up the putative 
signal peptide are indicated by a dashed underline and the putative TMD is indicated by a solid 
underline.  The WSxWS like motif (YGEFS in hGHR) is indicated by the grey box, and the Box1 
and Box2 motifs are indicated by white boxes. Figure developed from (Waters, 1999). 
 
  
 424 
Appendix IX: A new cytokine receptor activation paradigm: 
activation of Jak2 by GHR 
 
Accepted manuscript comprising part of Chapter 3. 
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A new cytokine receptor activation paradigm: activation of JAK2 by the 
Growth Hormone Receptor 
Authors: Andrew J. Brooks1*, Wei Dai3, Megan L. O’Mara2, Daniel Abankwa1, Yash Chhabra1, 
Rebecca A. Pelekanos1, Olivier Gardon1, Kathryn A. Tunny1, Kristopher M. Blucher1, Craig J. 
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*Corresponding authors: m.waters@uq.edu.au, a.brooks@uq.edu.au   
Abstract:  
JAK-STAT signaling is key to many aspects of biology and medicine, yet the mechanism used 
by cytokine receptors to initiate signaling is enigmatic. We present the first complete mechanistic 
model for JAK2 activation based on an archetypal cytokine receptor, the growth hormone 
receptor. To formulate this model we have used FRET to monitor positioning of the JAK2 
binding motif, Jun-zipper receptor constructs to control receptor transmembrane (TM) helix 
position, atomistic modeling of TM helix interactions and docking of JAK2 kinase and inhibitory 
pseudokinase crystal structures with an opposing pair in trans. Surprisingly, we find that 
activation of the receptor dimer induces a separation of its JAK2 binding motifs, driven by a 
ligand-induced transition from a parallel TM helix pair to a left handed crossover arrangement. 
This mechanism leads to removal of the pseudokinase domain from the kinase domain of the 
partner JAK2 and pairing of the two kinase domains, facilitating trans-activation. This model 
may generalize to other class I cytokine receptors. 
One Sentence Summary:  
We present a novel mechanism for activation of JAK2 tyrosine kinase by a typical cytokine 
receptor, the growth hormone receptor, and the molecular movements involved. 
Dedication: Dedicated to Professor Henry G Friesen  
Main Text:  
Class I cytokine receptors are key regulators of many processes including postnatal growth, 
erythropoiesis, myelopoiesis, lactation, and metabolism. These receptors utilize the JAK-STAT 
signaling pathway, which when deregulated becomes an important oncogenic pathway (1). 
Despite this, the molecular process responsible for activation of JAK2 tyrosine kinase by class I 
cytokine receptors has remained elusive.  
The first class I cytokine to be cloned was growth hormone (GH), as was its receptor. 
These have been mechanistic exemplars for class I signaling molecules since publication of the 
crystal structure of the 2:1 complex of GH receptor (GHR) extracellular domains (ECDs) with 
the hormone (2). That structure led to a model of receptor activation wherein hormone-induced 
receptor dimerization resulted in close proximity of the receptor intracellular domains (ICDs) 
and apposition of the activation loops within the catalytic domains of a pair of receptor-bound 
JAK2 kinases, resulting in kinase activation (3). However, for the GHR and other related 
cytokine receptors such as the erythropoietin (EPO), prolactin, and thrombopoietin receptors, this 
model was superseded with the demonstration that these receptors exists largely as an inactive 
dimer in the absence of ligand (4-9). It was found that the transmembrane domain (TMD) of 
these single pass cytokine receptors play an important role in the constitutive dimerization 
through use of the ToxCAT/ToxR assay for the EPO Receptor (EPOR), and FRET and Co-IP 
studies with the GH and prolactin receptors. The existence of such dimers implies that a specific 
ligand-induced conformational change is required for signal transmission to the associated 
cytoplasmic JAK2 kinases.  
Comparison of receptor subunit 1 in the 2:1 complex of the GHR with our unliganded 
crystal structure showed only minor conformational differences, implying that the signal is 
initiated by subunit realignment as a result of the asymmetric placement of the receptor binding 
sites on GH (5). How this realignment is used to bring the dimeric receptor-associated JAK2 pair 
into productive interaction has remained elusive, despite the obvious importance of JAK-STAT 
signaling in biology. Single particle electron microscopic imaging of homologous JAK1 has not 
thus far been able to resolve this issue, while the full crystal structure of JAK2 itself is not yet 
resolved (10). An appropriate model for JAK2 activation by its associated cytokine receptor 
should provide a means of removing the inhibitory pseudokinase domain from the kinase domain 
of JAK2, and then align the kinase domains for their transactivation and signal initiation. This 
model should also account for the observation that mutations V617F and Y613E, which result in 
constitutively active JAK2 mutants, are only active at physiological expression levels in the 
presence of receptor dimers (11, 12). It should also encompass the finding that JAK2 binds to the 
juxtamembrane (JM) Box1 sequence of GHR via residues close to the end of the N-terminal 
FERM domain (13). 
We present here a model for activation of JAK2 by GH and the molecular movements of 
its receptor which bring about this activation, based on experimentation and molecular modeling 
(view animation at http://web-services.imb.uq.edu.au/waters/hgh.html). We anticipate this has 
application to other class I cytokine receptors. 
Results 
GHR TMD interaction supports the role of the TMD in constitutive dimer formation and the 
importance of key residues in TMD helix packing 
Previous data have indicated a key role for the GHR TMD in ligand-independent receptor 
association (5). To characterize which interactions within the TMD contribute to constitutive 
GHR dimerization, the ToxR assay (14) was used. This assay provides a colorimetric measure of 
TMD interactions using isolated TMDs expressed in the inner cell membrane of E. coli (fig. S2), 
and has been used to demonstrate TMD association for the homologous EPOR and TpoR (8, 15). 
The ToxR assay showed that the GHR TMDs self-associate (Fig. 2A), although less strongly 
than the homodimeric EPOR or the leucine zipper control, but strongly compared to the non-
interacting poly-alanine (Alanine 16) control. The N-, C-terminal and central portions of the 
GHR TMD were all shown to interact in this assay. Pro266 and the first glycine (274) of the 
GxxG motif (both of which are highly conserved, fig. S1) appear to weaken the TMD helix 
interaction, since interaction increased on conversion of these residues to Ile (Fig. 2B and 2C). 
Substitution of individual residues within the TMD with alanine is known to have negligible 
effect on helix interactions for these cytokine receptors (15), so we introduced disruptive Gly-Pro 
double substitutions at 272IF and 282LF. These substitutions significantly decreased helix 
interaction (as they do for the EPOR TMD interaction, where they are thought to introduce a 
kink (6). Conversely, substitution of 280VM with GP has the opposite action, increasing GHR 
TMD helix interaction (Fig. 2C). These results support the view that the GHR TMD helices do 
associate constitutively in a specific manner, but not so strongly as to preclude realignment as a 
result of ligand binding to the ECD.  
Verification of constitutive dimer formation of GHR in mammalian cells was obtained by homo-
FRET using confocal microscopy anisotropy analysis at the cell surface (16, 17) (Fig. 2D). As 
controls for these experiments we determined the FRET efficiency measured by fluorescence 
anisotropy of constitutive monomeric and dimeric versions of the Receptor-type tyrosine-protein 
phosphatase alpha (RTPTĮ) transmembrane protein and compared with that of the GHR fused to 
mCitrine (mCit) after residue 341, 37 residues after the Box1 sequence. For the monomeric 
RTPTD construct the TMD was exchanged for the monomeric LDL receptor (18), while the 
dimeric RTPTD construct a constitutive disulfide bond was introduced in the extracellular 
domain adjacent to the TMD (19-21) (see Supplementary Materials). This data shows that it is 
evident that the GHR receptor exists primarily as a dimer at the surface of live cells.  
Cysteine scanning analysis of GHR TMD interactions indicates relative orientation of helices 
in the receptor dimer 
TMD association was verified using cysteine crosslinking of the TMD and juxtamembrane (JM) 
residues. For these studies a receptor construct was truncated in the intracellular domain after 
residue 388 and Cys259 was converted to Ser, resulting in a receptor that was absent of cysteines 
C-terminal of the lower cytokine domain. Within this construct each amino acid from the top of 
the JM linker that joins the lower cytokine domain to the TMD, down to the end of the TMD 
(Leu251 to Ser288) was individually mutated to cysteine, and crosslinking between receptors 
was examined. For these experiments both intact cells and cell membranes were used. We 
crosslinked with either a cell-permeable 5Å linker (MTS) or through the formation of a disulfide 
bond using Cu-phenanthroline. Crosslinking with MTS in intact cells revealed  dimeric and 
monomeric forms, with all of the N-terminal JM residues (Cys259-Phe265) crosslinking 
similarly, presumably reflecting flexibility in the absence of ligand. However, within the bulk of 
the TMD there was a helical periodicity evident in dimer formation, and when crosslinked 
residues were plotted on a helix wheel projection, an interaction interface was apparent, which 
included Ileu272/Phe273, Ile275/Phe276, and Val280 with crosslinking just visible at Phe283 
(Fig. 3A and 3B). It should be noted that MTS has limited accessibility to residues buried deep in 
the bilayer where little reactive thiolate anion is present (22), which is presumably the reason for 
the low efficiency of dimer formation towards the cytoplasmic side. This interface correlates 
well with the basal state configuration predicted by molecular dynamics (MD) simulations (Fig. 
6). Notably, the conserved GxxG motif is not involved in the TMD interaction in the basal state. 
Crosslinking of cell membranes with Cu-phenanthroline, though less able to penetrate the cell 
membranes, did show crosslinks could form from Thr258 to Ileu268, and again from Thr280 to 
Leu286 at the lower TMD boundary. 
The extent of crosslinking in the presence or absence of human GH (hGH) was next 
investigated in cell membrane preparations. We observed increased Cu-phenanthroline-induced 
crosslinking of Asp262Cys, located in the JM region, in the presence of hGH (Fig. 3C), although 
other residues did not yield consistent results. This supports the view that ligand binding 
increases the proximity between JM residues in this conserved membrane proximal sequence, 
and is consistent with hGH-induced formation of disulfide dimers at the adjacent Cys259 residue 
in the native receptor as reported by others (23). 
GHR dimerization by disulfide bond formation at the extracellular JM and TMD results in 
constitutively active receptors 
GH, like its structural homologs EPO and Prolactin, has two asymmetrically placed receptor 
binding sites which would change the interaction geometry between the two receptor subunits on 
binding. To understand the nature of this change we began with the observation that a minor 
fraction of the cysteine-substituted receptors described above form crosslinked dimers 
spontaneously in the absence of ligand (fig. S3). Hence, we could observe the activity of full 
length dimerized receptor in the absence of ligand through cysteine substitution at crosslinked 
residues within the JM linker and upper TMD helix regions. For these experiments we also 
mutated wild type (WT) Cys259 to serine. Transient expression in HEK293 cells revealed that 
constitutive crosslinking of the GHR with cysteine substitutions between Glu260 and Leu269 is 
accompanied by receptor activation (measured as STAT5 Y694 phosphorylation), while above 
this the dimer formation and activation is weak. No significant dimer formation or signaling was 
seen with Cys259 converted to serine, ie when no JM or TMD free cysteines are present (Fig. 
3D). Evidently dimerization within the upper TMD or the extracellular EED sequence can 
initiate signaling, ie only close apposition of the upper TMD is required for signaling. 
Accordingly, introducing two disulfide bonds by cysteine substitution at E260C and I270C 
resulted in even stronger receptor activation (Fig. 3D). 
Controlled dimerization of GHR using Jun zipper-receptor chimeras combined with FRET 
analysis reveals that increased receptor activation correlates with an increase in separation of 
the Box1 motifs 
To better understand the steric requirements for receptor activation we substituted the GHR ECD 
with a leucine zipper from c-Jun. This allowed us to control the positioning of the TMD without 
compensatory movements by the ECDs. The positioning of the cytoplasmic JAK2-binding Box1 
motif was then monitored by placing C-terminal FRET reporters (mCit or mCFP) 37 residues 
below the Box1 sequence. The receptor truncation and addition of FRET reporters did not 
prevent JAK2 binding, and GH addition was able to activate JAK2 with these receptor constructs 
(fig. S4 and S5). 
We first positioned the Jun zipper 12 residues above the presumed TMD boundary, where 
the GHR linker joins to the lower cytokine receptor domain. We had previously shown that this 
construct results in constitutive activation (24). Shortening the linker by 4 residues at a time 
revealed that the closer the Jun zipper came to the TMD, the stronger was the signal that was 
generated, as measured by cell proliferation (Fig. 4A and 4B). Surprisingly, strength of signal 
correlated inversely with FRET ratio, ie signal activation was associated with separation of the 
Box1 sequences (Fig. 4C to 4E). Next the Jun zipper was placed at the upper TMD boundary and 
the helices were rotated by inserting 1-4 alanines sequentially at the junction with the TMD. 
There was an optimum rotational position for signal activation, with the active and inactive 
positions adjacent. Again, the FRET ratio indicated that separation of the Box1 sequences occurs 
in the active rotational position (Fig. 4F to 4H). In order to exclude the possibility that the 
changes in FRET ratio resulted from reorientation of the fluorophores rather than their 
separation, the comparison of the 3Ala and 4Ala Jun insertion constructs was repeated using a 
flexible linker RSIAT (25) between the fluorophores and residue 341 of the receptor. This did 
not influence the FRET ratio comparison, from which we conclude that the decreased FRET 
ratio in the active states is due to an increased distance and not a result of fluorophore rotation 
(fig. S6). 
Because clamping the receptors together at the upper TMD interface, either by use of the 
Jun zipper (Fig. 4A to 4E) or through disulfide bond formation (Fig. 3D) resulted in receptor 
activation, the role of the conserved EED acidic sequence (fig. S1) positioned therein was 
examined. It seemed likely that like-charge repulsion could maintain separation of the receptors 
here and play a role as a gating mechanism to maintain the receptor in an inactive state in the 
absence of ligand. Repulsion could then be overcome by ligand binding inducing closer 
apposition of the receptors within the constitutive dimer. This hypothesis was explored by 
comparing the Jun-3Ala construct with an equivalent construct where the three alanines were 
reverted to the WT 260EED sequence. As shown in Fig. 5A, this showed the presence of the AAA 
sequence compared to EED substantially increased the proliferative activity and again decreased 
the FRET ratio at the Box1 domain, again indicating that when the receptor dimer is clamped 
tighter together at the upper TMD interface, the Box1 motifs separate. 
We then asked if this phenomenon applied to the full length receptor and could act as a 
gate for receptor activation. We introduced the charge reversal mutations KKR in place of the 
EED sequence and co-transduced the full length KKR construct together with the WT construct, 
or separately, into Ba/F3 cells and looked for constitutive activity. Electrostatic attraction at this 
position was found to partially activate the full length receptor (Fig. 5B). This activation was 
again shown to be associated with separation of the Box1 sequences below the membrane by 
using GHR constructs that contained the full ECD with mCFP/mCit reporters placed after the 
Box1 motif in the same manner as the Jun zipper constructs (Fig. 5C). Expression of WT-GHR 
or KKR-GHR individually gave similar FRET values, while co-expression of both constructs 
gave a significantly lower FRET value, again demonstrating the inverse correlation between 
activation and separation of the Box1 motif.  
Importantly, by using the full ECD WT-GHR FRET constructs we verified that the 
binding of hormone alone to the receptor on intact cells also resulted in a significantly decreased 
FRET ratio with membrane extracts from these cells (Fig. 5D). The GHR D170H mutation (often 
referred to as D152H using numbering of the mature protein) which results in GH insensitive 
Laron dwarfism (26) was then introduced into these FRET constructs and was found to prevent 
the decrease in FRET seen with WT receptor in response to GH binding (Fig. 5D). Finally, the 
decrease in FRET ratio induced by WT GH was not seen with the clinical GH antagonist G120R 
hGH, and this blocked the decrease in FRET ratio induced by WT GH (Fig. 5D). 
We believe that a previous observation that hormone binding to GHR produced a 
transient increase in FRET signal (27) is a result of their FRET reporters being placed at the C-
terminus. Given the relative immobilization of receptor-bound JAKs below the TMD, the lower 
cytoplasmic domains must move toward the JAKs for tyrosine phosphorylation to occur. This 
would be facilitated by an unstructured cytoplasmic domain as is known to occur in the JAK1-
gp130 couple (28). 
Lysine 289 at the GHR TMD-ICD boundary plays a critical role in receptor activation 
The data presented above are consistent with a gating mechanism at the upper TMD boundary 
that holds the receptors apart, minimizing activation in the absence of ligand. We then 
investigated whether there are residues which hold the submembrane sequences together in the 
inactive state similar to the TPO receptor (TpoR or c-Mpl), where mutations within the 
conserved sequence above the Box1 domain results in constitutive activation and 
myeloproliferative neoplasms (29). As shown in Fig. 5E and 5F alanine substitution within the 
equivalent conserved SKQQRIK sequence (fig. S1) in the GH receptor revealed conversion of 
the first lysine residue (289) to alanine resulted in increased signaling. This finding parallels the 
result of Staerk et al (2006) (29) showing increased activation for the equivalent K507A mutant 
in TpoR. Again, for K289A GHR, the submembrane FRET reporters indicate increased 
separation of the Box1 sequences (Fig. 5E) through movement of the JM Į-helical sequence 
(30). 
Molecular simulations of GHR TMDs identify active and inactive dimer orientations. 
In order to understand the above experimental data in terms of a molecular model, extensive in 
silico modeling of the hGHR TMD helix dimers was undertaken, initially in vacuo. As shown in 
fig. S7, searches in vacuo of helix rotation angles for both right and left handed crossing angles 
predicted a helix alignment corresponding to crosslink data (Fig. 3A), with interactions between 
Phe276 and Phe283 (lowest free energy, Cluster 1, fig. S7A). The rather different chicken GHR 
sequence was predicted to give a similar alignment (fig. S7C). 
To understand the dynamics of receptor activation, we then used MD simulations to 
model the behavior of the TMDs in a lipid bilayer (Fig. 6A, B and Supplementary Materials). A 
coarse grained (CG) representation of the peptide, lipids and solvent (31) was used to obtain the 
free energy profile as a function of distance (PMF) between two TMD by exhaustive Monte 
Carlo simulations using 128 replica pairs for a range of separations between the centers of mass 
of the helices (32). The fact that the PMF has a deep minimum at a separation of 0.7-0.8nm with 
a predicted free energy of binding around 10 kcal/mol supports the finding that two TMDs 
interact strongly with minimal free monomer present (Fig. 6B). 
We next sought measures to characterize our modeling data such as the crossing angle  
between the helix axes, the helix tilt angles Ĳ, and contact maps between specific amino acids 
within the two TMDs. Fig. 6C shows the maps of the contacts between the two helices as they 
approach within a lipid bilayer. Helices tilt and interact first when the lateral separation of the 
centers of mass is ~2nm. Repulsive interactions at the N-termini result in formation of an initial 
contact at the C-termini. Subsequently, the TMDs follow a path that maximizes interactions 
between the Phe residues and Thr-Thr hydrogen bonding. This initially leads to an essentially 
parallel dimer (State 1 in Fig. 6D) with a low  value but with many interactions. Closer 
approach of the helices (as could result from hormone binding) leads to a close-packed structure 
(State 2 in Fig. 6E) with increased tilting and , resulting in a left handed cross over dimer with 
increased separation at the C-terminus (see below). Both State 1 and 2 lie within the energy 
minimum shown in Fig. 6B, indicating a relatively facile State1-State2 transition. This transition 
has been observed for other TMDs using coarse-grained and atomistic simulations in simpler 
environments (33, 34). GHR TMDs form the left handed dimer by rotating Phe276 and 283 out 
of the interface. Importantly, right handed essentially parallel dimers at close separation readily 
rearrange to left handed dimers (State 2) by substitution of disulfide bonds at Glu260 and Ile270 
(Fig. 7A and 7B) which correlates with the constitutive receptor activation seen in Fig. 3D with 
such dimers. 
To better identify structures correlated to activity we needed to compare our predictions 
with mutation and crosslinking experiments. Therefore, atomistic models of helical TMDs were 
superimposed onto the structures from the CG simulations and subjected to MD in large lipid-
bilayer systems for several months of CPU time. For State 1, three structures were each 
simulated for 0.3µs. Fig. 6D shows a snapshot of one such dimer (State 1) together with an 
analysis of the separation between specific residues for which cysteine substitutions had been 
performed for each of the three trajectories. All three dimers fluctuated significantly but 
maintained a separation of between 0.9-1.2nm, slightly tilted relative to the normal of the bilayer 
and in a parallel arrangement with low . These dimers are characterized by extensive 
interactions between Phe residues and appear to be stabilized by Lys289 that anchors the lower 
C-termini at the water-hydrophobic region boundary. The predicted sulfur-sulfur separation 
distances closely resemble the experimental crosslink pattern seen with cysteine-crosslinking 
experiments in the absence of ligand, supporting State 1 as the inactive state. Note that Gly274 is 
far from the helix interface in the absence of hormone. 
Fig. 6E presents the results of a 0.7ȝs full atomistic simulation for the most stable dimer 
predicted by the simpler coarse-grain CG model (State 2), which remained helical throughout the 
0.7ȝs simulation. Backbone atoms presented small fluctuations with an overall lateral separation 
of 0.8nm. Helices tilt, rotate and pack against Gly274 with a separation of substituted cysteines 
distinctively different from the experimental data obtained for the inactive receptor. Importantly, 
when the inactive state (Fig. 6D) is compared with the left handed crossover form in Fig. 6E, 
separation between the C-termini has increased substantially (evident in the Cys substitution 
sulfur-sulfur distances). The increased separation parallels our finding that activity correlates 
with higher separation of the C-termini as monitored by FRET. Moreover, in the proposed active 
State2 form the N-terminal Trp267 sits favorably at the membrane interface, facing outward to 
favor association, while the C-terminal Lys289 is in an unfavorable configuration for helix 
interaction (ie allowing greater separation), consistent with NMR studies using model peptides 
(35). Thus the model can explain how alanine substitution of Lys289 promotes the left handed 
dimer form, correlating with the increased activation seen on conversion of Lys289 to alanine 
(Fig. 5E and 5F). 
Finally, a chimeric model was constructed in which the proposed TMD dimer 
configurations were joined to the crystal structure of the human GH:ECD receptor complex 
(PDBid:3HHR). Missing residues were generated using Modeller 
(http://salilab.org/modeller/about_modeller.html). The overall best configuration based on 
Modeller’s objective function for the linking amino acids is shown in Fig. 7C. This shows a good 
fit between the ECD positioning and the State2 configuration and places the two Cys259 residues 
in close enough proximity to form a disulfide bond, as previously shown experimentally after 
GH addition (23). We could also identify potential inter-receptor hydrogen bonds in the linker 
that could assist in stabilizing the active configuration, between Glu260 of receptor 1 and the 
amide of Trp267 in receptor 2, as well as between the backbone carbonyl of Phe257 and amide 
of Glu260 in receptor 2. The ECDs without the hormone were then attached to the parallel TMD 
(State1). This simulation produced rotation of the ECDs, as described previously for isolated 
ECDs (36). Interestingly, in these simulations the linker region sat on the membrane, although 
the ECD domains did not separate. This observation is consistent with our inability to crosslink 
receptors above Cys259 efficiently in the basal state. Potentially this is related to repulsion 
between the acidic EED sequences. 
A new model for GHR activation 
The above findings are consistent with a receptor activation model wherein binding of the GH 
through its asymmetrically placed binding sites (2) would realign the two receptors by relative 
rotation as evident in MD simulations (36), and together with elevation of receptor 1, lock the 
two dimerization domains in the ECD closely together. This locking is necessary for signal 
transduction (37, 38), and brings the upper TMD sequences close together by overcoming the 
electrostatic repulsion of the EED gate. Closer apposition of the adjacent juxtamembrane 
sequences is presumably the reason for resistance to proteolytic attack on the receptor when GH 
is bound, in contrast to its sensitivity when the G120R hGH antagonist is bound (39). Closure of 
the upper TMD would promote the transition to the left handed TMD form, with increased 
separation of the Box1 sequences. 
A new model for JAK2 activation by GH 
Separation of the JAK2 binding Box1 sequences as a mechanism for JAK2 activation is novel. 
We have considered how such a separation might occur within a receptor dimer containing a 
JAK2 molecule bound to each receptor, given the finding that even constitutively activated 
oncogenic JAK2 mutants V617F, L611S, and Y613E require the presence of receptor for 
significant activity (11, 12), ie the receptors need to be present to correctly appose the kinase 
domains for efficient transactivation. We hypothesized that if the kinase domain of the first 
JAK2 was inhibited by the complimentary pseudokinase domain of the second JAK2, and vice 
versa, then moving the JAK2 molecules apart in a sliding motion would remove the 
pseudokinase domain inhibitions, and bring the kinase domains into productive proximity (Fig. 
7D and animation at http://web-services.imb.uq.edu.au/waters/hgh.html). 
Activation of JAK2 by GH involves removal of trans inhibition  
To provide experimental evidence for this model we placed FRET reporters (mCFP or mCit) at 
strategic locations within JAK2, then compared the FRET ratios when cells were co-transduced 
with WT rGHR (rabbit GHR) or rGHR that had the EED/KKR substitution either individually 
(inactive) or together (providing a subset of active receptors). This strategy allowed 
measurement of FRET ratios when all receptors were fixed in an inactive basal state in 
comparison to having a subset of receptors fixed in an active orientation. FRET reporters were 
placed at the C-terminus of JAK2 to monitor movement of the catalytic domains, or C-terminal 
to the SH2 domain at Asn533, in place of the pseudokinase domain. Reporter pairs were co-
transfected (or transfected separately for FRET calculations) into HEK293T cells with the rGHR 
expression plasmids. Washed membrane preparations were then prepared from these cells (to 
reduce the background signal from free JAK2) and FRET ratios were determined. While FRET 
ratio changes were modest (Fig. 7E and 7F), they were consistent. The modest changes in FRET 
would be due in part to FRET observed between three receptor interaction possibilities when the 
KKR mutant is expressed with the WT receptor, ie WT-WT (inactive), KKR-KKR (inactive), 
and WT-KKR (active). The significant increase in FRET ratio for the C-terminal reporters (Fig. 
7E) is consistent with the requirement for the kinase domains to transactivate, while the reporters 
positioned in the location of the pseudokinase domain (ie C-terminal to the SH2 domain, Fig. 7F) 
showed a decreased FRET ratio in accord with the model in Fig. 7D and the animation. 
To further substantiate our JAK2 activation model, the kinase and pseudokinase domains 
were swapped (JAK2-KP), then co-transfected together with a WT JAK2 construct and the GH 
receptor into JAK2 deficient J2A cells. Our model would predict constitutive JAK2 activity only 
when these two JAK2 constructs are together, but not for either alone. This result is evident in 
Fig. 8A where STAT5 phosphorylation by JAK2 is significantly increased when WT JAK2 and 
JAK2-KP are present, noting that in each experiment the total amount of JAK2 transfected was 
the same. Overexpression of JAK2 is known to lead to constitutive activation (40), which 
explains why some activated STAT5 is detectable when each JAK2 construct is transfected 
separately.  
Molecular modeling of the JAK2 kinase/pseudokinase domain dimer interaction 
Currently only the crystal structures of individual JAK2 kinase and pseudokinase domains are 
known (41, 42). To test if the proposed model is compatible with these structures the 
pseudokinase and kinase domain structures were docked using HADDOCK. The resulting 
equilibrated dimer after 40ns of unrestrained MD simulations (Fig. 8B) represents the interaction 
between the kinase of one molecule and the pseudokinase domain of another. In particular, the 
docked structures predict a close complementary interaction between the opposing kinase and 
pseudokinase domains. Importantly, the structure shows a close relationship between the 
activation loops and V617 in the pseudokinase domain which, when mutated, results in 
constitutive activation and oncogenesis. To make a model of the complete complex, docked 
kinase and pseudokinase pairs were placed in alternative orientations with another pair, and the 
cognate domains of each JAK2 were joined with their 30 residue interdomain linker. Fig. 8C and 
7D show two orientations and their movements that are consistent with our experimental results.  
We then verified that the pseudokinase-kinase pair can associate with a second such pair using 
AlphaScreen (fig. S9A to C) based on cell free expression of N-terminal eGFP or C-terminal 
mCherry-Myc tagged pairs. We supported this with single molecule brightness coincidence 
results consistent with dimerization of pseudokinase-kinase pairs using cell free expressed GFP 
tagged proteins (fig. S9D). As is evident in fig. S9F while the separate kinase domains do not 
associate under these conditions, the pseudokinase-kinase pairs do associate effectively in trans. 
Discussion 
This study has allowed us to propose a novel mechanism for activation of JAK2 by the growth 
hormone receptor, an archetypal class I homomeric cytokine receptor. We have shown that the 
receptor exists as a constitutive dimer with its TMDs held in an inactive orientation in the 
absence of hormone (with the caveat that some monomer is likely present). The central 
observation on which our model is based is that activation of the receptor is associated with the 
separation of the membrane proximal signaling domains below the TMD, as assessed by FRET, 
and consistent with MD modeling of the TMD.  
In formulating a model to explain the increased separation of Box1 sequences on ligand 
binding, we were cognizant of our earlier finding that locking together of the ECD “dimerization 
domains” of the membrane proximal cytokine receptor module by specific hydrogen bonds and 
electrostatic bonds is essential for GH signaling (37). Based on MD modeling (36) this locking 
requires a relative rotation of receptor subunits of around 40q, and disruption of this lock with the 
D170H mutation results in GH insensitive (Laron) dwarfism (1). We previously proposed that 
this locking resulted in activation of the receptor by relative rotation of the TMDs that was 
transmitted to the JAK2 binding Box1 sequence to allow contact of their catalytic kinase 
domains (5). However, when we introduced alanine insertions in the upper TMD of full-length 
receptor we observed only weak receptor activation, indicating some other ligand-induced 
movement was necessary for robust activation. 
We explored the geometry of activation by clamping the receptor signaling units (TMD 
and cytoplasmic domain) together in defined ways, and observed that bringing a Jun zipper 
clamp down to the membrane surface gave the strongest activation, although concurrent insertion 
of alanines at the upper TMD boundary did show an optimum rotational position within the 
clamped receptor. Support for this model was provided by cysteine crosslink scanning of the 
upper linker and TMD residues, which showed that crosslinking at the EEDF sequence just 
above the TMD could activate the receptor in an analogous manner to the Jun zipper clamp. 
Similar crosslinking results have been reported for the full length EPOR (43), and an optimum 
rotational position for activation has been reported for both EPOR (44) and TpoR (45). These 
findings suggest a common mechanism within related class I receptors involving both an 
optimum rotational position and the need to closely appose the upper JM sequences for 
activation, resulting in a “tilt and twist” movement of the TMDs. This is supported by the finding 
that the TMD and ICD of the G-CSFR and GHR, both class I cytokine receptors, can be 
interchanged to produce signaling competent receptors (46). This result implies that the 
conserved GxxG sequence of the GHR TMD is not necessary for receptor activation, and indeed, 
we have found that substituting either Gly, or both, with bulky Ile residue does not have a 
significant effect on proliferative signaling or STAT5 activation (not shown). 
Our activation model requires separation of the Box1 motifs. Given that, how could 
separation result in activation of JAK2 bound by its FERM domain to the lower JM segment of 
each receptor? Current models of JAK2 assume that it exists as a monomer, where each JAK2 is 
autoinhibited by its own pseudokinase domain in the basal state (47). However, other studies (11, 
12) show that constitutively active JAK2 point mutations require a receptor dimer to manifest at 
physiologic expression. Clearly a new model is needed to account for this finding and our FRET 
observations. The original JAK2 structural model (48) has been superseded by the recent 
elucidation of the JAK2 kinase and pseudokinase domain crystal structures. We used these to 
determine if two kinase domains and two pseudokinase domains could pair in a complementary 
fashion such that an increased distance between the receptors and their attached JAK2 would 
slide the pseudokinase domains away from the kinase domains of their opposing counterpart, and 
bring the two kinase domains together for trans-activation. Indeed, we found optimized docked 
solutions which allowed this interaction, and also located key residues known to be associated 
with constitutive activation of JAK2 (eg in myeloproliferative disorders) in the interface between 
the inhibitory pseudokinase domain and its kinase domain complement in the basal state. By 
placing FRET reporters either at the C-teminus (kinase domain) or in place of the pseudokinase 
domain, we were able to show experimentally that the FRET ratio for the pseudokinase domains 
decreased on receptor activation (as predicted), while the ratio for the catalytic domains 
increased, supporting a model in which the domains slide apart. Further, by exchanging the 
kinase and pseudokinase domains we were able to obtain strong experimental support for our 
model, since when this domain reversal mutant was expressed together with WT JAK2, 
constitutive activity was evident. Finally, we could show with single molecule fluorescence 
brightness and AlphaScreen that the pseudokinase-kinase domain pair can indeed associate in 
trans with another such pair. 
We anticipate that these findings will provide valuable insights into the design of new 
cytokine receptor therapeutics and will facilitate understanding of a variety of relevant cytokine-
related genetic disorders. 
Methods: 
ToxR Assay of TMD Interaction 
This well validated assay provides a means for testing the interaction of TM helices that are 
placed in the inner membrane of bacteria. ToxR assays were performed essentially as previously 
described (14) using regions of the GHR TMD described in the Results. See fig S2 for the 
principle of this assay. 
Cysteine Crosslinking Studies 
A series of N-terminal HA-tagged hGHR mutants in pcDNA3.1 was constructed using 
Quickchange mutagenesis where every residue from Pro252 to Ser288 was converted to a 
cysteine after converting Cys259 to serine. Two sets of these mutants were used: either truncated 
at residue 389 (for crosslinking studies) or full length GHR (for STAT5 activation studies). 
These mutants were used for crosslinking according to (49) and immunoblotting or signal 
activation studies as detailed in Supplementary Materials. 
Analysis of Proliferative Signal from GHR Constructs 
The strength of constitutive proliferation signal from GHR constructs was assessed by starving 
Ba/F3 cells overnight in Ba/F3 starve media (see Supplementary Materials). Cultures were then 
counted using a Scepter with 40 µM sensors (Millipore) and seeded at equal concentrations into 
three flasks for each sample and cultured in starve media. Cell concentration was subsequently 
counted on following days and plotted as shown. 
FRET Analysis 
FRET measurements, using expression constructs detailed in Supplementary Materials, were 
performed on single cells by confocal microscopy and flow cytometry essentially as previously 
described (50). Membrane extracts and FRET analysis with a fluorescence plate reader was 
essentially as described previously and detailed in Supplementary Materials. Live cell membrane 
Homo-FRET methods are described in the Supplementary Materials.  
Signaling Analysis of JAK2 Co-transfected with Kinase-Pseudokinase Domain Swap JAK2 
Expression constructs for WT murine JAK2 and for JAK2 with the kinase domain and 
pseudokinase domain swapped (referred to as JAK2-KP corresponding to: (Met1-Ile540)-
(Asp840-Ala1132)-(Gly831-Arg839)-(Asn542-Gly834)) were constructed as described in 
Supplementary Materials. JAK2 deficient (and STAT5 deficient) J2A cells (a gift from G. Stark, 
ICRF, London), were transfected with expression plasmids for hGHR, STAT5B, and either WT-
JAK2 or JAK2-KP separately, or WT-JAK2 and JAK2-KP co-transfected. In each set of 
experiments where P-STAT5 signal from co-transfected WT-JAK2 and JAK2-KP was compared 
with each JAK2 construct transfected separately, the total amount of JAK2 transfected was 
identical. Details are given in Supplementary Materials. 
JAK2 Interface Model 
To construct a model of the interface between the pseudokinase and kinase domains of 
neighboring subunits the crystal structures of the JAK2 pseudokinase (PDB id: 4FVP) and kinase 
(PDB id: 2B7A) domains were docked using the HADDOCK webserver with distance 
constraints between Tyr1007 of the kinase domain and both Phe595 and Val617 of the 
pseudokinase domain. The docked model was then refined by simulating it for 40 ns in water. 
Full details are given in the Supplementary Materials. The actual interface between the two 
consecutive kinase-pseudokinase pairs is not known. To generate possible arrangements of JAK2 
dimers that are consistent both with the 30 amino acid linker sequence and with our experimental 
data, a second copy of the MD conformation of the pseudokinaseíkinase domain dimer was 
positioned adjacent to original pair. That this arrangement was possible was confirmed by 
modelling in the missing linker region. Note, while the proposed arrangement is possible the 
model does not preclude the possibility other arrangements being consistent with the data. 
Statistics 
One way ANOVA was undertaken with Tukey’s multiple comparison test, while for 
comparisons of two groups only unpaired Student’s t test was used. Significance shown as *P< 
0.05, **P<0.01, ***P<0.001, with SEM. 
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Figure Captions 
Fig. 1. Cartoon of GHR showing key features with residue numbers. 
Fig. 2. GHR exists primarily as dimers in cell surface membranes. (A-C) GHR TMD 
association shown by ToxR assay (A) ToxR assay showing self association of GHR and EPOR 
TMDs with controls showing amino acid sequences used for each transmembrane domain 
(TMD) construct together with a Maltose Binding Protein (MBP) immunoblot of the ToxR-
TMD-MBP chimeric proteins expressed in FHK12 E. coli which was used to normalize the E-
galactosidase values in Miller units (see fig S2 for detail). (B-C) GHR TMD sequences showing 
mutations introduced to perturb TMD association as monitored in the ToxR assay (n= 4-17 
independent experiments in triplicate, values expressed as % L-16 value after normalization of E-
galactosidase activity to MBP expression). Average r SEM, with one-way ANOVA and Tukey’s 
multiple comparison post-test (*= P<0.05, **= P<0.01, ***= P<0.001 compared to test 
constructs).  Data shows that the GHR TMD associates with itself and that the first glycine 
(G274) of the GxxG motif and Pro266 inhibit helix association, as shown by replacement with 
Ile and that introduction of helix disrupting GP mutations into the TMD helix disrupt TMD 
association. (D) homo-FRET using confocal microscopy anisotropy analysis at the surface of 
live mammalian cells shows GHR is essentially dimeric in comparison to constitutive 
monomeric and dimeric versions of the Receptor-type tyrosine-protein phosphatase alpha 
(RTPTĮ) transmembrane protein. 
Fig. 3. Crosslinking of cysteine substituted GHR TMD residues shows interacting residues 
together with crosslinked residues that can induce constitutive activation. (A) Cysteine scan 
of TMD with crosslinking of transiently expressed GHR by MTS crosslinker in intact cells as 
described in Supplementary Materials. No evident orientation constraints are seen within the 
upper JM linker, but crosslinking within the TMD is periodic, and plots to one side of a helix 
wheel projection shown in (B). (C) Addition of 2 nM hGH promotes disulfide dimer formation at 
D262C in the JM linker using cell membrane preparations. Three independent experiments are 
shown with Cu-o-phenanthroline crosslinking (49). (D) Constitutive activation of spontaneously 
crosslinked cysteine substituted receptors, evident as STAT5 tyrosine phosphorylation in 
transiently transfected HEK293 cells. Level of receptor expression is shown by corresponding 
HA-blot for hGHR, and histogram shows pSTAT5 level normalized to receptor protein 
expression for three replicate experiments (mean +/- SEM).  
Fig. 4. Replacement of ECD with Jun zippers enables analysis of orientational constraints 
in constitutive signaling by GHR. Activation of proliferative signaling correlates with 
increased separation of FRET reporters placed below Box1 of the intracellular domain (ICD). 
(A) Shortening of the linker between the Jun zipper and the TMD results in (B) increased 
receptor activation in Ba/F3 cells stably expressing Jun fusion constructs. (C and D) FRET 
analysis by FACS and live cell confocal microscopy shows an inverse relation between cell 
proliferation (shown for day 8 from Fig. 4B for illustrative purposes) and FRET ratio for these 
constructs (E). (F) Rotation of the Jun clamped TMD by insertion of 1-4 alanines into the HA-
JUN-0aa-rGHR construct reveals an optimum orientation of the TMD helix for signaling (G), 
and this correlates with decreased FRET reporter signal below the TMD (H). 
Fig. 5. The GHR upper and lower JM sequences act as a signaling gates. Validation of 
FRET movement with WT receptor ECD and GH addition. (A) Replacement of the WT 
acidic EED linker sequence with 3Ala promotes proliferative signaling by Jun-GHR in stable 
Ba/F3 cells (shown for proliferation assay at day 8), and decreases FRET signal in the ICD with 
membrane preparations. (B) Expression of full length GHR in transduced Ba/F3 cells with WT 
GHR, or GHR with the 260EED residues substituted to AAA or KKR reveals that charge 
complementation of linker EED sequence by co-expression WT GHR with GHR-KKR results in 
constitutive activation. (C) When FRET reporters are placed below Box1, this activation 
correlates with decreased FRET. (D) Addition of 5 nM hGH to rGHR with FRET reporters 
below Box1 induces a decrease in FRET ratio in membrane preparations from transiently 
expressed constructs in HEK293T cells while no significant change is observed with addition of 
500 nM G120R hGH. Incubation of 500 nM G120R hGH for 10 min prior to 5nM hGH impairs 
the GH induced decrease in FRET. GHR D170H Laron mutant shows no FRET change upon GH 
addition. (E and F) Substitution of Lys289 with Ala promotes proliferative signaling in stably 
expressing Jun GHR Ba/F3 cells (shown for proliferation assay at day 3), and this correlates with 
decreased FRET from reporters placed below Box1.  
Fig. 6. Coarse Grain and Atomistic simulations of GHR TMDs. (A) Single helix showing 
predicted helicity between Phe265 and Lys289, and positioning of Trp267 at upper membrane 
boundary, with Lys289 at lower membrane boundary (see Supplementary Materials). (B) Free 
energy profiles for approach of helices showing different energetic contributions of lipid and 
protein. Note that there is only a modest total free energy difference (black line) between the 
parallel form at 11Å separation and the left handed crossover form at 8Å separation. (C) The 
three stages of helix interaction – firstly contact at the C-terminus,  then the parallel form with 
interactions between Phe276 and Phe283 (D), State1, and finally the left handed crossover form 
(E), State2, after rotation to bring the GxxG motif (green spheres) in close packing.  S-S 
separation distances are modeled for the latter two states, with 3 simulations for the parallel 
form, which corresponds to the pattern seen in the absence of hormone by crosslinking (Fig. 3). 
Fig. 7. Validation of the GHR homology model. Repositioning of JAK2 observed by FRET. 
(A) Disulfide bonding between cysteines substituted at Glu260 and Ile270 rapidly converts State 
1 to State 2 in MD simulations, correlating with constitutive activation seen experimentally. (B) 
Separations of backbone residues from MD of the active disulfide dimer overlay closely on those 
for State 2 calculated by MD simulation for 0.5-0.9 nM separations. (C) Full length simulations. 
The best model of the JM linker joined to the hGH:ECD receptor complex crystal structure (PDB 
id:3HHR) is shown. Note the proximity of Cys259s, which form a disulfide bond on addition of 
ligand. There are also two potential hydrogen bonds between linkers which could stabilize this 
conformation (see text). (D) Diagram of JAK2 dimer showing proposed movement of kinase and 
pseudokinase domains following receptor TMD separation in State 2. (E and F) FRET ratio 
measurements with activated receptor (WT + KKR charge reversal mutant as in Fig. 5B and 5C) 
and KKR or WT receptor alone, showing convergence of kinase domains and separation of 
pseudokinase domains on activation. 
Fig. 8. JAK2 kinase domain swap and modeling studies support the new activation model. 
(A) Diagram of JAK2 domain swap construct. Immunoblots showing constitutive activation of 
JAK2 when kinase and pseudokinase domains are swapped, and the domain swap is co-
transfected with WT JAK2. Result of 3 independent experiments shown with total JAK2 plasmid 
quantity identical. (B) The pseudokinase-kinase domain interface in the inactivated state after 
40ns of MD. The pseudokinase and kinase domains are shown in grey and blue ribbons, 
respectively. The following key residues are shown in spacefill representation: F595 (pink: 
required for V617F constitutive activation), V617 (red: mutation causing constitutive activation), 
substrate binding site D976 (blue). Activation loop phosphorylation residues Y1007 (yellow), 
and Y1008 (orange). The ATP binding site and catalytic K882 are shown in purple ribbons and 
spacefill, respectively. View of the dimer interface from below shows the ATP binding site is 
located in the center of residues implicated in constitutive activation. The dimer conformation 
derived from MD simulations can be used to construct two tetrameric orientations that fulfill the 
experimental data: (C) a stacked tetramer, (D) or an inverse stacked tetramer, with each JAK2 
circled. Arrows show proposed direction of movement induced by receptor separation below 
TMD, removing pseudokinase domain inhibition and bringing the kinase domains in proximity. 
  





 
 
  

Supplementary Materials: 
Supplementary Text 
In vacuo molecular dynamics modeling of TMD interactions predicts a minimum free energy 
dimer orientation 
Molecular modeling was undertaken to identify residues likely to interact in the unliganded state. 
Computational searches were carried out on a pair of human GHR transmembrane helices, 
(residues 265 to 288) in vacuo using CHI (51). The packing of the helix dimers was explored 
with helical rotation angles from 0° to 360° for each helix and both left and right handed crossing 
angles of 25° and -25° respectively. The step size was 45° with four trials carried out for each 
conformation, using a molecular dynamics (MD) simulation of all atomic coordinates allowing 
rotation- and crossing-angles to vary. These calculations used a non-bonded cutoff of 13Å with a 
switching function for van der Waals and electrostatic terms between 10Å to 12Å. The resulting 
structures were analyzed to determine the final crossing angle and rotation angles of both helices. 
Clustering the dimers identified seven significant left handed clusters (defined as a 
minimum of 8 structures within a 1Å cut off, see fig. S7A) and another three right handed 
clusters (data not shown). Of all clusters, Cluster 1 has the lowest average non-bonded 
interaction energy of -69.3kcal/mol, making it the “best” cluster overall. Unlike other clusters, 
Cluster1 has the helices packed in a two-fold symmetric orientation. The average molecular 
structure from cluster 1 is shown in fig. S7B. The dimer interface is lined by predominantly 
hydrophobic residues including Leu269, Ile272, Phe276, Phe283 and Leu286. Although there are 
two polar residues in the sequence (Thr279 and Ser288) theoretically capable of stabilizing the 
dimer through hydrogen bonding, these do not contribute to inter-helix bonding. The closest 
approach between the two helices is at Val280, where the axes of the helices are separated by 
8.3Å. This brings two phenylalanines, Phe276 and Phe283, into close proximity as pairs in the 
dimer interface. This stacking of the Phe rings explains the two substantial contributions to the 
interaction energy seen in fig. S7D at these positions in the helix, Phe276 and Phe283. These 
residues provide most of the observed binding energy. 
We carried out the same analysis with the chicken GHR TMD helix, which differs 
substantially in its sequence (fig. S7C). For the chicken GHR, there are four left handed clusters 
and two right handed clusters, with the best result being left handed Cluster4. When the average 
structure from Cluster4 was superimposed onto the best cluster from human GHR, the backbone 
RMSD was found to be 1.54Å, with the symmetry of the transmembrane helices unchanged (fig. 
S7C). From the average interaction energy plot (not shown), the residues that contribute to the 
dimer stability are similar to those in human GHR. The closest approach between the two helices 
is at Val253, equivalent to Val280 in human GHR. 
Coarse Grain Simulations in Lipid Bilayers  
The model for the GHR TMD was composed of a sequence of 33 amino acids that included the 
transmembrane domain EEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQR in di-palmitoyl 
phosphatidylcholine using the coarse-grain MARTINI model (31) imposing a helical structure 
between Phe265 and Phe287 based on input from atomistic simulations (Fig. 6A). The 
protonation state of interfacial amino acids in the coarse-grain and atomistic models was 
assigned according to neutral pH conditions. To drastically sample all accessible configurations 
at 323K we employed the multiple-walkers, multiple-windows expanded density of states 
(MW)2-XDOS method (32, 52), an efficient Monte Carlo algorithm that allows continuous 
uniform sampling of lateral centers of mass separations without a priori knowledge of the free 
energy profile. Simulations were performed over 16 windows with 8 pairs in each window; all 
128 pairs were capable of forming dimers or sample large separations where no correlations 
persist through replica exchanges between different processors. Free energy profiles and 
characteristics of the association process were extracted as described in the literature (32, 34, 53) 
(fig. S8). 
Atomistic Molecular Dynamics in Lipid bilayers 
Atomistic simulations in di-palmitoyl phosphatidylcholine bilayers were performed using the 
GROMOS 53a6 force field (54, 55) and GROMACS 4.5.1 and 4.5.4 (56) at 323K. We employed 
semi-isotropic pressure coupling at 1atm, a time-step of 2 s by constraining all bonds with 
LINCS, a twin range-cutoff for van der Waals interactions (0.9 and 1.4nm) and particle mesh 
Ewald for electrostatics (57-59). A single helical GHR TMD was inserted in a lipid bilayer. 
Removing overlapping molecules resulted in 110 lipid and 6364 water molecules being added 
with necessary ions included to maintain charge neutrality (counterbalancing E, E, D, K and R of 
the GHR TMD). For the single TMD simulation, after a pre-equilibration period the total 
simulations consisted of 0.4ȝs. For dimers, helices were first superimposed to the maintained 
helical domain of the coarse-grain model. Then after a similar insertion procedure starting with a 
larger bilayer of 256 lipids was followed, this resulted in structures with approximately 230 
lipids and total of 50,000 atoms subjected to simulations of 0.3-0.7ȝs. All mutations of TMDs 
were performed with Modeller and loop-refining protocols a posteriori on hundreds of snapshots 
from the trajectories created.  
Linking the GHR TMDs to ECD Structure 
The hGH:ECD hGH receptor crystal structure (PDB id: 3HHR structure; (2)) was retrieved from 
the Protein Data Bank and connected to the predicted left handed dimer using an iterative 
procedure. The two structures were aligned with their main axis parallel and five different 
separations along this axis were selected (2 to 4.5nm between Pro234 of the membrane-proximal 
domain in GHR and Glu260 of the TMD). For each separation 12 different rotations of the TMD 
dimer were performed (by 30q). For each TMD, missing residues were constructed with 
Modeller and a standard loop-refining protocol that included a series of energy minimization and 
MD steps with simulated annealing. The optimal structure out of the 600 constructed totally 
based on Modeller’s standard objective function is shown in Fig. 6C. 
Supplementary Materials and Methods 
Cell Culture 
Ba/F3 cells were cultured in Ba/F3 growth media: RPMI medium 1640 with 2 mM L-glutamine 
(Life Technologies), 10% Serum Supreme (Lonza), and IL-3 (supplemented to provide 1 × 
maximum growth determined by MMT assay on Ba/F3 cells; IL-3 produced from supernatant 
from baculovirus expression of SF9 cells, UQ Protein Expression Facility). Ba/F3 cells were 
starved in Ba/F3 starve media without IL-3 or GH (RPMI medium 1640 with 2 mM L-glutamine 
(Life Technologies), and 10% of Serum Supreme (Lonza) for Jun zipper fusions or 2.5% Serum 
Supreme for full length GHR proliferation assays). HEK293, HEK293T, COS-1, Plat-E, J2A, 
and BHK-21 cells were cultured in DMEM 10% FBS (Life Technologies).  
Expression Plasmid Constructs 
Expression constructs for retroviral transduction of Ba/F3 cells were cloned into pMX-IRES-
GFP (60) by exchanging the stuffer fragment with (human) hGHR or (rabbit) rGHR genes. The 
chimeric Jun leucine zipper GHR constructs were based on the previously described pcDNA3.1-
Jun-pGHR (comprising pGHR signal peptide, HA-tag, c-Jun leucine zipper (residues 277-315), 
porcine GHR (residues 251-638)) (24). The pGHR sequence coding for resides 251-638 was 
exchanged for the coding sequence for the same residues from either rGHR or hGHR. The GHR 
residues 251-638 include the ECD 12 amino acid linker; therefore constructs that were created 
without the linker comprise residues 263-638. The different length linkers, alanine insertions, 
and substitutions were made by restriction digestion and ligation of restriction digested annealed 
oligonucleotides or PCR mediated site-directed mutagenesis. Point mutations in full length 
constructs were created by PCR mediated site-directed mutagenesis (details including primers 
used are available upon request). The constructs containing the 260EED mutations to AAA or 
KKR in full length rGHR were moved into both pQCXP CMV/TO DEST and pQCXIH 
CMV/TO DEST (Addgene plasmid 17386 and 17394 (61)) by Gateway cloning. Expression 
constructs for HA-tagged hGHR and Box1 mutant GHR (299P, 300P, 302P, 304P all converted 
to alanine) were also moved into pQCXP CMV/TO DEST as above. The Box1 mutant (HA-
hGHR-Box1) was created by PCR mediated site-directed mutagenesis and overlap extension.  
All constructs were verified by DNA sequencing. 
Rabbit GHR (rGHR) FRET reporter constructs were created based on the previously 
described hGHR322ǻ-FP (5). This previous construct was numbered according to first residue 
after signal peptide cleavage. For consistency with this manuscript 322 is equivalent to 340 when 
numbering from the first translated residue. Jun zipper-rGHR constructs and full-length GHR 
constructs (described above) were amplified by PCR to include the N-terminal signal peptide and 
HA-tag and were cloned into pmCFP-N1 or pmCit-N1 so that the coding sequence following 
residue 341 of rGHR (fusion resulted in restoration of an extra GHR residue) was fused to the N-
terminus of mCFP or mCit using standard cloning techniques. The D170H mutation was 
introduced using overlapping oligonucleotides incorporating the mutation, PCR generating two 
fragments which were subsequently used in overlap extension and the mutant sequence was 
exchanged with the wild type sequence by restriction enzyme digestion and ligation. pJAK2 
FRET reporter constructs were created by amplifying full length murine JAK2 or truncated after 
residue 533 by PCR from pBSK-JAK2 (kindly provided by J. N. Ihle, St. Jude Children's 
Research Hospital, TN, USA). Full length JAK2 was fused N-terminal or C-terminal to mCFP or 
mCit by cloning into the vectors pmCFP-N1, pmCFP-C1, pmCit-N1 and pmCit-C1. In order to 
place FRET reporters in a similar position to the pseudokinase domain of JAK2, the JAK2 
coding sequence corresponding to the FERM and SH2 domains (amino acids 1-533) was fused to 
the N-terminus of mCFP and mCit as described above. All constructs were verified by DNA 
sequencing (primers and cloning details available upon request). Constructs used for cysteine 
crosslinking studies are detailed below.  
A JAK2 expression construct was made via PCR using primers incorporating NheI and 
NotI sites and pBSK-JAK2 as template, and subsequently cloned into the same sites of pJAK2-
mCFP. An expression construct for JAK2 with the kinase domain and pseudokinase domain 
swapped (referred to as JAK2-KP) was created by circular polymerase extension cloning (CPEC) 
based on the previously described method (62). Briefly, three PCR products were created using 
KOD Hot Start DNA Polymerase (Merck) following the manufacture’s protocol in a 50µl 
reaction with pJAK2-mCFP as template and the following primer pairs (Jak2 Kinase-C-N-
Pseudo R: 
CCCTGTCTTCAAAAGCACCAGAAAACCCCGCAGCTATACTGTCCCGGATTTGATCC 
and Jak2 KinaseN-SH2-F: 
GCATAATAATGTGAATCAAATGGTGTTTCACAAAATCGACCCTACACAGTTTGAAGA
GAGACACTTGAAGTTTC), Jak2 Kinase-C-N-Pseudo F: 
GGGGTTTTCTGGTGCTTTTGAAGACAGGAATGAAGATTTAATATTTAATGAAAGTCT
TGGCCAAGGT and Jak2 PseudoEndstop-vec-R: 
CAAATGTGGTATGGCTGATTATGATCTAGAGTCGCTCAACCAGAAAACCCTAGGGC
ACCTATTCTCATG), and (Vect3’F : 
GCGACTCTAGATCATAATCAGCCATACCACATTTG and Jak2 SH2 R: 
GATTTTGTGAAACACCATTTGATTCACATTATTATGC). Each amplified product was 
purified using a PureLink PCR purification Kit (Invitrogen). An equal molar amount of each 
product was used in a single 50µl reaction containing 1× Phusion HF Buffer, 0.5 µl Phusion Hot 
Start II DNA Polymerase (Finnzymes), and 200 µM each dNTPs. The reaction mixture was 
denatured at 98qC for 30 sec, 20 cycles of 98qC for 10 sec, 70qC for 30 sec, and 72qC for 155 
sec, followed by a final incubation of 72qC for 5 min. DH5D cells were transformed using 1µl of 
the CPEC reaction and single colonies were isolated and correct constructs were verified by 
DNA sequencing. The resulting construct for JAK2-KP corresponds to: FERM-SH2 (Met1-
Ile540) kinase (Asp840-Ala1132) -kinase-pseudokinase linker (Gly831-Arg839) pseudokinase 
(Asn542-Gly834).  
Retroviral transduction 
Retroviral expression vectors were transfected into Plate-E cells (63) using Lipofectamine 2000. 
Plat-E cells were kindly provided by Dr. Kitamura (Tokyo Univ., Tokyo, Japan). Supernatant 
from transfected Plat-E cells was used to transduce Ba/F3 cells in the presence of 8µg/ml 
polybrene and IL-3. Transduced cells were cultured as normal in Ba/F3 growth media and were 
sorted for GFP positive cells by FACS.  
Cysteine Crosslinking Studies 
Cells were transfected with a series of N-terminal HA-tagged hGHR mutants in pcDNA3.1 
truncated at residue 389 where each residue from Pro252 to Ser288 was converted to a cysteine 
after converting Cys259 to serine. Receptor constructs were titered to give a mimimal level for 
clear detection ie 100 ng/well (6 well plate). Crosslinking was performed 16-20 hours after 
transfection. Cells underwent cross-linking treatment with MTS-2-MTS (1,2-ethanediyl 
bismethanethiosulfonate; Toronto Research Chemical) or direct disulfide bond formation with 
Cu-o-phenanthroline. For cross-linking with MTS-2-MTS (64), COS-1 cells were transfected 
and MTS-2-MTS was added to intact cells at a 1mM final concentration in PBS 0.1mM CaCl2, 
1mM MgCl2, 0.015% saponin in DMEM pH 8.0 and incubated for 10 min. Samples were lysed 
in homogenizing buffer (1% NP-40, 10% glycerol, 150mM NaCl, 50mM Tris-HCl pH 7.6, 
50mM NaF, 1mM ZnCl2, 1mM Na3VO4, 2% ȕ-mercaptoethanol) containing 1 × Complete 
Protease Inhibitor Cocktail (Roche)), 12µl of cleared lysate was mixed with 6ȝl of 3× sodium 
dodecyl sulphate (SDS) sample buffer (20% SDS, 10% glycerol, +/- 1 M DTT, bromophenol 
blue), boiled and run on non-reducing SDS-PAGE gels, then immunoblotted and probed with 
HA.11-antibody (Covance). For direct disulfide bond formation with Cu-o-phenanthroline, 
transiently transfected HEK293 cell membranes were crosslinked essentially as previously 
described (49) with 0.40mM CuSO4 and 1.60mM o-phenanthroline for 10 min at 37qC after 
addition of 2 nM hGH. The reaction was terminated with 10 mM EDTA prior to SDS-PAGE. 
Samples were lysed in RIPA buffer and run on non-reducing SDS-PAGE gels as above, 
immunoblotted and probed with HA.11-antibody (Covance).  
For signaling analysis, HEK293 cells were transfected with full length hGHR expression 
constructs coding for the same cysteine mutations from Pro252 to Ser288 as above with Cys259 
to serine, together with 30 ng stat5 cDNA in pcDNA3.1. STAT5 phosphorylation was analyzed 
by resolving extracts using reducing SDS-PAGE, western blotting and probing with anti-
phospho-STAT5-tyrosine694 antibody (Cell Signaling Technology, cat 9351) and with total 
STAT5 antibody (SantaCruz C-17). 
FRET Analysis 
FRET analysis by live cell imaging was performed using confocal microscopy of BHK cells 24 
hours post-transfection. For live cell imaging 2 × 104 BHK-21 cells were seeded in 2 ml DMEM 
medium in a 35 mm glass bottom dish and transfected after 24 hours. Co-transfection was 
performed with 1ȝg of each plasmid. Confocal microscopy was carried out 48 hours after 
transfection. Using filter-settings for donor-channel, acceptor-channel and FRET-channel, three 
images were recorded and FRET calculated afterwards. All confocal images were acquired using 
a Zeiss LSM-510 META inverted laser scanning confocal microscope (Carl Zeiss GmbH, 
Oberkochen, Germany). As objective a 63× oil immersion plan apochromat with numerical 
apertures of 1.4 was used. Images were recorded at 12 bit depth and a size of 512 × 512 pixels. 
During measurements, regions of too high intensity (outside of the dynamic range) were 
excluded. All settings for detector gain and laser power were made at the beginning of imaging 
and not changed during FRET sample measurements. Zeiss LSM-510 software package was 
used to adjust settings and save pictures. Image editing and conversion was performed with Fiji 
(based on ImageJA 1.42I) with LSM-Toolbox (Patrick Pirrotte, v4.0b). The imaging raw data 
were exported and for each sample three images (donor-channel, acceptor-channel and FRET-
channel) were imported into IgorPro (v6.05, WaveMetrics Inc., Lake Oswego, USA). 
Background correction was done by defining and averaging a region-of-interest (ROI) outside of 
the cell and excluding all pixels below this value plus 3-fold its standard deviation. Areas which 
showed overexpression (signal out-of-range) were excluded as well. Cross-talk factors were 
calculated by setting and averaging a ROI within cells, which expressed donor and acceptor only. 
The G-factor, relating the loss of donor emission due to FRET in the donor-filter-set and the gain 
of acceptor emission due to FRET in the FRET-filter-set, was determined by calibration, using a 
cell expressing the covalently fused mCFP-mCitrine. The G-factor was adjusted to reach a 
FRET-efficiency of 0.35 ±0.03 (35% ±3%). FRET efficiencies were then calculated pixel wise in 
a batch procedure for all images, as previously described (65) and FRET efficiency images of 
cells were graphed. 
FRET analysis by flow cytometry was performed on transfected BHK cells (as described 
above) using a BD FACS CantoII flow cytometer (BD Biosciences) to measure fluorescence of 
cells in donor- (405 nm excitation, 450/50 nm emission), acceptor- (488 nm excitation, 530/30 
nm emission) and FRET-channels (405 nm excitation, 585/42 nm emission). Doublet 
discrimination was carried out to measure signals of single cells. FRET analysis of flow 
cytometer data was carried out as previously described with a custom written algorithms in 
IgorPro5 (Wavemetrics) (50). Calibration for normalized acceptor surface concentration cA was 
carried out essentially as described (50) using: cA=NAc/AcellR02, where NAc, the number of mCit 
fluorophores per cell, Acell is the surface area of a model spherical BHK cell and R0=4.7 nm, the 
Försters radius of mCFP/mCit, calculated using spectroscopic data. Fluorescent beads (#1139, 
Bangs Laboratories) with defined fluorescein loading and size were used to determine NAc and 
Acell. A fusion protein of mCFP-mCit was used to calibrate donor-acceptor ratio and FRET-
efficiency. The FRET-efficiency was calculated per cell by using an adapted sensitized acceptor 
emission method. Only cells with a donor-mole fraction xD=0.5±0.1, corresponding to a ~1:1 
donor-acceptor ratio, were analyzed. The characteristic Emax value was determined using the 
equation E=Emax-(A1 e-k1 a (cA+cA0) + A2 e-k2 a (cA+cA0)) as previously described (50) where 
A1=0.6322, k1=3.1871, A2=0.3678, k2=0.7515, for Rc/R0=0.7 (66), using Rc, the closest approach 
distance of the fluorescent proteins (=3.4 nm) (50). Curve fitting was carried out using IgorPro5 
software by iterative minimization of F2 with the Levenberg-Marquardt algorithm. Standard 
errors in the fitting of Emax were calculated based on the residuals. 
FRET analysis of membrane extracts from transfected HEK293T cells were performed 
on a fluorescence plate reader. For each sample 4 × 105 HEK293T cells were seeded into a well 
of a 6-well cell culture plate at an even distribution and incubated for 24 hours, then transfected 
with relevant constructs using 7µl Lipofectamine 2000. For analysis of HA-rGHR341ǻ-
mCFP/mCit and HA-rGHR(EED-KKR)341ǻ-mCFP 1µg of each construct was used for 
transfection. Analysis of C-terminal or N-terminal mCFP/mCit labeled JAK2 was performed 
with 5 µg of each construct per transfection with 2 µg of pQCXP-rGHR, or 2 µg pQCXP-
rGHR(EED-KKR), or 1 µg each of pQCXP-rGHR and pQCXP-rGHR(EED-KKR). Cells were 
treated, 24 hours after transfection, with 10mM sodium butyrate overnight and membrane 
extracts based on the method described by Han et al. (2005) (67) were performed. Briefly, cells 
were removed by quickly aspirating with a pipette, transferred to a centrifuge tube, centrifuged at 
600g and washed with 1.5 ml ice-cold phosphate-buffered saline (pH7.4) containing 2mM 
Na3VO4. Cells were resuspended in 1ml of ice-cold buffer A (25mM sodium phosphate, 5mM 
MgCl2, 2mM Na3VO4, pH 7.4 with 1× Complete Protease Inhibitor Cocktail (Roche)) and 
subjected to three rounds of freezing and thawing using a dry ice ethanol bath and 37ºC water 
bath with mixing between each thaw. Subsequently lysed cells were centrifuged at 17 000g for 
20 min, resuspended in buffer A and centrifuged again for 20 min followed by resuspension in 
100 µl of buffer A and stored at -80ºC. Each suspension was thawed and placed in a well of a 
black bottom 96 well plate (OptiPlate-96F, PerkinElmer) and fluorescence readouts were 
performed on a Synergy4-platereader (BioTek Instruments).  
For experiments with addition of GH transfection conditions were optimized to determine 
the most GH responsive conditions by titration of HA-rGHR341ǻ-mCFP/mCit. The minimal 
amount of GH required to give significant FRET responses was determined by titration of GH. 
Subsequent experiments used 10 ng of each plasmid for transfection with 6 µl Lipofectamine as 
above and 5 nM GH was added to cells in culture for 1 min prior to harvesting. For experiments 
using the antagonist G120R hGH cells were incubated for 10 min with 500 nM G120R hGH 
prior to addition of GH. G120R human GH (hGH) was expressed and purified as previously 
described (68). Cells were harvested in a similar manner as described above except ice-cold 
buffer B (25 mM Tris-HCl and 10 mM MgCl2, 2 mM Na3VO4, pH 7.4 with 1 × Complete 
Protease Inhibitor Cocktail (Roche)) was used in place of buffer A and membrane extracts were 
not frozen and read immediately on a Synergy4-platereader. Appropriate filter settings were used 
to record intensities of donor-channel (excitation 420/50 nm, emission 485/20 nm), acceptor-
channel (excitation 500/27 nm, emission 540/35 nm) and FRET-channel (excitation 420/50 nm, 
emission 540/35 nm). Background correction was performed by subtracting the intensity of a 
well with untransfected cells (background) from all other fluorescence intensities. Then cross-
talk factors were calculated with the donor-only and acceptor-only samples as described before. 
Using these cross-talk factors and the background-corrected FRET-samples in all three channels, 
the FRET-efficiency was calculated as previously described (65). 
Homo-FRET anisotropy analysis of live cell surface transmembrane receptors 
Construction of monomeric and dimeric homo-FRET controls were created by CPEC essentially 
as described above where primer sequences can be provided on request. The monomeric 
construct comprised the extracellular residues 1-142 of mouse RTPTD fused to the TMD of the 
LDL receptor (ALSIVLPIVLLVFLCLGVFLLW) and intracellular residues KNWRLKNINS 
followed by fusion to mCit resulting in RPTPD-LDLR(TMD)-mCit. The dimeric construct 
comprised the RTPTD residues 1-249 including the mutation P137C and fused at the C-terminus 
to mCit to give RPTPD(P137C)-mCit 
HEK293 cells were transiently transfected with mCit, RPTPD(P137C)-mCit, RPTPD-
LDLR(TMD)-mCit, and HA-rGHR341ǻ-mCit. Cells were imaged live at 37qC by confocal 
microscopy and images acquired on a LSM710 Zeiss confocal microscope equipped with a 40× 
oil immersion objective (Plan Apochromat 40× 1.4 NA, Zeiss, Jena, GER). Images were 
acquired by using a 514 nm laser excitation line and collecting the corresponding emissions in 
the range 530-560 nm using band pass emission filters. Fluorescence emissions parallel (Ipar) 
and perpendicular (Iper) to the plane of excitation were acquired by splitting the emission light 
path using a polarized beam splitter. The fluorescence anisotropy was determined by measuring 
average values of Ipar and Iper on regions of interest at the plasma membrane in ImageJ and 
using the following equation:ݎ ൌ ூ௣௔௥ିீήூ௣௘௥ூ௣௔௥ାଶήீήூ௣௘௥. where the correction factor G was estimated using 
r0=0.39 of soluble mCitrine as reference (16, 69). Then, anisotropy values were then converted to 
homo-FRET efficiency values using the following equation (17) ܧ ൌ ͳ െ ௥௥೘಴೔೟. Data presented 
are mean efficiency values calculated across the different images (~50 cells per conditions) and 
their standard errors. 
Analysis of GH stimulated JAK2 activation by rGHR341ǻ FRET constructs 
GH stimulated JAK2 activation was analyzed by expression of GHR constructs in HEK293 cells, 
immunoprecipitation (IP) of JAK2 and western blotting. Initially, small scale tests for expression 
of GHR constructs was performed in order to achieve similar expression levels for each GHR 
construct. For each experiment 3.8 × 105 HEK293 cells were seeded into a 25cm2 cell culture 
flask and transfected 6 hours later with 40 ng pHA-rGHRǻ-mCit or 300 ng pQCXP-HA-rGHR 
with Lipofectamine 2000, incubated in DMEM 10% FBS for 24 hours, then starved overnight by 
incubation in DMEM 0.5% FBS. Cells were stimulated with 5 nM hGH for 10 min at 37qC. 
Cells were harvested after washing in ice-cold PBS containing 2 mM Na3VO4, centrifuged at 
400g for 5 min at 4qC, washed again in ice-cold PBS containing 2 mM Na3VO4 and cell pellet 
resuspended in ice-cold extraction buffer (50 mM Tris pH7.5, 150 mM NaCl, 5 mM EDTA, 
0.5% Triton X-100, 2 mM Na3VO4, 30 mM NaF, 10 mM Na4P2O7, and 1× Complete Protease 
Inhibitor Cocktail EDTA-free (Roche)). Protein concentrations for each lysate were determined 
by BCA protein assay (Pierce). 2.5 µl of anti-Jak2 (D2E12) XP antibody (Cell Signaling 
Technology, cat 3230) was then added to an equal amount of protein for each sample in a final 
volume of 200 µl of extraction buffer and incubated for 1 hour at 4qC on a rotating wheel. 
Protein G Sepharose 4 Fast Flow (GE Healthcare Life Sciences) was washed in extraction buffer 
and 60 µl of a 50% resuspended sepharose solution was then added to each protein-antibody mix 
and incubated for a further hour at 4qC on a rotating wheel. Sepharose was pelleted by 
centrifugation at 5000g and washed twice with IP wash buffer (50 mM Tris pH7.5, 150 mM 
NaCl, 5 mM EDTA, 2 mM Na3VO4, 30 mM NaF, 10 mM Na4P2O7, and 1× Complete Protease 
Inhibitor Cocktail EDTA-free (Roche)). Sepharose pellets were resuspended in 15 µl of 6 × SDS 
sample buffer (containing 100 mM DTT), incubated at 98qC for 5 min, centrifuged at 17 000g 
for 1 min and the supernatant was analysed on 7% SDS-PAGE gels with transfer to PDVF and 
immunoblot using anti-Phospho-Jak2 (Tyr1007/1008) (Cell Signaling Technology, cat 3771), 
anti-Jak2 (D2E12) XP. Expression of HA-tagged GHR was analysed from cell lysates using 
equalised amounts of protein on SDS-PAGE and western blotting using anti-HA (HA.11), and ȕ-
tubulin antibodies (Cell Signaling Technology, cat 21461). 
Signaling analysis of JAK2 co-transfected with kinase pseudokinase domain swap JAK2 
JAK2 deficient (and STAT5 deficient) J2A cells (70), a gift from G. Stark (Imperial 
Cancer Research Fund, London), were seeded into 6 well plates at 1.5 × 105 cells per well and 
cultured overnight. Cells were then transfected with 3µl of Lipofectamine 2000, 100 ng 
pcDNA3.1-STAT5B, 150 ng pQCXP-hGHR (constructed as described above for rGHR), and the 
JAK2 expression construct. As overexpression of JAK2 leads to constitutive phosphorylation of 
STAT5, the amount of JAK2 required to give minimal background P-STAT5 while still give 
strong P-STAT5 signal upon GH stimulation was regularly determined as the amount required 
varied over time likely due to passage number of cells or batch variation in reagents such as 
Lipofectamine. The suitable amount of JAK2 expression plasmid used for transfection ranged 
between 10-0.1 ng DNA. Following transfection cells were incubated overnight and culture 
media was replaced with fresh media. Cells were cultured for another day and cells were starved 
overnight in DMEM with 0.5% FBS. Cells were washed in ice-cold PBS containing 1 mM 
Na3VO4, and harvested in ice-cold PBS containing 1 mM Na3VO4 using a cell scraper and 
centrifuged at 600g. Cells were lysed in RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing Na3VO4, 10 mM Na4P2O7, 30 mM 
NaF, and 1× Complete Protease Inhibitor Cocktail EDTA-free (Roche), and snap frozen in dry 
ice. JAK2 signaling was subsequently analysed by western blot for P-STAT5 signaling.  
Analysis of interaction of JAK2 with GHR341ǻ FRET constructs and kinase-pseudokinase 
domain swap JAK2 with GHR 
The interaction of JAK2-KP with GHR and WT JAK with rGHR341ǻ FRET constructs was 
determined by Co-IP. For each experiment, HEK293 cells at approximately 60% confluent in a 
75cm2 cell culture flask were transfected with 3 µg HA-hGHR, 3µg HA-hGHR-Box1, or 400 ng 
HA-rGHR341ǻ-mCit were co-transfected with 400 ng JAK2 or 400 ng JAK2-KP expression 
constructs with Lipofectamine 2000, incubated in DMEM 10% FBS for 24 hours, then starved 
overnight by incubation in DMEM 0.5% FBS. Immunoprecipitation of JAK2 was performed 
essentially as above except 6 µl anti-Jak2 antibody was used in each sample and each IP was 
incubated in a final volume of 600 µl of extraction buffer. Following SDS-PAGE and transfer, 
western blots were probed with anti-HA (HA.11) and anti-Jak2 (D2E12) XP. Expression of HA-
tagged GHR was analysed from cell lysates using equalised amounts of protein on SDS-PAGE 
and western blotting using anti-HA (HA.11). Note that the HA-rGHR341ǻ-mCit expression 
plasmid is much smaller than the retroviral pQCXP-HA-hGHR expression plasmid and the HA-
rGHR341ǻ protein lacks the FIELD internalization motif involved in ubiquitination and receptor 
degradation. Together these contribute to the difference expression levels observed when 
transfecting equal amounts of plasmid for the different GHR expression constructs.  
JAK 2 Pseudokinase-Kinase Docking Studies  
Janus kinase 2 (JAK2) consists of seven homologous subdomains, numbered from N-terminus to 
C-terminus as JH7 to JH1. Interactions between the JH1 (kinase) and JH2 (pseudokinase) 
subdomains are important for signal transduction in the growth hormone receptor. The 
pseudokinase domain spans residue 541 to 839 of JAK2, while the kinase domain spans residue 
840 to 1132. While crystal structures of the JAK2 kinase domain were first published in 2006 
(41) the structure of the JAK2 pseudokinase domain was only recently resolved (42). This crystal 
structure shows significant structural differences to previous homology models used to interpret 
functional and mechanistic aspects of JAK2 pseudokinase-kinase interactions.  
To facilitate modeling of the pseudokinaseíkinase domain interface, two lines of 
approach were taken. Firstly, the molecular docking program HADDOCK (71, 72) was used to 
generate physiologically plausible relative orientation of the kinase and pseudokinase domains. 
Here we imposed the distance constraints between Tyr1007 of the kinase domain and both 
Phe595 and Val617 of the pseudokinase domain. Co-mutation of these two residues, which lie in 
close proximity to each other, are required for constitutive activation. The second approach used 
the crystallographic symmetry of the JAK2 pseudokinase crystal structure (PDBID: 4FVP) to 
provide the relative orientation of domain pairs in the crystal structure. In this approach we 
hypothesized that exploiting the crystallographic packing of the individual domain structures 
may help identify a stable interface between the kinase and pseudokinase domain. The symmetry 
operator of 4FVP (P 1 21 1) was chosen over that of 2B7A (P 41) as it provided a greater number 
of possible interfaces. Starting from the crystallographic coordinates of 4FVP, the kinase domain 
(PDB id: 2B7A) was superimposed onto each of the pseudokinase domain crystal contacts to 
provide a possible relative orientation of the kinase-pseudokinase domains, using the protocol 
outlined below. 
Molecular dynamics (MD) simulations were performed using the GROMACS 
(Groningen Machine for Chemical Simulation) package version 3.3.3 (73) in conjunction with 
the GROMOS 54A7 (74) force field for proteins. The simple point charge (SPC) water model 
(75) was used to describe the solvent water. The dimensions of the box were chosen such that the 
minimum distance between the protein and the box wall was at least 1.0nm. The non-bonded 
interactions were evaluated using a twin-range method. Interactions within the short-range cutoff 
of 0.9nm were updated every step. Interactions within the long-range cutoff of 1.4nm were 
updated every 3 steps together with the pair list. To minimize the effect of truncating the 
electrostatic interactions beyond the 1.4 nm long range cutoff, a reaction field correction was 
applied using a relative dielectric constant of İr = 78.5 (76). Neutral pH was assumed. The 
SHAKE algorithm (58) was used to constrain the lengths of the covalent bonds. The SETTLE 
algorithm (77) was used to constrain the geometry of the water molecules. In order to extend the 
timescale that could be simulated, explicit hydrogen atoms in the protein were replaced with 
dummy atoms, the positions of which were calculated each step based on the positions of the 
heavy atoms to which they were attached. This eliminates high frequency degrees of freedom 
associated with the bond angle vibrations involving hydrogens, allowing a time step of 4fs to be 
used to integrate the equations of motion without affecting thermodynamic properties of the 
system significantly (78). The simulations were carried out in the NPT ensemble at T = 300 K 
and P = 1 bar. The temperature and pressure were maintained close to the reference values by 
weakly coupling the system to an external temperature and pressure bath using a relaxation time 
constant of 0.1 ps (57) and 0.5 ps, respectively. The compressibility was 4.5 × 10-5 bar. The 
pressure coupling was semi-isotropic in the case of the membrane simulation and fully isotropic 
in the case of the simulations in water. Configurations were saved every 40ps for analysis. 
Images were produced using VMD (79).  
Six individual conformations of the pseudokinase-kinase domain dimer were set up in 
MD simulations: five of these were derived from the crystallographic symmetry approach and 
one was derived from docking studies described above. All simulations were performed under 
periodic boundary conditions in a rectangular box. To equilibrate the system, 500 steps of 
steepest descent energy minimization were performed to relax the solvent while the 
conformation of the protein was restrained using a harmonic potential with a force constant of 
1000kJ·mol-1 ·nm-1. Then a series of 2 ns simulations were performed in which the force 
constant was progressively reduced (500, 100, 50 and 10kJ·mol-1 nm-1). Position restraints were 
then removed from all domains. New velocities were then assigned and unrestrained simulations 
were performed on each system for 40 ns. In each of the conformations derived from 
crystallographic symmetry, the interface between the pseudokinase and kinase domain was not 
stable in MD simulations and the domains adopted a random orientation throughout the 
simulations. In contrast, in the docked conformation, the contact interface between the domains 
associated more closely in simulations to form a stable pseudokinase-kinase domain 
conformation that was maintained throughout the 40 ns simulation.  
Analysis of JAK2 Pseudokinase-Kinase domain interaction 
We applied a unique combination of cell-free protein expression, AlphaScreen and single 
molecule fluorescence analysis to dissect the interaction between the Pseudokinase and Kinase 
domains of JAK2. We expressed fluorescently-tagged Pseudokinase-Kinase, Pseudokinase or 
Kinase truncations in the eukaryotic in vitro translation system derived from Leishmania 
tarentolae (80). This system is suitable for co-expression of multiple exogenous cDNAs and 
allows production of large multidomain proteins in active form.  
AlphaScreen cMyc detection and Proxiplate-384 Plus 384-wells plates were purchased 
from Perkin Elmer. Proteins (one bearing a N-terminal eGFP tag, the other labeled with C-
terminal mCherry-Myc) were co-expressed in the cell-free system by adding mixed DNA vectors 
in 10 ȝL of the Leishmania tarentolae-based cell-free system (to a final DNA concentration of 
30 nM for the GFP-vector and 60 nM for the Cherry-vector) The mixture was incubated for 3.5h 
at 27°C. Four serial dilutions of the proteins of ¼ were made in buffer A (25 mM HEPES, 50 
mM NaCl). The AlphaScreen Assay was performed in 384-well plates. Per well, 0.4 ȝg of the 
Anti-Myc coated Acceptor Beads (PerkinElmer) was added in 12.5 ȝL reaction buffer B (25 mM 
HEPES, 50 mM NaCl, 0.001% NP40, 0.001% casein). 2 ȝL of the diluted proteins and 2 ȝL of 
biotin labeled GFP-nanotrap (diluted in reaction buffer A to a concentration of 45 nM) were 
added to the acceptor beads, followed by incubation for 45 min at RT. Then 0.4 ȝg of 
Streptavidin coated Donor Beads diluted in 2 ȝL buffer A was added, followed by an incubation 
in the dark for 45 min at RT. AlphaScreen signal was recorded on a PE Envision Multilabel 
Platereader, using the manufacturer’s recommended settings (excitation: 680/30nm for 0.18 s, 
emission: 570/100nm after 37 ms). The signals were then averaged and normalized to 
background. 
Single molecule spectroscopy was performed based on the previously described methods 
(81, 82). The method is based on a simple principle: on a confocal microscope, an excitation 
laser creates a very small observation volume (~1 fL). The proteins are tagged with genetically-
encoded GFP fluorophores (fig. S9D). Proteins diffuse freely by Brownian motion, and they 
enter and exit the confocal volume constantly. For single-molecule brightness analysis, the 
samples were diluted to approximately 100 pM concentration, so that only single proteins are 
present in the confocal volume. The fluorescence intensity was binned in 1 ms intervals, ie we 
calculate the number of photons collected in 1 ms. When a protein goes through the focal 
volume, a fluorescent burst is detected, and its brightness is analyzed to access the number of 
proteins in possible oligomers. In case of a dimer, the burst size will be approximately twice as 
high as in case of a monomer. Samples were reduced to a volume of 20 ȝl and placed into a 
custom-made silicone 192-well plate equipped with a 70 × 80 mm glass coverslip (ProSciTech). 
Plates were analyzed on a Zeiss LSM710 microscope with a Confocor3 module, at room 
temperature. A 488 nm laser focused in solution using a 40× 1.2 NA water immersion objective 
(Zeiss); fluorescence was collected and filtered by a 505-540 band pass filter. The experiment 
was calibrated using GFP expressed in the same cell-free extracts. 
In fig. S9E, the brightness of the bursts is plotted against the number of bursts of that 
brightness. Due to random diffusion, most of the events are incomplete transfer through the focal 
volume, and few bursts represent the maximal number of photons that the GFP-tagged proteins 
can emit. For GFP, we obtained a profile of burst sizes that rapidly decreases and shows that the 
largest burst we observed was about 100-110 photons.  
The Jak2 Pseudokinase-Kinase domains were analyzed in the same conditions. The data 
in fig. S9E show a different slope of distribution of brightness, with a maximal value of 220-230 
photons, suggesting that this truncated domain can form stable dimers. The analysis of binding of 
the PseudoKinase and Kinase domains separately reveals that the PseudoKinase domain but not 
the Kinase domain can form dimers at single-molecule concentration (fig. S9F). In case of larger 
oligomerization of the GFP- labeled Jak2 domains, multiple proteins and their fluorescent labels 
would pass the confocal volume at the same time, resulting in an even higher photon count. The 
data show clearly that the Jak2 truncated domains do not form non-specific aggregates. 
Supplementary Figure Captions 
Fig. S1. Sequence conservation of the GHR TMD and JM residues. Sequence alignments of 
GHR TMDs and JMs showing key conserved residues including the GxxG motif and Lys 289. 
Fig. S2. A diagrammatic representation of the ToxR assay. The chimeric protein consisting of 
the N-terminal domain of the maltose binding protein (MBP, in red) was fused to the 
cytoplasmic domain of the ToxR transcriptional activator (in blue) via a transmembrane domain 
(TMD) of interest (in orange). The MBP is then located in the periplasmic space, between the 
inner and outer membranes of E. coli. TMD mediated homodimerization of this chimera leads to 
the ToxR dimer binding to the cholera toxin promoter, ctx (in light green) and activating 
transcription of the lacZ gene (in dark green) followed by translation of the E-galactosidase 
protein (E-gal), the activity of which is determined and expressed in Miller units, corrected for 
protein expression by MBP immunoblot.  Adapted from Langosch et al. (14). 
Fig. S3. Extent of dimer formation of GHR cysteine mutants in the absence of crosslinker 
shown as a HA-immunoblot of a non-reducing Laemelli gel. Samples run in parallel to 
experiment shown in Fig. 3D as described in Supplementary Materials. Note correlation of dimer 
formation with constitutive signaling shown in Fig. 3D and absence of dimer in C259S mutant. 
Fig. S4. The JAK2-KP construct is able to effectively bind GHR, and the GHR truncated 
FRET constructs are able to bind JAK2 effectively. The full length HA-GHR or HA-GHR-
341-mCit construct were co-transfected with the WT JAK2 or the domain reversed JAK2-KP 
expression plasmid into HEK293 cells as described in the Supplementary Materials, and after 
immunoprecipitaion with a JAK2 antibody, the subsequent immunoblot was probed for HA. As a 
control, a Box1 mutated construct was used which does not bind JAK2. Representative blot 
shown from three independent experiments.  
Fig. S5. Construct used for FRET studies (rGHR341-mCit) is able to activate JAK2 in 
response to GH addition in HEK293 cells. Cells were stimulated with 5 nM hGH for 10 min as 
detailed in the Supplementary Materials, and activation of JAK2 was demonstrated by 
immunoblot for Y1007/1008 in the activation loop of JAK2. Note that the mature form of the 
rGHR341-mCit at the cell surface would be the GH responsive form, with similar expression to 
the HA-GHR control. Representative blot shown from three independent experiments. 
Fig. S6. The decreased FRET in the ICD seen with 3Ala insertions for JUN-3Ala-rGHR-
341-mCFP/mCit insertions is not a consequence of FRET fluorophore orientation, since the 
decrease is seen when a flexible linker (RSIAT) attaches the reporter to the ICD.  
Fig. S7. In vacuo modeling of the hGHR TMD helices using CHI software (51). (A) Plot of 
the f1 and f2 helical rotation values for the left handed dimer clusters. The capital ‘A’ indicates 
the orientation of the average structure in each cluster. (B) Dimer structure of the hGHR TMD 
helices for Cluster 1. Residues contributing most to the interaction energy as indicated in (D) are 
shown as rods colored by atom type. (C) Sequence alignment of human and chicken GHR TMD 
sequences highlighting non-conserved residues in blue. Superimposition of the best cluster TMD 
helix backbone alignment of chicken GHR (blue) on to the Cluster 1 human GHR backbone 
alignment (yellow) showing close similarity (RMSD 1.54Å). The helices share the same 
symmetry, although the register of the helices is shifted by about 1.6Å. (D) Graph showing 
calculated helix interaction energy contributed by each residue in the Cluster 1 model of the 
helix dimer. 
Fig. S8. Atomistic MD modelling of GHR TMD in DPPC lipid bilayer shows helix from 
Phe265 to Lys289, and stable tilt angle relative to bilayer normal of around 20 degrees after 
only 0.2 µsec. The tilt of the helix is promoted by a hydrophobic mismatch and flanking residues 
that are on the same face of the helix but favor tilting in different directions. Specifically, Tyr264 
and Trp267 are located at the interface of the hydrophilic/hydrophobic domain with the Trp 
inducing helix tilting towards the opposite direction than Lys289 (see also Fig 6). 
Fig. S9. The JAK2 Pseudokinase-Kinase domain for dimers as determined by AlphaScreen 
and single-molecule brightness analysis. (A) JAK2 domain diagram illustrating positions of 
domains used for analysis. (B) Diagram illustrating set up used for AlphaScreen. (C) Domain 
interaction analysis by AlphaScreen shows Pseudokinase-Kinase domain formation. (D) 
Schematic of the focal volume and free diffusion of the GFP-tagged JAK2 domains. (E) 
Calibration of the brightness of GFP used for single molecule brightness analysis. Single-
molecule brightness analysis of truncated JAK2 reveals formation of dimers driven by the 
PseudoKinase-PseudoKinase (PK-PK) interaction (F). Distribution of bursts obtained for 
PseudoKinase-Kinase (PK-K), Pseudokinase (PK), and Kinase (K) respectively. Maximal burst 
size obtained for the different constructs, with the GFP calibrating the number of photons 
expected for a monomeric protein.  
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Six decades of research have established that 
growth hormone (GH) plays a crucial role in 
promoting proportionate postnatal growth, and 
that this is largely mediated through the induc-
tion of IGF-1. This action is supported by impor-
tant roles of GH in the regulation of metabolism, 
and of cardiovascular, renal, reproductive and 
immune functions. These roles are accom-
plished through ubiquitously expressed GH 
receptors (GHRs) which, similar to receptors 
for many other growth factors, signal through 
a tyrosine kinase (JAK2) able to activate STAT, 
Ras/ERK and PI3K/Akt pathways. The ability 
of GH to also induce IGF-1, both locally in a 
paracrine/autocrine manner [1,2] and in an endo-
crine manner via action on the liver, results in a 
particularly potent growth stimulus that requires 
tight control. This comprises feedback inhibi-
tion of GH secretion by pituitary somatotropes 
by hepatic (endocrine) IGF-1, as well as a set 
of negative regulators common to other growth 
factor/cytokine signaling factors: suppressors of 
cytokine signaling (SOCS), protein inhibitors of 
activated STAT (PIAS) proteins, phosphatases, 
receptor downregulation, and transcriptional 
regulation of receptor expression. Given the 
ability of GH and IGF-1 to promote cell prolif-
eration, cell movement and angiogenesis, and to 
suppress apoptosis, it is not surprising that dys-
regulation of the tightly controlled GH–IGF-1 
axis promotes neoplasia. As discussed here, con-
verging data from recent epidemiologic, animal 
and in vitro studies indicate that the state of the 
GH–IGF-1 axis has important influences on 
cancer biology, cancer risk and carcinogenesis.
Actions of the GH–IGF-1 axis in relation 
to cancer
The risk of developing cancer is determined by 
genetic elements and by environmental condi-
tions including diet and lifestyle. Recent evi-
dence suggests that the GH–IGF-1 axis might 
provide a link between these factors and the 
disposition to cancer through its effects on nor-
mal cell proliferation, differentiation and apop-
tosis. The GH–IGF-1 axis influences several 
stages and aspects of cancer development and 
behaviour: cellular proliferation, cell survival, 
angiogenesis and metastasis, and even resis-
tance to chemotherapy [3]. Being a potent and 
ubiquitous mitogen, IGF-1 can act on many cell 
types to bring about increased proliferation via 
the MAPK signaling pathway. Its anti-apoptotic 
actions are mediated via the PI3K/Akt pathway 
and can disrupt the tight control between cell 
proliferation and death leading to hyper-prolif-
eration [4]. Carcinogenesis is a multistep process 
which involves accumulation of a number of 
genomic ‘hits’ leading to complete transforma-
tion and/or survival of partially transformed 
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A substantial body of evidence supports a role for the growth hormone (GH)–IGF-1 axis in 
cancer incidence and progression. This includes epidemiological evidence relating elevated 
plasma IGF-1 to cancer incidence as well as a lack of cancers in GH/IGF-1 deficiency. Rodent 
models lacking GH or its receptor are strikingly resistant to the induction of a wide range of 
cancers, and treatment with the GH antagonist pegvisomant slows tumor progression. While 
GH receptor expression is elevated in many cancers, autocrine GH is present in several types, 
and overexpression of autocrine GH can induce cell transformation. While the mechanism of 
autocrine action is not clear, it does involve both STAT5 and STAT3 activation, and probably 
nuclear translocation of the GH receptor. Development of a more potent GH receptor antagonist 
or secretion inhibitor is warranted for cancer therapy.
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cells with one or a few hits [5]. In such a case, IGF-1 would 
increase the pool of transformed/damaged cells that are available 
for undergoing subsequent hits. This implies that higher levels of 
IGF-1 can bring about increased proliferation and survival and 
hence promote carcino genesis even though not being directly 
responsible for initiating cancer development. Hence, individuals 
with relatively high levels of IGF-1 may be at an increased risk as 
the anti-apoptotic actions of IGF supports partially transformed 
cells to provide an increased pool of cells for subsequent damag-
ing hits. It is important to note that the IGF-1 activity in a given 
tissue is not merely a function of its circulating levels but also 
the local expression of genes encoding for IGFs, IGF-1 recep-
tor (IGF-1R), IGFBPs and proteases that cleave the IGFBPs to 
regulate the release of IGF-1 (particularly for IGFBP-3). There 
is considerable heterogeneity in the levels of IGF-1 and IGFBP-3 
between normal individuals as a result of genetic and non-genetic 
determinants [6,7]. 
Recent evidence suggests a complex cross-talk between the 
GH–IGF-1 axis and estrogen receptor signaling that can stimu-
late mammary epithelial proliferation under normal conditions 
and increase the risk of breast cancer [8], as well as positive cross-
talk with the ErbB1 receptor [9]. The latter also undergoes direct 
tyrosine phosphorylation by the GHR [10], which itself is able to 
activate the classic oncogenic pathways directly through JAK2 
and Src [11]. Thus, the combination of GH and IGF-1 signaling, 
together with their interactions with other potentially oncogenic 
signaling proteins such as estrogen receptor and ErbB1 would lead 
one to expect involvement in cancer initiation or progression for 
this key growth-promoting axis (FIGURE 1).
Epidemiological studies
Numerous epidemiological studies have provided evidence that 
GH/IGF-1 is likely to be a driver of major human cancers. First, 
there is a link between tall stature, cancer risk and GH/IGF-1 
levels. With the use of final height as a marker for GH and IGF-1 
action, a review of over 300 case–control and cohort studies [12] 
found that taller individuals have a higher incidence of breast can-
cer (22% increase), prostate cancer (20% increase) and colon can-
cer (20–60% increase) relative to shorter individuals. A Danish 
study of 14-year-old children in the top quintile of height showed 
that they have an adjusted relative risk of over 1.5 for breast cancer, 
which surpasses other risk factors examined including BMI and 
age of first menarche [13]. A carefully controlled twin study from 
Scandinavia also found that tallness associates with increased 
breast cancer risk [14]. An anthropometric ana lysis revealed an 
association between rapid childhood growth during adolescence 
with the risk of developing several cancers, particularly of the 
breast, prostate and colon [3]. For breast cancer risk, a major pro-
spective meta-ana lysis of patients in 12 countries concluded that 
not only are serum IGF-1 concentrations positively associated 
with height, but they are also positively associated with breast 
cancer risk in women (high vs low serum IGF-1; OR: 1.28), but 
only in estrogen receptor-positive tumors [15]. Moreover, higher 
levels of free and total plasma IGF-1 have been reported in breast 
cancer patients [16]. In relation to the restriction of risk to estrogen 
receptor-positive women, synergistic interaction between estrogen 
action and IGF-1 action has been shown in vitro for epithelial cell 
proliferation [17]. IGF-1 levels are also positively related to high 
mammographic density, which is an indicator of increased breast 
cancer risk [18]. Of further relevance, loss of BRCA1 function 
associates with overactivation of the IGF-1 signaling axis [19].
There have been reports that genetic variants in the GH–IGF 
system can determine relative tumor risk. A genome-wide associa-
tion study (GWAS) in UK Caucasians has identified 64 SNPs that 
influence susceptibility for lung cancer, of which 11 were mapped to 
genes of the GH–IGF-1 axis, including GH1, GHR, GH-releasing 
hormone (GHRH) and IGFBP5 [20], and genetic variation at many 
genes in the GH–IGF pathway have been shown to associate with a 
variety of cancers [20,21]. A recent GWAS of over 1000 breast cancer 
cases matched with a similar number of controls concluded that the 
GH signaling pathway was the third most highly enriched pathway 
in breast cancer, but found insulin signaling intermediates rather 
than IGF-1 intermediates to co-associate with GH/JAK2 signaling 
in this ana lysis [22]. However, polymorphisms in the IGF-1 gene or 
in the GH synthesis pathway were not significantly associated with 
breast cancer [23]. Four IGFBP-3 SNPs have been reported to be 
associated with IGF-1 and IGFBP-3 levels in one study [24], and a 
strong association between a specific BP-3 promoter polymorphism 
and mammographic density, a known risk factor for breast cancer 
development, in another study [25]. However a larger cohort and a 
recent multi-ethnic cohort study reported no direct association of 
BP3 with breast cancer [23,26]. While IGFBP-3 polymorphic alleles 
were modestly associated with risk of colorectal cancer [27], there 
were contrasting associations between IGFBP-3 polymorphisms 
and the risk of prostate cancer in other studies [28,29]. It remains to 
be seen if these genetic variations could determine a higher cancer 
risk in susceptible individuals receiving GH treatment.
Elevated levels of IGF-1 have also been shown to confer an 
increased risk for other cancers such as colorectal cancer and pros-
tate cancer. A recent systematic review of 42 published studies 
concluded that raised circulating IGF-1 is positively associated 
with prostate cancer risk, with little evidence for a role of IGF-2, 
IGFBP-1, IGFBP-2, and inconclusive evidence for involvement 
of IGFBP-3 [30]. For colon cancer, the relative risk for IGF-1 
(RR: 1.07; 95% CI: 1.01–1.14) is modest compared with that 
seen in acromegaly [31]. This may be a consequence of the elevated 
insulin levels associated with acromegaly acting together with 
elevated IGF-1 and, of course, GH itself [31–33].
Acromegaly & cancer risk
Acromegaly is an important disease state for assessment of can-
cer risk because of the presence of persistently elevated levels 
of IGF-1. This is a result of hypersecretion of GH by pituitary 
somatotropes, particularly as a result of activating mutations in 
the GHRH signaling cascade. A number of studies have been car-
ried out to assess whether this condition is associated with cancer 
risk. The most recent meta-ana lysis by Renehan and Brennan 
across three population studies concluded that acromegaly 
is associated with a 2.46-fold (95% CI: 1.79–3.38) increased 
risk of colon cancer [34]. Adenomatous lesions tend to be larger 
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and more dysplastic in acromegaly, and are often multiple [35]. 
Acromegaly was also associated with an increased risk for thyroid 
cancer (3.64-fold; 95% CI: 1.63–8.11) in this meta-ana lysis. 
However, there is no statistical association between serum IGF-1 
and presence of colorectal neoplasia in the three existing stud-
ies [34], so one is left with the possibility of direct GH action on 
the colon, or elevated plasma insulin as a driving factor, conse-
quent to the diabetogenic action of elevated GH [36]. In relation 
to the other cancers, which showed a relationship to circulating 
IGF-1 in large population studies, in acromegaly there has been 
no confirmed association with breast cancer, although the lim-
ited sample number of untreated female acromegalics may have 
prevented small effects being observed [35]. This could also be a 
consequence of impaired ovulation in acromegalic women; hence, 
a lack of progesterone and estrogen, which together can promote 
breast cancer. Likewise, prostatic cancer shows no evident asso-
ciation with acromegaly, although benign prostatic hyperplasia 
with calcifications is evident across different studies [35]. A num-
ber of other cancers have been reported to be associated with 
acromegaly, but insufficient numbers are available for definite 
conclusions. These include various lympho-hematopoietic neo-
plasms (e.g., lymphoma, multiple myeloma, chronic myeloid or 
lymphocytic leukemia), brain tumors including meningiomas, 
adrenal tumors and melanomas [35].
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Figure 1. The major factors contributing to growth hormone-induced oncogenesis. GH receptor activation by endocrine or 
autocrine GH is feedback regulated by SOCS, phosphatases and PIAS. Receptor activation induces transcription of IGF-1, and the 
receptors for prolactin, EGF, estrogen and androgen, as well as promoting insulin synthesis and secretion. While GH receptor activation 
results in activation of oncogenic Src, Ras/ERK, PI3-kinase and NF-NB pathways, it also activates oncogenic STATs, STAT3 and particularly 
STAT5. The latter complexes with glucocorticoid receptors and TGF-E, and is necessary for the transforming actions of nuclear localized 
GHR. Finally, IGF-1 produced as a result of GHR activation and regulated by GH-dependent IGFBP3/ALS is a key element in tumor 
promotion. Text in bold shows standard abbreviaitons. 
ALS: Acid labile subunit; AR: Androgen receptor; EGFR: EGF receptor; ER: Estrogen receptor; GH: Growth hormone; GHR: Growth 
hormone receptor; GR: Glucocorticoid receptor; IGFBP3: Insulin-like growth factor-binding protein 3; PIAS: Protein inhibitors of activated 
signal transducer and activator of transcription; PRL: Pituitary hormone prolactin; PRLR: Pituitary hormone prolactin receptor; 
SOCS: Suppressor of cytokine signaling proteins; STAT: Signal transducer and activator of transcription.
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These studies indicate a low but significant risk for certain 
cancers, particularly of epithelial origin, in relation to elevated 
circulating IGF-1. What of the converse situation, that is, GH 
and/or IGF-1 deficiency? In the sole published study to date, a 
worldwide survey of 222 individuals with GHR mutation or iso-
lated GH deficiency, not a single case of malignancy was reported. 
Conversely, 338 first- and second-degree relatives reported a 
10–24% incidence of a range of malignancies [37]. The difference 
in average age between the two groups (32 vs 55 years, respec-
tively) probably contributed to this disparity, but the apparent 
resistance of GH-deficient and/or IGF-1-deficient individuals to 
cancer is supported by extensive animal studies. These will be 
discussed in the following sections, but at face value, the above 
findings imply that IGF-1–GH signaling is permissive for cancer 
but that beyond its essential role at low IGF-1 concentrations, has 
only modest effects in cancer promotion.
Children treated with GH & cancer risk
The administration of recombinant human GH was approved 
for the treatment of children with GH deficiency in 1985 and 
GH was one of the first therapeutic drugs to be produced by 
recombinant DNA technology. Over the past few years, several 
concerns have been raised in regard to its diabetogenic effects, 
adverse effects on skeletal growth, or increased risk of new or 
recurrent cancers [38]. A recent report by Bell et al. recorded 
findings generated from a study of 54,996 children treated with 
recombinant GH, corresponding to nearly 195,000 patient-years 
of monitoring [39]. This study found very low adverse effects 
of GH administration and no additional cancer cases in chil-
dren without other risk factors for malignancy. However, in 
children with hypothyroidism, the risk of second neoplasm was 
increased, suggesting that GH could aggravate neoplastic ten-
dencies resulting from underlying genetic abnormalities or radio-
therapy. Another independent study by Ergun-Longmire et al. 
had reported the same conclusion whereby GH therapy doubled 
the risk of second neoplasm in childhood cancer survivors [40]. 
Generally, most studies report that replacing circulating GH in 
humans does not promote cancer. However, while there were no 
additional cases relative to the general population, there was no 
data comparing GH-treated with GH-deficient untreated chil-
dren for ethical reasons. Given the finding of no malignancies in 
the aforementioned GH/IGF-1 deficiency referred to above, one 
would predict that such a comparison would show an increase 
in cancer incidence on GH replacement to normal levels. This 
would be concordant with the many animal studies verifying the 
resistance of GH/IGF-1-deficient animals to cancer.
Animal models
The prospect that GH is an etiologic factor in tumorigenesis 
was evident from the early clinical observation that hypophysec-
tomy inhibited metastasis and progression of specific malignan-
cies [41], and that high doses of GH induced neoplasms in rats [42]. 
Supporting these early observations, it was noted that transgenic 
mice overexpressing human GH exhibited higher incidences of 
tumors in mammary glands [43,44] and livers (TABLE 1) [45]. These 
mice have constitutively activated hepatic STAT3, Src, ERK and 
Akt [46]. An intermediatory role of IGF-1 in many GH actions 
is concordant with the observation that overexpression of IGF-1 
in the mammary epithelium leads to development of mammary 
cancers [47,48]. Similarly, expression of constitutively active IGF-1R 
leads to early development of mammary and salivary gland adeno-
carcinomas [48]. In GH-transgenic mice crossed with SOCS-2-
knockout mice, loss of the GH signaling antagonist SOCS-2 was 
found to be associated with increased local IGF-1 production and 
multiple hyperplastic and lymphoid polyps [49].
Conversely, GHR-knockout mice display a lower and delayed 
incidence of neoplastic disease with substantially fewer fatal neo-
plastic lesions, particularly lymphomas and pulmonary adenoma/
carcinomas compared with wild-type littermates [50]. Thus, 83% 
of C57Bl6 littermate controls died naturally from neoplastic dis-
eases, whereas only 42% of the GHR-deleted mice died from 
neoplasms in this study. In animal models of carcinogenesis, such 
as mammary tumors driven by the Simian virus 40 large T anti-
gen, tumors in GHR-deleted mice are also markedly reduced in 
size (50 vs 776 mm3) and number (3.2 ± 1.2 vs 9.8 + 1.4) com-
pared with those observed in the wild-type mice [51]. Likewise, 
lit/lit mice that are characterized by a nonfunctional GHRH 
receptor with GH and IGF-1 levels less than 10% of wild-type 
counterparts, exhibit marked retardation of human MCF-7 breast 
cancer xenograft growth (average: 35 large tumors in wild-type 
vs five in lit/lit by day 39 after implantation [52]). GH-deficient 
dwarf rats (dw/dw with 20% normal serum IGF-1) are resistant to 
mammary tumors induced by the carcinogen nitrosomethylurea 
(tumor incidence 100% in wild-type vs 4.8% in dw/dw rats) with 
an average tumor load of 7.0 per wild-type rat vs 1.0 per dw/dw 
rat. Hormone replacement of dw/dw rats with estrogen, progester-
one, GH or IGF-1 revealed a similar tumor incidence and tumor 
burden to wild-type rats only with bGH replacement, and a lesser 
increase with IGF-1 replacement (62% incidence with an average 
of 1.6 tumors per rat), [53]. This study was confirmed by Shen 
et al. with the additional finding that halting GH replacement 
led to tumor regression [54]. Likewise, development of prostate 
carcinomas in the Probasin/TAg rat is markedly decreased on 
a dw/dw background such that by 52 weeks of age, the major-
ity of dw/dw rats did not develop carcinomas, while all control 
Probasin/TAg rats did. Indeed, by 10 weeks of age, the dorsal 
and ventral prostate showed 100% tumor incidence in normal 
rats, while the GH-deficient dw/dw rats did not have measurable 
tumors [55]. 
It is clinically relevant that mice transgenic for the GH antago-
nist G120R GH (with 46% normal serum IGF-1) are partially 
resistant to 7,12-dimethylbenz(a)anthracene (DMBA)-induced 
mammary tumors (31.6% free of tumors vs 68% tumor free for 
the antagonist mice at 39 weeks after treatment) [56]. Accordingly, 
treatment of mice harboring MCF-7 xenografts with large doses 
of pegvisomant (an improved clinical version of the G120R GH 
antagonist) resulted in 70–80% suppression of circulating IGF-1 
and a 30% decrease in tumor volume together with a twofold reduc-
tion in proliferation and a twofold increase in apoptosis. However, 
no effect on IGF-1-independent MDA-MB235 or MDA-MB231 
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xenografts was evident [57]. Regression of 
all 15 human meningioma xenografts in 
nude mice was induced by daily pegviso-
mant treatment over 8 weeks at 45 mg/kg. 
Interestingly, this was accompanied by only 
a 20% decrease in serum IGF-1 [58], sug-
gesting a direct action of GH on this cancer. 
A similar study with colorectal cancer-205 
xenografts by Dagnaes-Hansen et al. showed 
a marked decrease in tumor weight (a40%) 
and increased apoptosis with second daily 
administration of 60 mg/kg pegvisomant, 
accompanied by a decrease in serum IGF-1 
to 36% of the control value [59].
These differences in tumor progression 
might relate to the extent of IGF-1 availabil-
ity, as IGF-1 has been shown to act in vitro as 
a tumor promoter by increasing proliferation 
and decreasing apop tosis, and by promoting 
angiogenesis and metastasis [4]. Indeed, local 
expression of IGF-1 in mouse mammary 
tissue resulted in spontaneous mammary 
tumors in 30% of mice [60]. Alternatively, 
these differences might also relate to GH 
availability or to a combination of both GH 
and IGF-1 availability. Some conclusions can 
be drawn from mouse models with lower lev-
els of circulating IGF-1 but which have nor-
mal/elevated tissue expression as a result of 
selective knockout of hepatic IGF-1 expres-
sion (liver IGF-1-deleted or LID mice). These 
mice have approximately 50% of normal 
circulating IGF-1, which results in a 40% 
significant decline in azoxymethane-induced 
colon adenocarcinoma number, largely as a 
result of increased apoptosis [61]. An earlier 
study with orthotopically transplanted colon-38 adenocarcinomas 
found the circulating IGF-1 in their LID mice to be approximately 
25% of normal, and this was associated with a substantial decrease 
in the number of mice with palpable colon tumors from 57 to 31%, 
together with a significant increase in tumor latency from 23 to 
27 days [62]. Hepatic metastases were also significantly decreased 
from 44 to 31%, and these improvements were reversed with IGF-1 
administration. Generation of mammary tumors by chemical or 
genetic means is also decreased in LID mice [63]. Both the DMBA 
carcinogen model and the C3(1)/Simian virus 40 large T-antigen 
expressing mouse model show decreased incidence and onset in 
LID mice. The decrease for DMBA-treated mice is from 56 to 
26% incidence, and latency from 60 to 74 days, while with the 
large T-antigen model approximately 60% of mice developed one 
tumor compared with approximately 40% with two tumors in 
control mice. At 4 weeks, the tumor volume in the large T-antigen 
model was approximately 50% of the control mice volume. These 
modest differences contrast with the striking blockade to tumor 
development seen in the GHR-deleted mice and the GH-deficient 
rats and mice discussed previously. This could be a result of insuf-
ficiently low circulating IGF-1 in the LID mice, or of paracrine 
IGF-1 generation in response to activation of the ubiquitous GHR. 
The elevated circulating GH consequent to lowered circulating 
IGF-1 in the LID mice would not appear to be making a major 
contribution to cancer promotion, since the LID mice do have a 
significantly lower tumor burden.
These studies clearly indicate the involvement of endocrine GH 
and IGF-1 in tumor growth promotion, and indicate that effective 
therapeutic options for cancer treatment need to drastically lower 
serum IGF-1.
GHR expression & cancer
The GHR is expressed in almost all cells, and its expression is 
subject to control by nine alternate first exons in humans [64]. 
The GHR transcript has been found to be overexpressed in a 
limited range of cancers, notably prostate carcinoma, glioblas-
toma, neuro ectodermal tumors, adult T-cell lymphoma, kidney 
clear cell carcinoma and parathyroid adenoma (see TABLE 2) [201]. 
Table 1. Animal models implicating growth hormone/IGF-1 in cancer 
incidence and progression.
Cancer status Animal model Ref.
Increased mammary tumor hGH-transgenic mice [43,103]
Increased hepatic tumor hGH-transgenic mice [45]
Increased mammary tumor Mammary epithelial 
overexpression of IGF-1
[47,60]
Increased mammary and salivary 
adenocarcinoma
Constitutively active 
IGF-1 receptor
[48]
Decreased lymphoma and pulmonary 
adenoma/carcinoma
GH-receptor null [50]
Decreased mammary tumors SV40 large T antigen in GHR null [51]
Decreased number of mammary tumors GH120 receptor antagonist-
transgenic mice with DMBA
[56]
Decreased growth of MCF-7 xenografts lit/lit GH-deficient mice [52]
Decreased growth of mammary tumors dw/dw GH-deficient rat
treated with NMU
[53,54]
Decreased prostate carcinomas Probasin T-antigen rat crossed 
with dw/dw
[55]
Decreased colon adenocarcinoma LID mice treated with 
azoxymethane
[61]
Decreased mammary tumor incidence LID mice treated with DMBA [63]
Decreased mammary tumor incidence SV40 large T antigen in LID mice [63]
Decreased growth of colon 38 
adenocarcinoma, some reversal with 
IGF-1 treatment
LID mice [62]
Decrease in MCF-7 xenograft growth Pegvisomant-treated nude mice [57]
Regression of meningioma xenografts Pegvisomant-treated nude mice [58]
Regression of Colo 205 xenografts Pegvisomant-treated nude mice [59]
DMBA: 7,12-dimethylbenz[D]anthracene; GH: Growth hormone; hGH: Human growth hormone; LID: Liver 
IGF-1 deficient; MCF: Michigan cancer foundation; NMU: N-methyl-N-nitrosourea; SV40: Simian virus 40.
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In addition, immunohistochemical and quantitative PCR studies 
have reported GHR overexpression in a high proportion of invasive 
breast ductal carcinoma [65], adrenal cortical neoplasms [66] and 
in colorectal cancer [67]. Moreover, elevated serum GH-binding 
protein (derived from the GHR by cleavage, and a measure of 
GHR expression [68]) is associated with a threefold increase in 
breast cancer incidence [69]. Immunohistochemical assessment has 
also revealed GHR overexpression in melanoma [70] and prostate 
carcinoma [71]. This expression has been found to be not only 
cytoplasmic but also within the nucleus (see later). To date, there 
are no reports of constitutively active GHR mutations.
Autocrine GH & cancer
15 years ago, expression of GH was reported in the mammary tis-
sue of dogs in response to progesterone administration, resulting 
in acromegalic symptoms [72]. The hormone is synthesized in the 
hyperplastic ductular epithelium of the mammary gland, since 
GH mRNA was present in dog and cat epithelia, and was shown 
to be elevated by progesterone [73]. As recently reported by Illera’s 
group, expression of GH protein in canine mammary tissue is 
markedly (20-fold) elevated in malignant tumors, and less so in 
benign tumors and dysplasias [74]. This expression correlates with a 
12-fold increase in IGF-1 protein expression and a fourfold increase 
in estradiol content of the malignant tumors, with a correspond-
ingly lower but still elevated expression of IGF-1 and estradiol in 
benign tumors [74]. Increased mammary GH and IGF-1 correlated 
with increased serum GH and IGF-1, with serum levels of GH 
greater than 6 ng/ml and IGF-1 greater than 43 ng/ml resulting in 
death of the majority of dogs within 6 months from neoplasia [13]. 
Is this striking evidence for autocrine/paracrine actions of GH in 
cancer promotion evident in humans? 
The study of Mol et al. reported the pres-
ence of GH transcripts in human mam-
mary tissue but with no evident relation 
to presence of carcinogenesis, and appar-
ently decreased transcript in most carci-
nomas [73]. Raccurt et al. later reported 
increased GH protein in three intraductal 
carcinoma samples relative to normal tissue, 
but not in invasive ductal carcinomas [75]. 
They also provided ISH and qPCR evi-
dence for GH transcript expression in these 
three carcinomas. Recently, Ratkaj et al. 
used IHC to study human GH expression 
in a larger series (n = 40) of ductal invasive 
breast carcinomas and fibroadenomas, and 
concluded that GH was expressed in all 
fibroadenomas and their stroma, but in only 
55% of ductal carcinomas and 20% of their 
stromal tissue [76]. There was no correlation 
between GH expression and tumor size or 
tumor grade. A search of the Oncomine 
database reveals underexpression of GH1 
and no listing for GH2 transcripts in inva-
sive ductal breast carcinoma against normal 
tissue, in contrast to the prolactin transcript, which is highly 
expressed [201]. In a survey of GH transcript expression across 
breast cancer lines, van Garderen and Schalken found only three 
of ten lines expressed GH1 transcript by PCR [77], (including 
MCF-7 cells, confirmed by Gil-Puig [78]), although all express 
GHR transcripts. Thus, it appears that humans are unlike dogs 
in overexpression of paracrine/autocrine GH in mammary cancer, 
but rather rely on prolactin. 
What about other cancers?
Many human prostate cancers overexpress GH1 or GH2 and GHR 
transcripts as evidenced in the Oncomine database (TABLE 2) [201]. 
Furthermore, an immunohistochemical study of 20 prostate 
cancers and 17 controls reported a fourfold increase in human 
GH expression in prostatic carcinoma Gleason scores 6–8. 
Co-expression of GH and GHR isoforms has also been reported at 
protein and mRNA levels in prostate cancer cell lines (e.g., ALVA-
41, PC-3, DU 145) [71,79], with van Garderen and Schalken report-
ing six of seven prostate cancer lines expressing GH1 transcripts, 
and all expressing GHR transcripts [77]. Association of autocrine 
GH expression with prostate cancer contrasts with clinical studies 
show that acromegaly is associated with prostate hypertrophy but 
not malignancy [80], and the observation that GH replacement 
in GHD patients increases prostate size to normal without any 
increase in neoplasia [81]. As previously noted, absence of GH or 
GHR signaling results in resistance to T-antigen induced pros-
tate cancer in mice and rats [55,82]. Loss of GH/IGF1 activity is 
also associated with impaired development of the prostatic ductal 
branching architecture that results from IGF-1 deficiency [83]. A 
reasonable hypothesis to explain these findings is that autocrine 
GH acts in a different manner from endocrine GH to promote 
Table 2. Summary of oncomine data for overexpression of growth 
hormone 1, growth hormone 2 and growth hormone receptor 
transcript expression (top 10% or better) compared with normal tissue.
Transcript Cancer type Oncomine reference
GH1 Prostate carcinoma
Bladder urothelial carcinoma
Colon, mucinous adenocarcinoma
Ovarian clear-cell carcinoma
Liu orostate
Dyrskjot bladder 3
Kurashina colon
Hendrix ovarian
GH2 Prostate carcinoma
Chronic adult T-cell leukemia/lymphoma
Bladder urothelial carcinoma
Colon mucinous adenocarcinoma
Ovarian mucinous adenocarcinoma
Ovarian endometrioid carcinoma
LaTulippe prostate
Choi leukemia
Dyrskjot bladder 3
Kurashina colon
Hendrix ovarian
Hendrix ovarian
GHR Prostate carcinoma
Prostatic intraepithelial neoplasia 
Glioblastoma
Primitive neuroectodermal tumor
Acute adult T-cell leukemia/lymphoma
Clear-cell sarcoma of the kidney
Parathyroid gland adenoma
Liu prostate 2, Yu prostate, 
Varambally
Tomlins prostate
Liang brain, Lee brain
Pomeroy brain
Choi leukemia
Cutcliffe renal
Morrison parathyroid
GH: Growth hormone; GHR: Growth hormone receptor. 
Data from [201].
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cancer formation, whereas endocrine GH promotes hypertrophy 
in an IGF-1-dependent manner. This situation may apply to other 
cancers overexpressing GH1 and GH2 evident in the Oncomine 
database, such as chronic adult T-cell leukemia, ovarian muci-
nous carcinoma, endometrioid and clear-cell adenocarcinomas, 
and bladder urothelial cancers (TABLE 2) [201]. The GHR itself is 
also reported as overexpressed in a range of neoplasias (see earlier). 
Moreover, since human GH can activate the human prolactin 
receptor [84], the presence of overexpressed prolactin receptor in 
prostate cancer, T-cell leukemias and ovarian adenocarcinomas [201] 
raises the possibility that autocrine GH may also drive oncogenesis 
in these cancers. 
The oncogenic actions of forced autocrine expression of human 
GH in immortalized human breast lines has been extensively stud-
ied by Lobie’s group. Thus, Zhu et al. have reported that overexpres-
sion of autocrine GH in mammary epithelial cell lines (particularly 
MCF-7 cells) results in increased cell proliferation, transformation 
and invasion, with an epithelial to mesenchymal transition [85]. This 
is associated with an altered transcript expression profile, with a 
number of oncogenic genes being upregulated by autocrine GH 
overexpression [86]. Autocrine GH led to increased expression of 
the oncogenic homeobox protein Hox-A1 and telomerase pro-
tein together with downregulation of junctional plakoglobin and 
increased DNA methyltransferase-3 activity resulting in methyla-
tion of the plakoglobin promoter [87]. Human GH overexpression 
also resulted in increased activity of matrix metalloproteases-2 and 
-9, redistribution of E-cadherin to the cytoplasm and increased 
secretion of trefoil factor 3 (TFF3), proposed to mediate the onco-
genic actions of autocrine GH by Lobie’s group by paracrine actions 
on adjacent cells (FIGURE 2) [87]. Autocrine production of human GH 
was associated with increased angiogensis in xenografts, in accord 
with its ability to recruit endothelial cell precursors and to induce 
VEGF [88]. Of interest, autocrine human GH-driven proliferation 
of MCF-7 cells, transcriptional activation and cell spreading was 
reported to be completely blocked by the addition of exogenous 
human GHR-specific antagonist B2036/pegvisomant [89]. These 
studies indicate that overexpression of human GH in transformed 
cells is oncogenic. Is there, then, a difference between autocrine and 
endocrine GH signaling? van den Eijnden and Strous examined 
this question in ts20 cells, finding that GHR signaling in cells with 
autocrine GH does not manifest before the Golgi, and is associated 
with a very low level of chronic STAT5 and GHR tyrosine phos-
phorylation, but robust induction of a STAT5-responsive luciferase 
reporter [90]. Sustained GHR signaling would be associated with 
induction of negative-feedback regulators such as SOCS proteins, 
hence the pulsatile nature of pituitary GH secretion. It would appear 
that sustained autocrine GH stimulation does something different, 
for example, results in the gain of a phenotype characteristic of 
oncogenic transformation, yet sustained endocrine GH stimula-
tion (as in acromegaly) results in only a modest increase in cancer 
susceptibility. One is driven to the conclusion that intracellular 
signaling events are important in the transformation process, par-
ticularly since Strous’ group found that autocrine GH-expressing 
cells are insensitive to external (endocrine) GH [90]. Conversely, 
Lobie’s group have reported that exogenous B2036/pegvisomant 
blocks autocrine growth, implying that autocrine GH is secreted 
and acts externally (or that the antagonist is internalized at high 
concentrations). It may be that both a hormone-induced signal from 
the plasma membrane and an intracellular signal are necessary for 
full autocrine action by GH.
Nuclear GHR & cancer
A likely possibility for altered intracellular signaling relates to the 
presence of the GHR in the cell nucleus, since this increases cell 
sensitivity to STAT5 [91]. Tissue immunohistochemistry reveals that 
the nuclear GHR is present in many proliferating cells, including 
a variety of cancers, such as breast cancer [92], colorectal carcinoma 
[93], hepatocellular carcinoma [94], melanoma [70] and uterine cervi-
cal neoplasms [95]. The translocation of a transmembrane receptor 
into the nucleus is known to occur for the EGFR, the FGF receptor 
and IFN-J receptor [96], and is often associated with cell transfor-
mation. Full-length GHR is translocated to the nucleus in a GH- 
and importin-E-dependent manner in cell models, and in vivo in 
response to regeneration after partial hepatectomy in the rat, which 
is a GH-dependent process [91]. There is a high correlation between 
the nuclear GHR and cell proliferation during the liver regenera-
tion process and targeting the GHR to the nucleus by fusion with 
a nuclear localization signal markedly increased the cell prolifera-
tive response to autocrine GH via STAT5 activation in pro-B cells, 
resulting in constitutively activated STAT5. Moreover, pro-B BaF3 
cell lines stably expressing nuclear-targeted GHR become trans-
formed, and form solid tumors in immunocompromised mice. This 
is associated with upregulation of transcripts for a number of genes 
involved in oncogenesis such as survivin, dysadherin and MybBP. 
Accordingly, a high proportion of nuclear GHR cells are evident 
in sections of highly proliferative lymphomas [91]. Further exami-
nation of the mechanism involved led to the identification of an 
important RNA splicing protein and transcriptional co-activator, 
CoAA, which binds to the extracellular domain of the receptor in 
response to GHs, potentially facilitating nuclear translocation by 
means of its nuclear localization motif [97]. Transfection of pro-B 
cells with CoAA markedly enhanced the proliferative response to 
GHs, but not to IL-3, the physiological cytokine for these pro-B 
cells. CoAA is an oncogene related to Ewing’s sarcoma protein and 
translocated in liposarcoma (TLS) oncoproteins, which is amplified 
in lymphoma, non-small cell carcinoma and squamous cell carci-
noma [98], and can drive osteosarcoma proliferation in vitro [99]. It 
is also a potent co-activator of the estrogen receptor, which is highly 
relevant to breast cancer [100]. 
GH & prolactin receptor activation in cancer
As mentioned previously, human GH also activates the human pro-
lactin receptor [84], although lower species have GHs and prolactins 
specific for their cognate receptors. PRL can upregulate local IGF-1 
expression in breast cancer cells, resulting in downstream activation 
of Erk1/2 and Akt [101], and PRL and IGF-1 augment neoplastic pro-
gression synergistically [102]. Following the initial observation that 
human GH-transgenic mice develop mammary cancer (human GH 
activates both GH and prolactin receptors in mice) [103], Wennbo 
et al. created rat prolactin-transgenic and bovine GH-transgenic 
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mice, which target their prolactin and GHRs, respectively [104]. Only 
in the prolactin transgenics were mammary tumors evident, sup-
porting the oncogenic role of autocrine/paracrine prolactin in mam-
mary tumorigenesis. This may be a consequence of the differences in 
level of receptor expression for GH and prolactin in the mammary 
gland since both receptors have similar signaling pathways. The 
role of prolactin in breast cancer has been extensively reviewed by 
Clevenger et al. [105]. Clinical and animal model studies also support 
a role for autocrine prolactin in prostatic cancer progression [106,107] 
and elevated prolactin receptor expression is evident in colorectal 
carcinoma and metastases [108]. These findings can be accommo-
dated in a model of abnormal signaling by these two closely related 
class-1 cytokine receptors involving excessive activation, particularly 
of STAT5, but also of STAT3 (FIGURES 1 & 2) [109–111].
The role of STAT5 activation in cancer
Constitutively activated STAT5 can act as an oncogene, and is a 
common feature of hematopoietic proliferative diseases. This is a 
consequence of activating mutations in the JAK kinase or relevant 
cytokine receptor such as JAK V617F [13,112,113], TEL-JAK2 [114], 
Bcr-abl [115] and MPL W515L [116]. Activation of STAT5 has been 
shown to be critical for transformation by several of these onco-
genic mutations [117–119]. There is now accumulating evidence that 
activated STAT5 plays a vital role in promoting a broad range of 
cancers, including prostate cancer [120], melanoma [121,122], hepato-
cellular carcinoma [123] and breast cancer [124]. Activation of STAT5 
has also been found to increase tumor growth and aggressiveness of 
hepatocellular carcinoma and squamous epithelial cell carcinoma by 
induction of epithelial–mesenchymal transition [123,125]. Induction 
of senescence is a common feature of oncogenes [126] and expres-
sion of constitutively active STAT5 has also been shown to induce 
senescence [127,128].
Several studies investigating human melanoma patient samples 
and melanoma cell lines have shown that phosphorylated STAT5 is 
a common feature in melanoma, particularly in metastasis [82,121,122]. 
Knockdown of STAT5 by RNAi in melanoma cells reduced Bcl-2 
and cyclinD2 transcription, reduced cell viability and induced apop-
tosis, and expression of a dominant negative (C-terminal truncated) 
STAT5 inhibited expression of Bcl-2, leading to G1 arrest and 
enhanced cell death [121,122]. In a fish model of melanoma, consti-
tutive activation of STAT5 has shown to correlate with the aggres-
siveness of the melanoma [129], suggesting that activation of STAT5 
plays an important role in metastasis. In a 3D skin reconstruction 
model of metastatic melanoma, differentiation and invasion is inhib-
ited by roscovitine [130], which is an inhibitor of cyclin-dependent 
kinases [131] and STAT5 activity [132]. 
Similarly, activated STAT5 has been detected in the majority 
of prostate cancer specimens, particularly in high histological 
grade cancers, but not in normal prostate epithelium [99,133]. It has 
recently been shown that activated STAT5 promotes growth and 
metastatic behavior of human prostate cancer cells in vitro and 
in vivo [120,134–136] and expression of a dominant-negative STAT5 
induces cell death in both androgen-independent and androgen-
sensitive prostate cancer cell lines [133]. Interestingly, STAT5 is able 
to synergise with androgen receptor by upregulating androgen 
receptor expression, which results in upregulation of STAT5 
expression. The liganded androgen receptor and STAT5 interact in 
prostate cancer cells and enhance each other’s nuclear uptake [137]. 
Because both the GHR and the prolactin receptor activate STAT5 
as a key signaling pathway, it is likely that both autocrine/para-
crine and endocrine GH and prolactin action would enhance active 
(oncogenic) STAT5 generation.
Many studies have shown STAT5 to be a major player in 
breast cancer [124], for example, expression of dominant-negative 
STAT5A in T47D breast cancer cells induces apoptosis [138], 
however, STAT5A and STAT5B show distinct effects in human 
mammary carcinoma cell lines [110]. Transgenic mice expressing 
a constitutively active variant of STAT5 (a C-terminal 44 amino 
acid deleted STAT5 fused to the JAK2 kinase domain via residues 
677–847 of STAT6) specifically in mammary epithelium via the 
E-lactoglobulin regulatory sequences are predisposed to mammary 
tumor formation [139]. However, it is interesting to note that over-
expression of the C-terminal deleted dominant-negative form of 
STAT5 from the same regulatory sequences also predisposes mice 
to mammary tumors; although the tumors from activated STAT5 
expression showed a more differentiated phenotype suggesting 
different mechanisms are at play [140]. 
To date there has been no identification of a constitutively active 
mutation of GHR, however, with current whole genome sequenc-
ing regimes of large numbers of tumor samples it is likely that 
such mutations may be identified, similar to those identified for 
other class-1 cytokine receptors such as the thrombopoietin recep-
tor W515L/K [141] and S505N [142] activating mutations, and the 
constitutively active prolactin receptor found in benign tumors [143].
Expert commentary
It is clear that GH/IGF-1 is necessary for the progression of a wide 
range of cancers in rodents and dogs. However, the situation is not 
so clear with humans, since only one study has reported on cancer 
incidence in GHR/GH-deficient patients. This needs to be rectified 
with further clinical data.
The relationship between autocrine GH expression and can-
cer incidence/progression needs to be firmly established with 
comprehensive studies of clinical samples.
The basis for the transforming actions of autocrine GH needs 
to be fully explored using cells with modest levels of GH expres-
sion corresponding to those evident in particular cancers. Prostate 
carcinoma would be a good model for these studies, because 
both autocrine GH and highly expressed GHR are present in 
prostate cancers.
There is no significant risk above that of the general population 
resulting from therapeutic replacement with GH. However, use of 
GH for prolonged periods at supraphysiologic levels could contribute 
to increased cancer risk, particularly colon and thyroid cancer, as it 
does in acromegaly.
Five-year view
Given the animal and human data supporting critical involvement 
of the GH–IGF-1 axis in cancer incidence and progression, the 
development of GH antagonists for use alone or in conjunction 
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